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The kynurenine pathway Chapter 1 
  2 
1.1  Kynurenine pathway 
Tryptophan is metabolized in several different ways (Figure 1). A physiologically 
important branch in the tryptophan metabolism is conversion into serotonin and 
melatonin. Up to 99% of tryptophan is metabolized in the kynurenine pathway 
(KP).
1  However,  until  recently,  this  pathway  was  thought  to  be  of  merely 
catabolic  importance.  Nowadays,  the  regulatory  role  of  this  pathway  is  under 
investigation.  Extensive  research  is  being  done  to  understand  the  effects  of 
kynurenine pathway metabolites, shortly ‘kynurenines’, on biological systems.  
The  key  intermediate  of  the  kynurenine  pathway  is  kynurenine  (KYN).  Two 
enzymes, indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase 
(TDO), convert tryptophan into N-formylkynurenine. This intermediate is rapidly 
converted  into  KYN.  At  this  point,  the  metabolic  pathway  splits  up  into  two 
branches.  One  branch  leads  via  3-hydroxykynurenine  (3-OH-KYN),  anthranilic 
acid  (AA)  and  3-hydroxyanthranilic  acid  (3-OH-AA)  to  the  endogenous  NMDA 
receptor  agonist  quinolinic  acid  (QUIN).  The  second  branch  leads  to  the 
biosynthesis  of  kynurenic  acid  (KYNA),  which  has  antagonistic  properties  on 
NMDA receptors and nicotinic acetylcholine receptors (nAChRs).  
 
The ability to influence the exquisite balance between excitation and inhibition of 
neuronal systems through the kynurenine pathway can lead to new classes of 
pharmacological  tools.  These  tools  might  be  important  in  understanding 
processes  in  normal  and  diseased  organisms  on  one  hand,  and  in  the  clinical 
treatment in a number of diseases with major social impact on the other hand. 
 
In  general,  QUIN  has  neurotoxic  and  KYNA  has  neuroprotective  properties. 
Therefore,  most  research  focuses  on  shifting  the  equilibrium  within  the 
kynurenine pathway away from QUIN and towards KYNA production. In a small 
number of cases, a shift away from KYNA production is desired. For example, 
elevated  levels  of  this  metabolite  have  been  found  in  patients  suffering  from 
schizophrenia.
2-4  Limiting  brain  levels  of  KYNA  might  also  be  beneficial  for 
cognitive  function.
5  This  thesis  focuses  on  the  characterization  of  the  KYNA 
producing branch of the kynurenine pathway. This branch involves the enzyme 
kynurenine  aminotransferase  (KAT),  which  catalyzes  the  conversion  of  key 
intermediate KYN into KYNA. However, due to the highly balanced nature of the 
pathway, research will also relate to the first two enzymes of the QUIN branch of 
the pathway, kynureninase (KYNase) and kynurenine 3-hydroxylase (kynurenine 
mono-oxygenase, KMO).   
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1.1.1  Kynurenine production: Indole-2,3-dioxygenase, tryptophan-2,3-
dioxygenase and kynurenine formamidase 
Conversion of tryptophan to N-formylkynurenine is the rate limiting step in the 
kynurenine pathway. This reaction is catalyzed by indoleamine 2,3-dioxygenase 
and tryptophan 2,3-dioxygenase.  
Indoleamine  2,3-dioxygenase ( IDO,  EC  1.13.11.17)  is  found  in  extrahepatic 
tissues,  including  the  brain.  It  has  broad  substrate  specificity.  IDO  has 
protoheme IX as prosthetic group, and occurs in monomeric form. For metabolic 
activity,  IDO  needs  superoxide  or  oxygen.  The  preferential  use  of  superoxide 
gives the enzyme important antioxidative properties.
1, 6-13  
The immune system plays an important role in the regulation of IDO activity. 
IDO  is  induced  by  lipopolysaccharides,  IFN- ,  TNF- ,  and  IFN-   and  other 
immuno-related  compounds.  Anti-inflammatory  cytokines,  such  as  IL-4  and 
TGF- ,  are  able  to  suppress  IDO  activity.
1  Immune  activation  in  mice  caused 
induction of IDO activity and elevation of QUIN brain and plasma levels. These 
effects  were  attenuated  by  immune  suppressors,  like  dexamethasone.
14 
However, high doses of glucocorticoids (hydrocortisone, dexamethasone) were 
found to enhance IFN-  mediated IDO activity in human cell lines.
15 Differences 
between  the  studies  could  be  explained  by  action  of  the  glucocorticoids  on 
different immunomodulatory systems. 
IDO activity also closely relates to the nitric oxide pathways. NO inhibits IDO. 
Inhibition  of  nitric  oxide  synthetase  results  in  elevated  tryptophan  to  KYN 
turnover by IDO.
1 
Competitive  substrates,  e.g.  6-chloro-D,L-tryptophan  and  4-chloro-3-
hydroxyanthranilate
14,  1-methyl-D,L-tryptophan,  and  the  benzofuranyl-  and 
benzo(b)thienyl  analogs  of  tryptophan
16  are  known  synthetic  IDO  inhibitors. 
Exiguamine  A  is  a  potent  inhibitor  (Ki  =  210  nM)  isolated  from  the  sponge 
Neopetrosia exigua.
17 
Induced IDO activity and resulting elevated levels of QUIN are important targets 
for the treatment of immune related diseases, like HIV, cardiovascular diseases 
and allergies.
18-22  
Tryptophan  2,3-dioxygenase ( TDO,  EC  1.13.11.11)  is  the  primary  tryptophan 
metabolizing enzyme in the liver. TDO selectively metabolizes L-tryptophan, and 
uses oxygen in its catalytic cycle. TDO naturally occurs as a tetramer, and has 
one  heme  group  in  each  monomer.
12  TDO  is  inducible  by  dexamethasone  in 
mice. QUIN levels are not elevated by TDO induction, probably due to extensive 
KYN metabolism into other metabolites in the liver.
14 TDO activity is inhibited Introduction: The kynurenine pathway 
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competitively at millimolar concentrations of some close tryptophan analogs and 
3-OH-KYN  in  vitro.
23  Several  3-pyridylvinyl  analogs  are  reported  selective 
inhibitors, as studied in vitro and in vivo.
24-26  
Kynurenine  formamidase  (arylformamidase,  AFMID,  EC  3.5.1.9)  catalyzes  the 
conversion of N-formylkynurenine to L-KYN.
27, 28 The enzyme is also capable of 
processing some other amides and esters.
27 AFMID is a member of the serine 
hydrolases. In mice, AFMID is present in most tissues, but the activity is highest 
in liver and kidney.
29 A brain specific formamidase was found in some species.
30 
AFMID knock out mice showed kidney failure and disturbances of the immune 
system.  Brain  function  was  not  affected.
29  AFMID  activity  is  modified  by 
organophosphates present in insecticides. These compounds inhibit the enzyme 
by coupling to a serine residue in the active site. The effect of organophosphate 
diazinon on KYN pathway metabolites was studied best.
31, 32 Diazinon was able 
to increase N-formylkynurenine and decrease KYN levels in mouse liver in vivo. 
Unexpectedly, plasma KYN levels were increased. Moreover, elevated levels of 
plasma  QUIN,  as  well  as  increased  renal  KYNA  and  xanthurenic  acid  (XA) 
excretion were found. The unexpected increases of these kynurenine metabolites 
were explained by a secondary mechanism for KYN level regulation by release 
from unidentified storage.
31 
1.1.2  Kynurenine 
L-Kynurenine  (KYN)  is  transported  over  the  blood  brain  barrier  by  the  large 
neutral amino acid transporter.
33 Elevated KYN levels result in higher conversion 
rates  into  3-OH-KYN,  QUIN  and  KYNA,  depending  on  available  enzymatic 
systems. The physiological function of KYN is thought to be rather limited. One 
study showed an induction of nerve growth factor production in cultured mouse 
astrocytes by L-KYN.
34 
KYN is metabolized into two different directions. The compound is converted to 
KYNA by kynurenine aminotransferases (KATs) and into QUIN by conversion into 
the  intermediates  3-OH-KYN  and  AA  by  kynurenine  3-hydroxylase  (KMO)  and 
kynureninase (KYNase), respectively. The conversion into either route is highly 
balanced.  The  balance  can  be  shifted  by  inhibition  of  the  KYN  converting 
enzymes. For the design of enzyme inhibitors, the chemical structure of KYN is 
used extensively as a basis. Chapter 1 
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Flavin monooxygenases 
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Flavin monooxygenases (FMO) are enzymes that 
facilitate reactions of a substrate with molecular 
oxygen.  The  catalytic  cycle  starts  with  the 
reduced  form  of  the  flavin-moiety.  The  transfer 
of  one  electron  to  molecular  oxygen  yields  a 
complex  between  superoxide  and  the  flavin 
radical,  which  is  stabilized  by  the  enzyme  as  a 
C(4a)-hydroperoxyflavin.  This  intermediate 
oxygenates  the  substrate  by  transfer  of  one 
atom of oxygen. The second atom is released as 
water.  FMOs  are  often  highly  regio-  and/or 
enantioselective.  Specificity  within  this  class  of 
enzymes  is  introduced  by  enzymatic  structure. 
[1]  KMO  is  a  NADPH-dependent  FMO,  meaning 
that transfer of protons occurs through NADPH. 
The flavin containing coenzyme is flavin adenine 
dinucleotide (FAD).[1-4] 
 
[1]  J.  Biotech.  2006,  124,  670-689;  [2]  FEBS  Lett. 
1997, 410, 407-412; [3] Eur. J. Biochem. 2000, 267, 
1092-1099;  [4]  Arch.  Biochem.  Biophys.  2005,  433, 
297-311 
1.1.3  Kynurenine 3-hydroxylase 
Kynurenine 3-hydroxylase (kynurenine monooxygenase, KMO, EC 1.14.13.9) is 
responsible for conversion of key intermediate KYN into 3-OH-KYN. The enzyme 
is a NADPH dependent flavin monooxygenase (FMO). Recombinant human KMO 
has 486 amino acid residues and has a weight of 56kDa. The enzyme has an 
optimal activity at pH 7.5.
35,  36 
The  mechanism  of  mono-
oxygenation  involves  one 
molecule  of  NADPH  and  one 
non-covalently  bound  molecule 
of  FAD.  The  active  site 
properties  indicate  close 
resemblance  to  p-hydroxy-
benzoate hydroxylase.
35-37  
Human  KMO  shows  high 
selectivity for L-KYN. AA, KYNA, 
L-Trp,  D-KYN,  and  D-
hydroxybenzoate  are  no  KMO 
substrates.  KMO  is 
competitively  inhibited  by 
pyridoxal  5’-phosphate  and  Cl
- 
ions.
36 
KMO  is  primarily  localized  on 
the outer membrane fraction of 
mitochondria.
38  Rat  KMO 
activity  is  highest  in  liver  and 
kidney.  In  the  brain,  the 
activity  was  found  to  be  0.1% 
of liver activity.
39  
3-OH-KYN  has  neurotoxic 
properties  starting  at  a 
concentration  of  1 µ M.  The 
neurotoxicity  is  caused  by  oxidation  of  the  compound  and  concomitant 
production of reactive oxygen species (ROS), including superoxide radicals and 
hydrogen peroxide. The ROS formed are able to cause apoptosis. Antioxidants 
can inhibit 3-OH-KYN toxicity. Prior to being oxidized, 3-OH-KYN is transported 
into neurons by Na
+ dependent neutral amino acid transporters. The different Introduction: The kynurenine pathway 
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vulnerability of brain regions (cortex > striatum > hippocampus > cerebellum) 
can be explained by availability of these transporters.
40  
 
KMO inhibitors 
Inhibition of KMO has been studied extensively. Structures of most known KMO 
inhibitors  are  closely  related  to  the  enzymatic  substrate  KYN.  A  selection  of 
published KMO inhibitors is listed in Table 1. 
 
Table 1 Selection of published KMO inhibitors 
Compound 
 
IC50 or % 
inhibition 
Enzyme 
source
# 
Effect on other enzymes  ref 
 
nicotinylalanine 
 
900±180 µM  liver, brain  KYNase: IC50 800+/-120 µM 
41 
0.9±0.1 µM  brain, liver  KYNase: IC50 100±12 µM 
41, 42 
3.0±0.2 µM  brain   <50% inhibition at 100 µM for 
KAT and KYNase 
43 
0.77±0.11 µM  kidney    
44 
(S): 4 µM,  
(S,R): 8 µM 
liver  (S): IC50 100 µM for QUIN 
formation in human monocyte-
derived macrophages 
45   
m-nitrobenzoylalanine 
(mNBA) 
 
0.8 µM   liver  KYNase: IC50 100 µM 
46 
0.2 µM  brain  KAT IC50>1000 µM, KYNase 
IC50>100 µM 
47 
0.2±0.02 µM  forebrain  <50% inhibition at 100 µM for 
KAT and KYNase 
43 
0.23±0.032 µM  kidney   
44 
(S) 0.1 µM 
(R) 85% @10 µM 
liver  IC50 0.7 µM for QUIN formation 
in cultured human monocyte 
derived macrophages 
45 
0.33±0.03 µM  liver   
48, 49 
 
3,4-dichlorobenzoyl-
alanine (FCE28833, 
PNU156561) 
 
0.20±0.02 µM  brain   
48, 49 
1.9 µM  liver   
45 
 
4-(3-chlorophenyl)-2-
hydroxy-4-oxo-but-2-
enoic acid methyl 
ester  
0.006 µM  human 
monocyte-
derived 
macrophages 
 
45 
0.02 µM     
50, 51 
0.040 µM     
52 
 UPF 648 
 
100±9%@0.1 mM 
92±7%@0.01 mM 
81±10%@0.001 mM 
brain  KAT in rat brain: 
5 ± 6%@0.1 mM 
4 ± 0%@0.01 mM 
4 ± 1%@0.001 mM  
53 
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Table 1 (continued) 
24.0±3.1 µM  liver  KAT: 24% at 100 µM;  
KYNase: 25% at 100 µM 
48 
 
7-chloro-3-methyl-
1H-pyrrolo[3,2-
c]quinoline-4-
carboxylic acid 
 
8.1±1.2 µM  brain   
48 
 
Ro 61-8048 
0.037±0.003 µM  kidney   
44 
#All values were obtained from rat tissue homogenates, unless stated otherwise. 
 
Two of the first compounds tested as KMO inhibitors were nicotinylalanine and 
m-nitrobenzoylalanine (mNBA).
41,  42,  54 3,4-Dichlorobenzoylalanine (FCE 28833, 
PNU 156561) was included into several studies focusing on inhibitory properties 
of KYN analogs. In 1996, it was published as part of a series of 2-, 3-, and 4-
substitued benzoylalanines (Figure 2).  
 
Figure 2 
O
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N
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R
COOH X
pyrrolo[2,3-c]quinolines
OH HO
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Classes of KMO inhibitors 
 
The  compound  was  shown  to  be  selective  for  KMO  over  KYNase  and  KAT  in 
vitro.
47  The  study  was  extended  with  several  other  KYN  analogs,  having  4-
phenyl-4-oxo-butanoic and 4-phenyl-4-oxo-butenoic backbones (Figure 2). The 
 -hydroxy- and   -benzyl analogs of FCE 28833 were almost equally potent.
49 
The 4-phenyl-4-oxo-butenoic acid series was further extended by the group of Introduction: The kynurenine pathway 
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Rainhard.
37,  45 The most potent compound of this series, 4-(3-chlorophenyl)-2-
hydroxy-4-oxo-but-2-enoic acid methyl ester (Table 1), had an IC50 as low as 6 
nM at QUIN formation in human macrophages, but had a much weaker effect on 
KMO in tissue homogenate.
37, 45 
A structurally slightly more restricted inhibitor is UPF 648. The compound is KMO 
over KAT selective at nanomolar concentrations.
50, 51, 53 
An example of an inhibitor that is structurally not closely related to KYN is 7-
chloro-3-methyl-1H-pyrrolo[3,2-c]quinoline-4-carboxylic  acid  (Table  1).  This 
compound was studied in a series of pyrrolo[3,2-c]quinoline derivatives (Figure 
2). Although the compound is less potent than KYN analogs, it shows good KMO 
over KYNase and KAT selectivity.
48 
A more extensively used structurally diverse KMO inhibitor is Ro 61-8048 (Table 
1).  This  compound  shows  high  KMO  inhibitory  potency  in  vitro  and  in  vivo.
44 
Finally,  the  metabolic  disruption  of  bisphenol  A  (Figure  2),  a  commonly  used 
monomer of polycarbonate plastics, was attributed to inhibition of KMO.
55  
In vivo effects of KMO inhibitors on KYNA brain production have been studied 
extensively. In mice, i.p. administration of UPF 648 caused an increase of KYN 
and KYNA in striatal brain tissue.
52 In rat, coinjection in striatum of UPF 648 with 
3H-KYN caused a decrease of 
3H-3-OH-KYN recovery from striatal brain tissue 
compared to injection of 
3H-KYN alone. Tritiated QUIN and KYNA recovery were 
not changed in these experiments by UPF 648.
53 mNBA (i.p.) caused increased 
KYN
41, 42 and KYNA
41, 42, 46 concentrations in rat hippocampus, as measured by 
microdialysis. Whole brain content of KYN and KYNA were also increased.
41, 46 In 
mice,  administration  of  KYN  (i.p.),  followed  by  oral  administration  of  mNBA 
caused a dose-dependent increase of KYNA and a concomitant dose-dependent 
decrease  of  QUIN  in  whole  brain  tissue.
45  Oral
43,  44  or  intraperitonal
43 
administration of FCE 28833, as well as administration of Ro 61-8048 (p.o.)
44 
caused increased extracellular KYNA levels in rat hippocampus. 
Endotoxin stimulated excessive QUIN production in rat cortical tissue could be 
antagonized by KMO inhibitor nicotinylalanine.
54 In these studies, effects of the 
inhibitors on 3-OH-KYN and AA were not taken into account.  
Local infusion in rats of KYNA (100 nM) resulted in decreased neuronal activity, 
marked by reduced extracellular levels of glutamate (Glu) in the cortex and the 
caudate, but not in the hippocampus. Interestingly, whereas Ro 61-8048 was 
able  to  elevate  extracellular  KYNA  levels  in  rat  cortex,  caudate  and 
hippocampus, expected concomitant decrease in extracellular glutamate levels 
was only seen in the caudate.
56 KMO inhibitors were shown to have sedative and 
anticonvulsive properties in rats and mice.
41 They are suggested candidates for Chapter 1 
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treatment of increased 3-OH-KYN levels in e.g. Huntington’s disease and AIDS 
dementia.
40 
1.1.4  Kynureninase   
Kynureninase (EC 3.7.1.3, KYNase) is a pyridoxal-5’-phosphate (PLP) dependent 
enzyme. KYNase has an aminotransferase type fold and belongs to family IVa 
within  the  aminotransferase  superfamily.
57-59  KYNase  catalyzes  the   , -
hydrolytic  cleavage  of  L-KYN  and  3-OH-KYN.  The  properties  of  the  human 
enzyme have been well characterized. The enzyme exists in homodimeric form. 
A monomer has a mass of 52.4 kDa. The human enzyme shares 85% homology 
with the rat variant. The human variant of KYNase can only convert 3-OH-KYN to 
3-OH-AA. Rat KYNase is also able to convert KYN to anthranilic acid (AA).
60 It is 
generally  believed  that  the  conversion  of  KYN  to  3-OH-KYN  and  subsequent 
hydrolysis to 3-OH-AA is the main route in mammalian brain.
60, 61 Literature is 
PLP dependent enzymes 
 
 
 
 
 
 
 
  
            
                      
 
Pyridoxal-5’-phosphate (PLP) dependent enzymes are enzymes that use PLP as their co-
enzyme. PLP is the active form of vitamin B6. It is covalently linked to the enzyme by a 
“Schiff base” linkage with a lysine residue. In most types of enzymes, the exchange of 
linkage to an amino-group within the substrate initializes the enzymatic reaction.  
PLP dependent enzymes are divided into at least 5 different fold types. 
Aminotransferases  form  a  large  distinctive  group  within  the  PLP  dependent  enzymes. 
They  belong  to  fold  types  I  and  IV  of  PLP  dependent  enzymes.  The  group  of 
aminotransferases is further divided into families and subgroups, based on evolutionary 
and structural relationships.[1-5] 
 
[1] Curr. Opin. Struct. Biol. 1998, 8, 759-769; [2] Eur. J. Biochem. 1993, 214, 549-561; [3] Chem. 
Rec. 2001, 1, 436-447; [4] Eur. J. Biochem. 1989, 186, 249-253; [5] J. Bacteriol. 1996, 178, 2161-
2171. 
 
 
PLP dependent enzymes 
-  Fold-type I 
-  Fold-type II 
-  Fold-type III 
-  Fold-type IV 
-  Fold-type V  -  Many superfamilies 
-  Aminotransferases 
 
-  Family I 
-  Family II 
-  Family III 
-  Family IV 
-  Subgroup I  
-  Subgroup I  
-  Subgroup I  
-  Subgroup I  
-  Subgroup I  
-  Subgroup I  
-  Subgroup I  Introduction: The kynurenine pathway 
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more divergent about the question whether KYNase is able to convert KYN to AA 
in the periphery and whether this is the preferred route of KYN metabolism in 
these  tissues.
7,  61-63  In  microbial  organisms,  two  distinct  enzymes  exist  for 
catabolism of KYN and 3-OH-KYN, respectively.
64 
 
The  mechanism  of  the  KYNase  catalytic  cycle  was  studied  in  detail  in 
Pseudomonas fluorescens. The initiating step is formation of an aldimine linkage 
between KYN and PLP. The key step is the formation of the gem-diolate in the 
presence of water and base. The release of AA shifts the equilibrium towards the 
product. Finally, pyruvate or alanine and the free co-enzyme are released. The 
reaction scheme
65-67 is shown in Figure 3. 
 
Figure 3 
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Catalytic mechanism of kynureninase
65-67 
 
The crystal structure of human KYNase reveals, that in addition to binding to 
PLP, the substrate interacts with a conserved arginine residue. This interaction Chapter 1 
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induces  a  conformational  change  of  the  enzyme  from  the  open  to  the  closed 
form of the binding pocket. In this closed state, the substrate is positioned in 
such a way, that the internal strain within the molecule facilitates formation of 
the  product.
58  Sigmoidal  velocity  plots  obtained  from  recombinant  human 
KYNase suggest, that the human enzyme has two binding sites: one catalytic 
site, and one regulatory non-catalytic site.
68 
 
KYNase inhibitors 
Published  KYNase  inhibitors  can  be  divided  into  different  classes.  The  classes 
and representative inhibitors are shown in Table 2. 
 
Table 2 Kynureninase inhibitors 
Compound  IC50/Ki  Species, method  Ref 
Transition state mimics 
 
dihydro-L-kynurenine 
4-S Ki = 0.3 µM 
4-R Ki = 1.4 µM 
Pseudomonas fluorescence 
69 
 
2-amino-4-[3'-hydroxyphenyl]-
4-hydroxybutanoic acid 
Rat Ki = 0.130 µM  
Human Ki = 0.100 µM  
Bacteria Ki = 10 µM 
Rat liver kynureninase, 
recombinant human 
kynureninase, bacterial 
kynureninase 
70 
  
R-2-amino-3-(hydroxy-phenyl-
phosphinoyl)-propionic acid 
Ki = 4280±100 µM  Pseudomonas fluorescence 
71 
  
R-2-amino-3-(methoxy-phenyl-
phosphinoyl)-propionic acid 
(±): Ki = 880±50 µM  Pseudomonas fluorescence 
71 
Ki = 0.07 µM  Pseudomonas fluorescence 
72 
 
S-(2-aminophenyl)-L-cysteine 
S,S-dioxide 
IC50 = 36 µM  Rat liver kynureninase 
73 
 
S-(2-amino-5-methylphenyl)-L-
cysteine S,S-dioxide 
IC50 = 11 µM  Rat liver kynureninase 
73 
 
 Introduction: The kynurenine pathway 
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Table 2 (continued) 
Substrate analogs 
 
3-methoxybenzoylalanine 
(mMBA) 
Bacteria Ki = 10 µM 
Rat Ki = 175 µM  
Human Ki = 15 µM 
Partly purified enzymes 
68 
IC50 = 4.65 µM  Rat brain homogenate 
47 
 
2-methoxybenzoylalanine 
(oMBA) 
IC50 = 3±0.8 µM  Rat liver homogenate 
46 
 
naphthylbenzoylalanine 
Bacteria Ki = 5 µM  
Human Ki = 22 µM 
Pseudomonas fluorescens, 
recombinant human 
74 
Mechanism based inhibitors 
 
S-(o-nitrophenyl)-L-cysteine 
Ki = 100 µM  Pseudomonas marginalis 
75 
 
 -Cl-L-alanine 
Ki = 8000 µM  Pseudomonas marginalis 
75 
other 
 
oestron sulphate 
Ki = 82±6 µM  Partially purified rat liver 
enzyme 
76 
 
An  important  class  of  KYNase  inhibitors  consists  of  transition  state  mimics. 
Compounds of this class have a tetrahedral moiety, which resembles the gem-
diolate intermediate (Figure 3). The most active of these series are the S-aryl-L-
cysteine S,S-dioxides.
72, 73 The second group of compounds consists of substrate 
analogs.  Among  those,  o-methoxybenzoylalanine  (oMBA)  is  the  most  studied 
compound. Similar to, but less pronounced than the KMO inhibitor mNBA, oMBA 
elevated  extracellular  KYNA  levels  in  rat  brain.  Sedative  and  anticonvulsive 
properties were seen.
46, 47 
Mechanism based inhibitors are designed to interfere with the catalytic cycle of 
the  enzyme.  A  group  of   -substituted  amino  acids  was  tested.  The  active Chapter 1 
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compounds  eliminate  their   -substituent,  releasing  aminoacrylate  compounds 
that most probably react with active site nucleophilic groups and thus inactivate 
the enzyme. These compounds are not KYNase selective.
75 
Oestron sulphate was found to inhibit KYNase competitively, causing abnormal 
tryptophan metabolism in women using this compound as oral contraceptive or 
menopausal hormone.
76 
1.1.5  Kynurenine aminotransferase  
Kynurenine aminotransferase (KAT, EC 2.6.1.7) is the enzyme that converts key 
intermediate kynurenine into kynurenic acid. KAT is a PLP-dependent enzyme. It 
belongs to subgroup 1 
57 or 1b
77 of the PLP-dependent aminotransferases. KAT 
is a functional homodimer, with two catalytic sites at the dimeric interface. The 
catalytic  cycle,  shown  in  Figure  4,  requires  the  co-enzyme  PLP,  the  substrate 
KYN and an  -ketoacid (co-substrate).  
 
Figure 4 
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KAT catalytic cycle 
 
Initially,  PLP  is  bound  to  a  conserved  lysine  residue  in  the  active  site  by  an 
aldimine linkage. When kynurenine binds to the binding site, the bond between 
the co-enzyme and the lysine residue is broken, and the co-enzyme binds to the 
 -amino group of the substrate. This  -amino group  is transferred to the co-
enzyme,  leaving  the   -keto  acid  analog  of  KYN  as  the  enzymatic  product. Introduction: The kynurenine pathway 
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Spontaneous ring closure of the keto acid affords kynurenic acid. The PLP form is 
regenerated  from  the  pyridoxamine  phosphate  (PMP)  form  by  transfer  of  the 
amino-group to the  -ketoacid.
78 Studies on crystal structures indicate, that the 
binding site can accommodate the substrate and a co-substrate of the size of 
pyruvate  simultaneously.  Whether  the  substrate  an  co-substrate  are  bound 
simultaneously or in turns during the catalytic cycle remains to be elucidated.
79 
 
Four KAT isoforms have been published (KAT I-IV). KAT I and KAT II are most 
studied. 
KAT  I  is  identical  to 
glutamine  trans-
aminase  K  (EC 
2.6.1.64) and cysteine 
S-conjugate   -lyase 
(EC  4.4.1.13).  Human 
KAT  I  has  422  amino 
acid  residues  per 
monomer.
80  The  rat 
enzyme  exists  as  a 
mitochondrial  and  a 
soluble, cytosolic form. 
The mitochondrial form 
appears  mostly  in 
brain,  the  cytosolic 
form  in  the  periphery. 
Differences  between 
the  mitochondrial  and 
cytosolic  forms 
originate  in  different 
splicing  of  the  same 
gene. This results in the presence of an additional peptide (32 amino acids) in 
the mitochondrial form, which leads the enzyme to the mitochondrial matrix. In 
humans, only the cytosolic form has been identified.
81-85 In the brain, KAT I is 
primarily located in glia, but is also found in neurons.
86, 87  
KAT  I  has  a  pH  optimum  at  pH  9.0-9.5.  However,  studies  in  human  KAT  I 
showed, that KAT I is active at a broader pH range, but is inhibited by Tris buffer 
at  physiological  pH  ranges.  KAT  I  prefers  pyruvate  as  the  co-substrate. 
Interestingly,  recombinant  human  KAT  I  prefers  several  other  2-oxoacids, 
Cell types in the CNS 
 
Two  major  cell  types  in  the  CNS  are  glial  cells  and 
neurons. Whereas neurons are responsible for signaling, 
glial cells have a more supportive function.  
 
Neurons  are  built  up  of  soma,  dendrites  and  axons. 
Afferent or sensor neurons transport information from the 
periphery into the brain. Efferent or motor neurons signal 
from  the  CNS  to  the  periphery,  where  they  regulate 
muscle  activity.  Interneurons  connect  neurons  within 
specific  regions  of  the  brain.  Neurons  can  be  inhibitory, 
excitatory  or  modulatory.  Inhibitory  neurons  usually  are 
GABAergic  neurons.  Excitatory  neurons  usually  use 
glutamate as neurotransmitter. Modulatory neurons have 
other  neurotransmitters,  like  dopamine,  serotonin, 
norepinephrine, acetylcholine etc.. 
 
Glia surround neurons. The two main types of glia in the 
CNS  are  microglia  and  macroglia.  Microglia  are 
macrophages,  which  are  capable  of  phagocytosis. 
Macroglia  have  diverse  functions.  The  most  important 
members  of  macroglia  are  astrocytes  or  astroglia. 
Astrocytes  are  star  shaped  cells.  They  supply  nutrients 
and  oxygen  and  are  responsible  for  removal  of 
neurotransmitters  from  synapses.  Astrocytes  can 
modulate  neurotransmission  by  release  of 
neuromodulatory agents amongst which glutamate. 
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especially   -ketobutyrate,  as  the  amino  group  acceptor  over  pyruvate.  KAT  I 
transaminates  most  naturally  occurring,  preferably  hydrophobic,  amino  acids, 
but is inhibited by Gln, Trp, Phe, and Cys.
88, 89  
The human KAT I enzyme shares 82% similarity with the rat enzyme.
89 Crystal 
structures of the human PLP-bound, the PMP bound and the PLP- and inhibitor-
bound  KAT  I  are  available.
79,  80  A  missense  mutation  in  KAT  I  was  found  in 
spontaneously hypertensive rats.
90 
 
KAT II is the second isoform and shows L-aminoadipate aminotransferase (EC 
2.6.1.39) activity.
91 The enzyme has 425 amino acid residues per monomer. The 
preferred  co-substrate  is  2-oxoglutarate,  and  enzymatic  activity  has  a  pH 
optimum at 7.0-7.5. KAT II is thought to be responsible for ca. 75% of KYNA 
production  in  mammalian  brain.
88  Rat  KAT  II  specific  antibodies  have  been 
developed.  These  antibodies  showed,  that  rat  KAT  II  is  primarily  localized  in 
astrocytes.
92  Having  broad  stubstrate  specificity,  KAT  II  catalyzes  the 
transamination of KYN, 3-OH-KYN, Trp, Phe, Asn, Asp and various other amino 
acids.  As  co-susbtrates,  a  variety  of   -ketoacids  can  be  accommodated.
88,  93 
Catalytic  efficiency  of  human  KAT  II  is  highest  for  aminoadipate  and  KYN. 
Although  the  Km  for  KYN  is  rather  high,  the  very  high  turnover  rate  (kcat) 
indicates  that  conversion  of  KYN  to  KYNA  is  one  of  the  major  physiological 
functions  of  the  enzyme.
93  Recently,  crystal  structures  of  human  KAT  II  in 
complex with PLP with and without KYN and with  -ketoglutarate have become 
available.
93-95 To study the function of KAT II, knock out (kat-2
-/-) mice were 
generated. Interestingly, brain tissue KYNA levels were reduced only in the first 
postnatal  days  in  these  mice.  At  this  age,  mice  showed  neuronal  (enlarged 
dendritic spines, increased spine density) and behavioral (hyperactivity, motor 
coordination) abnormalities, and enhanced vulnerability to QUIN induced lesions. 
In adult animals, KYNA levels in brain tissue were normalized, probably due to 
compensation  by  other  KAT  isoforms.  In  liver  tissue,  KYNA  was  reduced  by 
>90% throughout the lifecycle, but caused no apparent abnormalities.
52, 96 
KAT III and KAT IV are less established isoforms of KAT. KAT III was identified 
from  human  and  mouse  cDNA  libraries.  It  is  expressed  most  abundantly  in 
peripheral  tissues.
97  Biochemical  characterization  and  crystal  structures  of 
mouse KAT III showed close resemblance to KAT I. As KAT I, mouse KAT III 
shows relatively broad substrate and co-substrate specificity. In contrast to KAT 
I however, mouse KAT III prefers hydrophilic amino acids. The enzyme has a 
pH-optimum at pH 9-10 and is most active at relatively high temperatures (50 – Introduction: The kynurenine pathway 
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60
oC). KAT I and III are thought to compensate for KAT II activity in kat-2
-/- 
mice.
98 
KAT  IV  is  identical  to 
mitochondrial  aspartate 
aminotransferase  (EC 
2.6.1.1).  The  enzyme 
has a pH optimum of 8. 
It  is  mostly  present  in 
neurons,  but  is  also 
found in astrocytes.
99  
 
The relative percentages 
of KAT I, KAT II and KAT 
IV  isoform  activities 
were  determined  in 
mouse,  rat,  and  human 
brain. In mouse, KAT IV 
is  the  major  isoform 
(63.0%), whereas in rat 
and  human,  KAT  II  is 
most  abundant  (54.1% 
and  58.7%, 
respectively). 
Mitochondrial localization 
of  KAT  I,  KAT  IV  and 
also  of  KMO  might  be 
linked to major impact of 
mitochondrial  electron 
transfer  chain  inhibitors 
on  the  kynurenine 
pathway.
99  Further 
relevance  of  KAT  I,  III 
and  IV  under 
physiological  and 
pathological 
circumstances  remains 
to be elucidated.  
Glutamate receptors 
 
Glutamate  receptors  can  be  divided  into  metabotropic 
and  ionotropic  glutamate  receptors  (mGluRs  and 
iGluRs).  Metabotropic  glutamate  receptors  are  G-
protein  coupled  receptors  and  account  for  long-term 
effects  of  glutamatergic  neuromodulation.  Ionotropic 
glutamate receptors are ligand operated ion channels. 
iGluRs consist of heterogeneous subunits, determining 
activity and sensitivity of the channel.  
Three  types  of  iGluRs  are  known:  NMDA,  AMPA  and 
kainate  receptors.  NMDA  (N-methyl-D-aspartate, 
depicted)  receptors  are  assemblies  of  subunits  NR1, 
NR2 (NR2A-D) and NR3 (NR3A-B). Activity of the NMDA 
receptor is regulated at the agonist site and a variety of 
modulatory sites. The most important modulatory site 
is  the  allosteric  glycine  site.  This  site  is  important  in 
regulation of open-time and desensitization rate. Other 
sites  are  the  Zn
2+  site,  the  Mg
2+  site  and  the  PCP 
(phencyclidine) site. PCP, as well as ketamine and MK-
801  can  induce  symptoms  that  closely  resemble 
symptoms seen in schizophrenic patients.  
 
 
 http://www.uochb.cz/web/document/cms_library/212.jpg 
 
AMPA  ( -amino-3-hydroxy-5-methyl-4-isoxazole-pro-
pionic  acid)  receptors  are  assemblies  of  GluR1-4 
subunits.  AMPA  receptors  are  often  found  in  close 
vicinity  to  NMDA  receptors.  The  combination  of  these 
two  receptors  plays  an  important  role  in  synaptic 
plasticity.  
The kainate receptor consists of GluR5-7, KA1 and KA2 
subunits.  The  large  number  of  different  heteromers 
assembled  from  these  subunits  accounts  for  a  wide 
variety  of  physiological  functions  of  kainate  receptors. 
[1, 2] 
 
[1] J. Anat. 2007, 651-660; [2] Int. Rev. Neurobiol. 2007, 78, 
69-108 
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1.1.6  Kynurenic acid 
Kynurenic acid (KYNA) is the product of KYN transamination by KATs. KYNA has 
distinctive  physiological  functions.  It  is  an  antagonist  at  the  strychnine 
insensitive glycine coagonist site of NMDA receptors with an IC50 of 8-15 µM in 
the absence of glycine.
100-102 At  7* nicotinic acetylcholine receptors (nAChRs), 
KYNA  shows  non-competitive  antagonism  with  an  IC50  of  7  µM.
102  At  much 
higher, non-physiological millimolar concentrations, KYNA is an antagonist at all 
ionotropic glutamate receptors.
103 A biphasic effect of KYNA on AMPA receptors 
was  observed  in  hippocampal  cell  layers.  At  low  concentrations  (10  µM),  the 
effect  of  AMPA  is  potentiated.  At  higher  concentrations,  the  expected 
competitive  antagonism  is  observed.  Potentiation  is  thought  to  be  mediated 
through  positive  allosteric  modulation,  but  needs  to  be  further  established.
104 
Recently,  KYNA  was  found  to  activate  GPR35  orphan  receptors  at  micromolar 
concentrations (EC50 = 39.2 µM for human GPR35).
105  
KYNA is present in the brain and in peripheral tissues.
106, 107 In the brain, KYNA 
is  thought  to  have  important  physiological  functions.  As  will  be  discussed  in 
section 1.1.7, KYNA levels are highly regulated and levels vary over the specific 
brain regions. In rats, estimated levels of KYNA are 17 nM (with an expected 5-
10  fold  underestimation)  in  striatal  ECF  and  138  nM  in  plasma.
108  In  human 
cerebrospinal fluid, KYNA levels of 0.97 nM
3 and 1.06 nM
4 were reported. 
KYNA production in the periphery is less well investigated. Kidneys, liver, heart 
and vascular endothelium synthesize KYNA and KYNA is present in urine, serum, 
amniotic  fluid,  and  in  the  retina.
109,  110  In  the  gastrointestinal  tract,  KYNA 
concentrations can be up to micromolar concentrations (highest in distal ileum: 
16 µM). Preferential localization of GPR35 in the gastrointestinal tract suggests a 
physiological role of KYNA acting on these receptors in this area.
111 
1.1.7  Regulation of KYNA levels 
KYNA levels are regulated by an array of different mechanisms. Many of these 
mechanisms might function as targets for pharmacological manipulation of KYNA 
levels.  
1.1.7.1  Transporters 
KYNA  production  depends  on  the  availability  of  its  direct  precursor,  KYN.  The 
transport of KYN towards KAT enzymes within astrocytes depends on the sodium 
independent large neutral amino acid transporter.
112 Neuronal uptake occurs by 
a  sodium  dependent  mechanism,  which  is  less  efficient.
113  Transport Introduction: The kynurenine pathway 
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mechanisms  in  general  depend  on  ionic  environment  and  availability  of 
glucose.
114, 115  
Exogenous  and  endogenous  compounds  can  modify  the  transport  of  KYN. 
Homocysteine is transformed in vivo to S-adenosylhomocysteine in mammalian 
brain  and  aortic  rings
109,  116  or  cysteine  in  mosquito
117.  Both  metabolites  are 
suggested  endogenous  augmenters  of  KYN  transportation.  KYN  transportation 
and  KYNA  synthesis  are  dose-dependently  inhibited  by  L-leucine  and  L-
phenylalanine in human cultured astrocytes by competition of the amino acids at 
the KYN transporter site.
118 Similarly, the observed reduction of KYNA synthesis 
by  L- -aminoadipic  acid  can  be  explained  by  impaired  mitochondrial  KYN 
uptake.
119 
 
Transport  of  compounds  that  influence  KYNA  synthesis  on  other  than  KYN 
transport levels are of importance in at least some cases. The mGluR agonists 
quisqualate,  L-(+)-2-amino-4-phosphonobutyric  acid  (L-AP4), 4 -carboxy-3-
hydroxyphenylglycine  (4C3HPG)  and  L-serine-O-phosphate  (L-SOP)  are 
relatively  weak  KAT  II  inhibitors.  Interestingly,  the  compounds  were  found  to 
have much lower apparent IC50 values in tissue slices than for isolated KAT II 
enzymes.  The  compounds  are  actively  transported  into  cells  over  a  Na
+-
dependent transporter. Therefore, although the real IC50 values are rather high, 
concentrations high enough to effectively inhibit KAT II activity might be reached 
within these cells by this active transport.
114,  120,  121 The same holds for L-  -
aminoadipic  acid,  which  is  transported  into  astrocytes  by  high  affinity  Na
+ 
independent uptake mechanisms.
114 Accordingly, the action of quisqualate and 
L- -aminoadipic acid was shown to be dependent on the developmental status of 
the transporters involved.
114 
1.1.7.2  Ionic concentrations, cell energy status 
KYNA  synthesis  depends  on  ionic  concentrations  in  the  KAT  surrounding 
environment.  Na
+  dependent  transport  mechanisms  are  of  direct  influence  on 
KYN  availability  within  cells.  Depolarizing  conditions  (veratridine,  high  K
+) 
decrease extracellular KYNA concentrations.
114  
Impaired  energy  metabolism  influences  KYNA  synthesis.  Glucose  deprivation, 
impaired glucose uptake, and inhibition of glycolysis attenuate KYNA synthesis. 
This  is  at  least  partly  caused  by  impaired  cellular  KYN  uptake,  and  can  be 
reversed by glycolytic or tricarboxylic acid cycle intermediates.
120, 122 
In terms of energy status, mitochondrial complex inhibitors have been studied. 
Mitochondrial complex inhibitors MPP
+ (complex I)
123,  124, 3-nitropropionic acid Chapter 1 
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(complex II)
123, 125 and sodium azide (complex IV)
125 decrease KYNA availability. 
The  main  mechanism  behind  this  observation  seems  to  be  KAT  depletion  in 
affected  cells.
124,  125  Finally,  ammonium  acetate  was  shown  to  inhibit  KYNA 
synthesis in vitro and in vivo in rats by suggested metabolic dearrangements in 
astrocytes.
126 
1.1.7.3  KAT activity – pH, co-enzyme, co-substrates 
The  activity  of  KAT  enzymes  is  pH  dependent.  Therefore,  the  pH  in  the 
surrounding environment is of importance for the rate of KYNA synthesis.
88,  89 
KAT  activity  depends  on  availability  of  the  co-enzyme  pyridoxal  5’-phosphate 
(PLP).  The  anti-tuberculosis  drug  isonicotinic  acid  hydrazide  was  shown  to 
significantly  decrease  liver  KAT  activity  in  rats.  This  resulted  in  decreased 
urinary  excretion  of  KYNA.  A  suggested  explanation  is  reaction  of  isonicotinic 
acid hydrazide with the co-enzyme, resulting in reduced availability of the co-
enzyme. The precise nature of the reaction was not specified.
127  
The effect of availability of  -ketoacids, which function as co-substrates, on KAT 
activity is more complex. In general, broad co-substrate specificity is observed 
for KATs.
89, 115, 117 Good availability of  -ketoacids enhances KAT activity in rat 
brain,  but  to  varying  extents.  This  results  in  directly  enhanced  brain  KYNA 
concentrations. Recombinant mosquito KAT enzymes were found to be inhibited 
dose-dependently by most studied  -ketoacids at higher concentrations.
117 No 
such effect was seen in rat tissue.
115, 117  
Apart  from  its  direct  involvement  in  KAT  activity  as  a  co-substrate,  the   -
ketoacid pyruvate can influence metabolic activities within cells. It is the end-
product of glycolysis and a direct substrate of the tricarboxylic acid cycle. In this 
way, it can restore cell metabolism in energy deprived circumstances.
115, 122  
1.1.7.4  Competing reactions 
The balance between KYN metabolism into 3-OH-KYN, AA and KYNA is tightly 
regulated. Inhibition of one or more of the KYN metabolizing enzymes results in 
a shift in this balance. In particular, inhibitors of KMO and KYNase are commonly 
known tools to pharmacologically elevate KYNA levels (see sections 1.1.3 and 
1.1.4).  
1.1.7.5  Direct KAT inhibition 
Although the list of compounds that have been found to inhibit KAT is relatively 
extensive, until recently, no KAT inhibitor was known that was able to decrease Introduction: The kynurenine pathway 
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brain KYNA levels in vivo per se. This results mainly from a lack of selectivity 
and specificity.  
As for KMO and KYNase inhibitors, KAT substrate KYN was used as the template 
for the design of potential KAT inhibitors. Examples of KYN analogs that were 
studied for KAT inhibitory activity are shown in Table 3.  
 
Table 3 KAT inhibitors: Kynurenine analogs 
Compound  IC50 or % KYNA 
production from 
control 
Species/method  Mechanism  Ref  
micromolar  in vitro  selective KAT 
II over KAT I 
50 
 
D,L-5-bromokynurenine  
48% @ 100 µM  rat brain slices  KAT inhibition 
128 
39 % @100 µM  rat brain homogenate  KAT inhibition 
128 
 
L-5-chlorokynurenine 
14 µM  rat brain homogenate  KAT inhibition 
129 
71 µM  rat liver homogenate  KAT II 
inhibition 
129 
6.1 µM  partially purified KAT II 
(rat liver) 
KAT II 
inhibition 
129 
 
S-4-(ethylsulfonyl)-
benzoylalanine  
(S-ESBA) 
36% @ 1 mM  recombinant human 
KAT II 
KAT II 
inhibition 
130 
 
A close analog of KYN, 5-chlorokynurenine (5-Cl-KYN) was published as a potent 
inhibitor  of  KAT  enzymes.  However,  due  to  a  lack  of  KAT  selectivity,  this 
compound is not able to lower KYNA levels in vivo [personal communication]. 
Interestingly, a structural analog of 5-Cl-KYN, 4-chlorokynurenine, is a prodrug 
of 7-chlorokynurenic acid (7-Cl-KYNA). 7-Cl-KYNA is a prototypical antagonist of 
the  glycine  coagonist  site  at  NMDA  receptors.
131,  132  S-4-(Ethylsulfonyl)-
benzoylalanine (S-ESBA) is the only known KYN analog that selectively inhibits 
KAT II. In a microdialysis study in rats, local infusion of S-ESBA (5 mM, 2 hours) 
was  able  to  decrease  KYNA  levels i n  hippocampus.
129  Unexpectedly,  the 
inhibitory potency of S-ESBA was 10-20 fold less for human KAT II.
129, 130  
A  second  group  compounds  tested  for  their  KAT  inhibitory  activity  comprises 
naturally occurring amino acids and their derivatives (Table 4). Along with the 
third  group,  the  cysteine  analogs  (Table  5),  this  group  of  compounds  is  of 
particular  interest  regarding  their  roles  in  physiological  and  pathological 
circumstances. Finally, some (semi)-synthetic compounds are listed in Table 6.  
 Chapter 1 
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Table 4 KAT inhibitors: Naturally occurring amino acids and derivatives 
Compound 
 
IC50 or % KYNA 
production from 
control 
Species/method  Mechanism  Ref 
300/720/73 µM  rat: cortical slices/KAT I in 
brain homogenate/KAT II 
in brain homogenate 
KAT inhibition 
133 
 
L-aspartate 
58.9% @ 0.1 mM  bovine aortic endothelial 
cells 
KAT inhibition 
110 
790/1300/790 µM  rat: cortical slices/KAT I in 
brain homogenate/KAT II 
in brain homogenate 
KAT inhibition 
133 
 
L-glutamate  72.0% @ 0.1 mM  bovine aortic endothelial 
cells 
KAT inhibition 
110 
 
L-glutamine 
2 mM: 
pH 7.0: 78% 
pH 8.0: 43% 
pH 9.5: 3% 
brain homogenate  KAT I inhibition 
88 
1930 µM /397 µM/ 
no inhib 
rat: cortical slices/KAT I in 
cortical homogenate/ KAT 
II in cortical homogenate 
KAT I inhibition 
116 
 
L-methionine 
68.4% @ 500 µM  rat aortic rings  KAT inhibition 
117 
 
N( )-Nitro-L-arginine 
341 µM  KAT I in rat brain 
homogenate 
KAT I inhibition 
134 
 
N( )-nitro-L-arginine 
methyl ester 
421 µM  KAT I in rat brain 
homogenate 
KAT I inhibition 
134 
 
Table 5 KAT inhibitors: Cysteine analogs 
Compound  IC50 or % KYNA 
production from 
control 
Species/method  Mechanism  Ref 
1400 µM/no 
inhib/3390 µM 
rat cortical slices/KAT I in 
rat cortical 
homogenate/KAT II in rat 
cortical homogenate 
KAT II 
inhibition 
116 
70.6 µM  rat aortic rings  KAT inhibition 
109 
 
L-cysteine 
enhancement @ 
0.31-2.5 mM, inhib 
@ 5-40 mM 
recombinant AeKAT 
(mosquito) 
inhibition: 
competitive / 
covalent KAT 
inhibition 
117 
 
L-cysteine sulphinate 
80 µM/no inhib/2 
µM 
rat cortical slices/KAT I in 
rat brain homogenate/KAT 
II in rat brain homogenate 
KAT inhibition 
133 
 
L-cysteate 
1770/5380/1550 µM  rat cortical slices/KAT I in 
rat brain homogenate/KAT 
II in rat brain homogenate 
KAT inhibition 
133 
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Table 5 (continued) 
 
L-homocysteine 
sulphinate 
2900 µM/no inhib/ 
1590 µM 
rat cortical slices/KAT I in 
rat brain homogenate/KAT 
II in rat brain homogenate 
KAT inhibition 
133 
 
L-homocysteate 
3930/5000/2100 µM  rat cortical slices/KAT I in 
rat brain homogenate/KAT 
II in rat brain homogenate 
KAT inhibition 
133 
enhancement @ 
100-500 µM/IC50 
6400 µM 
rat cortical slices  KAT inhibition 
116 
566 µM/8046 µM  KAT I/KAT II in rat cortical 
homogenate 
KAT inhibition 
116 
 @<100 µM: 
increase KYNA, 
@500uM: 61.1% 
KYNA prod 
rat aortic rings  KAT inhibition, 
conversion to 
adenosyl-
homocysteine 
109 
 
D,L-homocysteine 
54 µM  bovine aortic endothelial 
cells 
KAT inhibition 
110 
enhancement @ 30-
80 µM/63.4% @ 
1000 µM 
rat cortical slices  KAT II 
inhibition 
116 
no inhib/260 µM  KAT I/KAT II in rat cortical 
homogenate 
KAT inhibition 
116 
 
S-adenosylhomo-
cysteine 
 @<80 µM 
enhanced to 124%, 
@500 µM: 
decreased to 62%  
rat aortic rings  KAT inhibition 
109 
 
dichlorovinyl-
cysteine 
48.6% @ 50 µM  rat cortical tissue slices  non-specific 
KAT inhibitor 
115 
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Table 6 KAT inhibitors: Other compounds  
Compound  IC50 or % KYNA 
production from 
control 
Species/method  Mechanism  Ref 
75 and 53% @ 500 
µM KYN, 300 and 
500 µM 
aminoadipate 
rat microdialysis  allosteric inhibition 
119 
micromolar  in vitro  selective KAT II 
over KAT I 
inhibition 
50 
 
L- -aminoadipate 
10-30 µM  rat cortical slices  KAT II inhibition 
114 
micromolar  in vitro  selective KAT II 
over KAT I 
inhibition 
50 
520 µM  partially purified  
KAT II 
KAT II inhibition 
88 
1-100 µM / 
10-1000 µM 
rat cortical tissue 
slices/rat brain 
homogenate 
KAT II inhibition, 
active transport 
120   
quisqualate 
15.9 µM  rat cortical slices  KAT II inhibition 
114 
 
4-carboxy-3-
hydroxy-
phenylglycine 
(4C3HPG) 
10-10000 µM / 
65%act @ 200 µM 
rat cortical tissue 
slices/rat brain 
homogenate 
KAT II inhibition, 
active transport 
120 
 
L-2-amino-4-
phosphono-butyric 
acid (L-AP4) 
10-10000 µM / 
100-10000 µM 
rat cortical tissue 
slices/rat brain 
homogenate 
KAT II inhibition, 
active transport 
120 
 
L-serine-O-
phosphate  
(L-SOP) 
100-10000 µM /  
10000-100000 µM 
rat cortical tissue 
slices/rat brain 
homogenate 
KAT II inhibition, 
active transport 
120 
0.1-1 µmol  in vivo, rat striatum  non-specific 
transaminase 
inhibitor 
135 
25 µM    non-specific 
transaminase 
inhibitor 
136 
3.20 µM  bovine aortic 
endothelial cells 
KAT inhibition 
110 
 
 
aminooxyacetic acid 
35.5% @ 50 µM  rat cortical tissue 
slices 
non-specific KAT 
inhibitor 
115 
 
 -acetylenic GABA 
43 µM /750 µM  rat hippocampal 
homogenate/slices 
non-specific KAT 
inhibitor 
137 Introduction: The kynurenine pathway 
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Table 6 (continued) 
 
trans-pyrrolidine-
2,4-dicarboxylate 
(trans-PDC) 
80% @ 1 mM  rat brain 
homogenate 
KAT II inhibition 
120 
 
 
veratridine 
3-5 µM  rat cortical slices  disturbance of 
energy 
114 
7% @ 1 mM 
10% @ 100 µM 
30% @ 10 µM 
rat brain 
homogenate 
KAT II inhibition 
53 
 
BFF 122 
0% @ 1 mM 
0% @ 100 µM 
0% @ 10 µM 
57% @ 1 µM 
partially purified  
KAT II 
KAT II inhibition 
53 
 
The compounds in Table 6 are occasionally used as research tools. Recently, BFF 
122 was published as a KAT II selective inhibitor. The compound was used as a 
research  tool  to  investigate  kynurenine  metabolism  in  brain  by  local 
application.
53  The  compound  is  not  able  to  cross  the  blood  brain  barrier 
[personal communication]. 
1.1.7.6  Mechanism based inhibitor: Vinylglycine 
Pyridoxal  5’-phosphate  dependent  enzymes  can  be  inhibited  by  mechanism 
based  inhibitors.  These  compounds  initially  bind  with  relatively  low  affinity. 
Catalytic  processing  by  the  enzyme  results  in  a  reactive  intermediate,  which 
binds covalently to an amino acid side chain in the active site of the enzyme. 
The covalently bound compound irreversibly inhibits the enzyme. For KATs, this 
was shown with vinylglycine. Apart from being converted into  -ketobutyrate, 
this  compound  showed  irreversible  inhibition  of  yeast  KAT  by  a   -addition 
reaction.
138 
1.1.7.7  Influx and efflux of KYNA 
KYNA  cannot  cross  the  blood  brain  barrier  by  passive  means.
33  A  probenecid 
sensitive  carrier  can  transport  KYNA  from  the  brain  into  the  periphery. 
Administration of probenecid increases KYNA levels in brain by competing with 
the efflux carrier. Probenecid in combination with systemic KYN administration 
increases levels of KYNA in brain.
139 Chapter 1 
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Systemic KYNA administration does not raise KYNA levels in brain. In rats that 
were  treated  with  glucosamine-KYNA  in  combination  with  probenecid  in  the 
periphery,  a  KYNA-related  reduction  of  population  spike  amplitudes  in  the 
hippocampus was observed already at low doses of the drug. Administration of 
KYNA had no electrophysiological effect. Presumably, glucosamine-KYNA is more 
easily transported into the brain and is hydrolyzed locally to KYNA.
140 
One  of  the  explanations  of  the  decrease  of  KYNA  concentrations  following   -
aminoadipic acid administration is interference with efflux of the compound from 
astrocytes. Although this has not been proven, interference of some compounds 
with transport mechanisms at the cellular level might be considerable.
119 
There  are  no  KYNA  metabolizing  enzymes  known.  The  only  way  of  systemic 
KYNA elimination is by renal excretion.
106 
1.1.7.8  Neurotransmitters 
D-amphetamine
141, selective D1 and D2 agonists
142 and L-DOPA
143 cause brain 
specific decreases in KYNA levels, as determined in whole brain tissue and by 
microdialysis.  The  mechanisms  of  KYNA  reduction  induced  by  dopaminergic 
signaling  are  not  completely  clear,  but  most  probably  involve  direct 
dopaminergic signaling of D1 and D2 receptors on astrocytes. Decreases in KYNA 
were especially pronounced in young rats and could be antagonized by D1- and 
D2-  selective  antagonists.  Interestingly,  whereas  aselective  or  D2-selective 
antagonists  alone  did  not  change  KYNA  levels  in  these  experiments,  a  D1-
selective antagonist increased KYNA levels. These effects of dopamine agonists 
on  KYNA  directly  enhance  neuronal  vulnerability,  which  could  be  reverted  by 
administration of KMO inhibitor Ro 61-8084.
141-144 
Nicotine  has  a  biphasic  effect  on  KYNA  brain  tissue  levels  in  hippocampus, 
striatum and cortex and extracellular levels in hippocampus, as determined in 
rats.
145 After 4-6 days of nicotine administration, decreased KYNA levels were 
seen. After 10-15 days, KYNA levels were increased. Mechanisms could involve 
desensitization  and  subsequent  supersensitization  of  nAChRs.  These  nAChRs 
regulate extracellular levels dopamine, which in turn regulate KYNA availability. 
An additional possibility involves altered Glu transmission. Presynaptic nAChRs 
on glutamate terminals regulate extracellular glutamate levels. Glutamate was 
shown to decrease extracellular KYNA levels, probably through direct effects on 
glial cells.
146 Therefore, nicotine, acting on the presynaptic nAChRs, might alter 
Glu transmission towards glia by causing desensitization and supersensitization 
of these nAChRs.
102, 145 Introduction: The kynurenine pathway 
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1.1.7.9  Pharmacological compounds that influence KYNA levels 
Some  compounds  used  in  research  or  clinic  have  pronounced  effects  on  the 
kyurenine pathway and KYNA levels in vitro or in vivo. NO-donors S-nitroso-N-
acetylpenicillamine  (SNAP)  and  3-morpholinosydnonimine  (SIN-1)  were  shown 
to increase KYNA production in rat cortical slices. The compounds had no effect 
on  KAT  activity.  Attenuation  of  the  effects  by  the  antioxidant  L-ascorbate 
suggests that the effect is mediated through reactive oxygen species.
147 
FK506, a modulator of intracellular Ca
2+ levels, increases KYNA production in rat 
cortical  slices.  The  mechanism  is  unknown,  but  KAT  independent.
148  The 
anticonvulsant  carbamazepine  activates  KAT  I,  but  not  KAT  II,  resulting  in 
increased KYNA production in rat cortical slices.
149  
NSAIDs  have  effects  on  KYNA  concentrations  in  vivo.  Aselective  and  COX-1 
selective  inhibitors  elevate  rat  KYNA  levels  in  brain  tissue.  COX-2  selective 
inhibitors decrease KYNA levels in brain tissue. Both effects seem to be mediated 
through prostaglandins E1/E2.
150, 151 After chronic (1 month – 1 year) treatment 
of rats with aselective dopamine antagonist haloperidol, D2 antagonist raclopride 
or  atypical  antipsychotic  clozapine,  decreased  brain  tissue  and  extracellular 
KYNA  levels  were  seen.  These  effects  were  not  observed  after  acute  or 
subchronic  (1  week)  treatment.  Therefore,  most  probably,  other  mechanisms 
than  direct  action  on  dopamine  receptors  are  involved.  Since  KYNA  synthesis 
was decreased selectively, the proposed mechanism behind this observation is 
that KAT activity is changed by altered cell energy metabolism.
152 
1.1.8  KYNA physiology 
Physiological implications of the presence of KYNA are being studied extensively. 
Different  levels  of  regulation  through  KYNA  can  be  distinguished.  The  role  of 
KYNA is concentration and brain region specific. At the neuronal level, the exact 
locations of receptors on neurons, as well as the nature of the affected neurons 
are  of  importance.  Most  research  of  the  effects  of  KYNA  on  specific 
neurotransmitter  systems  focuses  on  cholinergic,  glutamatergic  and 
dopaminergic systems. Some examples will be given of the results of research 
focusing on the effects of KYNA on physiological functioning. 
1.1.8.1  Regulation at the neuronal level: KYNA effects on neuronal activity 
A set of electrophysiological studies proved the physiological effects of KYNA via 
 7* nAChRs. First, it was demonstrated that KYNA decreases current amplitudes 
in hippocampal neurons that are activated by  7* nAChRs. Subsequently, the Chapter 1 
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effect of KYNA via interneurons was investigated. Activation of  7* nAChRs on 
GABAergic hippocampal interneurons induces a current in postsynaptic neurons. 
The amplitude of this postsynaptic current, again, can be reduced by KYNA.
102 
Currents  in  hippocampal  interneurons  are  mainly  caused  by  glutamatergic 
transmission. Blockade of this transmission results in a residual current, caused 
by cholinergic synaptic transmission. This is the residual current that is blocked 
by KYNA acting on  7* nAChRs.
153  
A decrease of amplitudes is seen only at higher KYNA concentrations. A recent 
report shows, that at nanomolar concentrations, a slight increase in amplitudes 
is seen.
154 These examples emphasize, that KYNA might be involved in different 
levels of regulation of neuronal activity in the brain.  
1.1.8.2  Region specific KYNA effects: KYNA regulated acetylcholine release 
Cortical  cholinergic  systems  are  innervated  by  GABAergic  neurons  from  the 
nucleus accumbens. Local infusion of high concentrations of KYNA in the nucleus 
accumbens  induced  ACh  efflux  in  the  cortex,  as  determined  by  microdialysis. 
These  effects  could  be  reproduced  by  AMPA/kainate  and  NMDA  antagonists, 
suggesting  that  effects  were  mediated  by  aspecific  inhibition  of  ionotropic 
glutamate receptors.
155 
In rat cortex, extracellular KYNA levels were decreased by local infusion of KAT 
II  inhibitor  S-ESBA.  This  resulted  in  an  elevation  of  cortical  ACh  levels.  The 
effect  of  S-ESBA  could  be  blocked  by  co-infusion  of  KYNA.  Accordingly, 
systemically  administered  D-amphetamine  results  in  enhanced  ACh  release  in 
the cortex, which could be attenuated by cortical KYNA infusion or systemic KYN 
administration. The mechanisms of local regulation of Ach release are thought to 
be mediated by aspecific iGlu inhibition or indirectly via glutamate and dopamine 
mediated cascades.
156, 157 
These opposite effects of KYNA in the nucleus accumbens and cortex on cortical 
ACh release exemplify the region specific effects of KYNA on neuronal systems. 
1.1.8.3  KYNA effects on glutamate, norepinephrine and dopamine 
As  discussed  previously,  KYNA  concentrations  are  influenced  by  dopaminergic 
and glutamatergic systems. Inversely, KYNA has effect on release of glutamate, 
norepinephrine and dopamine in the brain. 
The  effect  of  KYNA  on  glutamate  release  was  studied  in  more  detail  in 
synaptosomes.  In  synaptosomes,  release  of  Glu  or  Asp  can  be  invoked  by 
nicotine or 5-hydroxyindole, a positive modulator of  7* nAChRs. KYNA was able Introduction: The kynurenine pathway 
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to block these effects.
158 Depolarization induced release of glutamate or [
3H]-D-
Asp  from  synaptosomes  was  also  inhibited  by  KYNA.  The  blockade  was  not 
mediated through selective antagonism of  7* nAChRs. Involvement of NMDA 
receptors was also ruled out.
159   
In  microdialysis  studies,  KMO  inhibitors  were  able  to  increase  KYNA 
concentrations  in  cortex,  caudate  and  hippocampus.  Surprisingly,  Glu 
concentrations were decreased in the caudate region only, and were unaltered in 
hippocampus and cortex. Decrease of Glu concentrations in the caudate could be 
reproduced  by  a  selective   7*  nAChR  antagonist.  This  suggests,  that  KYNA 
mediated Glu regulation is brain region specific and is mediated, at least partly, 
through  7* nAChRs.
56, 159  
The activity of the noradrenergic locus coeruleus is regulated by excitatory and 
inhibitory neurotransmitters. Electrophysiology studies showed, that nicotine has 
a stimulatory effect on the locus coeruleus, which can be divided into an initial 
short-lasting phase and a subsequent, more moderate, long-lasting phase. The 
short-lasting  phase  is  thought  to  be  mediated  by  peripheral  modulation  of 
glutatmate  release  in  the  locus  coeruleus,  the  long-lasting  phase  by  central 
modulation.  KYNA  and  KMO  inhibitor  PNU  156561A  antagonized  the  nicotine 
induced NE neuron stimulation. 
This  extends  the 
neuromodulatory  role  of  KYNA 
via  the  glutamatergic  to  the 
norepinephrinic system.
160 
Effects  of  KYNA  on 
dopaminergic  activity  were 
studied  with 
electrophysiological  methods. 
Elevation  of  KYNA  levels 
results in an increase in firing 
rate and bursting activity of DA 
neurons in both the substantia 
nigra  (SN)
161  and  the  ventral 
tegmental  area  (VTA)
162.  The 
partial  glycine  site  NMDA 
agonist D-cycloserine was able 
to  reverse  the  effects  of 
elevated  KYNA  levels.  NMDA 
Dopaminergic neurotransmission 
 
 
 
Activity  of  dopaminergic  neurons  localized 
in the midbrain is proposed to be regulated 
by an “accelerator/brake” mechanism. 
The  accelerator  works  by  straightforward 
glutamatergic  excitation  of  dopamine 
neurons.  The  brake  is  mediated  through 
GABA-ergic  interneurons.  After  glutamate 
activation in the cortex, GABA interneurons 
are  activated.  These  interneurons  inhibit 
DA activity. [1-3] 
 
[1] Annu. Rev. Pharmacol. Toxicol. 2001, 41, 237-260; 
[2]  Curr.  Med.  Chem.  2004,  11,  267-277;  [3]  Dial. 
Clin. Neurosci. 2006, 8, 137-142. 
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receptor antagonist MK 801 mimicked KYNA effects. These data suggest, that 
the DA stimulatory effects of KYNA are mediated by acting on NMDA receptors 
localized on GABA interneurons (‘brake mechanism’).
161, 162 A subchronic study 
confirmed  the  results,  and  showed  that  no  adaptive  mechanisms  seem  to 
exist.
163   
KYNA  is  also  able  to  act  in  the  accelerating  part  of  DA  regulation.  Glutamate 
mediated  increased  nigral  DA  activity  was  effectively  inhibited  by  KYNA.  The 
inhibition  was  again  mimicked  by  MK  801,  suggesting  involvement  of  NMDA 
receptors.
164  
The delicate balance between inhibition and excitation of DA neurons was shown 
in a study of the effects of nicotine on DA neurons. Administration of nicotine 
showed an initial short lasting (<120 seconds) decrease in DA firing rate and a 
subsequent increase of burst firing. The decrease could be blocked by a GABAB 
antagonist. This suggests, that the initial decrease in DA firing rate is regulated 
by the brake mechanism. KYNA could effectively block the subsequent nicotine 
mediated increase in DA activity and even reversed it into a decreased activity. 
The  suggested  mechanism  behind  this  observation  is  blockade  of 
somatodendritic  NMDA  receptors  on  VTA  DA  neurons  (‘accelerator 
mechanism’).
165  
Above studies suggest a preferential action of KYNA on DA activity mediated by 
NMDA receptors. Involvement of  7* nAChRs has also been proven. In a set of 
microdialysis studies, elevated KYNA levels could reversibly reduce extracellular 
striatal DA concentrations. Effects were mimicked by methyllycaconitine (MLA), 
a selective  7* nAChR antagonist and reversed by  7* nAChR agonists choline 
and galantamine. NMDA receptor agonist D-serine could not reverse the effects 
of KYNA. The KYNA induced decrease of DA levels was therefore attributed to 
action  through   7*  nAChRs  on  corticostriatal  glutamate  neurons 
(‘accelerator’).
166,  167  In  a  follow-up  on  these  studies,  striatal  KYNA 
concentrations  were  decreased  by  KAT  II  inhibitor  S-ESBA.  This  resulted  in 
increased  dopamine  levels.  Increases  could  be  attenuated  by  local 
administration of KYNA, proving the direct role of KYNA in these effects.
168 
1.1.9  Xanthurenic acid 
Xanthurenic acid (XA) is the second kynurenine metabolite that is biosynthesized 
by kynurenine aminotransferase. The compound is synthesized from 3-OH-KYN, 
preferably by KAT II.
88 The importance of XA in mammalian species is not fully 
understood.  A  recent  study  in  rats  showed,  that  XA  crosses  the  blood  brain 
barrier. It can be taken up by synaptic vesicles and neurons and the release is Introduction: The kynurenine pathway 
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depolarization  dependent,  suggesting  a  neuroregulatory  role.
169  XA  was 
previously  seen  as  a  detoxicant  by  metabolizing  3-OH-KYN,  thus  preventing 
generation of reactive oxygen species (ROS). However, XA also has Fe-chelating 
properties, resulting in production of ROS.
170  
XA is able to complex with several substances and locally or systemically alters 
physiological environments. If XA levels are elevated, the compound complexes 
with insulin. This leads to insulin tolerance and altered glucose metabolism.
171 In 
the kidney, XA-8-O-beta-D-glucoside and XA-8-O-sulfate function as natriuretic 
hormones by inhibition of sodium resorption.
172 In the human lens, KAT activity 
and formation of XA increase with age. Oxidation of XA and binding to crystallins 
in the lens causes cataract.
173 XA causes apoptosis by various mechanisms.
174 
KYN metabolism can directly be influenced by XA. At a concentration of 10
-4M, 
the compound reduced NADPH oxidation by rat KMO to 39%.
175 
No  studies  of  selective  inhibition  of  XA  formation  are  known.  Presumably, 
inhibition of KMO, KYNase and KAT should have effects on XA availability.  
 
In  insects,  no  kynureninase  exists.  In  these  species,  conversion  of  3-OH-KYN 
into XA is the major route of 3-OH-KYN clearance. The transamination occurs by 
an  enzyme  that  shows  only  minor  resemblance  to  KAT.  The  enzyme  was 
identified as being an alanine glyoxalate aminotransferase. In insects, XA plays a 
role  in  eye  pigmentation  and  sexual  determination.  The  latter  makes  it  a 
potential new target of malaria treatment.
176 
1.1.10   3-Hydroxyanthranilic acid and quinolinic acid 
Kynurenine metabolism by KMO and KYNase yields 3-hydroxyanthranilic acid (3-
OH-AA).  Like  3-OH-KYN,  3-OH-AA  is  able  to  reduce  Cu(II)  and  Fe(III), 
generating superoxide and hydrogen peroxide. Copper dependent generation of 
ROS is involved in age related cataractogenesis.
177 3-OH-AA inhibits induction 
and activity of NOS II and activation of NF- B, which is needed for NOSII gene 
activation.
178  
3-OH-AA is the substrate for 3-hydroxyanthranilic acid oxygenase (3-HAO). 3-
HAO occurs both in the periphery and in the brain. It is a monomeric cytosolic 
Fe
2+-dependent enzyme and localized in glial cells mainly.
103 The enzyme can be 
inhibited effectively by 4-halo-3-hydroxyanthranilic acids.
179 
The product of 3-HAO is the unstable intermediate amino- -carboxymuconic acid 
 -semialdehyde.  Quinolinic  acid  (QUIN)  is  subsequently  formed  from  the 
intermediate by spontaneous ring closure (Figure 5). Chapter 1 
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Figure 5  
 
QUIN biosynthesis and metabolism 
 
QUIN is an NMDA receptor agonist. It induces excitation of cortical neurons. The 
excitatory effects of QUIN can result in neurotoxicity, at least partly mediated by 
liberation of free radicals. Neuronal cell loss caused by excessive QUIN seems to 
be caused by damage on dendrites, rather than axons.
180-182 Immune-responses 
can upregulate QUIN formation in microglia.
183 
QUIN  is  metabolized  by  quinolinic  acid  phosphoribosyl  transferase  (QRPT). 
Condensation  with  phosphoribosyl  phosphate  and  decarboxylation  affords 
nicotinic acid mononucleotide, finally yielding nicotinamide adenine dinucleotide 
(NAD,  Figure  5).  In  the  brain,  like  3-HAO,  QRPT  is  localized  primarily  in  glial 
cells, but in distinct regions. QRPT is inhibited by various QUIN analogs.
103   
1.2  Balances within the kynurenine pathway 
A balance exists between the kynurenine pathway in the periphery and in the 
central nervous system. KYN is transported over the blood brain barrier via the 
large  neutral  amino  acid  transporter.  3-OH-KYN  is  transported  by  the  same 
carrier, although less efficiently. QUIN, KYNA, 3-OH-AA and AA cross the blood 
brain barrier by passive means only. Influx rates of QUIN, KYNA and 3-OH-AA 
are low. The passive influx of AA only is biologically significant.
33 About 60% of 
brain KYN originates from the periphery. By means of intracerebral [5-
3H-KYN] 
injection,  a  functional  kynurenine  pathway  in  rat  brain  downstream  from  this 
intermediate  was  demonstrated.  Because  the  apparent  efficiency  of  KAT 
enzymes  exceeds  the  efficiency  of  metabolism  into  the  QUIN  branch  of  the Introduction: The kynurenine pathway 
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pathway, increases in KYNA production were most pronounced. In QUIN lesioned 
rat striatum, activities of all enzymes of the kynurenine pathway downstream 
from KYN were enhanced.
184 Interestingly, lesions in the early postnatal days (7 
days)  caused  upregulation  of  the  KYNA  branch  of  the  pathway,  whereas  the 
QUIN  branch  was  enhanced  more  effectively  at  later  ages  (28  days  –
adulthood).
185 
Within  the  brain,  kynurenine  metabolism  is  compartmentalized.  KYN  is 
transported into astrocytes by a sodium independent large neutral amino acid 
transporter  and  into  neurons  by  a  less  efficient  sodium  dependent 
transporter.
112, 113 KYNA is primarily formed in astrocytes, and is removed from 
the  brain  by  a  probenecid  sensitive  carrier.
136,  139 3 -OH-KYN  is  primarily 
synthesized  in  microglial  and  macroglial  cells,  and  is  further  metabolized  to 
QUIN and NAD
+.
186 The functional segregation of the pathways was shown in a 
study  using  selective  inhibitors.  Intrastriatal  [5-
3H-KYN]  injection  resulted  in 
decreased  formation  of  KYNA  after  selective  inhibition  of  KAT  II  enzymes, 
without affecting production of 3-OH-KYN or QUIN. Inhibition of KMO resulted in 
decreased 3-OH-KYN synthesis. KYNA synthesis was not changed.
53  
1.3  Indolepyruvic acid pathway 
At  least  one  alternative  pathway  for  the  biosynthesis  of  KYNA  is  known. 
Tryptophan can be transaminated by tryptophan aminotransferase or aromatic 
aminotransferases to indole-3-pyruvic acid (IPA). IPA is kept in vivo in its enol-
tautomeric  form  by  means  of  tautomerases,  probably  macrophage  migration 
inhibitory factor (MIF).
187 Enol-3-IPA reacts with reactive oxygen species to form 
KYNA (Figure 6).
188, 189  
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IPA  is  an  inhibitor  of  tryptophan  dioxygenase  and  serotonin-N-acetyl-
transferase.
190 As summarized in ref
191, administration of IPA improved sleep in 
volunteers in five independent studies and had significant anxiolytic effects with 
concomitant improvement of sleep in a phase II trial. These effects might partly 
be related to production of KYNA and reduced excitation. 
1.4  Kynurenine pathway: Pathology 
Changes in tryptophan metabolism are involved in many pathological states. In 
the first place, a balance exists of tryptophan metabolism into kynurenines and 
towards  5-HT  and  related  metabolites.  Imbalances  can  cause  increases  or 
decreases in these monoamines, resulting in physiological dysfunction. Enhanced 
tryptophan metabolism either way can result in tryptophan depletion. Within the 
kynurenine  pathway,  imbalances  between  the  KYNA-  versus  the  QUIN-branch 
greatly  influence  glutamatergic  neurotransmission  by  the  inverse  action  on 
NMDA  receptors  of  these  metabolites.  Furthermore,  many  of  the  kynurenines 
have  oxidative  properties,  resulting  in  neurotoxicity.  Finally,  activation  or 
inhibition  of  NAD  production  by  up-  or  downregulation  of  QUIN  synthesis  can 
result in general changes in cell metabolism. 
Many reviews have been published about the relationship of the KYN-pathway 
and physiological disorders [e.g. ref
1, 10, 50, 192-196] A short overview will be given 
here  of  the  most  studied  pathological  conditions  with  a  main  focus  on  CNS 
disorders.  
1.4.1  Immune related disorders 
As  was  stated  earlier,  immune  responses  have  major  effects  on  kynurenine 
pathway metabolism. In this respect, the kynurenine pathway stands in close 
relationship to the NO pathway.
1 For example, bacterial lipopolysaccharides and 
IFN-  induce both the kynurenine (by IDO induction) and the NO pathways in 
macrophages. NO inhibits IDO activity, and some of the kynurenines are able to 
inhibit NOS activation. Inhibition of NOS activity results in elevated IDO activity. 
Anti-inflammatory cytokines (IL-4 and TGF- ) have an inhibitory effect on IDO. 
Induced  kynurenine  metabolism  leads  to  elevated  levels  of  QUIN,  causing 
immune related excitatory neurotoxicity. On the other hand, upregulation of the 
pathway  also  leads  to  enhanced  NAD  production.  NAD  is  needed  to  repair 
immune related cell and DNA damage.
1, 178, 192, 194, 197 Induced KYN metabolism 
causes  suppression  of  T-cell  proliferation  by  tryptophan  depletion  and  direct Introduction: The kynurenine pathway 
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inhibition  by  3-OH-KYN,  3-OH-AA  and  QUIN.
198,  199  CNS  infections  with 
upregulated KYN-metabolism are polio, Lyme disease and malaria.
1, 200  
1.4.2  AIDS-dementia complex 
Activation of the immune system by HIV infection causes activation of IDO and 
consequently upregulation of the kynurenine pathway. QUIN levels are elevated 
in patients with HIV.
201 20% of HIV patients develop AIDS-related dementia. The 
cognitive  and  motor  dysfunctions  that  characterize  this  disorder  are  directly 
related  to  QUIN  induced  neuronal  damage  through  NMDA  receptor  activation. 
Zidovudine  treatment  results  in  lower  levels  of  QUIN  and  diminished 
symptomatology, probably by the reduction of immune related activation of the 
kynurenine pathway.
1, 192, 200, 202  
1.4.3  Huntington’s disease 
One of the (non-excluding) hypotheses about the origin of Huntington’s disease 
(HD) is enhanced NMDA receptor activation, resulting in excitotoxicity (reviewed 
in ref
203). In animal models of HD, QUIN is able to specifically mimic the early 
stage symptoms. In rats, administration of QUIN induced the huntingtin gene
204, 
and produced the neurotoxic effects seen in HD by means of activation of NMDA 
receptors,  oxidative  stress,  influencing  the  NO  pathway  and  the  immune 
system
203.  In  mutant  mkat  2
-/-  mice,  decreased  KYNA  levels  result  in  higher 
vulnerability  to  QUIN.
52  In  human  brain  tissue  originating  from  HD  patients, 
QUIN levels were found to be elevated in the early stage of the disease, but not 
in later stages.
205,  206 KYNA levels were decreased
207,  208 or increased
209 in HD 
patients.  KAT  activities  were  decreased.
208  Moreover,  3-OH-KYN  levels  were 
elevated
210 and the activity of 3-HAO was increased
211. Overall, imbalances in 
the kynurenine pathway might result in neurotoxicity, leading to symptoms seen 
in patients with HD. 
1.4.4  Alzheimer’s disease and cognitive function 
Norepinephrine release in the locus coeruleus as a response to NMDA receptor 
activation  is  an  important  regulator  in  cognitive  function.  Elevated  levels  of 
KYNA are believed to impair cognitive function by NMDA antagonism. In fact, 
some  of  the  known  cognitive  enhancers  directly  counteract  the  antagonistic 
action of KYNA on the NMDA receptor.
5 
In  Alzheimer’s  disease,  an  elevated  KYN/Trp  ratio  was  found,  implicating 
enhanced  Trp  metabolism.
212  KYNA  levels  were  increased  in  the  brain  of  AD Chapter 1 
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patients, correlating with increased KAT activity.
213 In serum and red blood cells, 
KYNA  levels  were  decreased.
214 3-OH-KYN  levels  were  unchanged.
210  Immune 
responses, e.g. to  -amyloid plaques, are thought to upregulate Trp metabolism 
via  the  kynurenine  pathway.  Whereas  increased  KYNA  levels  might  lead  to 
cognitive  impairment  seen  in  AD,  neurotoxic  kynurenines  might  cause  further 
brain damage.
196 
1.4.5  Parkinson’s disease, epilepsy 
Mitochondrial  complex  I  inhibitor  MPTP  causes  decreased  KYNA  availability  by 
KAT depletion in the substantia nigra, directly linking a widely used model of 
Parkinson’s disease to the kynurenine pathway.
123, 124 In patients suffering from 
Parkinson’s disease (PD), elevated levels of 3-OH-KYN and a decreased KYN/3-
OH-KYN ratio in the putamen and substantia nigra have been found. KYNA levels 
were  decreased  in  these  areas  in  PD  patients  with  and  without  L-DOPA 
treatment.
215  Interestingly,  diskenysia  as  a  side-effect  of  L-DOPA  treatment 
could effectively be treated by increasing KYNA levels.
216 In conclusion, shifts in 
KYN metabolism towards the QUIN branch might have detrimental effects on Glu 
and  DA  release  and  might  cause  direct  neurotoxicity  in  the  substantia  nigra. 
Pharmacological  manipulation  of  the  KYN  pathway  should  be  regarded  as  a 
possible target for treating symptoms of PD or at least side effects of current 
treatment. 
The discovery of convulsant properties of QUIN led to the first steps in accepting 
a  physiological  function  of  the  kynurenine  pathway  instead  of  solely  being  a 
route  of  Trp  catabolism.
100  Excessive  NMDA  receptor  stimulation  resulting  in 
overexcitation  is  a  cause  of  epileptic  seizures.  Soon,  the  knowledge  of  the 
physiological  effects  of  KYNA  and  QUIN  on  the  NMDA  receptor  led  to 
experimental  tools  to  be  used  in  the  attenuation  of  epileptic  seizures.  4-
Chlorokynurenine is converted in vivo into 7-Cl-KYNA by KATs. Like KYNA, 7-Cl-
KYNA  is  an  antagonist  at  the  glycine  site  of  the  NMDA  receptor  and  could 
attenuate  epileptic  symptoms  evoked  by  the  chemoconvulsant  kainate  in 
rats.
217,  218  KMO  inhibitors  have  been  published  which  were  shown  to  have 
sedative  and  anticonvulsive  properties  by  producing  elevated  KYNA  levels  in 
brain, blood, liver and hippocampal microdialysate in rats.
41 Clearly, shifting the 
balance  of  the  KYN  pathway  towards  neuroprotective  KYNA  might  be  an 
alternative  strategy  for  achieving  NMDA  antagonism  in  the  treatment  of 
epilepsy.  Introduction: The kynurenine pathway 
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1.4.6  Schizophrenia 
In recent years, the dopamine hypothesis of schizophrenia has been extended to 
a  broader  hypothesis  of  dysregulation  of  neurotransmitters  in  the  brain.  An 
important aspect in this view is the hypothesis of glutamatergic hypofunction. In 
short, this hypothesis proposes a glutamate deficiency. Dopamine release in the 
mesolimbic region is controlled by inhibitory GABAergic interneurons, which are 
stimulated by Glu neurons. Hypoglutamatergic tone results in elevated DA levels 
in  these  regions.  Elevated  mesolimbic  DA  levels  are  mainly  associated  with 
positive symptoms of schizophrenia. The mesocortical DA transmission is directly 
stimulated  by  glutamate.  Hypoglutamatergic  tone  therefore  results  in  reduced 
DA levels in the PFC. Reduced levels of DA in the PFC are mainly associated with 
negative symptoms and cognitive impairment.
219-222 The use of non-competitive 
NMDA  antagonists  to  evoke  schizophrenic  symptoms  is  a  commonly  accepted 
model  for  the  disorder.  (Sub)chronic  PCP  treatment  most  closely  mimics 
positive,  negative  and  cognitive  symptoms  and  concurrent  physiological 
changes.
223 In close relationship to the hypoglutamatergic hypothesis stands the 
KYNA hypothesis of schizophrenia, stating that elevated levels of this compound 
might play a role in the pathophysiology of the disorder. Elevated levels of KYNA 
have been found in cerebrospinal fluid (CSF) and brain of patients suffering from 
schizophrenia.
2-4 In a study comparing blood levels of patients (85% of which 
received antipsychotic treatment) and healthy volunteers, levels of tryptophan, 
KYN and KYNA did not show any differences. The KYN/Trp ratio was significantly 
higher  in  patients,  indicating  enhanced  tryptophan  metabolism  into  the 
kynurenine pathway.
224 
KYNA  is  able  to  reproduce  many  of  the  symptoms  seen  in  schizophrenia.
225 
Acute and subchronic exposure to KYNA disrupts prepulse inhibition in rats, a 
model of sensorimotor gating.
163, 226 Elevated levels of KYNA increased neuronal 
firing  of  dopamine  neurons  in  the  VTA  in  rats  (see  section  1.1.8.3).
162  The 
atypical antipsychotic clozapine was able to decrease this KYNA induced burst 
firing  of  VTA  DA  neurons.
163,  227  Although  effects  could  not  completely  be 
explained  by  action  on  NMDA  receptors,  KYNA  was  shown  to  disrupt  auditory 
processing  in  rats.
228  Spatial  working  memory  deficits  seen  in  schizophrenic 
patients  could  also  be  reproduced  by  elevated  KYNA  levels.
229  Interestingly, 
chronic  treatment  with  either  typical  (haloperidol,  raclopride)  or  atypical 
(clozapine) antipsychotics reduced rat brain KYNA levels.
152 
The  cause  of  elevation  of  KYNA  levels  in  schizophrenia  is  not  completely 
understood.  Evidence  suggests  upregulated  tryptophan  metabolism  with  an Chapter 1 
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inflammatory  background.  The  immune  response  was  identified  as  a  type  2-
immune activation. In this type of response, astrocytic TDO rather than IDO is 
upregulated.  In  accordance  with  upregulation  of  the  initial  step  of  Trp 
metabolism, the KYN/Trp ratio was significantly higher in schizophrenic patients 
than  in  controls.
224,  230  COX-2  inhibitors  are  able  to  shift  the  balance  of  type 
1/type  2  immune  responses  towards  the  type  1  response  by  inhibition  of 
prostaglandin E2 release. In this respect, it is interesting to know that COX-2 
inhibitors were also shown to decrease KYNA levels in rats.
150, 230 Downstream of 
kynurenine,  elevated  KAT  I  activities  were  observed  in  post  mortem  brain 
samples of schizophrenic patients.
231 
1.4.7  Other disorders 
Other  disorders  in  which  dysregulation  of  KYN  pathway  metabolites  has  been 
observed  include  depression,  traumatic  CNS  injury/ischemic  damage,  tumor 
growth, hepatic encephalopathy, diabetes, gastrointestinal tract disorders, (age 
related) cataractogenesis, hypertension, and renal failure.
1, 10, 90, 177, 193, 195, 200, 
202, 230, 232  
1.5  Conclusion 
In  conclusion,  the  kynurenine  pathway  is  a  metabolic  pathway  that  produces 
physiologically active compounds and plays a role in regulation of brain function. 
The pathway is highly balanced around key intermediate KYN. Depending on the 
specific  environment,  the  pathway  can  be  balanced  towards  glutamatergic 
agonism  (QUIN)  or  antagonism  (KYNA).  In  general,  the  enzymes  that  are 
involved in the pathway are known. However, much work needs to be done on 
detailed  characterization  of  most  of  the  enzymes.  An  important  issue  in  this 
context is the difference that seems to exist between different species.  
Concerning drug design, the major point of interest is finding pharmacological 
tools that can shift the KP balance towards one of the two branches - the KYNA 
or the QUIN branch. In most cases, a shift towards the neuroprotective KYNA 
branch  is  desired.  Potent  inhibitors  of  KMO  and  KYNase  are  known.  Indeed, 
these  compounds  are  able  to  shift  the  pathway  towards  the  KYNA  branch. 
Compounds  that  are  known  to  inhibit  the  KYNA  branch  and  are  able  to 
upregulate  the  QUIN  branch  are  less  abundant.  Characterization  of  the 
physiological effects of these compounds is ongoing. Again, species differences, 
as well as brain region specific effects are issues of consideration. Introduction: The kynurenine pathway 
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Being embedded in the complex network of brain functions, dysregulation of the 
kynurenine pathway can be related to many CNS disorders. Whether imbalances 
in this pathway are the cause or the consequence or even both of the disorder, 
is  mostly  unknown.  Ultimately,  research  in  the  field  of  pharmacological 
manipulation of the kynurenine pathway balances should lead to new methods 
for treatment of (CNS) disorders. 
1.6  Aim of thesis  
The aim of this work was to find pharmacologically active compounds that shift 
the  kynurenine  pathway  away  from  KYNA  synthesis.  With  such  compounds, 
effects  of  decreasing  KYNA  levels  could  be  studied  under  physiological  and 
pathological  circumstances.  Whereas  inhibitors  of  the  QUIN  branch  are  widely 
available, only few compounds are known that inhibit the KYNA branch of the 
pathway. 
For this purpose, different classes of compounds were synthesized. The in vitro 
inhibitory  activity  on  rat  brain  KATs  was  examined.  Furthermore,  selectivity 
towards KAT over KYNase and KMO was taken into account. Since the latter two 
enzymes are most abundant and active in the liver, rat liver homogenate was 
used for examination of inhibitory activities of compounds. 
In chapter 2, the synthesis and in vitro properties of conformationally restricted 
carboxylic acids are described. In these compounds, the KYN core structure is 
incorporated in a bicyclic ring system. For synthetic feasibility and examination 
of the role of the KYN  -amino group, this group is not included in the analogs. 
In  chapters  3  and  4,  the  corresponding  bicyclic  amino  acid  analogs  are 
presented.  The  synthesis  of  these  compounds  is  described  in  detail.  In  vitro 
activity is discussed and related to structural variation. In chapter 5, four fully 
flexible  KYN  analogs  are  presented.  These  compounds  were  synthesized  to 
examine  the  effect  of  omittance  of  the   -amino  group  on  KAT  inhibition  and 
selectivity with and without substitution of the aromatic ring. Furthermore, the 
effect of bioisosteric replacement of the carboxylate group was examined. The in 
vitro profiles of these compounds elucidate some interesting features of activity 
and selectivity. 
Chapter 6 reviews the current knowledge of kynurenine aminotransferases. KAT 
II  homology  models  are  presented  and  discussed  in  the  light  of  recently 
published  crystal  structures.  In  the  future,  the  structural  knowledge  of  KP 
enzymes should provide easily accessible tools for design of new compounds.  Chapter 1 
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In  chapter  7,  the  current  status  of  research  in  the  kynurenine  pathway  is 
discussed, taking into account the work presented in chapters 2-6. Concluding 
remarks are given on current and future work in the area. 
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2.1  Introduction 
The kynurenine pathway is the main metabolic route of tryptophan degradation. 
The key intermediate in this pathway is kynurenine (KYN, 2.1, Scheme 1).  
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Kynurenine  aminotransferase  (KAT)  catalyzes  the  transformation  of  KYN  to 
kynurenic  acid  (KYNA).  The  enzyme  is  member  of  the  pyridoxal  5’-phosphate 
dependent aminotransferases. At least four isoforms exist, named KAT I-IV. KAT 
II is thought to be the main KYN metabolizing KAT in the human brain. KYNA is 
an  antagonist  at  the  strychnine  insensitive  glycine  coagonist  site  of  NMDA 
receptors  and  a  non-competitive  antagonist  at   7*  nicotinic  acetylcholine 
receptors. At much higher concentrations, KYNA is an antagonist at all ionotropic 
glutamate receptors. Apart from being metabolized into KYNA, key intermediate 
KYN  functions a s  substrate  of  kynureninase  (KYNase)  and  kynurenine  3-
hydroxylase  (kynurenine  mono-oxygenase,  KMO),  ultimately  leading  to 
quinolinic  acid  (QUIN).  QUIN  is  a  NMDA  receptor  agonist  and  has  neurotoxic 
properties. A delicate balance exists between metabolism of KYN into KYNA and 
metabolism into QUIN.
1-5  
 
Elevated levels of KYNA in brain have been associated with CNS disorders, most 
importantly  schizophrenia
6-8  and  cognitive  dysfunction
9.  The  relationship 
between  KYNA  levels  and  these  disorders  remains  unclear.  Elevation  of  KYNA 
levels  can  be  achieved  pharmacologically  by  means  of  increasing  KYN 
availability.  Effects  have  been  studied  in  vivo  (e.g.  ref
10-12).  In  order  to 
pharmacologically decrease KYNA levels, efforts have been made to design KAT 
inhibitors. One of the most urgent challenges in the design of compounds that 
decrease  KYNA  levels  in  vivo  is  the  issue  of  selectivity.  A  limited  number  of 
compounds  are  known  that  can  inhibit  KAT.  Most  known  KAT  inhibitors  are 
equally or even more effective in inhibiting KYNase and KMO. If the latter two 
enzymes  are  inhibited,  increased  levels  of  KYN  ultimately  result  in  elevated 
instead of decreased KYNA levels. S-4-(Ethylsulfonyl)-benzoylalanine (S-ESBA, KAT inhibitors: Conformationally restricted carboxylic acids 
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2.2, Scheme 1) has been published as the first KAT II selective inhibitor.
13,  14 
The compound shows selectivity for KAT II over KAT I, but is ineffective against 
KYNase and KMO.  
As S-ESBA, most compounds that are known to inhibit KAT are close structural 
KYN analogs. In this study, an attempt was made to introduce conformational 
restriction into structures of inhibitors, using KYN as the template structure. A 
series of bicyclic compounds is presented and their ability to inhibit KAT, KYNase 
and KMO is discussed. 
2.2  Chemistry 
For the design of the structures of this study, the natural substrate KYN (2.1) 
was  used  as  a  template.  To  achieve  conformational  rigidity,  an  aliphatic  ring 
system was introduced in the structures, as shown in Scheme 2.  
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Several  heterocyclic  structures  were  applied  in  compounds  2.3-2.6.  As  in  S-
ESBA,  an  ethylsulfonyl  substituent  was  introduced  in  compound  2.7  to 
investigate  effects  of  this  sidechain  on  selectivity.  In  compound  2.8,  the 
carboxylic acid moiety was replaced by the bioisosteric tetrazole ring.  
 
Compound  2.3  was  synthesized  by  two  different  methods  (Scheme  3). 
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Scheme 3 
O O
O
OH
O
O
O
O
O
OH
2.9 2.10
2.12
2.3
b.
O
O
O
c.
d.
2.11
a.
O
2.9
e. f.
 
Reagents and conditions: a. glyoxylic acid.H2O, 160
oC, 1h; b. MeOH, H2SO4, reflux; c. 
NaOH, dioxane/H2O; d. Zn, AcOH; e. 1. LHMDS, -80
oC, 2. ethyl bromoacetate, -80
oC to 
r.t.; f. KOH, MeOH/H2O. 
 
For the first method, the carboxylic acid containing side chain was introduced 
into   -tetralone  2.9  by  condensation  with  glyoxylic  acid  in  a  Dean-Stark 
apparatus. After condensation, separation of intermediate 2.10 from reagents 
proved  time  and  yield  consuming.  Simple  methyl  esterification  improved  the 
ease  of  handling  of  the  compound  and  2.11  could  be  purified  by  column 
chromatography. Methyl ester 2.11 was hydrolyzed and reduced with Zn/AcOH 
by published methods.
15  
To  circumvent  the  elaborate  purification  of  intermediate  and  final  product,  a 
second method was tested for the synthesis of compound 2.3. In this method, 
the alkyl side chain was introduced after formation of the lithiated enolate from 
 -tetralone.  The  crude  mixture  of  starting  material  and  product  2.12  was 
directly subjected to hydrolysis. The product could be isolated from the starting 
material by acid/base extraction and was purified by column chromatography. 
Apart from improving the ease of purification, this second method proved to be 
less time consuming and the overall yield was improved. 
 
In compounds 2.4, 2.5 and 2.6 heterocyclic chromanone, thio-chromanone and 
 -methylchromanone systems were applied as the core structures, respectively. KAT inhibitors: Conformationally restricted carboxylic acids 
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Compound  2.4  was  synthesized  from  2.13  (Scheme  4).  This  compound  was 
obtained  in  considerable  quantities  from  other  studies  [data  not  published]. 
Intermediate 2.14 was obtained by Zn/acetic acid reduction. Hydrolysis afforded 
final product 2.4. 
   
Scheme 4 
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Reagents and conditions: a. Zn, AcOH; b. NaOH, H2O/MeOH. 
 
Compounds 2.5 and 2.6 were synthesized from the bicyclic core structures by 
alkylation with LHMDS/ethyl bromoacetate and hydrolysis (Scheme 5). Starting 
material 2.16 was obtained by published methods.
16 
 
Scheme 5 
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Reagents and conditions: a. 1. LHMDS, -80
oC, 2. ethyl bromoacetate, -80
oC to r.t.; b. 
NaOH, H2O/MeOH. 
 
The ethyl-sulfonyl analog 2.7 of 2.3 was synthesized from 3-bromothiophenol 
(2.19) as shown in Scheme 6.  Chapter 2 
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Scheme 6 
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Reagents and conditions: a. 1. NaH; 2.ethyliodide, 3h, r.t.; b. 1. t-BuLi, -90
oC;2. tri-n-
butyltin chloride, -80
oC; c. (Ph3P)2Pd(II)Cl2, DIBAL-H, methyl 4-bromocrotonate, THF; d. 
LiOH,  EtOH,  H2O;  e.  Pd/C,  MeOH;  f.  PPA,  100
oC;  g.  1.  LHMDS,  -80
oC,  2.  ethyl 
bromoacetate, -80
oC to r.t.; h. m-chloroperbenzoic acid, CH2Cl2; i. LiOH, MeOH. 
 
The  bicyclic  core  structure  2.25  was  obtained  from  3-bromothiophenol  in  6 
steps. In the first step, the sulfur group of 3-bromothiophenol was ethylated.
17 
The most challenging steps were the synthesis of unstable stannane 2.21 from 
ethylated  2.20  and  subsequent  Stille  coupling  of  the  stannane  and  4-
bromocrotonate.
18, 19 DIBAL-H was employed for in situ generation of the active 
Pd(0)-catalyst  from  bis(triphenylphosphine)palladium(II)  chloride  during  the 
reaction. Hydrolysis, catalytic hydrogenation and ring-closure in polyphosphoric 
acid yielded 2.25.  KAT inhibitors: Conformationally restricted carboxylic acids 
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Bicyclic  core-structure  2.25  was  subjected  to  enolization  with  LHMDS  and 
alkylation with ethyl bromoacetate. During purification of the alkylated product, 
starting material, as well as some bi-substituted product 2.28 (Scheme 7) were 
isolated.  
 
Scheme 7 
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To ensure minimal formation of 2.28, the reaction was conducted in a rather 
dilute environment. A limited amount of ethyl bromoactetate was added at a low 
temperature.  Careful  separation  of  2.26  and  2.28  at  this  stage  or  after 
oxidation in the next step was necessary, to avoid the presence of bi-substituted 
impurity in the final product. 
After  successful  isolation  of  mono-substituted  product  2.26,  the  ethylsulfanyl 
side  chain  was  oxidized  and  the  ester  was  hydrolyzed  to  obtain  ethylsulfonyl 
substituted compound 2.7. 
 
For the synthesis of compound 2.8, the Mannich approach was chosen (Scheme 
8). A Mannich reaction with  -tetralone 2.9 as the starting material, followed by 
alkylation and reaction with KCN yielded 2.31. Reaction with NaN3/NH4Cl in DMF 
afforded tetrazole 2.8. 
 
Scheme 8 
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Reagents and conditions: a. (CH3)2NH.HCl, paraformaldehyde, HCl, EtOH, reflux; b. MeI, 
EtOH, r.t.; c. KCN, HCl, MeOH/H2O, 70
oC; d. NaN3, NH4Cl, DMF, 140
oC, 19h.   Chapter 2 
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(S,R)-ESBA,  the  racemate  of  compound  2.2,  was  synthesized  by  published 
methods.
13 
2.3  Enzyme inhibition 
The  final  compounds  2.3  -  2.8  and  (S,R)-2.2  were  tested  for  their  ability  to 
inhibit  KAT  in  rat  brain  homogenate.  The  compounds  were  tested  for  KYNase 
and KMO inhibitory activity in rat liver homogenate. The results are shown in 
Table 1. 
 
Table 1 Enzyme inhibitory activity 
IC50 (mM) or % activity from basal at 1 mM  Compound 
KAT  KYNase  KMO 
IC50(KAT)/ 
IC50(KYNase) 
IC50(KAT)/ 
IC50(KMO) 
O
O
OH
2.3  
2.6 ± 0.23  0.40 ± 0.017  0.17 ± 0.02  6.5  15.0 
O
O
O
OH
2.4  
5.5 ± 2.1  1.5 ± 0.19  2.1 ± 0.34  3.6  2.6 
S
O
O
OH
2.5  
1.5 ± 0.30  0.42 ± 0.045  0.74 ± 0.07  3.6  2.0 
O
O
O
OH
2.6  
2.7 ± 0.52  10.9 ± 3.0  3.4 ± 0.78  0.2  0.8 
O
O
OH
S
O O 2.7  
5.2 ± 0.72  n.a.*  2.6 ± 0.37  n.a.  2.0 
O
N N
NH
N
2.8  
1.71 ± 0.16  4.4 ± 0.82  0.24 ± 0.04  0.4  7.2 
O NH2
O
OH
S
O O (S,R)-2.2  
58%  94%  88%  n.a.  n.a. 
* increased activity, maximum activity not reached; n.a. = not applicable 
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The  effects  of  compounds  2.3, 2.7  and (S,R)-2.2  on  enzymatic  activities  are 
shown in Figure 1.  
 
Figure 1 
a. 
 
b. 
 
c. 
 
Effects  of  compounds  2.3,  2.7  and  (S,R)-
2.2 on activity of (a) KAT, (b) KMO and (c) 
KYNase.   
Legend:     compound  2.3;     compound 
2.7;   compound (S, R)-2.2. 
 
 
2.4  Discussion and conclusion 
KYN  is  a  rather  flexible  molecule  and  can  adopt  at  least  several  low-energy 
conformations. The compounds of this study were designed as conformationally 
restricted KYN analogs in the search of KAT selective inhibitors. Introduction of 
conformational  rigidity  in  general  can  be  beneficial  for  several  reasons. 
Presumed  that  the  conformation  in  which  the  molecule  is  locked  mimics  the 
biologically  active  conformation,  restriction  can  influence  binding  affinity  in  a 
favorable  way  by  lowering  the  energy  barrier  between  the  most  favorable 
conformations in free versus bound state. By choosing a conformation that is 
accepted by one target in favor of another target, conformational restriction can 
result in improved selectivity. A third reason for introduction of conformational 
restriction  is  the  change  in  physicochemical  properties  of  a  compound. 
Incorporation of functional groups into larger systems might improve drug-like 
properties, and enhance chemical stability.  Chapter 2 
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The compounds described in this study contain a bicyclic homo- or heterogenic 
core structure based on  -tetralone. The benzoyl moiety of KYN is incorporated 
in the aliphatic homo- or heterocycle. Incorporation of the aliphatic ring assures 
that the structure is ‘locked’ in one of the low energy conformations of KYN (see 
Chapter 4).  
Compound  2.3  was  designed  as  the  lead  compound  in  the  present  set  of 
molecules. As is known for many PLP-dependent enzymes, the carboxylic acid 
group in the substrate is important for binding to a highly conserved arginine 
residue in the catalytic site of KAT.
20 Therefore, this group is conserved in the 
present structures, at the corresponding distance from the benzoylic core of the 
structures. The  -amino group is omitted in the compounds presented in this 
study.  The   -amino  group  of  KYN  is  transaminated  to  yield  the   -keto 
intermediate.  After  transamination,  KYNA  is  formed  by  spontaneous 
intramolecular  ring  closure.  Inhibitors  lacking  the   -amino  group  would  have 
several advantages over their amino-acid equivalents. In the first place, the lack 
of the amino-group ensures, that the possibility of elimination of the inhibitor 
and  formation  of  metabolites  by  transamination  is  excluded.  Secondly, 
physicochemical  properties  of  the  compounds  without  the  amino-moiety  are 
more drug-like. Thirdly, initial attempts to incorporate the amino-group into the 
structure  proved,  that  synthesis  of  bicyclic  amino  acids  is  challenging.  In 
comparison,  synthesis  of  the  present  compounds  is  rather  straightforward. 
Moreover,  in  the  bicyclic  structures,  a  center  of  chirality  is  added  in  the   -
position of the bicyclic structure of the ring. A second center of chirality would 
highly complicate separation and purification of isomers.  
Since the aromatic amino group seems not to be critical for inhibition (cf. S-
ESBA), this group was omitted in the current set of structures.  
 
Compounds  2.4  and  2.5  are  analogs  of  2.3,  based  on  4-chromanone  and 
thiochroman-4-one  structures,  respectively.  These  structures  were  included  to 
address  effects  on  inhibitory  activity  and  selectivity  of  different  heterocyclic 
systems. Compound 2.6 was designed to study the effects of a substituent on 
the carbon-atom at the  -position of the bicyclic core. Attempted synthesis of 
amino-acid  analog  2.32  of  2.4  yielded   -amino  eliminated  product  in 
considerable yields (Scheme 9).  KAT inhibitors: Conformationally restricted carboxylic acids 
  63 
 
Scheme 9 
O
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O
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O
OH
NH2
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Substitution of the beta position should prevent the formation of a double bond 
by  -amino elimination.  
 
In  compound  2.7,  an  ethylsulfonyl  side  chain  was  introduced  in  the  aromatic 
ring, correspondingly to S-ESBA (2.2). It was proposed, that this group in S-
ESBA binds in a cavity within the binding site of human KAT II. This cavity is 
aligned by non-conserved amino acids. Differences in amino acid alignment of 
the cavity may account for different affinities for the enzymes originating from 
different species.
14 
Compound  2.8  features  bioisosteric  replacement  of  the  carboxylic  acid  by  a 
tetrazole  ring.  Bioisosteric  replacements  can  be  applied  to  optimize  drug-like 
properties of compounds without changing the shape of the molecule as ‘seen’ 
by the biological target.
21 Functionally feasible bioisosteric replacements of the 
amino-acid group are scarce. In contrast, bioisosteric replacement of carboxylic 
acid moieties is widely applied. One of the most frequently used bioisosteres of 
carboxylic acid moieties is the tetrazole ring. Therefore, as a final modification 
on  lead  structure  2.3,  the  carboxylic  acid  moiety  was  replaced  by  the 
bioisosteric tetrazole (2.8). 
 
The current study aims for inhibition of KYNA production in the brain. Therefore, 
KAT inhibitory activity of compounds 2.3 – 2.8 was assessed in brain tissue. For 
this purpose, rat brain tissue homogenate was used. Racemic ESBA ((S,R)-2.2) 
was tested as a reference compound.  
KMO and KYNnase activities in liver are high. If compounds enter the organism 
systemically,  peripheral  enzymes,  including  liver  enzymes,  are  encountered  in Chapter 2 
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the first instance, rather than the brain enzymes. Inhibition of liver KMO and 
KYNase will result in elevated levels of KYN in the periphery. KYN rapidly enters 
the brain and enhanced availability of the KAT substrate will result in elevated 
levels of KYNA. Therefore, effects of the compounds on KYNase and KMO were 
assayed in rat liver homogenate.  
 
Apparently, ESBA is not as potent in the KAT assay used in this work as it is in 
rat liver homogenate (IC50 = 100  M)
13 or recombinant human KAT (36% of KAT 
II  activity  at  1  mM)
14.  Under  the  present  conditions,  the  brain  KAT  inhibitory 
activity of (S,R)-ESBA is in the millimolar range. Differences between published 
values  and  values  found  in  this  study  can  most  probably  be  attributed  to 
differences in assay conditions. It is known from literature that in the periphery, 
several aspecific aminotransferases are capable of KYN transamination.
22, 23 An 
assay  using  crude  liver  homogenate  probably  addresses  these  aspecific 
aminotransferases,  next  to  KAT.  Moreover,  the  pure  enantiomer  S-ESBA  was 
published to preferentially inhibit KAT II, and not KAT I. The inhibitory activity 
assayed in this work addresses non-specific KAT inhibition. This is accomplished 
by performing the assay at pH = 8, which is in between the pH optima for KAT I 
and KAT II.
22  
 
As can be concluded from the data presented here, the bicyclic structures in this 
study have just limited KAT inhibitory potencies in rat brain, with IC50 values in 
the  millimolar  range.  Apparently,  the  conformational  restriction  of  the  KYN 
analogs  applied  here  is  not  favorable  for  enzyme  binding.  Whether  the  exact 
cause  lies  in  steric  hindrance  within  the  active  site  or  in  suboptimal  relative 
orientation of functional groups, remains unclear.  
However,  some  conclusions  can  be  drawn  from  the  present  data.  The  lead 
structure  of  this  set,  compound  2.3,  inhibits  KYNase  and  KMO  at  micromolar 
concentrations. Compared to reference compound (S,R)-2.2, the compound has 
selectivity  for  rat  liver  KYNase  and  KMO,  rather  than  for  rat  brain  KAT.  This 
means,  that  in  vivo,  KYN  metabolism  in  the  brain  would  be  upregulated. 
Accordingly, administration of the compound in vivo caused increased levels of 
KYNA in rat brain, as determined by microdialysis [preliminary results, data not 
shown].  
Introduction of the chromanone bicyclic structure in 2.4, and a methyl group at 
the   -position  (2.6)  impairs  KYNase  and  KMO  inhibition  in  particular,  shifting 
inhibitory  preference  more  towards  KAT.  The  methyl  group  in  the   -position KAT inhibitors: Conformationally restricted carboxylic acids 
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seems to have no negative effects on the compound in terms of KAT inhibition 
and positive effects in terms of preference towards KAT.  
The  thiochroman-4-one  analog  2.5  shows  an  interesting  shift  in  inhibitory 
profile. Compared to compound 2.3, KAT inhibition is slightly improved. KYNase 
inhibitory  activity  is  conserved,  but  the  compound  inhibits  KMO  activity  less 
effectively.  Apparently,  introduction  of  the  sulfur  containing  heterocycle 
improves, although not optimizes the selectivity profile of the compound.  
Bioisosteric replacement of the carboxylic acid group by a tetrazole ring in 2.8 
causes a 10-fold increase in IC50 value of KYNase inhibition, but does not affect 
KMO and KAT inhibition. Therefore, whereas the replacement does not interfere 
in the interaction with KAT or KMO, a difference exists for KYNase between the 
carboxylic acid moiety and the tetrazole replacement. 
  
The most important finding of this study is the effect on inhibitory activities of 
introduction of the ethylsulfonyl side chain (Figure 1). Compound 2.7 shows KAT 
inhibition  similar  to  parent  compound  2.3,  but  inhibition  of  KMO  is  strongly 
impaired. KYNase inhibition of 2.3 is converted into apparent activation of the 
enzyme in compound 2.7. The exact nature of apparent activation of KYNase by 
compound  2.7  is  unclear.  Whereas  enzyme  inhibition  is  an  abundantly  used 
mechanism  used  for  drug  design,  activation  of  enzymes  is  less  well  studied. 
However,  some  remarks  can  be  made  about  enzyme  activation.  Enzyme 
activators can be divided into endogenous and exogenous substances. In some 
enzymes,  the  substrate  can  function  as  activator  (substrate  activation).  An 
example of a substrate activator was described for butyrylcholinesterase. This 
enzyme is activated by its own substrate at higher substrate concentrations.
24 
Exogenous activators are activators that do not occur in the organism naturally, 
but are present after pharmacological treatment or by food intake. 
In  terms  of  mechanism  of  activation,  activators  that  bind  in  the  substrate 
binding  site  and  activators  that  bind  to  a  different  site  can  be  distinguished. 
Usually, activators that bind in the binding site of the enzymes are considered 
co-factors. In some special cases, the substrate molecule can act either as an 
activator or as a substrate by adoption of two different orientations within the 
binding site.
25 Activators that bind to a site distinct from the substrate binding 
site most frequently exert their effect by allosteric means. Butyrylcholinesterase 
can be activated by the non-substrate-activator homocysteine thiolactone. This 
compound binds to an anionic site in the periphery of the enzyme and activates 
the  enzyme  by  allosteric  rearrangements.
24  In  a  different  example,  the 
proagulant/antiagulant thrombin can be activated by a Na
+ ion, which induces Chapter 2 
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an allosteric rearrangement from the “slow” form of the enzyme to the “fast” 
form.
26 
In  some  cases,  endogenous  metabolic  pathways  are  regulated  by  means  of 
enzyme  activation.  This  is  exemplified  by  the  regulation  of  two  metabolic 
pathways, which are linked by key intermediate homocysteine. The first pathway 
is  the  methyl  group  transfer  pathway.  In  this  pathway,  a  methyl  group  is 
eliminated from methionine. The methyl group can be used in a wide range of 
biochemichal reactions. As an intermediate in the methyl elimination reaction, S-
adenosylmethionine  (SAM)  is  formed.  SAM  is  further  metabolized  to 
homocysteine. From homocysteine, methionine can be regenerated by addition 
of  a  methyl  group.  This  reaction  is  catalyzed  by  methionine  synthase.  The 
enzyme  activity  of  methionine  synthase  can  be  inhibited  by  allosteric 
interactions of SAM. The second pathway functions as an alternative elimination 
pathway  for  homocysteine.  The  pathway  produces  cysteine.  The  reaction  is 
catalyzed by the PLP-dependent key enzyme cystathionine  -synthase. Cysteine 
is  metabolized  or  excreted.  In  this  second  pathway,  SAM  is  an  allosteric 
activator of cystathionine  -synthase. Consequently, at high homocysteine and 
thus high SAM concentrations, the methyl group transfer pathway is inhibited by 
inhibition  of  methionine  production.  Concomitantly,  the  homocysteine 
elimination  pathway  is  activated.  If  SAM  concentrations  are  low,  neither 
inhibition  occurs  of  methionine  production,  nor  is  the  elimination  pathway 
activated.
27 
A  fascinating  example  of  so-called  asymmetric  allosteric  activation  of  PLP-
dependent enzymes is seen in plant threonine synthase. Like KYNase and KAT, 
plant threonine synthase is a functional homodimer. Similar to cystathionine  -
synthase,  the  enzyme  is  activated  by  SAM.  The  mechanism  of  activation  was 
studied  in  detail.  By  binding  to  an  allosteric  site,  SAM  induces  a  pronounced 
conformational change of the PLP co-enzyme, switching the enzyme to the high-
activity  state.  The  conformational  change  observed  upon  binding  of  SAM  is 
asymmetric,  activating  just  one  active  site.  It  is  suggested,  that  upon  ligand 
binding in the activated site, a conformational change is induced which makes 
the second active site more favorable for substrate binding.
28 
One  can  only  speculate  about  the  type  of  apparent  activation  of  KYNase  by 
compound 2.7 observed in this study. The presence of a regulatory non-catalytic 
site in human KYNase has been suggested before.
29 The activation observed for 
2.7 might be exerted through this or a similar site. The mechanism of activation 
can  occur  at  different  points  in  the  catalytic  process.  During  catalysis,  a 
conformational change of the enzyme from the open to the closed stated occurs. KAT inhibitors: Conformationally restricted carboxylic acids 
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Possibly, an activator facilitates the conformational change, or even reduces the 
necessity  of  a  conformational  change  for  catalytic  activity.  Alternatively,  the 
activator  might  function  as  a  stabilizer  of  the  gem-diolate  intermediate  state, 
reducing the energy necessary to reach this state. The compound might act in 
the direct vicinity of the active site or at a more distant site of the enzyme.  
Irrespective  of  the  mechanism  of  KYNase  activation  by  2.7,  the  present  data 
confirm that indeed, the ethylsulfonyl substituent in S-ESBA (2.2), as well as in 
compound  2.7  is  responsible  for  the  enhanced  KAT  selectivity  in  these  KYN 
analogs. 
 
In conclusion, the conformationally restricted KYN analogs presented here are 
rather  weak  inhibitors  of  KAT.  Relative  preference  to  inhibit  KAT  rather  than 
KYNase  and  KMO  could  be  influenced  by  variation  within  the  core  bicyclic 
structure of the molecules. Introduction of an ethylsulfonylic side chain in the 
aromatic  part  of  the  bicyclic  core  enhances  selectivity  for  KAT  over  KMO 
inhibition, and activates KYNase activity. To study whether the absence of the  -
amino group or the conformational restriction or both structural properties cause 
the weak KAT inhibitory potency, it might be interesting to study KAT inhibition 
of bicyclic  –amino acid analogs on one hand, and activity of the non-restricted 
carboxylic acid analog of KYN on the other hand. 
2.5  Experimental section 
General NMR spectra were taken on a Varian spectrometer, at the frequency as stated in 
the  text.  Chemical  shifts  are  given  in  ppm.  The  splitting  patterns  are  designated  as 
follows: s = singlet, d = doublet, t = triplet, m = multiplet, bs = broad singlet. Coupling 
constants  are  given  in  hertz  (Hz).  IR  spectra  are  taken  on  an  ATI-Mattson 
spectrophotometer. GCMS analysis were performed on a Shimadzu GCMS-QP500 system 
equipped an AOC-20i auto injector and a CP-Sil 5 CB column (15 m x 0.25 mm; 0.10 µm 
film thickness). Mass spectra (ESI) were taken on an API 3000 MS/MS system. Accurate 
mass  measurements  (HRMS)  were  performed  using  a  flow  injection  method  on  a  LTQ-
Orbitrap XL mass spectrometer (Thermo Electron, Bremen, Germany) with a resolution of 
60000 at m/z 400. All final compounds had ad least 95% purity, as determined by HPLC. 
Solvents and reagents were obtained from general sources and used as such. THF was 
dried by distillation over Na. 
 
(1-Oxo-3,4-dihydro-1H-naphthalen-2-ylidene)-acetic acid (2.10) 
A mixture of  -tetralone (4.40 g, 30.1 mmol) and glyoxylic acid.H2O (2.96 g, 32.2 mmol) 
was heated using a Dean Stark apparatus in an oil bath preheated to 160 
oC for 1 hour. 
The mixture was left to cool to room temperature and triturated with EtOAc. The solid was 
filtered  off.  The  filtrate  was  washed  with  1  N  HCl,  and  extracted  with  1  N  NaOH.  The 
combined  alkaline  extracts  were  acidified  with  4  N  HCl  and  extracted  with  EtOAc.  The 
combined organic layers were washed with brine, dried (MgSO4), filtered, and the solvent 
was evaporated, yielding 2.77 g of a brown solid. The crude solid was heated in 40 mL 
MeOH, containing 0.4 mL concentrated H2SO4 to yield the methyl ester of 2.10 which was 
purified by column chromatography (silica, Hex/EtOAc). The obtained product 2.11 (1.34 Chapter 2 
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g, 6.25 mmol) was hydrolyzed in a solution of NaOH (0.53 g, 13.2 mmol) in water (15 mL) 
and dioxane (35 mL) at room temperature overnight. The dioxane was evaporated. The 
aqueous layer was washed with EtOAc, acidified with 4 N HCl, and extracted with EtOAc. 
The combined extracts were washed with brine, dried (MgSO4), filtered, and the solvent 
was evaporated. 1.08 g (18%) of an orange oil was obtained, which was sufficiently pure 
to use in the next reaction step.  
1H NMR (200 MHz, CDCl3)   2.88-2.95 (t, 2H, CH2CH2), 3.24-3.32 (m, 2H, CH2CH2), 3.99 
(bs, 1H, COOH), 6.75-6.77 (t, J=1.71 Hz, 1H, C=CH), 7.61-7.29 (m, 2H, ArH), 7.38-7.46 
(m, 1H, ArH), 7.93-7.98 (dd, J=1.22, 7.81 Hz, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   
186.0, 166.6, 147.6, 142.8, 132.6, 130.8, 126.9, 126.7, 125.6, 122.4, 26.9, 25.5 ppm; IR 
(KBr) 2925, 1692, 1671, 1292, 1255, 1206, 750 cm
-1. 
 
(1-Oxo-1,2,3,4-tetrahydro-naphthalen-2-yl)-acetic acid (2.3) 
Method A: Preparation of compound 2.3 by reduction of 2.10 with Zn in acetic acid was 
done as described previously.
15 
Method B: To a solution of  -tetralone (0.501 g, 3.42 mmol) in 20 mL dry THF, cooled to -
80 
oC under N2, a solution of LHMDS (0.907 g, 5.42 mmol) in 10 mL dry THF was added 
dropwise.  The mixture was left to warm up to -20 
oC over 1 h. After cooling back to -80 
oC, ethyl bromoacetate (0.38 mL, 3.43 mmol) was added at once. The mixture was left to 
warm  up  to  room  temperature  and  stirred  at  room  temperature  overnight.  Water  was 
added  for  quenching.  The  layers  were  separated,  and  the  aqueous  layer  was  extracted 
with EtOAc. The combined organic layers were washed with brine, dried (MgSO4), filtered, 
and  the  solvent  was  evaporated.  The  crude  mixture  contained  starting  material  and 
product 2.12 in a ratio of ca. 1:1. The ethyl ester 2.12 was stirred in a solution of KOH 
(0.415  g,  7.40  mmol)  in  10  mL  H2O  and  10  mL  MeOH.  After  3.75  h,  the  MeOH  was 
evaporated. The aqueous layer was washed with CH2Cl2 and then acidified with 4 N HCl. 
The aqueous layer was extracted with CH2Cl2. The combined extracts were washed with 
brine, dried (MgSO4), filtered, and the solvent was evaporated. The product was purified 
by column chromatography (silica, CH2Cl2/MeOH and EtOAc/Hex). 0.276 g (40%) of an off-
white solid was yielded. 
1H NMR (200 MHz, CDCl3)   1.89-2.08 (dq, 1H, CH), 2.22-2.35 (m, 1H, CH), 2.42-2.55 
(m,  1H,  CH),  2.92-3.23  (m,  4H,  CH2-CH2),  7.23-7.35  (q,  2H,  ArH),  7.45-7.53  (dt,  1H, 
ArH),  8.02-8.05  (d,  1H,  ArH),  9.40  (bs,  1H,  COOH)  ppm; 
13C  NMR  (50  MHz,  CDCl3)    
198.7, 178.3, 144.25, 133.8, 132.2, 129.0, 127.8, 127.0, 44.9, 35.3, 29.5 ppm; MS m/z 
203 (M-H)
-, 249 (M+45)
-, 407 (2M-H)
-; IR (KBr) 2923, 1705, 1689, 1428, 1268, 1237, 
958, 734 cm
-1. 
 
(4-Oxo-chroman-3-ylidene)-acetic acid ethyl ester (2.13) 
The  compound  was  obtained  in  considerable  quantities  from  other  studies  (data  not 
published).  
1H  NMR  (200  MHz,  CDCl3)     1.30-1.37  (t,  J=7.05  Hz,  3H,  CH2CH3),  4.21-4.32  (q,  2H, 
CH2CH3), 5.61-5.62 (d, J=2.35 Hz, 2H, OCH2), 6.90-6.93 (t, 1H, C=CH), 6.98-7.10 (m, 
2H, ArH), 7.48-7.56 (m, 1H, ArH), 7.94-7.98 (dd, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3) 
  180.6, 165.5, 162.0, 144.2, 137.0, 128.2, 124.0, 122.4, 121.3, 118.5, 67.9, 61.5, 14.4 
ppm; IR (KBr) 2986, 1708, 1674, 1602, 1465, 1306, 1241, 1207, 1020, 762 cm
-1; GCMS 
m/z 232 (M
+). 
 
(4-Oxo-chroman-3-yl)-acetic acid ethyl ester (2.14) 
A  mixture  of  (4-oxo-chroman-3-ylidene)-acetic  acid  ethyl  ester  (2.13,  0.383  g,  1.65 
mmol), zinc dust (0.184 g, 2.81 mmol), and acetic acid (10 mL) was heated at 100 
oC for 
2.5 h. Then another portion of zinc dust (0.107 g, 1.64 mmol) was added to the mixture. 
The reaction was heated at 100 
oC for another 45 minutes, and was then left to cool to 
r.t.. The mixture was filtered over Celite
®, the Celite
® cake was washed with EtOAc. The 
filtrate was then washed with saturated NaHCO3 solution until the aqueous layer remained 
alkaline  (3x).  The  organic  layer  was  then  dried  (MgSO4),  filterd,  and  the  solvent  was KAT inhibitors: Conformationally restricted carboxylic acids 
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evaporated. Column chromatography (silica, Hex/EtOAc 5:1) yielded 0.314g (81 %) of a 
colorless oil. 
1H NMR (200 MHz, CDCl3)   1.24-1.31 (t, J=7.05 Hz, 3H, CH3), 2.34-2.47 (q, 1H, CH), 
2.88-2.98 (dd, 1H, CH), 3.25-3.40 (m, 1H, CH), 4.128-4.23 (q, 2H, OCH2CH3), 4.23-4.35 
(t,  1H,  CH),  4.58-4.64  (q,  1H,  CH),  6.95-7.05  (m,  2H,  ArH),  7.43-7.52  (dt,  1H,  ArH), 
7.86-7.91 (dd, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   192.8, 171.6, 162.0, 136.2, 
127.6, 121.7, 120.7, 118.1, 70.5, 61.2, 42.7, 30.6, 14.4 ppm; GCMS m/z 234 (M
+); IR 
(NaCl) 2981, 1729, 1694, 1605, 1480, 1455, 1324, 1302, 1214, 1177, 1036, 1013, 760 
cm
-1. 
 
(4-Oxo-chroman-3-yl)-acetic acid (2.4) 
A mixture of (4-oxo-chroman-3-yl)-acetic acid ethyl ester (2.14, 0.231 g, 0.984 mmol), 
NaOH (81.5 mg, 2.0 mmol), H2O and MeOH was stirred at r.t. for 1h. The methanol was 
then evaporated. H2O was added, and the aqueous layer was washed with CH2Cl2 (3x). 
The aqueous layer was then acidified with 4 N HCl, and extracted with CH2Cl2 (3x). The 
combined extracts were dried (MgSO4), filtered, and the solvent was evaporated. Column 
chromatography (silica, CH2Cl2/MeOH) yielded a white solid (0.206 g, quantitative) 
1H NMR (200 MHz, CDCl3)   2.92-3.05 (q, 1H, CH), 3.44-3.55 (dd, J=5.0 Hz, 1H, CH), 
3.77-8.92 (m, 1H, CH), 4.74-4.86 (t, J=11.75 Hz, 1H, CH), 5.07-5.16 (q, J=5.6Hz, 1H, 
CH), 7.46-7.57 (q, 2H, ArH), 7.94-8.03 (dt, 1H, ArH), 8.37-8.41 (dd, J=1.47, 7.93Hz, 1H, 
ArH) ppm; 
13C NMR (50 MHz, CDCl3)   192.7, 177.3, 162.0, 136.4, 127.7, 121.8, 120.6, 
118.1,  70.3,  42.5,  30.3  ppm;  IR  (NaCl),  3300-2900,  1720,  1692,  1604,  1479,  1299, 
1216, 752 cm
-1; HRMS (M+H)
+ m/z obs. 229.1084 calc. 229.1084 (C12H13O1N4). 
 
(4-Oxo-thiochroman-3-yl)-acetic acid (2.5) 
(4-Oxo-thiochroman-3-yl)-acetic  acid  ethyl  ester  (2.17)  was  synthesized  from 
thiochroman-4-one  (2.15,  1.00  g,  6.09  mmol)  according  to  method  B  of  synthesis  of 
compound 2.3. After addition of ethyl bromoacetate, the mixture was stirred for 4.5 hours 
until workup. The crude mixture contained starting material and product in a ratio of 1:1. 
The crude mixture was purified by column chromatography, yielding 0.79 g of the mixture 
of 2.15 and 2.17. This mixture was hydrolyzed, yielding 0.276 g (20 % overall yield) of 
the purified product as a white solid. 
1H NMR (200 MHz, CDCl3)   2.58-2.69 (m, 1H, CH), 2.98-3.19 (2H, CH2), 3.29-3.41 (m, 
2H,  CH2),  7.16-7.27  (m,  2H,  ArH),  7.35-7.43  (dt,  1H,  ArH),  8.07-8.11  (dd,  J=1.47, 
7.93Hz, 1H, ArH), 10.31 (bs, 1H, COOH) ppm; 
13C NMR (50 MHz, CDCl3)   194.5, 177.8, 
142.0, 133.7, 130.5, 130.0, 127.7, 125.3, 44.6, 34.4, 31.1 ppm; IR (KBr) 3115-2871, 
1705,  1679,  1586,  1438,  1422,  1245,  956,  758,  730  cm
-1;  HRMS  (M+H)
+  m/z  obs. 
223.0416 calc. 223.0423 (C11H11O3S1).  
 
3-Methyl-4-chromanone (2.16) 
Synthesized by published methods.
16  
1H NMR (200 MHz, CDCl3)   1.19-1.23 (d, J=7.08 Hz, 3H, CH3), 2.80-2.91 (m, 1H, CH), 
4.08-4.20 (t, J=11.23 Hz, 1H, CH), 4.45-4.53 (q, 1H, CH), 6.92-7.04 (m, 2H, ArH), 7.41-
7.50 (m, 1H, ArH), 7.87-7.91 (dd, J=1.71, 7.81 Hz, 1H, ArH) ppm; 
13C NMR (50 MHz, 
CDCl3)   193.3, 160.2, 134.2, 125.8, 119.8, 119.0, 116.2, 70.7, 39.2, 9.2 ppm; IR (NaCl) 
3070-2875, 1687, 1605, 1474, 1325, 1213, 758 cm
-1; GCMS m/z 162 (M). 
 
(3-Methyl-4-oxo-chroman-3-yl)-acetic acid ethyl ester (2.18) 
This  compound  was  synthesized  according  to  method  B  of  synthesis  of  compound  2.3 
starting from 3-methyl-4-chromanone (2.16, 1.01 g, 6.23 mmol) The product was purified 
by column chromatography (silica, Hex/EtOAc) as a colorless oil (1.306 g, 84 %). 
1H NMR (200 MHz, CDCl3)   1.20-1.27 (t, 3H, OCH2CH3), 1.29 (s, 3H, CH3), 2.47-2.83 (dd, 
J=15.86,  56.11Hz,  2H,  CH2C(CH3)CH2),  4.06-4.17  (q,  2H,  OCH2CH3),  4.21-4.67  (dd, 
J=11.46, 81.09Hz, 2H, CH2C(CH3)CH2), 6.95-7.06 (q, 2H, ArH), 7.43-7.52 (dt, J=1.76Hz, 
1H,  ArH),  7.88-7.93  (dd,  J=1.77,  7.94Hz,  1H,  ArH)  ppm; 
13C  NMR  (50  MHz,  CDCl3)    Chapter 2 
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195.5, 170.8, 161.3, 136.0, 128.1, 121.9, 119.8, 118.0,74.5, 60.9, 44.0, 38.2, 19.3, 14.4 
ppm; GCMS m/z 234 (M-14), 248 (M); IR (NaCl) 2977, 1733, 1691, 1606, 1479, 1308, 
1198, 1035, 761 cm
-1. 
 
(3-Methyl-4-oxo-chroman-3-yl)-acetic acid (2.6) 
(3-Methyl-4-oxo-chroman-3-yl)-acetic  acid  ethyl  ester  (2.18,  0.412  g,  1.66  mmol)  was 
stirred at r.t. in a solution of KOH (0.189 g, 3.38 mmol) in 7 mL water and 7 mL MeOH. 
The reaction was monitored by TLC. The mixture was washed with EtOAc. The aqueous 
layer was acidified with 1N HCl and extracted with EtOAc. The combined aqueous layers 
were washed with brine, dried (MgSO4), filtered, and the solvent was evaporated. 0.258 g 
(71 %) of an off-white solid was yielded. 
1H  NMR  (200  MHz,  CDCl3)     1.26  (s,  3H,  CH3),  2.45-2.53  (dd,  J=1.18,  16.16Hz,  1H, 
CH2C(CH3)CH2),  2.73-2.81  (d,  J=16.16Hz,  1H,  CH2C(CH3)CH2),  4.13-4.58  (dd,  J=11.46, 
78.74Hz, 2H, CH2C(CH3)CH2), 6.89-7.01 (q, 2H, ArH), 7.38-7.47 (dt, J=0.88, 8.23Hz, 1H, 
ArH), 7.81-7.86 (dd, J=1.47, 7.93Hz, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   160.3, 
136.4,  128.2,  122.0,  119.5,  118.0,  74.3,  43.7,  37.9,  19.3  ppm;  IR  (KBr)  IR07123103 
3101, 1705, 1684, 1606, 1478, 1318, 1225, 1144, 1020, 759 cm
-1; HRMS (M+H)
+ m/z 
obs. 221.0810 calc. 221.0808 (C12H13O4)  
 
1-Bromo-3-ethylsulfanyl-benzene (2.20) 
A  mixture  of  NaH  (1.43  g,  35.8  mmol,  60%  dispersion  in  mineral  oil,  prewashed  with 
hexane) in 80 mL dry THF was cooled on an ice-bath. 3-Bromothiophenol (2.19, 4.50 g, 
23.8 mmol) in 10 mL dry THF was added dropwise. The mixture was left to stir at r.t. 
under N2 for 10 minutes. Ethyliodide (2.3 mL, 4.5 g, 28.8 mmol) was added in one portion. 
The mixture was stirred at r.t. for 3 hours. The reaction was quenched by the addition of 
saturated  NH4Cl.  The  layers  were  separated  and  the  aqueous  layer  was  extracted  with 
Et2O. The combined organic layers were washed with brine, dried (MgSO4), filtered, and 
the solvent was evaporated. A yellow oil (5.26 g, quantitative) was obtained.  
1H NMR (200 MHz, CDCl3)   1.29-1.36 (t, J=7.3 Hz, 3H, CH3), 2.89-3.00 (q, 2H, CH2), 
7.09-7.31 (m, 3H, ArH), 7.43-7.45 (t, J=1.8 Hz, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3) 
  139.5, 131.1, 130.3, 128.8, 127.3, 123.0, 27.6, 14.4 ppm; 
IR (NaCl) 2972, 2925, 1574, 1556, 1460, 1257, 768, 753, 677 cm
-1; GCMS m/z 216 and 
218 (M). 
 
Tributyl-(3-ethylsulfanyl-phenyl)-stannane (2.21) 
A solution of 1-bromo-3-ethylsulfanyl-benzene (2.20, 1.00 g, 4.61 mmol) in dry THF (20 
mL) was cooled to -90
oC. tert-Butyl lithium (1.7 M solution in pentane, 5.8 mL, 9.9 mmol) 
was added dropwise, so that the temperature of the mixture did not rise above -85
oC. The 
solution was stirred at -90
oC for 2 hours. Then, the mixture was left to warm up to -80 
oC, 
and tri-n-butyltin chloride (90 %, 1.55 mL, 1.86 g, 5.14 mmol) was added, turning the 
color of the mixture from yellow to white. The mixture was stirred at -75 
oC for 1.6 hours, 
and was then left to warm up to r.t.. Water was added for quenching. The layers were 
separated, and the aqueous layer was extracted with Et2O. The combined organic layers 
were  washed  with  brine,  dried  (MgSO4),  filtered,  and  the  solvent  was  evaporated.  The 
crude  product  was  used  in  the  subsequent  reaction  without  further  purification.  An 
analytical sample was purified by column chromatography (silica, Hex/EtOAc).  
1H NMR (200 MHz, CDCl3)   0.85-0.92 (m, 10H, SnBu3), 1.00-1.09 (m,5H, SnBu3), 1.24-
1.41  (m,  11H,  SCH2CH3  and  SnBu3),  1.46-1.54  (m,  6H,  SnBu3),  2.88-2.99  (q,  2H, 
SCH2CH3), 7.25-7.27 (m, 3H, ArH), 7.41 (s, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   
143.09, 137.28, 136.178, 134.11, 129.07, 129.07, 128.50, 29.29, 28.07, 27.58, 14.69, 
13.89, 9.86 ppm; GCMS m/z 424/426/428 (M), 367/369/371 (M-C4H9); IR (NaCl) 2924, 
1562, 1462, 1375, 769, 694 cm
-1. 
 KAT inhibitors: Conformationally restricted carboxylic acids 
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4-(3-Ethylsulfanyl-phenyl)-but-2-enoic acid methyl ester (2.22) 
To a solution of bis(triphenylphosphine)palladium(II) chloride (23.4 mg, 0.032 mmol) in 
10 mL dry THF, stirring under N2 at r.t., DIBAL-H (1.7 M solution in toluene, 0.05 mL) was 
added. The mixture was stirred for 20 minutes. Then, a solution of the crude tributyl-(3-
ethylsulfanyl-phenyl)-stannane (2.21, 4.61 mmol), and methyl 4-bromocrotonate (85%, 
0.64 mL, 4.61 mmol) in 5 mL dry THF was added. The mixture was heated at reflux for 4 
hours. The mixture was then left to cool to r.t.. Water was added and EtOAc. The layers 
were separated, and the aqueous layer was extracted with EtOAc. The combined organic 
layers were washed with brine, dried (MgSO4), filtered, and the solvent was evaporated. 
The product was purified by column chromatography (silica, EtOAc:Hex 10:1), yielding an 
oil (0.45 g, 41 %).  
1H  NMR  (200  MHz,  CDCl3)     1.27-1.35  (t,  J=7.34  Hz,  3H,  CH3CH2S)  2.88-2.99  (q,  2H, 
J=7.34 Hz, CH3CH2S), 3.46-3.50 (dd, J=1.17, 6.76 Hz, 2H, ArCH2), 3.72 (s, 3H, OCH3), 
5.77-5.87 (dt, J=1.47, 1.76, 15.57 Hz, 1H, CH), 6.95-7.26 (m, 5H, ArH and CH) ppm; 
13C 
NMR  (50  MHz,  CDCl3)     167.0,  147.4,  138.58,  137.44,  129.40,  129.36,  127.3,  126.5, 
122.40,  51.7,  38.5,  27.7,  14.6  ppm;  IR  (NaCl)  2950,  1724,  1656,  1434,  1274,  1201, 
1036, 981, 781, 691 cm
-1; GCMS m/z 236 (M) 
 
4-(3-Ethylsulfanyl-phenyl)-but-2-enoic acid (2.23) 
4-(3-Ethylsulfanyl-phenyl)-but-2-enoic acid methyl ester (2.22, 0.45 g, 1.89 mmol) was 
dissolved in ethanol (10 mL). Lithiumhydroxide (0.22 g, 9.0 mmol) was added, followed by 
10 mL water. The reaction was stirred at r.t. overnight. Then, the EtOH was evaporated, 
and the aqueous layer was washed with Et2O. The aqeous layer was acidified with 4 N HCl 
and  extracted  with  Et2O.  The  combined  acidic  extracts  were  washed  with  brine,  dried 
(MgSO4), filtered, and the solvent was evaporated. The crude product was used in the next 
reaction  step  without  further  purification.  An  analytical  sample  was  purified  by  column 
chromatography (silica, CH2Cl2), yielding an off-white solid.  
1H NMR (200 MHz, CDCl3)   1.28-1.35 (t, J=7.3 Hz, 3H, CH3), 2.89-3.00 (1, 2H, CH2CH3), 
3.28-3.32 (dd, J=6.8 Hz, ArCH2), 6.20-6.52 (m, 2H, CH=CH), 7.14-7.26 (m, 3H, ArH), 
7.33 (s, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   177.6, 137.5, 137.2, 133.7, 129.21, 
128.5, 127.2, 124.1, 121.8, 38.2, 27.9, 14.6 ppm; IR (NaCl) 3015, 1694, 1415, 1285, 
1216, 1172, 967, 776, 689 cm
-1; MS m/z 177 (M-45)
-, 221 (M-H)
-, 267 (M+46 (formeate)-
H)
-, 443 (2M-H)
-. 
 
4-(3-Ethylsulfanyl-phenyl)-butyric acid (2.24) 
A mixutre of 4-(3-ethylsulfanyl-phenyl)-but-2-enoic acid (2.23, 1.28 g, 5.74 mmol) and 
10%  Pd/C  (1.00  g)  in  methanol  (50  mL)  was  reacted  in  a  Parr  apparatus  at  4  bar 
overnight.  The  reaction  was  filtered  over  Celite
®,  and  the  solvent  of  the  filtrate  was 
evaporated. Water and saturated aqueous NaHCO3 were added, and the aqueous layer was 
extracted  with  EtOAc.  The  combined  organic  layers  were  washed  with  brine,  dried 
(MgSO4), filtered, and the solvent was evaporated, yielding 1.1 g of a red oil. The aqueous 
layer was acidified with 4 N HCl, and extracted with EtOAc. The combined organic extracts 
of the acidic extraction were washed with brine, dried (MgSO4), filtered, and the solvent 
was evaporated. 0.106 g of a brown oil was obtained. TLC, GCMS and IR showed that the 
product was mainly present in the extracts of the alkaline layer as the methyl ester. IR 
(NaCl) 2949, 1740, 1591, 1435, 1261, 1206, 783, 700 cm
-1; GCMS m/z 238 (M of the 
methyl ester). 
The crude product (methyl ester) was dissolved in methanol (10 mL). LiOH (0.38 g, 15.8 
mmol)  was  added,  and H 2O  (10  mL).  The  mixture  was  stirred  at  r.t.  overnight.  The 
methanol was the evaporated in vacuo, and the remaining aqueous layer was washed with 
Et2O. The aqueous layer was then acidified with 4 N HCl, and extracted with Et2O. The 
combined  organic  extracts  were  washed  with  brine,  dried  (MgSO4),  filtered,  and  the 
solvent  was  evaporated,  yielding  0.794  g  (62  %)  of  an  off-white  solid.  A  sample  was 
purified for analysis (column chromatography, silica, CH2Cl2). Chapter 2 
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1H NMR (200 MHz, CDCl3)   1.28-1.35 (t, J=7.35 Hz, 2H, CH3), 1.89-2.03 (m, 2H, CH2), 
2.34-2.42 (t, 2H, CH2), 2.61-2.68 (t, 2H, CH2), 2.89-3.00 (q, 2H, CH2) 6.97-7.01 (m, 1H, 
ArH),  7.15-7.26  (m,  3H,  ArH)  ppm; 
13C  NMR  (50  MHz,  CDCl3)     179.6,  142.1,  136.9, 
129.2, 129.1, 126.8, 126.3, 35.1, 33.5, 27.8, 26.3, 14.6 ppm; IR (KBr) 2925, 1710, 1590, 
1444, 1340, 1211, 924, 771 cm
-1; MS m/z 223.2 (M-H)
-, 269 (M+46(formeate)-H)
-, 447 
(2M-H)
-. 
 
6-Ethylsulfanyl-3,4-dihydro-2H-naphthalen-1-one (2.25) 
Polyphosphoric  acid  (10  g)  was  preheated  to  100 
oC.  4-(3-Ethylsulfanyl-phenyl)-butyric 
acid (2.24, 0.716 g, 3.19 mmol) was added. The mixture was stirred at 100 
oC for 1 h. Ice 
was added. The resulting brown slurry was poured into water, and extracted with EtOAc. 
The  combined  organic  layers  were  washed  with  brine,  dried  (MgSO4),  filtered,  and  the 
solvent  was  evaporated.  The  product  was  purified  by  column  chromatography  (silica, 
Hex/EtOAc 15:1). 0.536 g (81 %) of the product was isolated as a yellow oil. 
1H NMR (200 MHz, CDCl3)   1.33-1.40 (t, J=7.3 Hz, 3H, CH3), 2.04-2.17 (m, 2H, CH2), 
2.58-2.65 (t, 2H, CH2), 2.87-2.93 (t, 2H, CH2), 2.95-3.03 (q, 2H, CH2CH3), 7.08 (s, 1H, 
ArH), 7.12-7.17 (dd, J=8.23, 1H, ArH), 7.90-7.94 (d, J=8.23, 1H, ArH) ppm; 
13C NMR (50 
MHz, CDCl3)   197.9, 154.2, 145.1, 129.8, 127.9, 126.0, 124.7, 39.2, 30.0, 26.1, 23.4, 
14.2 ppm; IR (NaCl) 2929, 1678, 1587, 1346, 1282, 1188, 1096, 853, 819 cm
-1; GCMS 
m/z 206 (M). 
 
(6-Ethylsulfanyl-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl) acetic acid ethyl ester 
(2.26) 
A  solution  of  6-ethylsulfanyl-3,4-dihydro-2H-naphthalen-1-one  (2.25,  0.407  g,  1.97 
mmol) in THF (20 mL) was cooled to -80 
oC under N2. LHMDS (0.497 g, 2.97 mmol) in THF 
(10 mL) was added dropwise. The mixture was stirred for 1h. The temperature was left to 
raise to -20 
oC. Then, the mixture was cooled to -80 
oC, and ethyl bromoacetate (0.22 mL, 
0.33 g, 1.97 mmol) was added to the solution at once. The mixture was left to warm up to 
-60 
oC over 1 hour, and then was left to warm to room temperature. Water was added to 
quench the reaction. The layers were separated, and the aqueous layer was extracted with 
EtOAc. The combined organic layers were washed with brine, dried (MgSO4), filtered, and 
the solvent was evaporated. The mixture of starting material and product was separated 
by column chromatography (silica, Hex/EtOAc 10:1). 0.249 g (43 %) of the product was 
obtained as a colorless oil. 0.151 g (37 %) of the starting material 2.25 was recovered, 
along with 19 mg (2.5 %) of the disubstituted product 2.28.  
1H NMR (200 MHz, CDCl3)   1.24-1.31 (t, J=7.1 Hz, 3H, CH2CH3), 1.33-1.40 (t, J=7.3 Hz, 
3H, CH2CH3), 1.89-2.04 (dt, 1H, CH), 2.16-2.29 (m, 1H, CH), 2.33-2.46 (q, 1H, CH), 2.63-
3.07 (m, 6H, CH2), 4.12-4.23 (q, OCH2CH3), 7.06 (s, 1H, ArH), 7.12-7.17 (dd, 1H, ArH), 
7.89-7.93 (d, J=8.23 Hz, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   197.8, 172.8, 145.3, 
144.6, 129.3, 128.1, 126.0, 124.8, 60.8, 44.8, 35.4, 29.5, 29.4, 26.1, 14.5, 14.2 ppm; IR 
(NaCl) 2928, 1729, 1678, 1588, 1177, 1029, 956, 826 cm
-1; GCMS m/z 292 (M) 
 
Spectral  data  of  (2-ethoxycarbonylmethyl-6-ethylsulfanyl-1-oxo-1,2,3,4-tetrahydro-
naphthalen-2-yl) acetic acid ethyl ester (2.28): 
1H NMR (200 MHz, CDCl3)   1.18-1.25 (t, 6H, OCH2CH3), 1.33-1.41 (t, J=7.35 Hz, 3H, 
SCH2CH3), 2.31-2.37 (t, J=6.47 Hz, 2H, CH2), 2.57-2.65 (d, J=15.86 Hz, 2H, CH2), 2.88-
3.06 (m, 6H, CH2), 4.05-4.16 (q, 4H, OCH2CH3), 7.06 (s, 1H, ArH), 7.13-7.18 (dd, J=1.76, 
8.52 Hz, 1H, ArH), 7.92-7.96 (d, J=8.23Hz , 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3) 
 198.4, 171.1, 145.4, 143.4, 128.9, 128.4, 125.9, 125.0, 60.8, 45.9, 39.6, 30.2, 26.1, 
25.4,  14.4,  14.2  ppm;  GCMS  m/z  378  (M);  IR  (NaCl)  2978,  1728,  1678,  1587,  1223, 
1176, 1100, 1030, 955 cm
-1. 
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(6-Ethanesulfonyl-1-oxo-1,2,3,4-tetrahydronaphthalen-2yl)  acetic  acid  ethyl 
ester (2.27)  
A  solution  of  (6-ethylsulfanyl-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)  acetic  acid  ethyl 
ester  (2.26,  0.221  g,  0.756  mmol)  in  CH2Cl2  (4  mL)  was  stirred  at  0
oC.  m-
Chloroperbenzoic acid (70-75 %, 0.37 g, 1.6 mmol) in CH2Cl2 (4 mL) was added dropwise, 
giving a white precipitate. The mixture was stirred for 1.5 h. NaHCO3 (aq) was added, and 
CH2Cl2 to dissolve the precipitate. The layers were separated, and the aqueous layer was 
extracted  with  CH2Cl2.  The  combined  organic  layers  were  washed  with  brine,  dried 
(MgSO4), filtered, and the solvent was evaporated. The product was purified by column 
chromatography (silica, Hex/EtOAc). Yield: 0.231 g (94 %) colorless oil. 
1H NMR (200 MHz, CDCl3)   1.233-1.31 (dt, 6H, OCH2CH3 and SCH2CH3), 1.92-2.15 (m, 
1H, CH), 2.23-2.36 (m, 1H, CH), 2.44-2.55 (q, 1H, CH), 2.90-3.20 (m, 6H, CH), 4.11-4.22 
(q, 2H, OCH2CH3), 7.78-7.81 (s and d, 2H, ArH), 8.15-8.20 (d, J=8.82Hz, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   197.5, 172.3, 145.1, 142.6, 136.0, 129.0, 128.8, 126.3, 61.0, 
50.7, 45.0, 35.1, 29.5, 28.9, 14.43, 7.6 ppm; GCMS m/z 324 (M); IR (KBr) 2928, 1722, 
1689, 1408, 1302, 1200, 1141, 730 cm
-1. 
 
(6-Ethanesulfonyl-1-oxo-1,2,3,4-tetrahydro-naphthalen-2yl)-acetic acid (2.7) 
A mixture of (6-ethanesulfonyl-1-oxo-1,2,3,4-tetrahydronaphthalen-2yl) acetic acid ethyl 
ester (2.27, 0.210 g, 0.647 mmol), lithium hydroxide (63.4 mg, 2.65 mmol), H2O (7.5 
mL) and MeOH (7.5 mL) was stirred at r.t.. After 2.25 h, the MeOH was evaporated. The 
aqueous layer was washed with CH2Cl2 (3x), and acidified with 4 N HCl. The acidic layer 
was extracted with CH2Cl. The combined extracts were washed with brine, dried (MgSO4), 
filtered,  and  the  solvent  was  evaporated.  The  crude  product  was  purified  by  column 
chromatography (silica, CH2Cl2/MeOH). A white solid was obtained (0.158 g, 83 %). 
1H NMR (200 MHz, CD3OD)   1.183-1.256 (t, J=7.35 Hz, 3H, CH3), 1.95-2.16 (m, 1H, CH), 
2.23-2.36 (m, 1H, CH), 2.48-2.60 (dd, J=6.17, 16.74 Hz, 1H, CH), 2.81-2.92 (dd, J=5.88, 
16.75  Hz,  1H,  CH),  3.00-3.32  (m,  6H,  CH  and  solvent  residual  peak),  7.80-7.84  (d, 
J=8.23 Hz, 1H, ArH), 7.88 (s, 1H, ArH), 8.12-8.16 (d, J=8.22Hz, 1H, ArH) ppm; 
13C NMR 
(50  MHz,  CD3OD)     145.8,  142.6,  135.9,  128.9,  128.0,  125.8,  49.8,  44.8,  34.4,  28.9, 
28.6, 6.3 ppm; IR (KBr) 2959, 1705, 1685, 1319, 1301, 1136, 960, 779, 735 cm
-1; MS 
295  (M-H)
-,  341  (M+46(formeate)-H)
-,  591  (2M-H)
-;  HRMS  (M+H)
+  m/z  obs.  297.0792 
calc/ 297.0791 (C14H17O5S). 
 
(1-Oxo-1,2,3,4-tetrahydronaphthalen-2-yl)-acetonitrile (2.31) 
A  mixture  of   -tetralone  (2.9,  5.00  g,  34.2  mmol),  dimethylamine.HCl  (8.30  g,  102 
mmol), paraformaldehyde (4.17 g, 139 mmol) and 0.5 mL 37 % HCl in 35 mL ethanol was 
heated at reflux for 5 hours. The solvent was evaporated. The residue was converted to 
the free base by addition of NaOH (1 N aq) and extraction with CH2Cl2. The extract was 
dried (MgSO4), filtered, and the solvent was evaporated. The crude Mannich base 2.29 
was  stirred  with  3.4  mL  (7.8  g,  54.0  mmol)  iodomethane  in  100  mL  ethanol  at  room 
temperature  overnight.  The  solvent  was  evaporated.  The  crude  product  2.30  was 
dissolved in 50 mL methanol and 25 mL water and added to a solution of KCN (11.25 g, 
172.8 mmol) in 80 mL methanol and 10 mL water, preheated to 70 
oC. After 10 minutes, 
concentrated HCl was added to neutral pH. After 1.5 hours, another portion of KCN (4.00 
g,  61.4  mmol)  was  added.  HCl  was  added  to  acidify  the  solution.  After  20  minutes  no 
starting material was left (TLC). The mixture was left to cool to r.t. and the solvent was 
evaporated. Water was added, and the aqueous layer was extracted with CH2Cl2 (3x). The 
combined  organic  layers  were  washed  with  brine  and  the  solvent  was  evaporated.  The 
residue was dried by azeotropic distillation with ethanol. The crude product was purified by 
column chromatography (silica, Hex/EtOAc). 2.28 g (34 % overall yield) of an off-white 
solid was obtained. 
1H NMR (200 MHz, CDCl3)   1.93-2.15 (m, 1H, CH), 2.42-2.67 (m, 2H, CH), 2.79-2.94 (m, 
1H, CH), 2.99-3.16 (m, 3H, CH), 7.25-7.36 (q, 2H, ArH), 7.47-7.55 (dt, J=1.47 Hz, 1H, 
ArH), 8.00-8.04 (dd, J=1.17, 7.64 Hz, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   196.3, Chapter 2 
  74 
144.0, 134.3, 131.7, 129.2, 127.9, 127.2, 118.9, 44.7, 29.1, 28.9, 18.7 ppm; GCMS m/z 
185 (M); IR (NaCl) 2933, 2247, 1678, 1599, 1454, 1238, 947, 743 cm
-1. 
 
2-(2H-Tetrazol-5-ylmethyl)-3,4-dihydrox-2H-naphthalen-1-one (2.8) 
A  mixture  of  (1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)-acetonitrile  (2.31,  5.38  mmol), 
NaN3 (1.41 g, 21.7 mmol) and NH4Cl (0.404 g, 7.56 mmol) in 10 mL DMF was heated at 
140 
oC under N2 for 19 hours. The reaction was left to cool to room temperature. The 
insolubles  were  filtered  off,  and  the  residue  was  washed  with  EtOAc.  The  filtrate  was 
concentrated in vacuo. The resulting cake was taken up into water, 0.5 N HCl and EtOAc. 
The layers were separated and the aqueous layer was extracted with EtOAc. The combined 
organic  layers  were  washed  with  brine,  dried  (MgSO4),  filtered,  and  the  solvent  was 
evaporated.  The  crude  product  was  purified  by  column  chromatography  (silica, 
CH2Cl2/MeOH) and subsequent recrystallization from EtOAc/Hex. The product was yielded 
as grey (1
st crop, 0.2356 g) and green (2
nd crop, 0.2626 g) needles (total yield: 0.4979 g, 
41%). 
1H NMR (200 MHz, CDCl3)   1.89-2.11 (dq, 1H, CH), 2.32-2.42 (m, 1H, CH), 2.96-3.24 
(m, 3H, CH), 3.33-3.56 (m, 2H, CH), 7.22-7.33 (q, 2H, ArH), 7.47-7.54 (dt, 1H, ArH), 
7.97-8.01 (d, J=7.64, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   200.7, 155.0, 144.6, 
134.6, 132.0, 129.2, 127.8, 127.1, 47.0, 30.0, 29.4, 24.9 ppm; MS m/z 229 (M+H)
+, 251 
(M+Na)
+, 457 (2M+H)
+, 479 (2M+Na)
+; IR (KBr) 3001-2464, 1474, 1598, 1550, 1454, 
1428,  1233,  1048,  949,  738  cm
-1;  HRMS  (M+H)
+  m/z  obs.  229.1084  calc.  229.1084 
(C12H13O1N4).  
 
Kynurenine aminotransferase activity in rat brain homogenate 
KAT  inhibitory  activity  was  determined  in  rat  brain  tissue  homogenate  as  described 
previously,  with  modifications.
22,  30  Rat  brain  (male  Wistar  rats,  whole  brain)  was 
homogenized  in  a  5  mM  Tris-acetate  buffer  at  pH  8.0,  containing  50  µM  pyridoxal  5’- 
phosphate  and  10  mM  2-mercaptoethanol  (10  %  w/v).  The  homogenate  was  dialyzed 
against  this  buffer  for  24  hours  at  4 
oC  (12  mL  homogenate  /  2.5  L  buffer).  Enzyme 
activity was tested in an assay consisting of 200 µL of dialyzed tissue homogenate, 150 
mM Tris acetate buffer, pH 8.0, 70 µM pyridoxal 5’-phosphate, 1 mM pyruvate, 10 µM L-
kynurenine  and  the  inhibitor  in  a  final  volume  of  250  µL  (all  concentrations  final).  The 
mixture was incubated at 37 
oC for 2 h. The reaction was terminated by addition of 100 µL 
7%  perchloric  acid.  The  mixture  was  centrifuged  for  15  minutes  at  14000  rpm,  4
oC. 
Kynurenic acid concentrations were determined in the supernatant by HPLC (Supelcosil
TM 
HPLC column, 15 cm x 3 mm, 3 µm). The mobile phase consisted of a buffer containing 
15% methanol, 10 g/L Na2HPO4.2H2O, 150 mg/L EDTA and 0.17 % (v/v) THF, adjusted to 
pH 5.27 with phosphoric acid. The product was detected fluorimetrically at an extinction of 
344 nm and emission of 398 nm. Each concentration of inhibitor was assayed in triplo. The 
KYNA concentration in each sample was determined in triplo. 
 
Kynureninase activity in liver tissue homogenate 
Kynureninase  activity  was  determined  in  rat  liver  tissue  homogenate  as  described 
previously, with modifications.
31, 32 Liver tissue was homogenated in a buffer (10 % w/v) 
consisting of 20 mM Tris-acetate pH 8.0, 0.5 mM 2-mercaptoethanol, and 50 µM pyridoxal 
5’-phosphate. The homogenate was centrifuged at 14000 rpm for 30 minutes at 4
oC. The 
supernatant was dialyzed against the buffer as described above (12 mL supernatant/2.5 L 
buffer) for 24 hours at 4
oC. Enzyme activity was determined using 100 µL of the dialyzed 
tissue, 50 µL of a solution consisting of 400 mM Tris-HCl buffer pH 8.0, 200 µM pyridoxal 
5’-phosphate and 40 µM L-kynurenine (final concentration 10 µM), and 50 µL inhibitor at 
varying concentrations. The mixture was incubated at 37 
oC for 30 minutes. The reaction 
was terminated by mixing with 100 µL 7% perchloric acid. The samples were centrifuged 
at 14000 rpm for 15 minutes at 4
oC. Anthranilic acid concentrations in the supernatant 
were measured by HPLC.  KAT inhibitors: Conformationally restricted carboxylic acids 
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The supernatant was applied to a Supelcosil
TM HPLC column (15 cm, 4.6 or 3 mm ID, 3 µm 
particle size). The mobile phase consisted of a buffer containing 26 % methanol, 10 g/L 
Na2HPO4.2H2O,  150  mg/L  EDTA  and  0.17  %  (v/v)  THF,  adjusted  to  pH  5.27  with 
phosphoric acid. The product was detected fluorimetrically at an extinction of 313 nm and 
emission of 420 nm. Each concentration of inhibitor was assayed in triplo. The anthranilic 
acid concentration in each sample was determined in triplo. 
 
Kynurenine 3-hydroxylase activity in liver tissue homogenate 
Kynurenine  3-hydroxylase  activity  was  determined  in  rat  liver  tissue  homogenate  as 
described previously, with modifications.
31 The tissue was homogenized in icecold 0.32 M 
sucrose  solution (1 g tissue /8 mL sucrose solution). The homogenate was centrifuged at 
11000  rpm,  4 
oC,  30  min.  The  supternatant  was  taken  off,  and  the  residue  was 
resuspended in sucrose solution (1 mL 0.32 M sucrose /residue of 1 mL homogenate). The 
tissue was centrifuged (11000 rpm, 4
oC, 30 min). This washing procedure was repeated 
twice. The resulting tissue was resuspended in 0.14 M KCl, 20 mM potassium phosphate 
buffer at pH 7.0.  
Enzyme activity was measured using 75 µL of the tissue homogenate, 100 µL of a 100 mM 
potassium phosphate buffer pH 7.5, containing 1 mM NADPH, 4 mM MgCl2, and 20 µM L-
kynurenine (final concentration 10 µM), and 25 µL of a solution of the inhibitor at varying 
concentrations.  The  mixture  was  incubated  at  37 
oC  for  30  minutes.  The  reaction  was 
terminated by the addition of 100 µL 7% perchloric acid. The samples were centrifuged 
(14000  rpm,  15  minutes,  4
oC).  The  concentrations  of  3-hydroxykynurenine  in  the 
supernatant  were  determined  by  HPLC.  The  supernatant  was  applied  to  a  Supelcosil
TM 
HPLC column (15cm, 4.6 or 3 mm ID, 3 µm particle size). The mobile phase consisted of a 
solution of 100 mg EDTA, 150 mg heptane sulphonic acid, 5.9 mL phosphoric acid, 9.0 mL 
triethylamine  and  20  mL  acetonitrile  in  950  mL  H2O  (adapted  from  ref
33).  Each 
concentration of inhibitor was assayed in triplo. The 3-hydroxykynurenine concentration in 
each sample was determined in triplo. 
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3.1  Introduction 
Kynurenic acid (KYNA) is one of the major products of tryptophan metabolism. It 
is  a  non-competitive  antagonist  at  NMDA  receptors  and  an  antagonist  at   7* 
nicotinic acetylcholine receptors. At higher concentrations, KYNA is an antagonist 
at  all  ionotropic  glutamate  receptors  and  an  agonist  at  GPR35  receptors. 
Elevated  levels  of  KYNA  have  been  found  in  patients  suffering  from 
schizophrenia. KYNA is thought to impair cognitive functions.
1-9  
 
KYNA  is  synthesized  by  kynurenine  aminotransferases  (KAT)  from  its  direct 
precursor kynurenine (KYN, 3.1, Scheme 1).  
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At least four isoforms of this enzyme exist, named KAT I-IV. Under physiological 
circumstances, KAT II is the major KYNA producing enzyme in the brain.
10 The 
production of KYNA can be impaired by inhibition of the biosynthetic enzyme. 
Since  the  kynurenine  pathway  is  highly  balanced,  KAT  inhibiotors  need  to  be 
selective  over  kynureninase  (KYNase)  and  kynurenine  3-hydroxylase 
(kynurenine mono-oxygenase, KMO). These enzymes convert KYN in competing 
reactions  into  anthranilic  acid  (AA)  and 3 -hydroxykynurenine  (3-OH-KYN), 
respectively.  
Two selective inhibitors are known for KAT II. The first inhibitor is S-ESBA (3.2, 
Scheme 1).
11, 12 This compound is a close KYN analog. The second inhibitor is BF 
122 (3.3, Scheme 1).
13 This compound is not a direct structural analog of KYN.  KAT inhibitors: Conformationally restricted amino acids 
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To  study  requirements  for  compounds  that  selectively  inhibit  brain  KAT,  this 
study  aimed  for  the  synthesis  of  conformationally  restricted  KYN  analogs  3.4 
(Scheme 1).  
 
Structurally,  compounds  3.4  are  non-natural   -amino  acids.  Divergent 
strategies have been published in literature for the synthesis of natural and non-
natural amino acids.  
A classical method is the Strecker synthesis.
14 In this approach, an aldehyde is 
treated with ammonia in the presence of HCN. A cyanate intermediate is formed, 
which is hydrolyzed to obtain the amino acid (Scheme 2).  
 
Scheme 2 
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Many  efforts  have  been  made  to  synthesize  enantiopure  amino  acids  using 
asymmetric Strecker-type methods (e.g. ref
15-19). 
 
A second set of synthetic methods includes the Hofmann, Curtius and Lossen 
rearrangements (Scheme 3). 
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In  these  reactions,  the  amino  function  is  introduced  by  rearrangement  of  an 
amide,  carboxylic  azide  or  hydroxamic  acid,  respectively,  via  an  isocyanate 
intermediate to finally obtain the amino acid.
20 Chapter 3 
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A rather aselective method for amino acid synthesis involves the amination of  -
halo-carboxylic acids (Scheme 4). 
 
Scheme 4 
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For N-substituted amino acids, instead of ammonia, the accordingly substituted 
amine can be used as the reagent. 
 
Introduction of the amino acid moiety as a nitroacetate ester is another method 
that has been widely described in literature and is particularly suitable for the 
synthesis of  , -disubstituted amino acids (Scheme 5, e.g. ref
21-26). 
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The amino acids are yielded by reduction of the nitro group and ester hydrolysis. 
 
In search of methods that seemed feasible for the synthesis of KYN analogs, two 
synthetic  strategies  were  found  in  literature  for  published  inhibitors.  The  first 
method employs alkylation of N-acetylaminomalonic esters (Scheme 6). 
 
Scheme 6 
R1
X +
R1 COOH
NH2 HN
O
O
OR2
R2O
O
R1
HN O
OR2
O R2O
O
 
 
The  N-acetylaminomalonic  ester  can  be  alkylated  at  the   -carbon  atom. 
Hydrolysis  and  decarboxylation  affords  the  free  amino  acid.  This  route  was 
employed for the synthesis of racemic KYN analogs that were tested as inhibitors KAT inhibitors: Conformationally restricted amino acids 
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of  the  kynurenine  pathway.
11,  27-30  Analogs  3.4a  and  3.4b  were  synthesized 
previously  using  this  method  and  were  tested  for  their  KYNase  inhibitory 
activity.
31 
 
A second strategy involves amino acid precursors that are protected in a five-
membered  ring  system.  Methods  include  Erlenmeyer  and  Bucherer-Bergs 
reactions and reactions of oxazolidinones and imidazolidinones (Scheme 7). 
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Hydantoins, oxazolidinones and imidazolidinones are useful intermediates in the 
synthesis  of   , -disubstituted  amino  acids.  For  oxazolidinones  and 
imidazolidinones,  substitution  in  the   -position  is  readily  achieved  via  enolate 
formation.  Using  this  method,  enantioselective  synthesis  of   -amino  acids  is 
possible.
32-37 For KYN and KYN analogs, syntheses based on oxazolidinones have 
been explored most frequently.
11, 28, 38, 39 
 
For the synthesis of bicyclic KYN analogs 3.4, synthetic strategies based on the 
examples above were explored. However, in our hands, none of the methods 
was  successful.  Therefore,  an  alternative  approach  was  explored.  In  this Chapter 3 
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approach, the enolate form of the tetralone-derived bicyclic core is coupled to an 
aldimine, which incorporates the amino acid moiety of the desired structures. 
After  the  coupling,  deprotection  of  the  amino  acid  moiety  led  to  the  desired 
structures in a reasonably straightforward way. 
Inhibitory activity of the compounds for KAT, KYNase and KMO was tested and 
compared to the inhibitory activity of reference compound (S,R)-ESBA ((S,R)-
3.2). 
3.2  Chemistry 
The key step in the synthesis of compounds 3.4 is coupling of the bicyclic core 
structure to an amino acid moiety. The coupling reaction is catalyzed by SmI2, 
which acts as a Lewis type acid (electron pair acceptor). The general reaction 
scheme for synthesis of compounds 3.4 is shown in Scheme 8. 
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Z
O
Z
O
Si
Z
O
O
N
O
O HN
O
O
O
Z
O NH2
O
OH
3.5a: Z = CH2
3.5b: Z = O
3.5c: Z = S
3.6a: Z = CH2
3.6b: Z = O
3.6c: Z = S
3.7
3.8a: Z = CH2
3.8b: Z = O
3.8c: Z = S
3.4a: Z = CH2
3.4b: Z = O
3.4c: Z = S
a. b.
c, d, e.
 
Reagents and conditions: a. 1. LHMDS, THF, -80
oC 2. TMSCl; b. SmI2(THF)2, CH2Cl2, 
r.t.;  c.  1.  PhI(OAc)2,  MeOH,  2.  acetic  anhydride,  Na2CO3,  H2O/CH2Cl2  or  d.  CAN, 
CH3CN/H2O; e. HCl or NaOH 
 
The  tetralone  derived  core  structure  3.5  is  brought  into  its  enolate  form  by 
reaction with LHMDS and TMSCl. Trimethylsilyl enolate 3.6 is then coupled to 
aldimine 3.7
40 in a SmI2-catalyzed nucleophilic addition reaction.  
 
The reaction mechanism for SmI2-catalyzed condensation has been studied in 
detail for coupling of enoxysilanes and aldehydes.
41 It was concluded that the 
samarium catalyst functions as a pre-catalyst, and that a silyl iodide derivative is 
generated. The silyl iodide derivative can function as an additional catalyst. The 
mechanism  as  proposed  for  the  present  set  of  reactions,  according  to  the 
findings in ref
41, is shown in Scheme 9. 
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In the first step of the cycle, the aldimine is activated by the SmI2- catalyst by 
formation of complex I. In the next step, enoxysilane 3.6 adds to the aldimine 
complex  I  to  form  complex  II.  From  this  complex,  trimethylsilyl  iodide  is 
liberated by exchange of one atom of iodide from the samarium complex to the 
silyl-complex.  This  intermediate  can  either  exchange  with  the  samarium 
substituent  of  complex  III  to  regenerate  the  samarium-catalyst,  or  act  as  a 
catalyst itself in a new silyl iodide catalyzed coupling cycle. Either way, complex 
IV is formed, which gives coupling product 3.8 by aqueous hydrolysis of the silyl 
substituent.  
 
Samarium iodide complexes can exist in bivalent and trivalent complexes. The 
bivalent SmI2(THF2) has a blue color, whereas trivalent SmI3(THF)3 has a yellow 
color. In the usual course of the procedures followed here, the SmI2-solution in 
THF  turned  from  blue  to  brightly  yellow  during  evaporation  of  the  THF.  This 
indicates, that the actual complex formed is trivalent SmI3(THF)3, acting as the 
pre-catalyst in the coupling reaction, rather than bivalent SmI2(THF)2. Since the 
reaction proceeds well, this confirms the observation reported in ref
41 that the 
actual  catalytic  species  is  the  trivalent  complex.  It  is  assumed,  that  the 
mechanism of the reaction with the trivalent catalyst form is analogous to the 
mechanism as shown in Scheme 9 for the bivalent catalyst form. 
 
After the coupling reaction between the bicyclic core structure and the amino 
acid moiety, deprotection of the coupled amino acids 3.8 was desired. The  -Chapter 3 
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tetralone and the 4-oxochromanone derivatives were deprotected oxidatively by 
reaction  with  iodobenzene  diacetate.  To  facilitate  the  isolation  of  the  product 
from reaction materials, the deprotected primary amino-group was reprotected 
immediately by acetylation (Scheme 10).
42 
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Reagents  and  conditions:  a.  1.  PhI(OAc)2,  MeOH,  2.  acetic  anhydride,  Na2CO3, 
H2O/CH2Cl2 b. HCl, H2O 
 
At this stage, diastereomers of 3.9a or 3.9b could be isolated by simple silica 
column  chromatography.  Final  products  3.4a  and  b  could  be  obtained  by 
hydrolysis in HCl. To our disappointment, even though the pure diastereomer of 
3.9a was hydrolyzed, the free amino acid could only be isolated as a mixture of 
both diastereomers. Probably, racemisation at the position   to the amino acid 
by  keto-enolization  had  occurred  during  deprotection  of  the  acetyl  ester. 
Interestingly,  during  the  synthesis  of  3.4b,  it  was  noticed  that  one  of  the 
diastereomers  was  formed  preferentially  over  the  other.  After  hydrolysis  of 
acetyl  ester  3.9b,  one  of  the  two  diastereomers  was  present  in  the  reaction 
mixture  in  excessive  amounts  if  compared  to  the  other  diastereomer. 
Apparently, the conformation of one diastereomer is significantly more favorable 
over the conformation of the second diastereomer. For enzyme inhibition assays, 
a  mixture  of  diastereomers  3.4b  was  tested  that  contained  the  more  stable 
diastereomer  in  excess  of  the  less  stable  diastereomer  (77  %  /  23  %,  as 
determined by HPLC). 
 
For  the  thiochoman-4-one  derivative  3.8c,  oxidative  deprotection  by  reaction 
with iodobenzene diacetate was unsuccessful. Several attempts were made to 
reprotect  the  free  amino-group  with  an  acetyl  or  a  BOC  protective  group. 
However,  attempted  protection  of  the  amino-group  after  reaction  with 
iodobenzene diacetate yielded S-oxidized products based on MS analysis in low KAT inhibitors: Conformationally restricted amino acids 
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yields only. The BOC-protected or free amino acid could not be isolated. Finally, 
deprotection could be achieved by treatment with ceric ammonium nitrate (CAN) 
in acetonitrile/water (Scheme 11). 
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Reagents and conditions: a. CAN, ACN/H2O b. NaOH, H2O 
 
Apparently, already under weakly acidic conditions, the amino group of 3.4c is 
protonated.  Therefore,  for  successful  extraction  of  the  deprotected  product, 
treatment  of  the  reaction  mixture  with  base  was  necessary.  However,  upon 
addition  of  NaOH  or  NaHCO3  to  the  aqueous  reaction  mixture,  the  remaining 
reagent  precipitated,  causing  severe  emulsification.  This  complicated  the 
extraction of the unprotonated amine 3.10 into the organic layer. Still, yields 
were acceptable to proceed to the next step in the reaction scheme. The free 
amino acid 3.4c was obtained from 3.10 by direct hydrolysis with NaOH and 
subsequent column chromatography. For 3.4c, a mixture of both diastereomers 
in equal amounts was obtained. 
3.3  Enzyme inhibition 
The final compounds 3.4a, b and c were tested for their ability to inhibit KAT, 
KYNase and KMO. Rat brain homogenate was used as the enzyme source for the 
KAT assay. Rat liver homogenates were used to assay activities of KYNase and 
KMO. Data for enzyme inhibition are shown in Table 1. As a reference, racemic 
ESBA ((S,R)-3.2) was tested. Chapter 3 
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Table 1 Enzyme inhibition 
Compound  % KAT activity 
(inhibitor 
concentration) 
% KYNase activity 
(inhibitor 
concentration) 
% KMO activity 
(inhibitor 
concentration) 
O NH2
O
OH
 
3.4a 
64.0±3.0 (3 mM)  83.7±1.7 (1 mM)  16.9±0.6 (1 mM) 
O NH2
O
OH
O  
3.4b 
56.1±1.7 (3 mM)  70.1±1.4 (1 mM)  24.3±1.1 (1 mM) 
O NH2
O
OH
S  
3.4c 
57.4±0.9 (3 mM)  57.0±0.9 (1 mM)  7.2±0.3 (1 mM) 
S
O O
O
O
OH
NH2
 
(S,R)-3.2 
57.7±1.9 (1 mM) 
44.7±1.6 (3 mM) 
94.2±3.3 (1 mM) 
74.5±2.8 (3 mM) 
87.6±2.5 (1 mM) 
85.6±1.3 (3 mM) 
3.4  Discussion and conclusion 
The  compounds  presented  in  this  work  were  designed  as  conformationally 
restricted KYN analogs to aim for inhibition of KAT in the brain. In general, the 
affinity  and  inhibitory  activity  of  conformationally  restricted  substrate  analogs 
can provide information about the preferred conformation at the time of binding 
of  the  substrate  to  the  enzyme  binding  site.  If  the  compound  is  already 
restricted  in  this  preferred  conformation,  this  results  in  a  decreased  energy 
demand for binding. Therefore, the affinity of the compound for the enzyme will 
be enhanced. Another reason for conformational restriction is the optimization of 
drug-like  properties  of  a  compound.  KYN  is  a  rather  polar  compound. 
Introduction of hydrophobic elements might facilitate crossing over membranes 
and brain penetration of the compound. 
 
The  aim  for  the  present  compounds  is  to  inhibit  brain  KAT  selectively  over 
KYNase and KMO. In this way, brain KYNA concentrations can be decreased. For 
KAT, only two selective inhibitors are known, one of which is a direct structural 
analog of KAT substrate KYN (Scheme 1).  
 KAT inhibitors: Conformationally restricted amino acids 
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KYN  can  adopt  two  low  energy  conformations.  The  conformations,  arbitrarily 
named conformation A and B, are shown in Scheme 12 (see Chapter 4). 
 
Scheme 12 
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In low energy conformation A, the benzoylic carbonyl group points towards the 
aromatic NH2-group. In low energy conformation B, the benzoylic carbonyl group 
points away from the aromatic NH2-group. 
 
From the crystal structure of human KAT II in complex with kynurenine
43 it is 
known  that  the  position  of  the  substrate  is  highly  defined  by  a  conserved 
interaction between the carboxylic acid group of KYN and the guanidinium group 
of an Arg residue. The position of the aromatic part of the molecule is defined by 
the position of the N-terminal arm of the KAT enzyme monomer that points into 
the binding site. In the substrate bound crystal structure of human KAT II, a 
shift of this chain is observed if compared to the unbound structure, to create 
space  for  accommodation  of  the  aminophenyl  group  of  KYN.  The  benzoylic 
oxygen interacts with the sidechain of a Tyr residue that lines the binding site. 
Although the orientation of the benzoyl group is not entirely planar in the crystal 
structure, the conformation adopted by kynurenine approximates conformation 
B in Scheme 12. 
Bicyclic structures 3.4 were designed as analogs of this conformation of KYN. 
Heteroatoms  Z  represent  the  position  of  the  aromatic  amino  group.  If  the 
bicyclic structure indeed binds in an orientation that is similar to the orientation 
of KYN, the methylene bridge connecting heteroatoms Z and the  -C atom of the 
amino  acid  side  chain  would  point  towards  the  flexible  N-terminal  arm. 
Hypothetically,  the  flexibility  of  the  N-terminal  arm  portion  within  the  binding Chapter 3 
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site is high enough to accommodate the additional steric bulk of the methylene 
bridge in compounds 3.4. 
 
After  synthesis  of  the  carbon,  oxygen  and  sulfur  analogs  of  3.4,  these 
compounds  were  tested  for  their  ability  to  inhibit  KAT  enzymes  in  rat  brain 
homogenate. Racemic ESBA (compound (S,R)-3.2) was tested under the same 
circumstances for reference. For enantiopure S-ESBA, an IC50 value of 100 µM 
was  found  for  KAT  II  inhibition  in  rat  liver  homogenate.
11  For  recombinant 
human KAT II, KAT activity was reduced to 36% at an inhibitor concentration of 
1 mM.
12 In the assay used in the present study, ESBA showed a more limited 
potency.  Apart  from  inter-assay  variation,  deviations  from  literature  values 
might reflect differences in enzyme source and differences in potency of racemic 
ESBA  used  here  versus  enantiopure  S-ESBA  used  in  literature.  Furthermore, 
whereas  literature  values  are  for  KAT  II  in  particular,  the  present  assay  was 
performed  at  a  higher  pH  to  take  into  account  both  KAT  I  and  KAT  II  (and 
optionally KAT III and IV) activity. 
 
Compounds  3.4a,  b  and  c  inhibit  KAT  slightly  less  potently  than  ESBA  at  an 
inhibitor  concentration  of  3  mM.  More  importantly  however,  the  compounds 
potently inhibit rat liver KMO activity. At a bath concentration of 1 mM, KMO 
activity is reduced to up to 7% of total activity for compound 3.4c. Additionally, 
rat  liver  KYNase  activity  is  inhibited  at  a  bath  concentration  of  1  mM.  These 
results  imply,  that  the  compounds  designed  in  this  study  are  not  suitable  to 
achieve  a  decrease  of  KYNA  concentrations  in  the  brain.  More  likely,  if  the 
compounds  are  delivered  systemically  in  vivo,  inhibition  of  peripheral  KYNase 
and KMO will result in elevated KYN availability in the periphery. KYN passes the 
blood brain barrier and elevated levels in the periphery will result in elevated 
brain levels of KYN. The enhanced availability of substrate for KAT will result in 
an increase rather than a decrease in brain KYNA production.  
What  can  be  learned  from  this  study  is  that  apparently,  replacement  of  the 
aromatic amino group by carbon, sulfur or oxygen and concomitant introduction 
of  a  methylene  bridge  between  this  atom  and  the   -CH2  group  is  tolerated 
reasonably well in terms of interaction between the compound and KAT enzyme. 
For future studies, introduction of the ethylsulfonyl side chain as present in ESBA 
is an interesting option for introduction of selectivity. Furthermore, variation in 
the size of the heterocyclic ring can provide insight into the degree of flexibility 
within the KAT binding site. A drawback of the bicyclic compounds presented in 
this  study  is  the  presence  of  two  chiral  centers  in  the  molecules.  Even  after KAT inhibitors: Conformationally restricted amino acids 
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separation of enantiomers, the chiral center next to the carbonyl moiety will be 
subject  to  racemisation  due  to  keto-enolization  of  the  carbonyl  function. 
Therefore, in future compound series, replacement of this carbon atom should 
be considered. For this purpose, a nitrogen atom might be of particular interest. 
Substitution by a nitrogen function would not only circumvent the problem of 
chirality, but would also simplify the synthesis of bicyclic KYN analogs. 
 
In conclusion, the SmI2-catalyzed nucleophilic addition reaction provides a novel 
method for synthesis of bicyclic KYN analogs. Bicyclic analogs 3.4 a, b and c 
show KAT inhibitory activity, but the compounds are not selective KAT inhibitors. 
The  compounds  potently  inhibit  liver  KMO.  Liver  KYNase  is  inhibited  with 
moderate potency. The compounds can function as leads for a conformationally 
restricted  class  of  KYN  pathway  inhibitors.  Further  characterization  and 
structural  optimization  is  needed  to  obtain  pharmacologically  useful  new 
inhibitors. 
3.5  Experimental section 
General NMR spectra were taken on a Varian spectrometer, at the frequency as stated in 
the  text.  Chemical  shifts  are  given  in  ppm.  The  splitting  patterns  are  designated  as 
follows: s = singlet, d = doublet, t = triplet, m = multiplet, bs = broad singlet. Coupling 
constants  are  given  in  hertz  (Hz).  IR  spectra  are  taken  on  an  ATI-Mattson 
spectrophotometer. GCMS analysis were performed on a Shimadzu GCMS-QP500 system 
equipped an AOC-20i auto injector and a CP-Sil 5 CB column (15 m x 0.25 mm; 0.10 µm 
film thickness). Mass spectra (ESI) were taken on an API 3000 MS/MS system. Accurate 
mass  measurements  (HRMS)  were  performed  using  a  flow  injection  method  on  a  LTQ-
Orbitrap XL mass spectrometer (Thermo Electron, Bremen, Germany) with a resolution of 
60000 at m/z 400. All final compounds had ad least 95% purity, as determined by HPLC. 
Solvents and reagents were obtained from general sources and used as such. THF was 
dried by distillation over Na. 
 
General procedure for the synthesis of 3.6 
(3,4-Dihydronaphthalen-1-yloxy)-trimethylsilane (3.6a) 
A solution of  -tetralone (5.00 g, 34.2 mmol) in dry THF (100 mL) was cooled to -78 
oC 
under an atmosphere of N2. A solution of LHMDS (8.64 g, 51.6 mmol) in dry THF (40 mL) 
was added dropwise over 20 minutes. The mixture was left to warm up to -15 
oC over 1.5 
h, and then cooled again to -78 
oC. Trimethylsilylchloride (6.6 mL, 5.6 g, 51.3 mmol) was 
added at once. The reaction was left to warm up to 5 
oC over 1.75 h and quenched by the 
addition of water. The layers were separated, and the aqueous layer was extracted with 
EtOAc. The combined organic layers were washed with brine, NH4Cl and again with brine, 
dried (MgSO4), filtered, and the solvent was evaporated. The crude product (10.6 g) was 
used in the following reaction step without further purification. 
IR (NaCl) 2957, 1638, 1337, 1251, 1092, 918, 845, 760 cm
-1; GCMS m/z 218 (M), 146 
(starting material, decomposition during analysis). 
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(2H-Chromen-4-yloxy)-trimethylsilane (3.6b) 
Synthesized from 4-chromanone (5.00 g, 33.8 mmol) according to the general procedure. 
An analytical sample was purified by column chromatography (silica, petroleum ether 40-
60/EtOAc 4:1).  
1H NMR (200 MHz, CDCl3)   0.29 (s, 9H, Si(CH3)3), 4.81-4.92 (m, 3H, CH2CH), 6.76-6.81 
(dd, 1H, ArH), 6.86-6.95 (dt, 1H, ArH), 7.10-7.19 (dt, 1H, ArH), 7.31-7.35 (dd, ArH); 
13C 
NMR (50 MHz, CDCl3)   154.1, 144.3, 128.0, 121.0, 120.7, 119.4, 113.9, 96.7, 64.3, -1.4 
ppm;  GCMS  m/z  220  (M),  148  (starting  material,  decomposition  on  GCMS);  IR  (NaCl) 
2959, 1650, 1486, 1355, 1252, 880, 846, 756 cm
-1. 
 
Trimethyl-(2H-thiochromen-4-yloxy)-silane (3.6c) 
Synthesized  from  thiochroman-4-one  (5.00  g,  30.4  mmol)  according  to  the  general 
procedure. 
IR (NaCl) 2957, 1637, 1344, 1254, 1232, 900, 874, 846, 760 cm
-1. 
 
(4-Methoxy-phenylimino)-acetic acid ethyl ester (3.7) 
To a solution of ethyl glyoxalate (50% solution in toluene, 7 mL) in 70 mL dry CH2Cl2, a 
solution of p-anisidine (4.21 g, 34.2 mmol) in 20 mL dry CH2Cl2 was added dropwise. The 
mixture was stirred at r.t. for 30 minutes. Then, molsieves 4   (7.5 g) were added, and 
the mixture was stirred at r.t. overnight. The mixture was filtered over Celite
®, and the 
solvent of the filtrate was evaporated. 7.73 g of a brownish oil was obtained which was 
used as such in the next reaction step. 
1H NMR (200 MHz, CDCl3)   1.35-1.43 (t, 3H, CH2CH3), 3.82 (s, 3H, OCH3), 4.35-4.45 (q, 
2H, CH2), 6.90-6.94 (dd, J=6.8 Hz, 2H, ArH), 7.33-7.37 (dd, J=6.8 Hz, 2H, ArH), 7.93 (s, 
1H, CH) ppm; 
13C NMR (50 MHz, CDCl3)   146.5, 122.1, 113.0, 60.4, 54.0, 12.7 ppm; IR 
(NaCl) 2981, 1739, 1713, 1588, 1505, 1290, 1251, 1031, 838 cm
-1; GCMS m/z 207 (M). 
 
General procedure for the synthesis of 3.8  
(4-Methoxyphenylamino)-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)-acetic  acid 
ethyl ester (3.8a) 
The solvent of a 0.1 M solution of SmI2 in THF (34 mL, 3.4 mmol SmI2) was removed by 
distillation under an atmosphere of N2. A yellow solid was obtained. Dry CH2Cl2 (100 mL) 
was  added.  (4-Methoxy-phenylimino)-acetic  acid  ethyl  ester  (3.7,  34.2  mmol)  in  some 
CH2Cl2  was  added  and  subsequently,  crude  (3,4-dihydronaphthalen-1-yloxy)-
trimethylsilane (3.6a, 34.2 mmol) was added. The yellow/brown mixture was stirred at 
room temperature overnight. Then, 100 mL 0.1 N HCl was added and the biphasic system 
was stirred vigorously for 30 minutes. The layers were separated and the aqueous layer 
was  extracted  with  CH2Cl2  (3x).  The  combined  organic  layers  were  washed  with  brine, 
dried (MgSO4), filtered, and the solvent was evaporated. The product was isolated as the 
mixture of diastereomers by column chromatography (silica, Hex/EtOAc 2:1) as a red solid 
(7.51 g, 62% over 2 steps). 
1H NMR (200 MHz, CDCl3)   1.13-1.26 (m, 3H, CH2CH3), 2.06-2.30 (m, 2H, CHCH2), 3.01-
3.09 (m, 2H, CCH2), 3.27-3.37 (dq, 1H, COCH), 3.73 (s, 3H, OCH3), 4.11-4.22 (m, 2H, 
CH2CH3), 4.45-4.46 (d, J=2.9 Hz, 1H, NHCH), 6.67-6.83 (m, 4H, ArH), 7.22-7.35 (q, 2H, 
ArH), 7.44-7.51 (dt, 1H, ArH), 7.02-7.06 (dd, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   
151.4,  142.5,  139.8,  132.2,  130.9,  127.2,  126.2,  125.9,  125.3,  115.4,  114.1,  113.4, 
113.2, 59.9, 57.7, 54.2, 49.3, 27.5, 27.3, 24.6, 23.7, 12.7, 12.5 ppm; GCMS m/z 353 
(M),  230  (M-NH2PhOMe),  123  (NH2PhOMe);  IR  (NaCl)  3381,  2929,  1730,  1678,  1513, 
1231, 1035, 821 cm
-1. 
From earlier studies, the diastereomers were analyzed: 
First fraction: 
1H NMR (200 MHz, CDCl3)   1.13-1.20 (t, 3H, CH2CH3), 2.06-2.36 (m, 2H, CH2), 3.01-3.09 
(m, 2H, CH2), 3.26-3.36 (m, 1H, COCH), 3.73 (s, OCH3), 4.12-4.22 (q, 2H, OCH2CH3), 
4.44-4.46 (d, J=3.23 Hz, CHNH), 6.64-6.82 (m, 4H, ArH), 7.22-7.35 (m, 2H, ArH), 7.44-
7.52  (dt,  1H,  ArH),  8.02-8.06  (dd,  1H,  ArH)  ppm; 
13C  NMR  (50  MHz,  CDCl3)     197.9, KAT inhibitors: Conformationally restricted amino acids 
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172.9, 153.0, 144.2, 141.8, 133.9, 132.7, 128.9, 127.7, 127.0, 115.7, 115.1, 61.7, 59.3, 
56.0, 51.1, 29.1, 26.4, 14.3 ppm. 
Second fraction: 
1H NMR (200 MHz, CDCl3)  1.19-1.26 (t, 3H, OCH2CH3), 2.18-2.30 (m, 2H, CH2), 2.97-
3.07 (m, 3H, CH2 and CH), 3.73 (s, 1H, OCH3), 4.13-4.24 (q, 2H, OCH2CH3), 4.69-4.68 (d, 
J=3.82 Hz, 1H, CHNH), 6.71-6.84 (m, 4H, ArH), 7.22-7.34 (q, 2H, ArH), 7.43-7.51 (dt, 
1H, ArH), 8.02-8.06 (dd, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   197.2, 173.8, 153.5, 
144.0, 141.6, 133.8, 132.7, 128.9, 127.9, 127.0, 117.2, 116.8, 115.1, 115.0, 61.5, 59.3, 
55.9, 51.2, 29.3, 25.4, 14.4 ppm. 
 
(4-Methoxy-phenylamino)-(4-oxochroman-3-yl) acetic acid ethyl ester (3.8b) 
Synthesized  from  crude  3.6b  (33.8  mmol)  according  to  the  general  procedure.  The 
product was isolated by column chromatography (silica, EtOAc/Hex 5:1) in three fractions. 
The first fraction (yellow oil, 1.46 g, 12 %) contained the first diastereomer, the second 
fraction  (yellow  oil,  3.84  g,  32  %)  was  a  mixture  of  both  diastereomers  and  the  third 
fraction  contained  the  second  diastereomer  (yellow  oil,  1.56  g,  13  %).  An  analytical 
sample  of  the  third  fraction  was  triturated  with  methanol,  yielding  the  pure  product  as 
white crystals.  
First diastereomer: 
1H NMR (200 MHz, CDCl3)   1.03-1.10 (t, 3H, OCH2CH3), 3.46-3.55 (m, 1H, COCH), 3.74 
(s, 3H, OCH3), 3.98-4.09 (m, 2H, OCH2CH3), 4.33-4.35 (d, J=4.11 Hz, 1H, NHCH), 4.57-
4.61 (d, J=7.05 Hz, 2H, OCH2CH), 6.63-6.69 (m, 2H, ArH), 6.95-7.07 (m, 2H, ArH), 7.44-
7.52 (m, 1H, ArH), 7.89-7.93 (dd, J=7.93, 1.47 Hz, 1H, ArH); 
13C NMR (50 MHz, CDCl3)   
192.2,  172.0,  161.9,  153.3,  140.7,  136.4,  127.5,  121.9,  121.6,  118.1,  115.7,  115.2, 
68.7, 62.1, 56.4, 55.9, 48.7, 14.0 ppm; IR (NaCl) 3379, 1933, 1730, 1692, 1605, 1515, 
1466, 1299, 1235, 1149, 1036, 823, 763 cm
-1; GCMS m/z 355 (M), 232 (M-NH2PhOMe), 
123 (NH2PhOMe). 
Second diastereomer: 
1H NMR (200 MHz, CDCl3)   1.16-1.23 (t, 3H, OCH2CH3), 3.11-3.21 (m, 1H, COCH), 3.73 
(s, 3H, OCH3), 4.10-4.21 (dq, 2H, CH2CH3), 4.46-4.49 (d, J=5.88 Hz, 1H, CH), 4.55-4.73 
(m, 2H, OCH2), 6.76 (s, 4H, ArH), 6.97-7.07 (m, 2H, ArH), 7.45-7.54 (m, 1H, ArH), 7.87-
7.92  (dd,  J=1.47,  7.94  Hz,  1H,  ArH)  ppm; 
13C  NMR  (50  MHz,  CDCl3)     191.8,  172.8, 
161.8, 153.7, 140.9, 136.5, 127.7, 122.0, 121.3, 118.1, 116.8, 115.0, 68.7, 61.9, 57.2, 
55.9, 49.3, 14.3 ppm; 
IR (KBr) 3342, 2933, 1728, 1689, 1601, 1511, 1463, 1306, 1242, 1187, 1045, 839, 765 
cm
-1; GCMS m/z 355 (M), 232 (M-NH2PhOMe), 123 (NH2PhOMe). 
 
(4-Methoxyphenylamino)-(4-oxo-thiochroman-3-yl) acetic acid ethyl ester (3.8c) 
Synthesized from crude 3.6c (33.8 mmol) according to the general procedure. The crude 
mixture was purified by column chromatography (silica, Hex: EtOAc 3:1) yielding 4.68 g of 
a yellow oil. This oil was triturated with methanol, yielding the pure product as a mixture 
of diastereomers (2.91 g, 26 %).  
An analytical sample was used to separate diastereomers. 
First diastereomer: 
1H NMR (200 MHz, CDCl3)   1.12-1.19 (t, 3H, OCH2CH3), 3.11-3.18 (dd, J = 3.2 Hz, 12.6 
Hz, 1H, SCH2), 3.45-3.70 (m, 2H, (C=O)CH and  -CH), 3.74 (s, 3H, OCH3), 4.11-4.21 (dq, 
2H, OCH2CH3), 4.47-4.48 (d, J=3.2 Hz, SCH2), 6.66-6.81 (m, 4H, ArH), 7.15-7.28 (m, 2H, 
ArH), 7.35-7.43 (dt, 1H, ArH), 8.08-8.13 (dd, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   
194.0,  171.9,  153.1,  141.7,  141.0,  133.4,  131.1,  129.6,  127.6,  125.2,  115.7,  114.9, 
61.7, 59.0, 55.7, 50.8, 28.9, 14.0 ppm; GCMS m/z 248 (M-(H2N-Ph-OMe)), 123 (NH2-Ph-
OMe); IR NaCl 3381, 2930, 1735, 1674, 1513, 1237, 1037, 823, 763, 733 cm
-1. 
Second diastereomer: 
1H  NMR  (200  MHz,  CDCl3)     1.17-1.24  (t,  3H,  OCH2CH3),  3.22-3.33  (m,  2H,  SCH2  and 
(C=O)CH), 3.51-3.64 (m, 1H,  -CH), 3.74 (s, 3H, OCH3), 4.11-4.22 (dq, OCH2CH3), 4.57-
4.60 (d, J = 5.58 Hz, CH), 6.79 (s, 4H, ArH), 7.14-7.44 (m, 3H, ArH), 7.08-8.12 (dd, 1H, Chapter 3 
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ArH) ppm; 
13C NMR (50 MHz, CDCl3)   193.5, 172.8, 153.5, 141.5, 140.6, 133.4, 130.8, 
129.8, 127.5, 125.1, 116.7, 114.8, 61.5, 58.5, 55.7, 51.1, 28.6, 14.1 ppm; GCMS m/z 
248  (M-(H2N-Ph-OMe)),  123  (NH2-Ph-OMe);  IR  (KBr)  3313,  1713,  1674,  1509,  1233, 
1182, 1034, 827, 765, 732 cm
-1. 
 
General  procedure  for  the  iodobenzene  diacetate  mediated  deprotection  and 
subsequent acetylation  
Acetylamino-(1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)  acetic  acid  ethyl  ester 
(3.9a) 
To a mixture of iodobenzene diacetate (25.0 g, 77.8 mmol) in 150 mL MeOH, a suspension 
of  (4-methoxyphenylamino)-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)-acetic  acid  ethyl 
ester (3.8a, 6.87 g, 19.4 mmol) in 100 mL MeOH was added dropwise. The brown solution 
was stirred at room temperature for 1 hour. 100 mL 1N HCl was added and the resulting 
mixture was stirred for another 1.5 h. The MeOH was removed in vacuo and the aqueous 
layer was washed with a 50/50 (v/v) mixture of Et2O/EtOAc (total 125 mL). The combined 
organic layers were back-extracted with a total of 100 mL 0.1N HCl. The aqueous layers 
were combined and 200 mL CH2Cl2 was added. Acetic anhydride (9.1 mL, 9.9 g, 97 mmol) 
was added and the mixture was brought to pH ~8 with solid K2CO3. The biphasic system 
was stirred vigorously at room temperature for 20 h. The layers were separated and the 
aqueous layer was extracted with CH2Cl2 (3x). The combined organic layers were washed 
with brine, dried (MgSO4), filtered, and the solvent was evaporated. As the crude product, 
5.3 g of a viscous oil was yielded. The product was purified by column chromatography 
(silica,  Hex/EtOAc  1:1  to  1:2),  yielding  three  fractions.  The  first  fraction  primarily 
contained the first diastereomer (1.34 g, 24%, brown foam). The second fraction was a 
mixture  of  both  diastereomers  (1.07g,  19%,  brown  oil).  The  third  fraction  primarily 
contained the second diastereomer (1.04 g, 18%, brown oil). Total yield: 61%. Samples of 
each diastereomer were further purified for analyses.  
First diastereomer: 
1H NMR (200 MHz, CDCl3)   1.24-1.31 (t, 3H, CH2CH3), 1.92-2.17 (m, 1H, CH), 2.01 (s, 
3H,  COCH3),  2.26-2.39  (m,  1H,  CH),  2.94-3.27  (m,  2H,  CH2),  3.50-3.60  (dq,  1H,  CH), 
4.18-4.30 (dq, 2H, CH2CH3), 4.90-4.96 (dd, 1H, NCH), 6.23-6.27 (bd, J=9.28 Hz, 1H, NH), 
7.23-7.34 (q, 2H, ArH), 7.46-7.54 (dt, 1H, ArH), 7.95-7.99 (dd, 1H, ArH) ppm; 
13C NMR 
(50 MHz, CDCl3)   198.8, 171.3, 170.9, 144.5, 134.3, 132.4, 129.2, 127.5, 127.0, 62.0, 
52.6, 51.6, 29.4, 27.6, 23.5, 14.3 ppm; IR (KBr) 3369, 2939, 1731, 1685, 1666, 1517, 
1267, 1228, 1027, 754 cm
-1; GCMS m/z 289 (M), 230 (M-NH2Ac). 
Second diastereomer: 
1H NMR (200 MHz, CDCl3)   1.15-1.22 (t, 3H, CH2CH3), 2.04 (s, 3H, CHCH3), 2.27-2.62 
(m,  2H,  CH),  2.92-3.10  (m,  3H,  CH),  4.09-4.22  (dq,  2H,  CH2CH3),  4.77-4.83  (dd,  1H, 
NCH),  6.76-6.80  (bd,  J=8.06  Hz,  1H,  NH),  7.23-7.34  (q,  2H,  ArH),  7.45-7.53  (dt,  1H, 
ArH),  7.96-8.00  (dd,  1H,  ArH)  ppm; 
13C  NMR  (50  MHz,  CDCl3)     197.1,  169.3,  168.0, 
142.7, 132.4, 130.6, 127.3, 125.7, 125.2, 60.0, 51.8, 50.9, 28.2, 26.8, 21.7, 12.5 ppm; 
IR (KBr) 3294, 2940, 1748, 1683, 1644, 1547, 1197, 1145, 1027, 745 cm
-1; GCMS m/z 
289 (M), 230 (M-NH2Ac). 
 
Acetylamino-(4-oxochroman-3-yl) acetic acid ethyl ester (3.9b) 
Prepared from 3.8b (3.52 g, 9.9 mmol) according to the general procedure. After addition 
of K2CO3, the reaction was stirred at room temperature for 2 h. 
The  pure  product  was  obtained  from  column  chromatography  in  3  fractions.  The  first 
fraction (0.82 g, 28 %) contained the first diastereomer, the second fraction (0.55 g, 19 
%)  contained  both  diastereomers  and  the  third  fraction  (0.17  g,  6  %)  contained  the 
second fraction. Total yield: 53 %. 
First diastereomer: 
1H  NMR  (200  MHz,  CDCl3)     1.22-1.29  (t,  J=7.05  Hz,  3H,  CH2CH3),  2.01  (s,  3H, 
(C=O)CH3), 3.78-3.89 (dq, 1H, (C=O)CH), 4.17-4.29 (m, 3H, CH2CH3 and  -CH), 4.69-
4.77 (q, 1H, OCH2), 4.84-4.89 (dd, 1H, OCH2), 6.33-6.37 (d, J=8.23 Hz, 1H, NH), 6.95-KAT inhibitors: Conformationally restricted amino acids 
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7.04 (m, 2H, ArH), 7.44-7.52 (dt, 1H, ArH), 7.80-7.84 (dd, J=1.77, 7.94 Hz, 1H, ArH); 
13C 
NMR 50 MHz, CDCl3)   .192.7, 171.0, 170.4, 162.1, 136.8, 127.3, 121.7, 120.9.118.3, 
69.6, 62.4, 49.1, 23.3, 14.3 ppm; IR (KBr) 3295, 1748, 1686, 1651, 1605, 1537, 1476, 
1328, 1212, 1150, 1035, 994, 759 cm
-1; GCMS m/z 232 (M-NH2PhOMe), 291 (M), 246 (M-
C2H5O), 245 (M-C2H6O).  
Second diastereomer: 
1H  NMR  (200  MHz,  CDCl3)     1.18-1.25  (t,  J=7.05  Hz,  3H,  CH2CH3),  2.03  (s,  3H, 
(C=O)CH3), 3.27-3.33 (m, 1H, (C=O)CH), 4.06-4.24 (m, 2H, CH2CH3), 4.66-4.82 (m, 3H, 
OCH2 and  -CH), 6.68-6.72 (d, J=8.81 Hz, 1H, NH), 6.95-7.05 (m, 2H, ArH), 7.44-7.53 
(dt, 1H, ArH), 7.81-7.86 (dd, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   193.2, 170.2, 
169.9, 162.1, 136.7, 127.4, 121.8, 120.9, 118.2, 69.8, 62.3, 50.3, 49.9, 23.3, 14.3 ppm; 
IR (KBr) 3246, 3070, 1752, 1692, 1654, 1550, 1478, 1305, 1186, 1133, 1046, 758 cm
-1; 
GCMS m/z 232 (M-NH2PhOMe), 291 (M), 246 (M-C2H5O), 245 (M-C2H6O).  
 
Amino-(4-oxo-thiochroman-3-yl)-acetic acid ethyl ester (3.10) 
A  solution  of  (4-methoxyphenylamino)-(4-oxo-thiochroman-3-yl)  acetic  acid  ethyl  ester 
(3.8c,  1.97  g,  5.30  mmol)  in  40  mL  acetonitrile  was  cooled  to  0 
oC  on  ice.  Ceric 
ammonium nitrate (CAN, 8.72 g, 15.9 mmol) was dissolved in 40 mL water and added 
dropwise to the solution over 15 minutes, turning the color to black/brown. The mixture 
was stirred at 0 
oC for 45 minutes, and was then left to warm to room temperature over 
30 minutes. 40 mL 1 N HCl was added. The aqueous layer was washed with EtOAc. The 
EtOAc  washes  were  back-extracted  with  1  N  HCl.  The  combined  aqueous  layers  were 
brought to alkaline pH with saturated NaHCO3 solution and were extracted with EtOAc. The 
combined  organic  extracts  were  washed  with  brine,  dried  (MgSO3),  filtered,  and  the 
solvent was evaporated, yielding 0.85 g of a brown oil (impure product).  
Since  the  EtOAc  washes  contained  a  major  amount  of  the  product,  this  fraction  was 
extracted with 5 N HCl (1x), 1 N HCl (2x) and water. The combined organic layers were 
brought to alkaline pH with saturated NaHCO3 solution and were extracted with EtOAc. The 
combined  organic  extracts  were  washed  with  brine,  dried  (MgSO4),  filtered,  and  the 
solvent was evaporated. 0.70 g (50%) of a brightly yellow oil was yielded, which contained 
the pure product. This product was used as such in the next reaction step. 
1H  NMR  (400  MHz,  CDCl3)    1.22-1.26  (t,  J=6.97  Hz,  3H,  CH2CH3),  3.00-3.06  (dt,  1H, 
SCH2), 3.37-3.40 (bd, J=9.53 Hz, 0.5H,  -CH), 3.61-3.75 (m, 2.5H, SCH2, (C=O)CH and 
 -CH), 4.18-4.24 (q, J=6.97, 7.33 Hz, 2H, OCH2CH3), 7.14-7.19 (m, 1H, ArH), 7.25-7.27 
(d, J=7.7 Hz, ArH), 7.36-7.40 (dt, 1H, ArH), 8.05-8.10 (m, 1H, ArH) ppm; IR (NaCl) 3374, 
2979, 1730, 1680, 1216, 792, 734 cm
-1; MS m/z 266 (M+H)
+, 288 (M+Na)
+. 
 
Amino-(1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl) acetic acid (3.4a) 
A  mixture  of  acetylamino-(1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)  acetic  acid  ethyl 
ester (3.9a, 0.551 g, 1.91 mmol) in 4 mL 37 % HCl was heated by microwave irradiation 
at 120 
oC for 14 minutes at 20 bar. The mixture was poured on water and the aqueous 
layer was washed with CH2Cl2. The combined organic layers were back extracted with H2O. 
The combined aqueous layers were concentrated in vacuo. The residue was purified by 
column  chromatography  (silica,  CH2Cl2/MeOH  1:1).  The  product  was  stirred  in  10  mL 
isopropanol and 4 mL propylene oxide at room temperature overnight. The solvent was 
evaporated,  yielding  a  brown  solid  (0.330  g).  For  further  purification,  the  product  was 
triturated  with  acetone/MeOH/H2O.  A  brownish  solid  (0.167  g  in  3  fractions,  40%)  was 
yielded.  The  first  fraction  contained  the  product  as  a  50/50  mixture  of  diastereomers 
(determined by HPLC). 
1H NMR (400 MHz, D2O)   1.99–2.32 (dq + m + dq, 2H, CHCH2CH2), 3.07-3.18 (m, 2H, 
CHCH2CH2), 3.33-3.45 (td + ddd, 1H, CHCH2CH2), 4.15-4.17 (d, J=4.03 Hz, 0.5H,  -CH), 
4.44 (d, J=2.56 Hz, 0.5H,  -CH), 7.37-7.41 (dt, 2H, ArH), 7.59-7.64 (m, 1H, ArH), 7.93-
7.99  (ddd,  1H,  ArH)  ppm;  IR  (KBr)  2945,  1673,  1598,  1686,  1405,  744  cm
-1;  HRMS 
(M+H)
+ m/z obs. 220.09682 calc. 220.09682 (C12H14O3N1). 
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Amino-(4-oxochroman-3-yl)-acetic acid (3.4b) 
A mixture of acetylamino-(4-oxochroman-3-yl) acetic acid ethyl ester (3.9b, 0.395 g, 1.36 
mmol) in 3 mL 37 % HCl was heated by microwave irradiation at 120 
oC for 15 minutes at 
18 bar. The mixture was poured on water, and washed with EtOAc and CH2Cl2. The organic 
layers were back-extracted with H2O. The combined aqueous layers concentrated in vacuo. 
The  residue  was  purified  by  column  chromatography  (silica,  CH2Cl2:MeOH  2:1).  The 
resulting  brown  solid  was  triturated  with  CH2Cl2/MeOH,  yielding  0.212  g  (71  %)  of  the 
product as a white solid in 3 fractions. The first fraction (88.5 mg) contained a mixture of 
both  diastereomers  in  equal  quantities.  The  second  fraction  contained  a  mixture  of 
diastereomers in a ratio of 77/23 (diastereomer 1/diastereomer 2) as determined by HPLC.  
1H NMR (400 MHz, D2O/DCl, based on a 50/50 mixture of both diastereomers)   3.38-3.42 
(dt, 0.5H, J=.57, 8.8, 9.9 Hz,(C=O)CH), 3.44-3.49 (td, 0.5H, (C=O)CH), 4.03-4.04 (d, 
0.5H, J=2.57 Hz,  -CH), 4.11-4.17 (m, 0.5+0.5H,  -CH and CH2), 4.32-4.38 (m, 1+0.5H, 
CH2) ppm; IR (KBr) 3437, 2924, 1743, 1686, 1608, 1583, 1479, 1330, 1215, 768, 755 
cm
-1; HRMS (M+H)
+ m/z obs. 222.07607 calc. 222.07608 (C11H12O4N1). 
 
Amino-(4-oxo-thiochroman-3-yl)-acetic acid (3.4c) 
A  mixture  of  amino-(4-oxo-thiochroman-3-yl)-acetic  acid  ethyl  ester  (3.10,  0.67g,  2.5 
mmol) and 0.204 g (5.10 mmol) NaOH in 7.5 mL MeOH and 7.5 mL H2O was stirred for 1 
h at room temperature. The MeOH was evaporated. The aqueous layer was washed with 
CH2Cl2 and then acidified with 5 N HCl. The acidified aqueous layer was again washed with 
CH2Cl2  and  was  then  concentrated  in  vacuo.  The  product  was  isolated  by  column 
chromatography (silica, CH2Cl2/MeOH 10:1), yielding 0.564 g of a brown oily solid. The 
product  was  further  purified  by  trituration  in  acetone/MeOH,  yielding  a  fraction  of  the 
product in pure form (mixture of equal amounts of diastereomers, 0.157 g, 26 %). 
1H NMR (400 MHz, CD3OD)   3.15-3.28 (d and dd, J=10.63, (3.67, 12.83) Hz, 1H, SCH2), 
3.50-3.57 (t, 0.5H,  -CH), 3.69-3.85 (m, 1.5H, (C=O)CH and  -CH), 4.51-4.53 (d and d, 
J=3.3 and 1.83 Hz, 1H, SCH2), 7.23-7.27 (t, J=7.33, 7.70 Hz, 1H, ArH), 7.34-7.36 (d, 
J=7.70 Hz, 7.47-7.51 (t, J=7.33, 7.70 Hz, 1H, ArH), 8.08-8.12 (t, J=8.43 Hz, 1H, ArH) 
ppm; IR (KBr) 2922, 2862, 1747, 1674, 1586, 1215, 762, 729 cm
-1; HRMS (M+H)
+ m/z 
obs. 238.05321 calc. 238.05324 (C11H12O3N1S1). 
 
Kynurenine aminotransferase activity in rat brain homogenate 
KAT  inhibitory  activity  was  determined  in  rat  brain  tissue  homogenate  as  described 
previously,  with  modification.
44,  45  Rat  brain  (male  Wistar  rats,  whole  brain)  was 
homogenized  in  a  5  mM  Tris-acetate  buffer  at  pH  8.0,  containing  50  µM  pyridoxal  5’- 
phosphate  and  10  mM  2-mercaptoethanol  (10  %  w/v).  The  homogenate  was  dialyzed 
against this buffer for 24 hours at 4
oC (12 mL homogenate/2.5 L buffer). Enzyme activity 
was tested in an assay consisting of 200 µL of dialyzed tissue homogenate, 150 mM Tris 
acetate buffer, pH 8.0, 70 µM pyridoxal 5’-phosphate, 1 mM pyruvate, 10 µM L-kynurenine 
and the inhibitor in a final volume of 250 µL (all concentrations final). The mixture was 
incubated  at  37 
oC  for  2  h.  The  reaction  was  terminated  by  addition  of  100  µL  7% 
perchloric acid. The mixture was centrifuged for 15 minutes at 14000 rpm, 4
oC. Kynurenic 
acid  concentrations  were  determined  in  the  supernatant  by  HPLC  (Supelcosil
TM  HPLC 
column, 15 cm x 3 mm, 3 µm). The mobile phase consisted of a buffer containing 15 % 
methanol, 10 g/L Na2HPO4.2H2O, 150 mg/L EDTA and 0.17 % (v/v) THF, adjusted to pH 
5.27 with phosphoric acid. The product was detected fluorimetrically at an extinction of 
344 nm and emission of 398 nm. Each concentration of inhibitor was assayed in triplo. The 
KYNA concentration in each sample was determined in triplo. 
 
Kynureninase activity in liver tissue homogenate 
Kynureninase  activity  was  determined  in  rat  liver  tissue  homogenate  as  described 
previously, with modifications.
46,  47 Liver tissue was homogenated in a buffer (10% w/v) 
consisting of 20 mM Tris-acetate pH 8.0, 0.5 mM 2-mercaptoethanol, and 50 µM pyridoxal 
5’-phosphate. The homogenate was centrifuged at 14000 rpm for 30 minutes at 4 
oC. The KAT inhibitors: Conformationally restricted amino acids 
  97 
supernatant was dialyzed against the buffer as described above (12 mL supernatant/2.5 L 
buffer) for 24 hours at 4
oC. Enzyme activity was determined using 100 µL of the dialyzed 
tissue, 50 µL of a solution consisting of 400 mM Tris-HCl buffer pH 8.0, 200 µM pyridoxal 
5’-phosphate and 40 µM L-kynurenine (final concentration 10 µM), and 50 µL inhibitor at 
varying concentrations. The mixture was incubated at 37 
oC for 30 minutes. The reaction 
was terminated by mixing with 100 µL 7% perchloric acid. The samples were centrifuged 
at 14000 rpm for 15 minutes at 4
oC. Anthranilic acid concentrations in the supernatant 
were measured by HPLC.  
The supernatant was applied to a Supelcosil
TM HPLC column (15 cm, 4.6 or 3 mm ID, 3µm 
particle size). The mobile phase consisted of a buffer containing 26 % methanol, 10 g/L 
Na2HPO4.2H2O,  150  mg/L  EDTA  and  0.17  %  (v/v)  THF,  adjusted  to  pH  5.27  with 
phosphoric acid. The product was detected fluorimetrically at an extinction of 313 nm and 
emission of 420 nm. Each concentration of inhibitor was assayed in triplo. The anthranilic 
acid concentration in each sample was determined in triplo. 
 
Kynurenine 3-hydroxylase activity in liver tissue homogenate 
Kynurenine  3-hydroxylase  activity  was  determined  in  rat  liver  tissue  homogenate  as 
described previously, with modifications.
46 The tissue was homogenized in icecold 0.32 M 
sucrose solution (1 g tissue/8 mL sucrose solution). The homogenate was centrifuged at 
11000  rpm,  4 
oC,  30  min.  The  supternatant  was  taken  off,  and  the  residue  was 
resuspended in sucrose solution (1 mL 0.32 M sucrose/residue of 1 mL homogenate). The 
tissue was centrifuged (11000 rpm, 4 
oC, 30 min). This washing procedure was repeated 
twice. The resulting tissue was resuspended in 0.14 M KCl, 20 mM potassium phosphate 
buffer at pH 7.0.  
Enzyme activity was measured using 75 µL of the tissue homogenate, 100 µL of a 100 mM 
potassium phosphate buffer pH 7.5, containing 1 mM NADPH, 4 mM MgCl2, and 20 µM L-
kynurenine (final concentration 10 µM), and 25 µL of a solution of the inhibitor at varying 
concentrations.  The  mixture  was  incubated  at  37 
oC  for  30  minutes.  The  reaction  was 
terminated by the addition of 100 µL 7% perchloric acid. The samples were centrifuged 
(14000  rpm,  15  minutes,  4
oC).  The  concentrations  of  3-hydroxykynurenine  in  the 
supernatant  were  determined  by  HPLC.  The  supernatant  was  applied  to  a  Supelcosil
TM 
HPLC column (15 cm, 4.6 or 3 mm ID, 3 µm particle size). The mobile phase consisted of a 
solution of 100 mg EDTA, 150 mg heptane sulphonic acid, 5.9 mL phosphoric acid, 9.0 mL 
triethylamine  and  20  mL  acetonitrile  in  950  mL  H2O  [adapted  from  ref
48].  Each 
concentration of inhibitor was assayed in triplo. The 3-hydroxykynurenine concentration in 
each sample was determined in triplo. 
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4.1  Introduction 
Kynurenine (KYN, 4.1) is the key intermediate in the kynurenine pathway, the 
major pathway of tryptophan metabolism. KYN is metabolized by kynureninase 
(KYNase),  kynurenine  3-hydroxylase  (kynurenine  mono-oxygenase,  KMO)  and 
kynurenine  aminotransferase  (KAT).  KAT  catalyzes  the  reaction  of  KYN  into 
kynurenic  acid  (KYNA).  KYNA  is  an  antagonist  at  the  strychnine  insensitive 
glycine coagonist site of NMDA receptors and a non-competitive antagonist at 
 7* nicotinic acetylcholine receptors. At much higher concentrations, KYNA is an 
antagonist at all ionotropic glutamate receptors and an agonist at orphan GPR35 
receptors.
1-5 KYN metabolism by KYNase and KMO results in the formation of 3-
hydroxykynurenine  (3-OH-KYN),  anthranilic  acid  (AA)  and  quinolinic  acid 
(QUIN). QUIN is a precursor of NAD
+ and has neurotoxic properties. 
Imbalances of the kynurenine pathway are associated with several disorders of 
the  central  nervous  sytem.  Upregulation  of  tryptophan  metabolism  into  the 
kynurenine  pathway  leads  to  formation  of  neurotoxic  3-OH-KYN  and  QUIN. 
Elevated  levels  of  3-OH-KYN  and  QUIN  are  associated  with  Huntington’s 
disease.
6-8 Elevated levels of KYNA have been found in patients suffering from 
schizophrenia.
9-11 KYNA is thought to impair cognitive function.
12 
 
This study aims for the design of compounds that pharmacologically decrease 
KYNA  levels  in  the  brain.  For  this  purpose,  inhibitors  are  desired  that  are 
selective towards KAT over KYNase and KMO. Conformationally restricted KYN 
analogs 4.2 and 4.3 were designed (Scheme 1). 
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In these structures, the conformation of KYN is restricted by introduction of a 
methylene bridge between the aromatic amino group and the  -CH2 group. In 
analog 4.3, the  -amino-group is omitted. The compounds were synthesized and 
their ability to inhibit rat brain KAT and rat liver KYNase and KMO was tested. KAT inhibitors: Quinolinones 
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4.2  Chemistry 
4.2.1  Synthesis of 2,3-dihydro-4(1H)-quinolinone 
2,3-Dihydro-4(1H)-quinolinone (4.4) is the core structure for the compounds of 
this  study.  The  structure  is  known  from  literature.  The  substance  is  colored 
brightly yellow. The color is caused by extensive possibilities of tautomerism into 
tautomers B, C, D and E (Scheme 2).
13-15 
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In order to stabilize intermediates and prevent aromatization or other ways of 
decomposition,  proper  protection  of  functional  groups  is  essential  in  synthetic 
procedures.  
Synthesis  of  the  core  structure  was  accomplished  by  published  methods, 
according to Scheme 3.
13-15  
 
Scheme 3 
+
NH2
O
O a.
N
H
O
O b.
N O
O
S O O
N OH
O
S O O
d. c.
N
H
O
4.5 4.6 4.7
4.8
4.4 4.9
 
Reagents and conditions: a. acetic acid, 80
oC; b. p-TosCl, pyridine, 25 min, r.t., then 
reflux 1 h; c. KOH/H2O, MeOH; d. PPA. 
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Briefly,  addition  of  aniline  to  methylacrylate  in  the  presence  of  acetic  acid 
yielded  methyl  ester  4.7.  The  amine  was  then  protected  with  para-toluene 
sulfonyl  chloride  (p-TosCl).  The  ester  of  tosyl-protected  product  4.8  was 
hydrolyzed. Product  4.9 was subjected to ring-closure with PPA to obtain the 
brightly yellow colored product 4.4. 
4.2.2  Synthesis  of  amino-(4-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-
acetic acid 
From core structure 4.4 different synthetic strategies were applied in order to 
finally obtain product 4.2. In the first attempt, the tosyl-protected quinolinone 
4.10  was  brominated  at  the  3-position,  followed  by  attempted  coupling  with 
diethylacetamidomalonate (Scheme 4).  
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Reagents and conditions: a. p-TosCl, pyridine, 25 min, r.t., then 1.25h, 95 
oC; b. Br2, 
CH3Cl; c. NaH, diethylacetamidomalonate, DMF. 
 
This strategy had been employed successfully before in many monocyclic and 
some bicyclic KYN derivatives.
16-19 Unfortunately, for the present derivative, the 
procedure yielded HBr-eliminated quinolinone 4.13 only. 
 
As outlined in Scheme 2, abundant possibilities exist for electron delocalization 
within the bicyclic quinolinone core structure. The possibility of formation of the 
enol-form was used in a second strategy.  KAT inhibitors: Quinolinones 
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Quinolinone 4.4 was protected with either a tosyl group (4.10a) or an acetyl 
group  (4.10b).  In  earlier  studies,  attempted  formation  of  enamines  from 
quinolinone  4.4  by  keto-enolization  was  reported  to  succeed  only  after  N-
protection  with  an  electron-withdrawing  group  like  a  tosyl  group.  An  electron 
withdrawing  group  prevents  formation  of  tautomer  C  (Scheme  2).  For  the 
current  reaction  scheme,  tautomer  C  is  not  favorable,  because  obviously, 
reaction at the 3-position is less favorable in that state.
20, 21 
The protected quinolinones were enolized with LHMDS and trimethylsilylchloride 
to  obtain  enoxysilanes  4.14.
22  In  our  hands,  the  formation  of  enoxysilanes 
proceeded smoothly at both protected quinolinone cores, without decomposition. 
This observation confirms the stabilizing contribution of the protective group.   
 
In the subsequent step, the amino acid moiety was introduced by coupling of the 
enoxysilanes to imine 4.15
23 (Scheme 5).  
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Reagents and conditions: a. LHMDS, TMSCl, THF, -80 
oC; b. SmI2, CH2Cl2. 
 
The  reaction  is  a  SmI2-catalyzed  nucleophilic  addition  reaction.
24  The  method 
had  been  applied  successfully  before  to  other  bicyclic  structures  in  our 
laboratory (see Chapter 3). Coupling products could be obtained for both 4.14a 
and  b.  During  purification  of  the  product  4.16a,  the   -amine-eliminated 
compound 4.17 was formed, probably by decomposition on silica. Interestingly, 
no  such  amino-eliminated  side-product  was  found  in  the  acetylated  series  of 
compounds. 
 
In earlier studies using similar methods, it was found that deprotection of the  -
amino  group  with  either  iodobenzene  diacetate
25  or  ceric  ammonium  nitrate 
(CAN) and subsequent protection by acetylation yielded a stable intermediate. At Chapter 4 
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that stage, diastereomers could be separated easily by column chromatography 
or crystallization (see Chapter 3). The equivalent procedure for tosyl protected 
coupling product 4.16a is shown in Scheme 6. 
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Reagents and conditions: a. CAN, ACN/H2O; b. acetic anhydride, CH2Cl2; c. HCl. 
 
For  the  current  compound  however,  attempted  acetylation  after  deprotection 
yielded no product but the deaminated compound  4.17. The reason could be 
promotion of delocalization under the alkaline conditions used for the acetylation 
reaction. Attempts were made to isolate compound 4.18 and proceed from this 
point  without  further  protection  of  the  amino-group.  Due  to  instability, 
compound 4.18 could not be purified sufficiently for full characterization. Only 
combination  of  partially  elaborated  analyses  confirms  the  identity  of  the 
compound. I n  the 
1H  NMR  spectrum,  a  large  singlet  representing  the  tosyl-
methyl protons can be seen clearly. In the 
13C NMR spectrum, clear signals are 
seen  for  the  CH3  groups  of  both  the  ethyl  and  the  tosyl  groups.  In  addition, 
signals are present for the two carbonylic carbon atoms (ketone and ester) and 
the remaining four aliphatic carbon atoms. Signals of atoms in the aromatic area 
are less well defined. Detection by mass spectrometry shows an m/z value that 
corresponds with the (M+H)
+ of the product. In the IR spectrum, the presence 
of  a  double  peak  at  3393-3331  cm
-1  proves  the  presence  of  the  primary   -KAT inhibitors: Quinolinones 
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amino-group.  The  detection  of  ester  (1735  cm
-1),  ketone  (1688  cm
-1)  and 
sulfonylic  (1165  cm
-1)  peaks  confirms  the  presence  of  the  other  functional 
groups in 4.18. 
To test the conditions needed for cleavage of the tosyl protective group from the 
quinolinone  core,  compound  4.10a  was  deprotected.  Using  methods  as 
described  in  literature
26,  refluxing  in  concentrated  HCl  and  acetic  acid  with  a 
minor  amount  of  water  gave  4.4  in  good  yields.  Therefore,  partially  purified 
4.18  was  subjected  to  hydrolysis  under  these  conditions.  Unfortunately,  the 
harsh conditions caused severe decomposition for this intermediate. A mixture of 
at  least  5  compounds  was  yielded.  Analysis  by  mass  spectrometry  of  the 
obtained mixture suggested the presence of components as shown in Scheme 7. 
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In the first place, as indicated by structures 4.21 and 4.22, aromatization of the 
quinolinone core had occurred. Aromatization of the bicyclic system yields the 
energetically more favorable quinoline system. This seems to be feasible from 
quinolinone-tautomer  B  (Scheme  2),  especially  under  the  harsh  conditions  as 
applied during deprotection. In side-products 4.23 and 4.24, the amino group is 
eliminated.  This  is  analogous  to   -amine-eliminated  product  4.17,  which  was 
formed during purification of 4.16a.  
In a last attempt in the tosyl-protected series, direct hydrolysis from 4.16a to 
yield  4.20  was  tested  (Scheme  6).  Again,  only  decomposition  products  were 
obtained from this reaction. 
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In contrast to 4.16a, for derivative 4.16b, deprotection and acetylation of the 
 -amino group proceeded without any difficulties (Scheme 8).  
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Reagents  and  conditions:  a.  (i)  iodobenzene  diacetate,  MeOH  (ii)  acetic  anhydride, 
CH2Cl2, K2CO3; b.(i) iodobenzene diacetate, CH2Cl2, (ii) Boc2O, CH2Cl2, K2CO3. 
 
For  the  deprotection  of  4.16b,  reaction  with  iodobenzene  diacetate  was 
applied.
25 For subsequent protection of the  -amine, two protective groups were 
chosen.  Following  the  previously  developed  general  method,  the  amine  was 
acetylated.  Alternatively,  the  BOC  protective  group  was  employed.  The  BOC 
protective  group  could  have  two  advantages  for  this  compound.  First,  the 
physicochemical differences between the two diastereomers can be emphasized 
by the size of the group. If large groups are attached next to diastereocenters, 
the  differences  between  the  orientations  are  extended  to  a  larger  part  of  the 
molecule. This could facilitate the separation of the diastereomers. The second 
advantage of a BOC group over an acetyl group is the ease of cleavage of such a 
group.  Whereas  acetyl  groups  are  cleaved  under  strongly  alkaline  or  acidic 
conditions with heating, BOC cleavage can already be performed at mildly acidic 
conditions at ambient temperatures. 
To  our  disappointment,  diastereomers  of  neither  4.25  nor  4.26  could  be 
separated. Moreover, again, cleavage of the acetyl protective groups from the 
quinolinone core of both compounds was problematic and gave many unwanted 
side-products. 
 KAT inhibitors: Quinolinones 
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Therefore,  in  a  final  attempt  to  synthesize  4.2,  BOC  protective  groups  were 
chosen for protection of both the quinolinone core and for protection of the  -
amino group after cleavage of the p-anisidino-group (Scheme 9).  
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Reagents and conditions: a. Boc2O, DMAP, THF; b. LHMDS, TMSCl, THF, -80 
oC; c. SmI2, 
CH2Cl2;  d.  (i)  iodobenzene  diacetate,  MeOH,  (ii)  Boc2O,  CH2Cl2,  K2CO3;  e.  KOH, 
EtOH/H2O; f. TFA, CH2Cl2. 
 
This approach proved to be successful. The BOC protective groups significantly 
improved the stability and ease of handling of all intermediates. After synthesis 
of 4.29, diastereomers could be separated. Subsequent deprotection and BOC-
protection  yielded  a  mixture  of  diastereomers  of  4.31.  Separation  of  the 
diastereomers  was  possible,  but  caused  significant  loss  of  product  by 
decomposition on silica. Compound 4.31 was treated with KOH first to achieve 
ester hydrolysis. Although pure diastereomers of 4.31 were used, a mixture of 
4.32  containing  equal  amounts  of  each  diastereomer  by  HPLC  was  yielded. 
Keto-enolization  explains  the  racemisation  during  hydrolysis.  Under  alkaline 
conditions, formation of the enol tautomer of the bicyclic structure is promoted 
by extraction of the slightly acidic proton at the  -position of the ring. The two 
diastereomers could be detected on silica-TLC by different colors of fluorescence 
but could not be separated by column chromatography. Therefore, the mixture Chapter 4 
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of all four stereoisomers was used in the next reaction step. Reaction with TFA in 
CH2Cl2 yielded 4.2 as a brightly yellow solid.  
4.2.3  Synthesis of (4-oxo-1,2,3,4,-tetrahydroquinolin-3-yl)-acetic acid 
Since BOC-protection of the quinolinone core structure had proven successful for 
the synthesis of 4.2, this protective group was chosen again for the synthesis of 
4.3. The synthetic method is shown in Scheme 10.  
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Reagents and conditions: a. 1. LHMDS, THF, -80
oC, 2. Ethyl bromoacetate, THF, -80
oC; 
b. NaOH, H2O/EtOH; c. TFA, CH2Cl2. 
 
In the first step, the protected quinolinone was enolized with LHMDS and the 
alkyl  chain  was  introduced  in  the  enol-intermediate  by  treatment  with  ethyl 
bromoacetate. Hydrolysis of the ethyl ester and subsequent BOC-deprotection of 
the bicyclic core yielded compound 4.3 in racemic form. 
4.3  Enzyme inhibition 
The final compounds  4.2 and 4.3 were tested for their ability to inhibit KAT, 
KYNase and KMO. Rat brain homogenate was used as the enzyme source for the 
KAT assay. Rat liver homogenates were used to assay activities of KYNase and 
KMO. Data for enzyme inhibition are shown in Table 1. As a reference, racemic 
ESBA  ((S,R)-4.35)  was  tested.  ESBA  was  the  first  published  KAT  II  selective 
inhibitor.
18, 27 KAT inhibitors: Quinolinones 
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Table 1 Enzyme inhibition 
Compound  % KAT activity 
(inhibitor 
concentration) 
% KYNase activity 
(inhibitor 
concentration) 
% KMO activity 
(inhibitor 
concentration) 
O NH2
O
OH
N
H  
4.2 
74.1±1.8 (3 mM)  92.9±1.2 (1 mM)  75.8±1.5 (1 mM) 
N
H
O
O
OH
 
4.3 
64.2±0.9 (3 mM)  17.4±0.4 (1 mM)  63.4±0.8 (1 mM) 
O NH2
O
OH
S
O O  
(S,R)-4.35 
57.7±1.9 (1 mM) 
44.7±1.6 (3 mM) 
94.2±3.3 (1 mM) 
74.5±2.8 (3 mM) 
87.6±2.5 (1 mM) 
85.6±1.3 (3 mM) 
4.4  Conformational analysis and docking studies in kynureninase 
Compounds  4.2  and  4.3  show  pronounced  differences  in  KYNase  inhibitory 
activity  (Table  1).  To  examine  the  origin  of  the  observed  differences,  the 
energetically  favorable  conformations  of  these  compounds  in  comparison  with 
KYN and their interactions with KYNase were studied in more detail. 
4.4.1  Structures 
Structures that were used for the computational part of this work are shown in 
Scheme 11. Chapter 4 
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The key structure is KYN  (4.1). The aromatic amino substituent of KYN can be 
oriented  in  two  ways.  In  one  orientation,  arbitrarily  named  orientation  A,  the 
aromatic amino group and the benzoyl carbonyl group are oriented towards each 
other,  implying  the  presence  of  an  intramolecular  H-bond.  In  an  alternative 
orientation,  arbitrarily  named  orientation  B,  the  aromatic  amino  group  is 
oriented into the opposite direction, away from the benzoyl carbonyl group. As 
depicted in Scheme 11, an equilibrium exists between both orientations.  
Compound  4.36  is  an  equivalent  of  KYN,  lacking  the   -amino  group.  This 
compound  showed  inhibitory  activity  in  the  micromolar  range  for  rat  liver 
KYNase (data not shown). 
Recently,  the  crystal  structure  of  human  KYNase  in  complex  with  3-
hydroxyhippuric  acid  (4.37),  an  analog  of  3-OH-KYN  (4.38),  has  become 
available.
28 Docking studies were performed in this crystal structure and 4.37 
was used as the reference conformation for comparison of docked ligands. The 
aromatic nuclei in compounds 4.36, 4.37 and 4.38 are represented in Scheme 
11 in an orientation that corresponds with orientation A of KYN. 
Compounds  4.2  and  4.3  were  synthesized  and  tested  in  this  study.  For 
discussion of the structures, C , C  and C  positions are defined as shown in KAT inhibitors: Quinolinones 
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Scheme 11. For the amino acid group in 4.2, the C -S-enantiomers were taken 
into  account  only,  because  these  enantiomers  are  most  analogous  to  the 
naturally occurring enantiomer of KYN. For both 4.2 and 4.3, the C -R and C -S 
enantiomers were studied. In addition to chiral centers, the directionality of the 
NH group in the bicyclic core was taken into account. Conformational analysis 
was performed with the NH-proton directed out of the plane (named N1) and 
towards the back of the plane (named N2). Most probably, at both the C  and 
the quinolinone NH positions, both forms, R and S or N1 and N2, respectively, 
are in continuous equilibrium. Since in silico methods do not take into account 
that the enantiomers/conformations are in equilibrium by tautomerization, the 
orientations need to be described and treated separately here.  
4.4.2  Conformational analysis 
To  obtain  insight  into  low  energy  conformations  of  KYN  and  the  designed 
inhibitors, conformational analyses were performed. For KYN, both orientations 
A  and  B  of  the  aromatic  amino  group  were  found  during  the  conformational 
analysis with equal frequencies and equal conformational energies. The aliphatic 
side chain is fully extended in the low energy conformations.  
The  co-crystallized  conformation  of  3-hydroxyhippuric  acid  in  the  crystal 
structure of human KYNase
28 most probably reflects the binding orientation of 
KYN  and  3-OH-KYN  analogs.  This  conformation  was  used  as  a  reference 
conformation adopted for binding to KYNase. Low energy conformations of KYN 
reflecting orientations A and B were superimposed on this conformation of 3-
hydroxyhippuric acid.
28 Results are shown in Figure 1.  
From the superposition it can be concluded, that the low energy conformations 
found  for  KYN  highly  resemble  the  conformation  of  KYNase  bound  3-
hydroxyhippuric acid. The superposition shows, that in orientation A of KYN, the 
aromatic amino group is oriented in between the aliphatic side chain and the 
phenolic  OH-group  of  3-hydroxyhippuric  acid.  In  orientation  B  of  KYN,  the 
aromatic amino group is placed in a position that corresponds to the position 
para to the phenolic OH-group in 3-hydroxyhippuric acid. 
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Figure 1 
 
Superposition  of  KYN  (orientation  A:  white  and  B:  cyan)  on  3-hydroxyhippuric  acid 
(yellow). 
 
To  examine  whether  bicyclic  structures  4.2  and  4.3  are  likely  to  reflect 
energetically  favorable  conformations  of  KYN,  conformational  analysis  of  the 
structures  was  performed  and  resulting  low  energy  conformations  were 
compared to the conformations of KYN.  
For all studied enantiomers, the bicyclic ring core structures were found to be 
merely planar. The planarity of the aromatic ring is extended over the carbonyl 
moiety  and  the  NH-group.  Some  degree  of  flexibility  is  seen  for  the  torsional 
angle  C(=O)-C -C -N.  Two  distinct  conformations  were  found  for  this  angle, 
which can interconvert by ring inversion. This is shown in Figure 2 for R-4.3.  
 
Figure 2 
a. 
 
 
              
             
 
 
 
 
b. 
 
 
            
Conformations of R-4.3, view along the plane of the bicyclic structure. (a) C  points into 
the plane, the carboxylate group is in an equatorial orientation. (b) C  points out of the 
plane, the carboxylate group is in an axial orientation.  
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In  Figure  2,  the  plane  is  defined  by  the  aromatic  core  ring  system.  In  one 
conformation (Figure 2a), the C  group points into the plane. Conversely, in the 
other conformation (Figure 2b), the C  atom points out of the plane. Since the 
bond from the carbonylic C-atom is in an sp2 state, the deviation from the plane 
of the C  atom is much less pronounced than the for the C  atom. In the case of 
C  pointing into the plane (Figure 2a), the C  has a slight deviation out of the 
plane. If C  points out of the plane (Figure 2b), the C  atom is oriented slightly 
into the plane. The orientation of the proton attached to the amino group has 
virtually no influence on the orientations of the C(=O)-C -C -N torsional angle 
but has by itself an equilibrium by N-H inversion between a semi axial and a 
semi equatorial position (Figure 2). 
The  orientation  of  the  amino  acid  or  carboxylate  substituent  in  4.2  and  4.3, 
respectively,  depends  on  the  angle  of  the  C(=O)-C -C -N  torsion  and  the 
chirality at the C  atom. For example, for the R-enantiomer of 4.3 (Figure 2), if 
the C -atom is oriented to point into the plane, the carboxylate substituent is 
oriented equatorially (Figure 2a). In contrast, if C -atom is oriented to point out 
of the plane, the carboxylate substituent is oriented axially (Figure 2b). For the 
S-enantiomer,  orientation  of  the  C -atom  out  of  the  plane  corresponds  to  an 
equatorial orientation of the carboxylate substituent. Orientation of the C -atom 
into  the  plane  corresponds  with  an  axial  orientation  of  the  carboxylate 
substituent.  
The same pattern is observed for enantiomers of 4.2. In most instances, a slight 
preference in terms of energy and numbers of unique low energy conformations 
was observed for equatorially substituted conformations. If an axially substituted 
conformation was found as the global minimum structure, this conformation was 
not  taken  into  account  for  further  studies.  Instead,  the  most  favorable 
conformation  with  an  equatorially  oriented  side  chain  was  chosen  for  these 
enantiomers.  The  energies  found  for  the  most  favorable  equatorial 
conformations differed just marginally from the global minimum energies.  
It  must  be  noted  that  due  to  free  keto-enolization  of  the  carbonyl  bond,  the 
distinct conformations of the bicyclic core structure described here in reality are 
easily interconvertible. Hence, during binding of the compounds to proteins, the 
most favorable conformation can be adopted relatively easily.  
 
A  database  alignment  was  performed  of  all  selected  conformations  of  the 
enantiomers of 4.2 and 4.3, KYN and 3-hydroxyhippuric acid. The aromatic core 
and  the  carboxylic  acid  moieties  were  chosen  as  templates  for  alignment.  In 
Figure 3, results of the database alignment are shown.  Chapter 4 
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Figure 3 
 
Superposition of kynurenine (Orientation A: white and B: cyan), 3-hydroxyhippuric acid 
(yellow) and low energy conformations of 4.2 (green) and 4.3 (magenta).  
 
From the alignment it appears, that a good fit can be established of all aromatic 
and  all  carboxylate  groups.  Bicyclic  compounds  align  in  an  orientation  that 
corresponds to orientation B of KYN. 
4.4.3  Docking in kynureninase 
For  docking  studies,  3-hydroxyhippuric  acid ( 4.37)  was  extracted  from  the 
crystal  structure  of  human  KYNase  in  complex  with  the  inhibitor.
28  KYN  and 
compounds 4.2, 4.3 and 4.36 were docked into the active site of KYNase. Each 
molecule could be docked successfully.  
The  docked  conformation  of  KYN,  compared  to  the  conformation  of  co-
crystallized 3-hydroxyhippuric acid is shown in Figure 4. 
 
Figure 4 
a. 
 
b. 
 
Overlay of docked KYN (white) and co-crystallized 3-hydroxyhippuric acid (magenta).  
(a) Front view and (b) side view.  
 
KYN  docks  into  the  binding  site  in  an  orientation  that  is  analogous  to  the 
orientation of 3-hydroxyhippuric acid (Figure 4a). The aromatic amino group is 
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oriented  downwards  and  can  interact  by  H-bond  formation  with  Tyr275.  The 
carboxylate group interacts with Arg434. Compared to the carbonyl group of 3-
hydroxyhippuric acid, the KYN carbonyl group is oriented more towards the back 
to form a hydrogen bond with the side chain of Ser75 (Figure 4b). The  -amino 
group  also  interacts  with  the  side  chain  of  Ser75.  As  is  shown  in  Figure  4b, 
although  the  orientation  of  the  carbonyl  group  is  not  in  the  plane  with  the 
aromatic  core,  the  relative  orientation  of  the  carbonyl  and  the  aromatic  NH2 
group represents orientation A as defined in Scheme 11. 
  
To examine the influence of the  -amino group in KYN on the docked orientation 
of the molecule, compound 4.36 was docked into the KYNase binding site. The 
found orientation as compared to the orientation of KYN is shown in Figure 5. As 
appears from the figures, 4.36 docks in a conformation that is identical to the 
docked  conformation  of  kynurenine.  In  the  case  of  4.36,  only  the  carbonyl 
group can interact with the side chain of Ser75. 
 
After successful docking of kynurenine and 4.36, experimental compounds 4.2 
and 4.3 were docked into the crystal structure of human KYNase. In terms of 
docking energies, 4.2 and 4.3 docked equally well. Closer examination revealed 
some differences between the structures.  
For compound 4.2,  -R and  -S enantiomers were docked, with the NH group 
oriented in the N1 or N2 position. As stated earlier, there is a natural equilibrium 
between  the  two  enantiomers  by  tautomerization  and  also  between  the 
orientation  of  the  NH  group  in  N1  or  N2.  The  results  found  for  docking  of 
compound 4.2, superimposed on docked KYN, are shown in Figure 6. For  -R-
4.2, a convergent docking orientation was found for the N1 and N2 tautomers 
(Figure 6a). In this orientation, the aromatic moiety occupies a position that is 
slightly  shifted  downwards  in  the  binding  space  compared  to  the  aromatic 
moiety  of  KYN.  As  observed  for  the  aromatic  amino  group  of  KYN,  the 
heterocyclic NH-group interacts with the side chain OH group of Tyr275 by H-
bond  formation.  Relative  to  KYN,  the  amino  acid  moiety  of  4.2  is  positioned 
higher in the binding space. The  -amino group points towards the opening in 
the binding site. Analysis of interactions with surrounding amino acid side chains 
showed,  that  the  carboxylate  group  could  still  interact  with  Arg434  in  this 
position.  Furthermore,  as  observed  for  KYN,  the   -amino  group  of  4.2 
approaches  Ser75  closely  enough  for  H-bond  formation  (in  the  back  of  the 
plane, not shown in Figure 6). 
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Figure 5 
a. 
 
b. 
 
Docked 4.36 (magenta) and KYN (white). (a) Front view and (b) side view. 
 
 
Figure 6 
a. 
 
b. 
 
Enantiomers of 4.2 (white) superimposed on KYN (black): (a)  -R-4.2 and (b)  -S-4.2.  
 
 
Figure 7 
a. 
 
b. 
 
(a)  -S- and  -R-4.3 (white) superimposed on KYN (black) and (b) second orientation 
for R-enantiomers of 4.3 (white) superimposed on KYN (black). 
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The  orientation  of  the   -S  tautomers  (Figure  6b)  is  less  well  defined.  The 
position  of  the  carboxylate  group  is  in  accordance  with  the  corresponding 
position  of  the  KYN  carboxylate  group.  The  orientation  of  the  quinolinone 
structure seems to be less optimal and is either in a higher or in a lower position 
than the aniline group of KYN. In the former case, if any, only weak hydrogen 
bonding between the nitrogen atom and the Tyr275 phenolic OH is possible. 
In summary, docking positions are different for  -R-4.2 and  -S-4.2. For the  -
R tautomers, the orientation of the NH proton can be in either N1 or N2, without 
changing  the  position  in  the  binding  site.  For  the   -S  tautomers,  the  optimal 
position of the conformation with the NH in an N1 orientation is different from 
the position of the conformation with the NH in the N2 orientation. This means 
that  the   -R  tautomers  have  more  conformational  freedom  than  the   -S 
tautomers.  Therefore,  it  is  to  be  expected  that  binding  of  4.2  preferentially 
occurs  in  the   -R  enantiomeric  form.  Overall,  the  conformational  freedom  of 
KYNase bound 4.2 is restricted by this preference. 
 
For compound 4.3, corresponding conformations were docked, reflecting the N1 
and N2 orientation of the heterocyclic NH-group, and the S and R enantiomers 
at the  -carbon atom. Surprisingly, a convergent docking pose was found for all 
tautomeric forms of the molecule. This position, compared to KYN, is shown in 
Figure 7a. For the R-enantiomers, a second position was found, which is equally 
favorable (Figure 7b). For the S-enantiomers, a corresponding conformation was 
found with a slightly less favorable orientation of the carboxylic side chain (not 
shown).  
As  is  apparent  from  Figure  7a,  in  the  first  docked  pose,  the  position  of  the 
quinolinone NH atom of 4.3 approaches the position of the corresponding atom 
in KYN. The carbonyl moiety points upwards, out of the binding site. The bicyclic 
compound occupies a space that corresponds well with the binding space of KYN. 
In particular, the carboxylate group is oriented in an identical position, favoring 
salt bridge formation with Arg434. Analysis of H-bonding interactions revealed, 
that  the  heterocyclic  nitrogen  atom  interacts  with  the  phenolic  OH  group  of 
Tyr275.  The  aromatic  ring  system  is  in  a  position  favorable  for  hydrophobic 
interactions  with  His102.  In  the  second  orientation,  the  bicyclic  system  is 
‘mirrored’. The carbonyl group points down and interacts with Tyr275. Again, the 
carboxylate group is in a position that allows salt bridge formation with Arg434. 
The convergent orientations of all enantiomers and tautomers of this molecule 
suggest,  that  the  docking  space  does  not  prevent  the  compound  from  free 
tautomerization from one enantiomer to the other and back and from free ring Chapter 4 
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inversion with the NH oriented in the N1 or N2 position. This is in contrast to 
4.2, for which docking positions differ for the tautomers and docking in the  -R 
tautomeric form is clearly preferred over the  -S tautomeric form. 
4.5  Discussion and conclusion 
In the present work, the synthesis of conformationally restricted KYN analogs is 
presented. The molecules were tested for their ability to inhibit key kynurenine 
pathway  enzymes.  Interactions  of  the  molecules  with  KYNase  were  further 
explored by conformational analysis and docking studies. 
4.5.1  Compound design and in vitro activity 
Conformational restriction of molecules is a powerful tool to study the properties 
of  ligands  as  favored  by  the  target  proteins.  In  the  ideal  case,  a  ligand  is 
restricted in a conformation that reflects the conformation when bound to the 
target protein. This results in a lower energy barrier towards binding, causing 
enhanced  affinity  for  the  target.  Furthermore,  enhanced  selectivity  for  the 
desired target can be achieved by conformational restriction.  
In the present case, inhibition of KAT is desired. The compounds should inhibit 
KAT selectively over KYNase and KMO to achieve a decrease in brain KYNA levels 
in vivo. Compared to reference inhibitor (S,R)-4.35, KAT inhibitory activity of 
4.2  and  4.3  in  the  performed  enzyme  assays  is  limited.  Apparently,  the 
introduction  of  the  aliphatic  ring  in  the  structure  causes  a  conformational 
restriction that is not optimal for interaction with KAT. Still, species differences 
exist in KATs, and inhibition should be tested in assays using alternative enzyme 
sources.  
Liver  KMO  is  inhibited  moderately  well  by  4.2  and  4.3.  After  systemic 
administration, the effects of the compounds on liver enzymes are likely to most 
pronouncedly define the overall effect of the molecules. Therefore, in the ideal 
situation, inhibitory activity for KMO should be absent in KAT selective inhibitors.  
The most striking finding of this study is the difference between 4.2 and 4.3 in 
inhibition of KYNase. At a bath concentration of 1 mM, amino acid 4.2 shows 
virtually no inhibitory activity. In contrast, carboxylic acid analog 4.3 inhibits the 
enzyme to 17 % of its original activity at the same bath concentration. 
 
Conformational analyses and docking experiments using the crystal structure of 
human  KYNase  were  performed  to  understand  the  large  difference  in  KYNase 
inhibitory potency between the structurally very similar compounds 4.2 and 4.3. KAT inhibitors: Quinolinones 
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For the discussion of the results, it should be noted, that in the present study, 
inhibition of this enzyme is disfavored. 
4.5.2  Conformational analysis  
Conformational analysis of KYN showed, that the compound adopts either one of 
two defined low energy conformations, referred to as orientations A and B. In 
both orientations, the aliphatic side chain is fully extended. The superposition on 
3-hydroxyhippuric  acid  (Figure  1)  reveals  that  the  energetically  favorable 
conformations of KYN and the conformation of 3-hydroxyhippuric acid bound to 
human KYNase align well. 3-Hydroxyhippuric acid was designed as a structural 
analog  of  3-OH-KYN  (4.38,  Scheme  11).  The  aromatic  OH-group  of  3-
hydroxyhippuric  acid  corresponds  to  the  3-OH  group  in  3-OH-KYN.  In  the 
superposition, the aromatic amino group of KYN in orientation A is located in the 
position  that  would  be  accommodated  by  the  aromatic  NH2  of  3-OH-KYN,  in 
between the aromatic OH and the aliphatic chain substituent (see Scheme 11). 
Therefore,  from  the  current  superimposition  it  can  be  concluded  that  the 
conformation  of  3-hydroxyhippuric  acid  bound  to  KYNase  corresponds  to 
orientation A rather than orientation B of KYN. Interestingly, crystal structures of 
KAT II in complex with kynurenine
29 show, that the preferred conformation of 
KYN  for  interaction  with  KAT  II  more  closely  resembles  orientation  B  than 
orientation A.  
 
Compounds 4.2 and 4.3 were designed as potential selective KAT inhibitors. The 
compounds  are  KYN  analogs,  locked  in  orientation  B  by  introduction  of  a 
methylene bridge between the C  of the aliphatic side chain and the aromatic 
NH2 group. Conformational analysis showed that different orientations of the C  
atom  in  combination  with  the  substitution  pattern  at  C   result  in  an  axial  or 
equatorial orientation of the amino acid or carboxylate ring substituent (Figure 
2).  Due  to  the  possibility  of  tautomerization  at  the  carbonyl  group  and 
consequent racemisation at C , all conformations found for 4.2 or 4.3 are in 
constant  equilibrium  under  natural  conditions.  Therefore,  conformational 
energies  merely  reflect  the  relative  preferences  or  percentage  of  time  for  a 
molecule  to  be  in  a  certain  conformation.  Energy  barriers  between  the 
conformations are relatively low and unless restricted by environmental factors 
like  enzyme  binding,  the  conformation  of  the  molecule  is  changing  constantly 
and  freely  from  one  conformation  to  another.  The  flexibility  of  the  molecules 
caused by the tautomerization might be favorable for finding the correct binding 
conformation in the enzyme. This might enhance the binding affinity. Chapter 4 
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The structures 4.2 and 4.3 represent energetically favorable conformations of 
KYN.  Superposition  of  the  compounds  with  KYN  and  3-hydroxyhippuric  acid 
(Figure  3)  shows,  that  the  compounds  indeed  align  most  favorably  in  a  way 
representing orientation B of KYN (Scheme 11). This means, that theoretically, 
binding to KYNase is less favorable for these conformationally restricted analogs 
than for KYN. Accordingly, compound 4.2 lacks KYNase inhibitory potency (Table 
1). Unexpectedly however, compound 4.3 inhibits KYNase much more potently 
than KAT II. To find a probable explanation for this observation, docking studies 
in KYNase were performed.  
4.5.3  Docking 
4.5.3.1  Docking of kynurenine 
First, the docked position of KYN in KYNase was examined and compared to co-
crystallized 3-hydroxyhippuric acid. Binding of KYN to the binding site of KYNase 
is  a  dynamic  process.  KYNase  is  a  pyridoxal  5’-phosphate  (PLP)  dependent 
enzyme. The co-enzyme PLP facilitates the catalytic process. In the resting state 
of the enzyme, the co-enzyme is bound to the side chain of a lysine residue in 
the  active  site  in  a  so-called  internal  aldimine  linkage.  During  binding  of  the 
substrate  in  the  catalytic  site,  the  internal  aldimine  linkage  is  broken  and  an 
external aldimine is formed with the  -amino group of the substrate. For proper 
positioning of the incoming substrate, a strictly conserved interaction between 
the side chain carboxylate group of the ligand and a conserved Arg residue is 
crucial. In human KYNase, the Arg residue is Arg434.
28, 30  
Overall, KYN fits well in the docking space. The ligand adopts an orientation that 
is equivalent to the orientation of co-crystallized 3-hydroxyhippuric acid (Figure 
4).  The  aromatic  moiety  of  KYN  aligns  with  the  aromatic  ring  of  the  co-
crystallized ligand. As expected, the aromatic amino group is oriented in a way 
reflecting orientation A. The KYN carboxylate group points towards Arg434.  
In the catalytic cycle, after formation of the aldimine link between the cofactor 
and KYN, the  -  bond of the substrate is catalytically broken. This reaction is 
initiated  by  formation  of  a  tetrahedral  gem-diolate  intermediate  around  the 
carbonyl C-atom. Based on the crystal structure of KYNase in complex with 3-
hydroxhippuric  acid,  it  was  hypothesized  that  Ser75  has  a  key  role  in 
stabilization of this gem-diolate intermediate. Additionally, Tyr275 is involved in 
stabilization.
28 In the docked conformation of KYN, the benzoylic carbonyl group 
points towards the side chains of Ser75 and Tyr275. As for 3-hydroxyhippuric 
acid, this reflects the role of these residues in the catalytic mechanism. KAT inhibitors: Quinolinones 
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In the present results, the  -amino group of KYN points upwards, towards the 
opening of the binding site, rather than towards PLP. This is not an orientation 
that would be expected based on the mechanistic properties of the enzyme. For 
proper interaction with the co-enzyme, the  -amino group should be oriented 
towards the PLP aldimine bond, to participate in transaldimination for formation 
of  the  external  aldimine  bond  with  the  co-enzyme.
31,  32  Therefore,  the 
orientation of the group in docked KYN does not reflect the natural situation. 
This discrepancy can be explained by the rigidity of the model. In the dynamic 
process  of  binding,  the  incoming  KYN  enforces  the  hydrolysis  of  the  internal 
aldimine  and  formation  of  the  external  aldimine  bond  accommodating  the   -
amino group. In the docking experiment, the internal aldimine bond cannot be 
hydrolyzed to make space for this group. Instead, the amino group is forced into 
an unoccupied area in the binding space. Apparently, this space is available in 
the access channel of the enzyme.  
Although  the  -amino  group  is  important  for  covalent  interaction  of  substrate 
and  co-enzyme,  binding  affinity  is  determined  by  interaction  of  the  entire 
substrate  molecule  in  the  binding  pocket.  To  examine  whether  the  overall 
conformation of the remainder of the molecule is directed by the orientation of 
the  -amino group, des-amino KYN 4.36 was docked into KYNase. As is shown 
in Figure 5, the docked conformation of 4.36 is identical to the conformation of 
KYN. From these results, it can be concluded that that binding of the remaining 
part of the molecule does not depend on the orientation of the  -amino group. 
In contrast, it is postulated that the orientation of the  -amino group is directed 
by salt bridge formation of the carboxylate group with Arg434 on one hand and 
the  hydrophobic  interactions  of  the  aromatic  core  on  the  other  hand. 
Consequently, the  -amino group is pushed towards the cofactor and formation 
of the external aldimine bond is enforced. For the present docking results, this 
means that, although the orientation of the  -amino group is not correct, the 
remainder of the molecule is docked correctly, reflecting the bound orientation 
of KYN in human KYNase. Binding of the aromatic and the carboxylate moieties 
to the binding site of KYNase can be seen as the first step in initiation of the 
catalytic cylce. 
4.5.3.2  Docking of 4.2 and 4.3 
Based on the results discussed above, for the discussion of the docking results of 
compounds 4.2 and 4.3, two anchor points of ligand-enzyme interaction can be 
defined. The first anchor point is defined by the position of the aniline moiety of 
the molecule. For KYN and 4.36, the aromatic ring is involved in  -stacking with Chapter 4 
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His102.  The  aromatic  amino  group  points  down  towards  the  side  chain  of 
Tyr275.  The  second  anchor  point  is  formed  by  the  carboxylate  group,  which 
interacts with Arg434 in a salt bridge. The preferred binding mode of a ligand is 
defined by the optimal position of both anchor points in the binding site. 
 
In terms of scoring results, all conformations of compounds 4.2 and 4.3 docked 
with  comparable  affinities  in  the  crystal  structure  of  KYNase.  Upon  closer 
inspection of orientations, some differences were found between binding of 4.2 
and  4.3  that  could  account  for  differences  in  in  vitro  inhibitory  activity. 
Obviously, the differences are caused by the presence of the  -amino group in 
4.2 and the absence of this group in 4.3.  
For  compound  4.2,  a  defined  binding  orientation  was  found  for  the  R-
enantiomers (Figure 6a). The orientation is irrespective of the orientation of the 
quinolinone  NH  proton.  In  this  orientation,  the  quinolinone  amino  group  is 
oriented towards Tyr275. The carboxylate group forms salt bridges with the side 
chain  of  Arg434,  but  in  a  position  that  is  not  as  optimal  as  adopted  by  the 
carboxylate moiety of KYN. The S-enantiomers are positioned differently. For the 
S-enantiomers,  the  carboxylate  group  is  oriented  for  good  interaction  with 
Arg434 (Figure 6b). However, here the position of the aromatic moiety seems to 
be forced into suboptimal orientations compared to the orientation of the aniline 
moiety in KYN. Apparently, conformational restriction forces the molecule into 
positions in which either the aromatic ring or the carboxylate moiety is oriented 
sub-optimally  for  interaction  with  the  enzyme.  As  discussed  above, 
tautomerization  allows  free  racemization  from  one  enantiomer  to  the  other. 
Since apparently, the R-enantiomer docks in a preferred orientation in KYNase, 
the molecule is driven to be in that enantiomeric form. This can be seen as a 
restriction of conformational freedom of the enzyme bound molecule. In terms of 
entropy,  the  restriction  is  a  factor  of  loss  of  entropy  during  ligand-enzyme 
binding. Since loss of entropy is disfavored, this has a negative effect on binding 
affinity. 
In contrast, for compound 4.3, two defined orientations were found that could 
both  be  adopted  by  both  enantiomers,  irrespective  of  the  orientation  of  the 
quinolinone  NH  proton.  In  the  first  orientation,  the  quinolinone  amino  group 
points down towards Tyr275 (Figure 7a). In the second orientation, the ring is 
mirrored. In this way, the carbonyl group of the quinolinone core points down 
towards  Tyr275.  The  amino  group  points  up.  In  either  orientation,  the 
caboxylate  group  is  in  a  position  that  is  optimal  for  interaction  with  Arg434. 
Therefore, in contrast to 4.2, all enantiomers and tautomers of 4.3 can adopt KAT inhibitors: Quinolinones 
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either of 2 orientations, both of which allow for (almost) optimal interaction of 
both anchor points within the KYNase binding site. For the bound molecule, the 
interconversion from one enantiomer to the other is not restricted. This means 
that the loss of entropy due to tautomeric restriction as seen for 4.2 does not 
apply  for  4.3.  Thus,  total  entropy  and  hence  binding  affinity  is  improved 
compared to 4.2, allowing for stronger competition with KYN for binding to the 
enzyme.  This  could  explain  the  pronounced  inhibition  of  KYNase  by  4.3  as 
observed in vitro. 
 
It must be noted that the orientation of the  -amino group in 4.2 is upwards, 
away from PLP in all docked conformations. Similar to what was discussed for 
kynurenine,  this  could  represent  and  artefact,  caused  by  the  rigidity  of  the 
internal aldimine bond in the docking experiment. Theoretically, the compound 
could act as a covalent inhibitor by formation of an external aldimine link with 
PLP. This possibility cannot be ruled out by the presented data. However, based 
on such mechanisms, an enhanced KYNase inhibitory potency compared to 4.3 
would be expected in vitro. Therefore, the possibility of covalent interaction of 
4.3 with the enzyme is not further taken into account. 
4.5.4  Summary and conclusion 
In summary, this work explores the effects of conformational restriction of KYN 
in  one  of  its  energetically  favorable  conformations.  Whereas  desired  KAT 
inhibitory  activity  seems  to  be  limited  in  the  assays  used  here,  the 
conformational  restriction  has  important  effects  on  inhibition  of  KYNase.  As 
explained by molecular docking studies, introduction of the restriction in amino 
acid analog 4.2 impedes optimal binding of the molecule in the KYNase catalytic 
site. This shifts selectivity of the compound towards KAT inhibition, rather than 
KYNase  inhibition.  In  contrast,  due  to  the  lack  of  the   -amino  group  in 
conformationally restricted analog 4.3, this compound can adopt positions that 
are optimal for both binding of the aromatic amino group and the carboxylate 
group, irrespective of the chirality at the C  atom. Therefore, KYNase inhibitory 
activity is much more pronounced for this compound than in 4.2.  
Overall, due to lack of pronounced potency and selectivity for inhibition of KAT if 
compared to potency towards KMO and KYNase, the molecules presented here 
are  expected  to  have  an  increasing  rather  than  a  decreasing  effect  on  brain 
KYNA levels in vivo. Compound 4.3 in particular will cause increased levels of 
KYN in the periphery by inhibition of metabolism of this key intermediate by liver 
KYNase. KYN will cross the blood brain barrier. This will result in elevated levels Chapter 4 
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of this KAT substrate in the brain. Enhanced turnover into KYNA will finally result 
in elevated levels of this metabolite in the brain. 
 
In  conclusion,  the  present  study  did  not  result  in  the  design  of  the  desired 
selective  KAT  inhibitors.  However,  insight  was  gained  into  properties  in  the 
KYNase binding site, which can be used in the search for selective inhibitors of 
KAT  or  KYNase.  For  future  studies  on  inhibitory  activity  and  selectivity  of 
compounds,  the  availability  of  crystal  structures  of  KMO  could  be  of  major 
importance.  Until  then,  more  work  should  be  done  on  the  characterization  of 
differences between KAT and KYNase and differences for each enzyme amongst 
different species. 
4.6  Experimental section 
General NMR spectra were taken on a Varian spectrometer, at the frequency as stated in 
the  text.  Chemical  shifts  are  given  in  ppm.  The  splitting  patterns  are  designated  as 
follows: s = singlet, d = doublet, t = triplet, m = multiplet, bs = broad singlet. Coupling 
constants  are  given  in  hertz  (Hz).  IR  spectra  are  taken  on  an  ATI-Mattson 
spectrophotometer. GCMS analysis were performed on a Shimadzu GCMS-QP500 system 
equipped an AOC-20i auto injector and a CP-Sil 5 CB column (15m x 0.25mm; 0.10µm 
film thickness). Mass spectra (ESI) were taken on an API 3000 MS/MS system. Accurate 
mass  measurements  (HRMS)  were  performed  using  a  flow  injection  method  on  a  LTQ-
Orbitrap XL mass spectrometer (Thermo Electron, Bremen, Germany) with a resolution of 
60000 at m/z 400. All final compounds had ad least 95% purity, as determined by HPLC. 
Solvents and reagents were obtained from general sources and used as such. THF was 
dried by distillation over Na. 
 
3-Phenylaminopropionic acid methyl ester (4.7) 
A mixture of aniline (4.5, 5.01 g, 53.8 mmol), methyl acrylate (4.6, 5.4 mL, 5.16 g, 60 
mmol) and acetic acid (0.5 mL) was stirred at 80 
oC overnight. Vacuum distillation (95 
oC, 
0.03 mbar) yielded 7.17 g (74 %) of 4.7 as a yellow solid. 
1H NMR (200 MHz, CDCl3)   2.60-2.66 (t, 2H, CH2), 3.4-3.49 (t, 2H, CH2), 3.70 (s, 3H, 
CH3), 6.60-6.77 (m, 3H, ArH), 7.15-7.26 (m, 2H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   
171.3, 146.0, 127.9, 116.3, 111.6, 50.2, 37.9, 32.2 ppm; IR (KBr) 3401, 2951, 1733, 
1603, 1508, 1175, 751, 694 cm
-1; GCMS m/z 179 (M). 
 
3-[Phenyl-(toluene-4-sulfonyl-amino)-propionic acid methyl ester (4.8) 
3-Phenylaminopropionic  acid  methyl  ester  (4.7)  (2.01g,  11.2  mmol)  was  dissolved  in 
pyridine (20mL). p-Toluene-sulfonyl chloride (2.33g, 12.2 mmol) was added portionwise. A 
precipitate appeared after several minutes, stirring the mixture at r.t.. After 15 minutes, 
the mixture was heated at reflux for one hour. The mixture was then left to cool to r.t., 
and water was added. The mixture was extracted with diethyl ether. The combined organic 
layers were washed with 4N HCl, 1N NaOH, water, and brine, dried (MgSO4), filtered and 
the solvent was evaporated. A yellow oil (3.46, 93%) was obtained, which was used in the 
subsequent reaction without further purification.  
1H NMR (CDCl3)   2.42 (s, 3H, TOS-CH3), 2.51-2.59 (t, 2H, J=7.63, 7.35Hz,  NCH2CH2), 
3.59 (s, 3H, COOCH3), 3.80-3.87 (t, 2H, J=7.64, 7.34Hz, NCH2), 7.00-7.05 (m, 2H, ArH), 
7.22-7.32 (m, 4H, ArH), 7.45-7.50 (d, 2H, ArH) ppm; 
13C NMR (CDCl3)   171.7, 143.8, 
139.2, 135.2, 129.7, 129.4, 129.1, 128.4, 128.0, 52.0, 47.0, 34.2, 21.8 ppm; IR (NaCl) 
2951, 1738, 1349, 1163, 697, 654 cm
-1; GCMS m/z 333 (M). KAT inhibitors: Quinolinones 
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3-[Phenyl-(toluene-4-sulfonyl)-amino]-propionic acid (4.9) 
3-[Phenyl-(toluene-4-sulfonyl-amino)-propionic  acid  methyl  ester  (4.8)  was  dissolved  in 
MeOH (20 mL), and 10% KOH in H2O(7.5 mL) was added. The mixture was stirred at r.t. 
overnight. The methanol was evaporated, and the aqueous layer was washed with CH2Cl2. 
The aqueous layer was then acidified with 4N HCl, and extracted with CH2Cl2. The organic 
extracts were merged, dried (MgSO4), filtered, and the solvent was evaporated. A white 
solid was yielded (2.87 g, 87 %). 
1H NMR (CDCl3)   2.42 (s, 3H, ArCH3), 2.55-2.63 (t, 2H, CH2), 3.79-3.87 (t, 2H, CH2), 
7.01-7.06 (m, 2H, ArH), 7.26-7.34 (m, 5H, ArH), 7.45-7.50 (m, 2H, ArH) ppm; 
13C NMR 
(CDCl3)   174.8, 142.2, 137.4, 133.4, 128.0, 127.7, 127.4, 126.8, 126.3, 44.9, 32.2, 20.1 
ppm; IR (KBr) 3051, 2922, 1703, 1349, 1159, 1094, 571 cm
-1. 
 
2,3-Dihydro-1H-quinolin-4-one (4.4) 
Polyphosphoric acid (17 g) was heated to 100
oC. 3-[Phenyl-(toluene-4-sulfonyl)-amino]-
propionic acid (4.9, 1.81 g, 5.67 mmol) was added. The mixture (orange solution) was 
stirred at 100 
oC for 1.25 h, and was then quenched by the addition of ice. The aqueous 
suspension obtained was brought to alkaline pH with 4 N NaOH and extracted with Et2O. 
The  combined  organic  layers  were  washed  with  brine,  dried  (MgSO4),  filtered,  and  the 
solvent was evaporated. A yellow oil was obtained (0.6245 g, 75 %). 
1H NMR (200 MHz, CDCl3)   2.64-2.71 (t, 2H, CH2), 3.5-3.58 (t, 2H, CH2), 4.47 (bs, 1H, 
NH), 6.64-6.75 (m, 2H, ArH), 7.23-7.32 (m, 1H, ArH), 7.80-7.85 (dd, 1H, ArH) ppm; 
13C 
NMR (50 MHz, CDCl3)   192.4, 150.7, 133.7, 126.1, 117.8, 116.3, 114.4, 40.7, 36.6 ppm; 
IR (NaCl) 3353, 2965, 2823, 1667, 1607, 1511, 1341, 1239, 1152, 761 cm
-1; GCMS m/z 
147 (M). 
 
1-(Toluene-4-sulfonyl)-2,3-dihydro-1H-quinolin-4-one (4.10a) 
To a mixture of 2,3-dihydro-1H-quinolin-4-one (4.4, 1.46 g, 9.92 mmol) in pyridine (20 
mL), p-toluenesulfonyl chloride (2.07 g, 10.8 mmol) was added. The mixture was stirred 
at r.t. for 25 minutes. Then, the mixture was placed on an oil bath preheated to 95 
oC, and 
was stirred at that temperature for 1.25 h. The mixture was left to cool to r.t.. Water was 
added, and the aqueous layer was extracted with CH2Cl2. The combined organic extracts 
were washed with 4 N HCl, 1 N NaOH, and brine, dried (MgSO4), filtered, and the solvent 
was evaporated. Recrystallization from EtOAc/Hex yielded 1.74 g (58%) brownish crystals. 
1H NMR (200 MHz, CDCl3)   2.34-2.41 (s and t, 5H, CH2 and CH3), 4.19-4.25 (t, 2H, CH2), 
7.20-7.30 (m, 3H, ArH), 7.52-7.61 (m, 3H, ArH), 7.84-7.95 (2H, 2H, ArH) ppm; 
13C NMR 
(50 MHz, CDCl3)   191.2, 143.1, 140.8, 135.3, 133.2, 128.6, 126.2, 125.4, 124.2, 124.1, 
123.1, 44.7, 35.0, 20.1 ppm; IR (KBr) 1681, 1596, 1474, 1456, 1351, 1294, 1163, 830, 
774, 731, 684 cm
-1; GCMS m/z 301 (M). 
 
3-Bromo-1-(toluene-4-sulfonyl)-2,3-dihydro-1H-quinolin-4-one (4.11) 
To  a  solution  of  1-(toluene-4-sulfonyl)-2,3-dihydro-1H-quinolin-4-one  (4.10a,  0.150  g, 
0.498 mmol) in dry CHCl3 (2.5 mL), a solution of Br2 (78.0 mg, 0.488 mmol) in CHCl3 (2.5 
mL)  was  added.  The  mixture  was  heated  at  reflux  for  3  hours.  After  cooling  to  room 
temperature, the solvent of the mixture was evaporated. Column chromatography (silica, 
petroleum ether 40-60:EtOAc 4:1) gave a slightly green viscous oil (0.155 g, 82%). 
1H NMR (200 MHz, CDCl3)   2.41 (s, 3H, CH3), 4.31-4.63 (m, 3H, CH2 and CHBr), 7.21-
8.03 (m, 8H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   143.6, 134.8, 133.9, 128.7, 127.7, 
125.6, 123.9, 121.2, 120.9, 51.1, 44.3, 20.1 ppm; IR (NaCl) 3066, 2924, 1691, 1597, 
1474, 1354, 1287, 1164, 1092, 898, 760, 676 cm
-1. 
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Attempted  synthesis  of  2-acetylamine-2-[4-oxo-1-(toluene-4-sulfonyl)-1,2,3,4-
tetrahydroquinolin-3-yl]-malonic acid diethylester (4.12), yielding 1-(toluene-4-
sulfonyl-4(1H)-quinolinone (4.13)  
Attempted  synthesis  of  4.12,  using  a  procedure  as  described  in  ref
16  gave  the  HBr 
eliminated product 4.13. 
1H  NMR  (200  MHz,  CDCl3)     2.38  (s,  3H,  TosCH3),  6.36-6.40  (d,  J=8.54Hz,  1H, 
COCH=CH), 7.26-7.41 (m, 3H, ArH), 7.52-7.61 (dt, 1H, ArH), 7.73-7.76 (dd, J=6.6, 1.7 
Hz),  8.15-8.19  (m,  1H,  ArH),  8.29-8.34  (m,  1H,  ArH),  8.53-8.57  (d,  J=8.55,  1H, 
COCH=CH) ppm; 
13C NMR (50 MHz, CDCl3)   177.0, 144.9, 136.4, 135.4, 132.3, 131.2, 
128.9, 128.6, 126.9, 1260, 125.7, 124.9, 124.1, 116.7, 111.0, 20.2 ppm; IR (KBr) 3080, 
2925, 1640, 1600, 1467, 1369, 1169, 1080, 1034, 953, 675 cm
-1; GCMS m/z 299 (M). 
 
1-Acetyl-2,3-dihydro-1H-quinolin-4-one (4.10b) 
A solution of 2,3-dihydro-1H-quinolin-4-one (4.4, 0.944 g, 6.42 mmol) and triethylamine 
(1.9 mL, 1.4 g, 14 mmol) in dry CH2Cl2 (20 mL) under an atmosphere of N2 was cooled on 
ice.  Acetylchloride  (1  mL,  14  mmol)  in  CH2Cl2  (5  mL)  was  added  dropwise  over  15 
minutes. The mixture was left to stir at 0 
oC for 5 minutes, and was then left to warm to 
room  temperature.  After  stirring  at  r.t.  for  1  hour,  water  was  added  to  quench  the 
reaction. The layers were separated, and the aqueous layer was extracted with CH2Cl2. The 
combined organic layers were washed with brine, dried (MgSO4), filtered, and the solvent 
was evaporated. Purification by column chromatography (silica, petroleum ether:EtOAc 4:1 
  1:1) yielded 0.62 g (48%) of a brightly yellow solid. 
1H NMR (200 MHz, CDCl3)   2.34 (s, 3H, AcCH3), 2.77-2.83 (t, 3H, CH2), 4.21-4.27 (t, 2H, 
CH2), 7.24-7.31 (m, 1H, ArH), 7.41-7.45 (bd, 1H, ArH), 7.52-7.59 (t, 1H, ArH), 7.99-8.03 
(d, J=7.63, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   192.5, 167.8, 142.5, 132.6, 126.3, 
124.6,  124.1,  122.6,  42.5,  38.0,  21.6  ppm;  IR  (KBr)  2949,  1690,  1649,  1599,  1475, 
1383, 1265, 1206, 1092, 1001, 849, 770 cm
-1; GCMS m/z 189 (M) 
Reaction with acetic anhydride and triethylamine in CH2Cl2 at r.t. gave the product in 40 % 
yield. 
 
General  method  for  the  preparation  of  1-protected  4-trimethylsilanyloxy-1,2-
dihydroquinolines 
1-(Toluene-4-sulfonyl)-4-trimethylsilanyloxy-1,2-dihydroquinoline (4.14a)  
A solution of 1-(toluene-4-sulfonyl)-2,3-dihydro-1H-quinolin-4-one (4.10a, 0.480g, 1.59 
mmol) in dry THF (14 mL) was cooled to -78
oC under N2. A solution of LHMDS (0.410g, 
2.45 mmol) in dry THF (2 mL) was added. The glassware was rinsed with another 1 mL 
dry THF. The mixture was left to warm up to -5
oC over 1 hour. The mixture was then 
cooled to -78
oC, and TMSCl (0.31mL, 0.26g, 2.39 mmol) was added in one portion. The 
mixture was left to slowly warm up, stirring under N2. After 1h (temperature 0
oC), water 
was added. The mixture was extracted with EtOAc (3x). The combined organic layers were 
washed with NH4Cl sat aq., dried (MgSO4), filtered, and the solvent was evaporated. 0.614 
g  of  an  orange  solid  was  obtained,  which  was  used  for  the  next  reaction  without 
purification.  
IR (KBr) 2960, 1642, 1352, 1248, 1165, 1068, 874, 846, 768, 669 cm
-1; GCMS m/z 373 
(M), 301 (M-Me3Si). 
1-(4-Trimethylsilanyloxy-2H-quinolin-1-yl)-ethanone (4.14b) 
IR (NaCl) 3322, 2957, 1692, 1644, 1600, 1483, 1335, 1245, 1212, 1083, 872, 759 cm
-1. 
 
(4-Methoxy-phenylimino)-acetic acid ethyl ester (4.15) 
To a solution of ethyl glyoxalate (50% solution in toluene, 2 mL) in 40 mL dry CH2Cl2, a 
solution of p-anisidine (1.21 g, 9.80 mmol) in 10 mL dry CH2Cl2 was added dropwise. The 
mixture was stirred at r.t. for 30 minutes. Then, molsieves 4 Å (2.5 g) were added, and 
the mixture was stirred at r.t. overnight. The mixture was filtered over Celite
®, and the 
solvent of the filtrate was evaporated. 1.87 g (92 %) of a brownish oil was obtained which 
was used as such in the next reaction step. KAT inhibitors: Quinolinones 
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1H NMR (200 MHz, CDCl3)   1.35-1.43 (t, 3H, CH2CH3), 3.82 (s, 3H, OCH3), 4.35-4.45 (q, 
2H, CH2), 6.90-6.94 (dd, J=6.8 Hz, 2H, ArH), 7.33-7.37 (dd, J=6.8 Hz, 2H, ArH), 7.93 (s, 
1H, CH) ppm; 
13C NMR (50 MHz, CDCl3)   146.5, 122.1, 113.0, 60.4, 54.0, 12.7 ppm; IR 
(NaCl) 2981, 1739, 1713, 1588, 1505, 1290, 1251, 1031, 838 cm
-1; GCMS m/z 207 (M). 
 
General method for the samarium diiodide catalyzed coupling reaction 
(4-Methoxy-phenylamino)-[4-oxo-1-(toluene-4-sulfonyl)-1,2,3,4-
tetrahydroquinolin-3-yl]-acetic acid ethyl ester (4.16a) 
The solvent of a samarium diiodide solution in THF (0.1 M in THF, 1.6 mL) was removed by 
placing the flask under vacuum. To the dry yellow solid, kept under an Ar atmosphere, dry 
CH2Cl2  was  added.  Freshly  prepared  (4-methoxy-phenylimino)-acetic  acid  ethyl  ester 
(4.15, 0.33 g, 1.59 mmol) in 2 mL CH2Cl2 was added, stirring the mixture under Ar at r.t.. 
Then,  the  freshly  prepared  1-(toluene-4-sulfonyl)-4-trimethylsilanyloxy-1,2-
dihydroquinoline (4.14a, 1.6 mmol) in 2 mL dry CH2Cl2 was added dropwise. The syringe 
was washed with 1 mL CH2Cl2. The resulting brown mixture was stirred at r.t. under Ar 
overnight. Then, 10 mL 0.1N HCl was added with vigorous stirring to quench the reaction. 
The  layers  were  separated,  and  the  aqueous  layer  was  extracted  with  CH2Cl2.  The 
combined organic layers were washed with brine, dried (MgSO4), filtered, and the solvent 
was evaporated. The product, which could be seen as a brightly yellow spot on TLC with I2 
oxidation, was purified by column chromatography (silica, petroleum ether:EtOAc 4:1). A 
yellow foam was obtained (0.41 g, 50%, mix of diastereomers). 
1H NMR (200 MHz, CDCl3)   1.06-1.29 (dt, 3H, CH2CH3), 2.32-2.37 (ds., 3H, Tos-CH3), 
2.92-2.98 (m, 1H), 3.82-3.96 (m, 1H), 3.75-3.78 (ds, OCH3), 4.06-4.22 (m, 3H), 4.43-
4.44 (d, 1H), 4.55-4.67 (m, 1H), 6.56-7.97 (m, 12H, ArH) ppm; 
13C NMR (50 MHz, CDCl3) 
  191.5, 169.5, 151.7, 142.9, 140.6, 138.7, 134.9, 133.4, 128.6, 126.3, 125.2, 124.2, 
124.1, 123.1, 114.0, 113.4, 60.3, 55.0, 54.2, 46.4, 45.6, 20.0, 12.4 ppm; IR (NaCl) 3372, 
2982, 2930, 1735, 1687, 1597, 1513, 1458, 1359, 1295, 1239, 1164, 1088, 1036, 820, 
766, 663 cm
-1; MS m/z 509 (M+H)
+; GCMS m/z 385 (M-(p-MeO-phenylamine)). 
 
(1-Acetyl-4-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-(4-methoxy-phenylamino)-
acetic acid ethyl ester (4.16b) 
The product was purified by column chromatography (silica, EtOAc:Hex 1:2   2:1). The 
collected pure fractions gave 0.44 g (42 % over two reaction steps) of a yellow foam. 
1H NMR (200 MHz, CDCl3)   1.06-1.10 (t, 3H, CH2CH3), 2.33 (s, 3H, AcCH3), 3.45-3.50 (m, 
1H, CH), 3.73 (s, 3H, OCH3), 3.92-3.98 (t, 1H, CH), 4.07-4.14 (m, 2H, CH2CH3), 4.25-4.30 
(q, 1H, CH), 4.43 (s, 1H, CH), 4.68 (bs, 1H, NH), 6.68-6.71 (d, 2H, ArH), 6.77-6.80 (d, 
2H, ArH), 7.26-7.30 (m, 1H, ArH), 7.45-7.57 (m, 2H, ArH), 8.02-8.04 (2, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   194, 171.6, 169.7, 153.2, 143.7, 140.6, 134.3, 127.8, 126.2, 
125.5, 123.9, 115.7, 114.9, 62.0, 57.8, 55.7, 51.0, 45.7, 23.2, 13.8 ppm; IR (NaCl) 3361, 
1983,  1737,  1666,  1600,  1514,  1372,  1304,  1238,  1035,  824,  767  cm
-1;  MS  m/z  397 
(M+H)
+. 
 
[4-Oxo-1-(toluene-4-sulfonyl)-1,4-dihydro-2H-quinolinylidene]-acetic  acid  ethyl 
ester (4.17) 
Obtained as a major side-product during purification of 4.16a.  
1H NMR (200 MHz, CDCl3)   1.40-1.43 (bd, 3H, CH2CH3), 2.35 (s, 3H, TosCH3), 4.30-4.34 
(bd, 2H, CH2CH3), 5.25 (s, 2H, NCH2), 6.49 (s, 1H, C=CH), 7.07-7.10 (d, 2H, ArH), 7.24-
7.27 (d, 2H, ArH), 7.39-7.43 (d, 2H, ArH), 7.68-7.72 (d, 2H, ArH), 7.81-7.93 (m, 2H, ArH) 
ppm; 
13C NMR (50 MHz, CDCl3)   191.9, 180.0, 163.5, 143.2, 141.2, 140.6, 133.4, 132.6, 
128.2, 126.7, 126.3, 126.0, 125.7, 123.2, 59.8, 46.0, 20.1, 12.7 ppm; IR (KBr) 2933, 
1714, 1683, 1597, 1459, 1361, 1299, 1250, 1165, 1061, 680 cm
-1; GCMS m/z 385 (M); 
MS m/z 386 (M+H)
+, 403 (M+NH4)
+, 424 (M+K)
+. 
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Amino-[4-oxo-1-(toluene-4-sulfonyl)-1,2,3,4-tetrahydroquinolin-3-yl]-acetic acid 
ethyl ester (4.18) 
A  solution  of  (4-methoxy-phenylamino)-[4-oxo-1-(toluene-4-sulfonyl)-1,2,3,4-
tetrahydroquinolin-3-yl]-acetic acid ethyl ester (4.16a, 0.34g, 0.66 mmol) in acetonitrile 
(50 mL) was cooled on an ice/water bath. A solution of ceric ammonium nitrate (1.09g, 
1.98 mmol) in water (10 mL) was added dropwise, turning the color of the solution from 
yellow to blue/black to brown/black to orange over several minutes. The reaction was left 
to  warm  to  r.t.  and  stirred  at  r.t.  for  1  hour.  The  mixture  was  concentrated  in  vacuo. 
Water was added, and the aqueous layer was extracted with EtOAc. The combined organic 
layers were washed with brine, dried (MgSO4), filtered, and the solvent was evaporated. 
The product was purified by column chromatography (silica, petroleum ehter: EtOAc 1:1 to 
pure EtOAc). A brown oil was obtained which was not pure enough for full characterization. 
13C  NMR  (50  MHz,  CDCl3)     192.0,  189.2,  143.1,  140.8,  134.6,  133.9,  133.5,  128.7, 
126.9, 126.0, 125.9, 123.6, 123.04 ppm; IR (NaCl) 3393, 3331, 2980, 2927, 1735, 1688, 
1597,  1458,  1358,  1165,  1088,  766,  733,  674  cm
-1;  MS  m/z  403  (M+H)
+,  386  (M-
NH3+H)
+. 
 
Acetylamino-(1-acetyl-4-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-acetic  acid  ethyl 
ester (4.25)  
To  a  solution  of  iodobenzene  diacetate  (2.00  g,  6.20  mmol)  in  methanol  (50  mL),  a 
solution  of  (1-acetyl-4-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-(4-methoxy-phenylamino)-
acetic  acid  ethyl  ester  (4.16b,  0.61  g,  1.55  mmol)  in  methanol  (15  mL)  was  added 
dropwise over 20 minutes. The mixture was stirred at r.t. for 1.5 hours. 1 N HCl (50 mL) 
was added, and the mixture was stirred for 0.5 h at r.t.. Then, the mixture was washed 
with CH2Cl2 (2x). The combined organic layers were back-extracted with 0.1 N HCl (1x30 
mL). Then, CH2Cl2 (50 mL) was added to the combined aqueous layers, followed by acetic 
anhydride (0.72 mL, 0.79 g, 7.7 mmol). The mixture was brought to pH 8-9 by addition of 
solid K2CO3, turning the color of the mixture to purple/brown. The biphasic mixture was 
stirred at room temperature for 1.5 h. The layers were then separated, and the aqueous 
phase was extracted with CH2Cl2. The combined organic layers were washed with brine, 
dried  (MgSO4),  filtered,  and  the  solvent  was  evaporated.  The  product  was  purified  by 
column chromatography (silica, CH2Cl2:MeOH 100:1  50:1), yielding 126 mg (25 %) of an 
off-white solid. 
1H NMR (200 MHz, CDCl3)   1.20-1.27 (t, 3H, CH2CH3), 1.99 (s, 3H, COCH3), 2.37 (s, 3H, 
COCH3), 3.60-3.67 (m, 2H, NCH2), 4.17-4.28 (q, 2H, CH2CH3), 4.76-4.81 (d, J=9.97, 1H, 
CH),  4.94-4.99  (dd,  1H,  CH),  6.28-6.32  (d,  J=8.22,  1H,  NH),  7.20-7.28  (m,  1H,  ArH), 
7.54-7.56 (d, J=3.81, 1H, ArH), 7.94-7.98 (d, J=7.92, 1H, ArH) ppm; 
13C NMR (50 MHz, 
CDCl3)     194.2,  170.7,  170.2,  169.6,  144.0,  134.7,  127.7,  125.4,  125.1,  124.2,  62.2, 
51.6, 50.5, 47.6, 23.5, 23.1, 14.0 ppm; IR (KBr) 3295, 2951, 1742, 1673, 1536, 1478, 
1371, 1245, 1216, 766 cm
-1. 
 
(1-Acetyl-4-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-tert-butoxycarbonylamino-
acetic acid ethyl ester (4.26) 
To  a  solution  of  iodobenzene  diacetate  (1.75g,  5.44  mmol)  in  methanol  (20  mL),  (1-
acetyl-4-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-(4-methoxy-phenylamino)-acetic  acid  ethyl 
ester (4.16b, 0.54 g, 1.4 mmol) in 15 mL methanol was added dropwise over 20 min. The 
reaction was stirred for 1 h at r.t., and was then acidified with 1 N HCl (35 mL). After 
stirring for 1.5 h at r.t., the mixture was concentrated in vacuo. The remaining aqueous 
layer was washed with CH2Cl2 (2x). The combined organic layers were back-extracted with 
30 mL 0.1 N HCl. The combined aqueous layers were stirred with CH2Cl2 (30 mL), and 
Boc2O (0.44 g, 2.0 mmol) was added with some CH2Cl2, followed by K2CO3 to pH 8-9. The 
mixture  was  stirred  vigorously  at  r.t.  for  2.3  h.  The  layers  were  separated,  and  the 
aqueous layer was extracted with CH2Cl2. The combined organic layers were washed with 
brine, dried (MgSO4), filtered, and the solvent was evaporated. The product was purified KAT inhibitors: Quinolinones 
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with column chromatography (silica, hexane:EtOAc 4:1 1:1). The product was isolated as 
an oil (147 mg, 28 %). 
1H NMR (200 MHz, CDCl3)   1.15-1.26 (q, 3H, CH2CH3), 1.39-1.41 (d, 9H, BOC-CH3), 2.35-
2.36  (d,  3H,  COCH3),  3.63-3.67  (d,  J=7.92  Hz,  2H,  CH2),  4.13-4.23  (m,  2H,  CH2CH3), 
4.57-4.82 (dd, 1H, CH), 4.70-4.82 (m, 1H, CH), 5.23-5.28 (d, J=8.22, 1H, CH), 7.19-7.27 
(m, 1H, ArH), 7.52-7.54 (d, J=4.7 Hz, ArH), 7.94-7.99 (dd, 1H, ArH) ppm; 
13C NMR (50 
MHz,  CDCl3)     194.0,  170.56,  169.6,  156.0,  143.9,  134.5,  127.8,  125.4,  124.1,  80.3, 
62.0, 52.4, 51.5, 47.3, 28.2, 23.4, 14.0 ppm; IR (NaCl) 3346, 1979, 1729, 1674, 1600, 
1480,  1371,  1245,  1163,  1029,  958,  860,  768  cm
-1;  MS  (ESI)  m/z  391  (M+H)
+,  408 
(M+NH4)
+, 413 (M+Na)
+. 
 
4-Oxo-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester (4.27) 
A solution of 4.4 (1.01 g, 6.89 mmol), di-tert-butyl dicarbonate (1.82 g, 8.34 mmol), and 
N,N-dimethylaminopyridine, (DMAP, 1.01 g, 8.27 mmol) in THF (25 mL) was stirred at r.t.. 
After 4 h, no starting material was left by TLC. Water was added, and EtOAc. The organic 
layer was washed with water (3x). The combined aqueous layers were back-extracted with 
EtOAc  (2x).  The  combined  organic  layers  were  washed  with  brine  (1x),  dried  (MgSO4), 
filtered,  and  the  solvent  was  evaporated.  The  crude  product  was  purified  by  column 
chromatography (silica, Hex/EtOAc) as a white solid (1.15 g, 68%). 
1H NMR (200 MHz, CDCl3)   1.55 (s, 9H, C(CH3)3), 2.73-2.80 (t, 2H, CH2), 4.12-4.18 (t, 
2H, CH2), 7.11-7.19 (m, 1H, ArH), 7.44-7.53 (m, 1H, ArH), 7.74-7.78 (d, J=8.43Hz, 1H, 
ArH), 7.96-8.00 (dd, J=1.46, 7.69Hz, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   133.9, 
127.3, 123.9, 123.7,  82.2, 44.3, 39.0, 28.3 ppm; GCMS m/z 247 (M); IR (KBr) 2982, 
1686, 1600, 1476, 1359, 1153, 766 cm
-1. 
 
4-Trimethylsilanyloxy-2H-quinoline-1-carboxylic acid tert-butyl ester (4.28) 
Synthesized according to general procedure. 
IR (NaCl) 2973, 1712, 1694, 1486, 1370, 1345, 1250, 1223, 1152, 881, 846, 757 cm
-1. 
 
3-[Ethoxycarbonyl-(4-methoxy-phenylamino)-methyl]-4-oxo-3,4-dihydro-2H-
quinoline-1-carboxylic acid tert-butylester (4.29) 
Synthesized  according  to  general  procedure.  The  product  was  purified  by  column 
chromatography (silica, Hex:EtOAc 10:1   5:1). The product was isolated in 3 fractions. 
The  first  fraction  contained  diastereomer  1  (upper  spot  on  TLC,  2.94  g),  the  second 
fraction  contained  both  diastereomers  (0.85  g,  and  the  third  fraction  contained 
diastereomer 2 (lower spot on TLC, 0.67 g). In total, 4.46 g product was yielded (40% 
over two steps). 
First fraction: 
1H NMR (300 MHz, CDCl3)   0.97-1.01 (t, 3H, COOCH2CH3), 1.57 (s, 9H, BOC-CH3), 3.42-
3.44 (m, 1H, (C=O)CH2), 3.74 (s, 3H, ArOCH3), 4.02-4.16 (m, 3H, NCH2 and OCH2CH3),  
4.29-4.35 (dd, J=4.76, 13.55 Hz, 1H, NCH2), 4.41-4.42 (d, J=3.67 Hz, 1H, NHCH), 6.68-
6.71 (m, 2H, ArH), 6.77-6.81 (m, 2H, ArH), 7.13-7.17 (t, 1H, ArH), 7.46-7.51 (dt, 1H, 
ArH), 7.74-7.76 (d, J=8.43 Hz, ArH), 7.99-8.02 (dd, J=1.47, 7.69 Hz, 1H, ArH) ppm; 
13C 
NMR (50 MHz, CDCl3)   194.4, 171.8, 153.3, 152.9, 144.1, 140.7, 134.3, 127.6, 125.3, 
124.0, 123.5, 115.7, 115.2, 82.8, 62.0, 57.5, 56.0, 50.2, 45.8, 28.5, 13.8 ppm; IR (NaCl) 
3384, 2980, 2935, 1739, 1713, 1693, 1681, 1514, 1369,m 1235, 1151, 1035, 821, 765 
cm
-1; HRMS m/z obs. 455.21810, calc. 455.21766 (M+H)
+. 
Second fraction: 
1H NMR (300 MHz, CDCl3)   1.18-1.23 (t, 3H, COOCH2CH3), 1.52 (s, 9H, BOC-CH3), 3.13-
3.19  (m,  1H,  (C=O)CH),  3.73  (3H,  ArOCH3),  4.02-4.22  (dd  and  m,  3H,  NCH2  and 
COOCH2CH3), 4.43-4.52 (dd and d, 2H, NCH2 and NCH), 6.76 (s, ArH-OMe), 7.12-7.17 (t, 
1H, ArH), 7.47-7.53 (dt, 1H, ArH), 7.76-7.79 (d, J=8.05 Hz, 1H, ArH), 7.97-8.00 (dd, 1H, 
ArH) ppm; 
13C NMR (50 MHz, CDCl3)   194.1, 172.8, 153.7, 152.9, 144.2, 141.0, 134.4, 
127.9, 125.0, 124.2, 123.8, 116.8, 115.0, 82.6, 77.9, 77.2, 76.6, 61.9, 58.2, 55.9, 50.7, Chapter 4 
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46.3, 28.4, 14.4 ppm; IR (KBr) 3359, 2976, 1735, 1700, 1683, 1516, 1387, 1262, 1238, 
1159, 1036, 827, 758 cm
-1; HRMS m/z obs. 455.21799, calc. 455.21766 (M+H)
+. 
 
3-[1-Ethoxycarbonyl-methylidene]-4-oxo-3,4-dihydro-2H-quinoline-1-carboxylic 
acid tert-butyl ester (4.30) 
Isolated as a side-product during the synthesis of 4.29.  
1H NMR (200 MHz, CDCl3)   1.304-1.376 (t, 3H, OCH2CH3), 1.53 (s, 9H, OC(CH3)3), 4.23-
4.33 (q, J=7.05, 14.39 Hz, 2H, OCH2CH3), 5.30 (s, 2H, NCH2), 6.88 (s, 1H, C=CH), 7.17-
7.24 (t, J=7.35, 7.64 Hz, 1H, ArH), 7.50-7.58 (t, J=7.35, 8.22 Hz, 1H, ArH), 7.69-7.73 (2, 
J=8.22 Hz, 1H, ArH), 7.96-8.00 (d, J=7.64Hz, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   
183.6, 165.4, 152.8, 144.8, 144.2, 134.6, 128.4, 126.2, 124.9, 124.6, 123.9, 82.6, 61.4, 
46.0, 28.4, 14.4 ppm; IR (NaCl) 2977, 1721, 1713, 1680, 1601, 1479, 1154, 758 cm
-1; 
MS m/z 332 (M+H)
+, 349 (M+NH4)
+, 354 (M+Na)
+. 
 
3-(tert-Butoxycarbonylamino-ethoxycarbonyl-methyl)-4-oxo-3,4-dihydro-2H-
quinoline-1-carboxylic acid tert-butyl ester (4.31) 
Prepared as described for compound 4.26 from diastereomer 1(upper) of 4.29. A mixture 
of diastereomers was obtained (0.87 g, 30 %) by column chromatography (silica, Hex: 
EtOAc 10:1   5:1). Diastereomers could be separated by column chromatography (silica, 
Hex: EtOAc (10:1   15:2) in a final total yield of 15 %.  
First fraction: 
1H NMR (400 MHz, CDCl3)   1.20-1.24 (t, 3H, J=6.97 Hz, OCH2CH3), 1.41 (s, 8H (expect 
9H),  BOC-CH3),  1.56  (s,  8H  (expect  9H),  BOC-CH3),  3.63-3.73  (m,  2H,  (C=O)CH  and 
NCH2),  4.20-4.23  (m,  2H,  OCH2CH3),  4.57-4.71  (m,  2H,  NCH2  and  NH),  5.24-5.26  (d, 
J=8.79  Hz,  1H,  NHCH),  7.11-7.15  (t,  1H,  ArH),  7.47-7.51  (m,  1H,  ArH),  7.77-7.79  (d, 
J=8.43 Hz, 1H, ArH), 7.93-7.95 (dd, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   194.5, 
170.92, 156.29, 152.9, 144.5, 134.6, 127.6, 124.5, 124.0, 123.8, 82.8, 80.5, 62.2, 52.5, 
50.7, 47.3, 28.5, 28.5, 14.2 ppm; IR (NaCl) 3347, 2978, 2933, 1738-1682, 1602, 1479, 
1368, 1325, 1247, 1220, 1157, 1071, 1029, 858, 765, 736 cm
-1; MS m/z 449 (M+H)
+, 
466 (M+NH4)
+, 471 (M+Na)
+, 897 (2M+H)
+, 914 (2M+NH4)
+, 919 (2M+Na)
+. 
Second fraction: 
1H NMR (400 MHz, CDCl3)   1.19-1.23 (t, 3H, OCH2CH3), 1.43 (s, 9H, BOC-CH3), 1.56 (s, 
8H  (expected  9H),  BOC-CH3),  3.13-3.18  (m,  1H,  (C=O)CH),  4.00-4.06  (bt,  1H,  NCH2), 
4.13-4.20 (m, 2H, OCH2CH3), 4.57-4.58 (m, 2H, NCH2 and NH), 5.64-5366 (bd, J=8.43Hz, 
NHCH),  7.11-7.15  (t,  1H,  ArH),  7.47-7.51  (m,  1H,  ArH),  7.78-7.80  (d,  J=8.07Hz,  1H, 
ArH),  7.94-7.96  (dd,  1H,  ArH)  ppm; 
13C  NMR  (50  MHz,  CDCl3)     195.1,  170.9,  155.6, 
152.8, 144.4, 134.6, 127.7, 124.6, 124.1, 123.7, 82.8, 80.4, 62.0, 53.2, 51.3, 47.6, 28.5, 
14.3 ppm; IR NaCl 3362, 2980, 2933, 1745-1680, 1601, 1480, 1370, 1299, 1221, 1152, 
858, 767, 732 cm
-1; MS m/z 449 (M+H)
+, 466 (M+NH4)
+, 471 (M+Na)
+, 897 (2M+H)
+, 
914 (2M+NH4)
+, 919 (2M+Na)
+. 
 
3-(tert-Butoxycarbonylamino-carboxymethyl)-4-oxo-3,4,-dihydro-2H-quinoline-
1-carboxylic acid tert-butyl ester (4.32) 
A mixture of 3-(tert-butoxycarbonylamino-ethoxycarbonyl-methyl)-4-oxo-3,4-dihydro-2H-
quinoline-1-carboxylic acid tert-butyl ester (4.31, 0.440 g, 0.980 mmol), 5 mL EtOH, 5 mL 
H2O and KOH (0.102 g, 1.81 mmol) was stirred at room temperature. After 4 hours, NH4Cl 
(sat. aq.) was added and some 1 N HCl for acidification. The aqueous layer was extracted 
with EtOAc. The combined organic layers were washed with brine, dried (MgSO4), filtered, 
and  the  solvent  was  evaporated,  yielding  0.433  g  of  a  colorless  oil/white  foam  (quant. 
yield). TLC and HPLC analysis showed the presence of both diastereomers. 
1H NMR (400 MHz, CDCl3)   [1.40; 1.43] (2 x s, 9H, BOC-CH3), [1.55; 1.56] (2 x s, 9H, 
BOC-CH3), [3.19-3.22; 3.6-3.73; 3.95-4.01] ([m, m, bt], 2H, [(C=O)CH diastereomer 1; 
(C=O)CH and NCH2 diastereomer 2; NCH2 diastereomer 1]), 4.63-4.76 (m, 2H, NCH2 and 
NH; on bs of COOH); 5.27-5.30 and 5.80-5.82 (d and bd, 1H, NHCH) ppm; 
13C NMR (50 
MHz, CDCl3)   194.7, [175.3, 174.4], 156.3, [153.0, 152.9], 144.6, 134.8, [127.9, 127.7], KAT inhibitors: Quinolinones 
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[124.4,  124.3],  [124.2,  124.1],  [123.9,  123.8],  [83.0,  80.8],  52.0,  [51.0,  50.7],  47.5, 
28.52, 28.48, 28.45 ppm; IR (KBr) 3382, 2976, 1715, 1686, 1601, 1479, 1368, 1156, 
856, 766 cm
-1. 
 
Amino-(4-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-acetic acid (4.2) 
A  mixture  of  3-(tert-butoxycarbonylamino-carboxymethyl)-4-oxo-3,4,-dihydro-2H-
quinoline-1-carboxylic acid tert-butyl ester (4.32, 0.506 g, 1.20 mmol), CH2Cl2 (10 mL), 
and trifluoroacetic acid (2 mL) was stirred at room temperature. After 3.5 hours, 1 mL of 
trifluoroacetic acid was added and the mixture was stirred for 0.5 hours. The solvent and 
trifluoroacetic acid were evaporated. The product was purified by column chromatography 
(silica,  CH2Cl2     CH2Cl2/MeOH  10:1     MeOH),  yielding  0.146  g  of  a  yellow  solid.  This 
fraction  was  triturated  with  acetone/MeOH  to  yield  0.142  g  of  the  pure  product  as  a 
brightly yellow solid (53 %). 
1H NMR (500 MHz, D2O)   3.26-3.31 (m, 1H, NH2CH), [3.35-3.40, 3.46-3.48, 3.54-3.59] 
([dt,  m,  dd],  2H,  [(C=O)CH  of  diastereomer  1,  (C=O)CH  and  NCH2  of  diastereomer  2, 
NCH2 of diastereomer 1]), 4.21-4.23 (m, 1H, NCH2), 6.57-6.71 (dd (J=8.3 Hz) and dt, 2H, 
ArH), 7.15-7.22 (dt, 1H, ArH), 7.41-7.47 (dd, J= 7.81, 21.24 Hz, 1H, ArH) ppm; 
13C NMR 
(125  MHz,  D2O)     [194.0,  193.2],  [170.2,  170.1],  [150.6,  149.3],  137.13,  137.07], 
[127.49,  127.46],  [121.1,  120.1],  [119.2,  118.6],  [118.2,  117.6],  [51.0,  50.9],  [46.1, 
45.7],  [44.0,  43.2]  ppm;  IR  (KBr)  3379,  2952,  1668,  1644,  1618,  1492,  1405,  1246, 
1151, 745  
cm
-1; HRMS (M+H)
+ m/z obs. 221.09212 calc. 21.09207 (C11H13O3N2). 
 
3-Carboxymethyl-4-oxo-3,4-dihydro-2H-quinoline-1-carboxylic  acid  tert-butyl 
ester (4.34) 
A  solution  of  4-oxo-3,4-dihydro-2H-quinoline-1-carboxylic  acid  tert-butyl  ester  (4.27, 
0.853 g, 3.45 mmol) in 20 mL THF under N2 was cooled to -80 
oC. A solution of LHMDS 
(0.891 g, 5.32 mmol) in 5 mL THF was added dropwise, changing the color from yellow to 
dark yellow. The mixture was left to warm up to -15 
oC over 1 h. Then, it was cooled back 
to -80 
oC and ethyl bromoacetate (0.38 mL, 0.58 g, 3.45 mmol) was added at once. The 
reaction mixture was left to warm up to r.t.. After 3.75 h the reaction was quenched by 
addition of water. The layers were separated and the aqueous layer was extracted with 
EtOAc.  The  combined  organic  layers  were  dried  (MgSO4),  filtered,  and  the  solvent  was 
evaporated.  The  product  was  partially  purified  by  column  chromatography  (silica, 
Hex:EtOAc), yielding 0.698 g of an oil which contained 4.33  as the main component.  
IR (NaCl) 2980, 1736-1686, 1601, 1476, 1363, 1234, 1156, 765 cm
-1. 
The product was stirred at r.t. in 10 mL EtOH and 10 mL 1 N NaOH for 1 h. More water 
was  added.  Washing  with  CH2Cl2  gave  an  emulsion.  The  mixture  was  acidified  with 
saturated NH4Cl and some 1 N HCl and was extracted with CH2Cl2. The combined organic 
layers  were  extacted  with  saturated  NaHCO3  solution.  The  combined  aqueous  extracts 
were acidified with 1 N HCl and extracted with CH2Cl2. The combined organic extracts were 
dried (MgSO4), filtered, and the solvent was evaporated. Column chromatography (silica, 
CH2Cl2)  gave  the  pure  product  as  a  colorless  oil,  which  solidified  over  time  to  obtain  a 
white solid (0.343 g, 33 % overall yield). 
1H NMR (200 MHz, CDCl3)   1.55 (s, 9H, BOC-(CH3)3),2.51-2.64 (q, 1H, CH2COOH), 2.88-
2.99 (dd, J=4.70, 17.34Hz, 1H, CH2COOH), 3.11-3.25 (m, 1H, CH), 3.68-3.80 (q, J=11, 
13.22 Hz, CH2), 4.51-4.60 (q, J=4.40, 13.22 Hz, CH2), 7.12-7.19 (t, 1H, ArH), 7.47-7.55 
(dt, 1H, ArH), 7.78-7.82 (d, J= 8.52 Hz, 1H, ArH), 7.97-8.01 (dd, J=1.18, 7.94 Hz, 1H, 
ArH), 9.32 (bs, 1H, COOH) ppm; 
13C NMR (50 MHz, CDCl3)   195.1, 177.1, 153.0, 144.4, 
134.5,  127.9,  124.3,  124.2,  123.8,  82.7,  48.5,  44.3,  32.1,  28.4  ppm;  IR  (KBr)  3048, 
2975, 1709, 1702, 1689, 1599, 1482, 1368, 1156, 764 cm
-1. 
 
(4-Oxo-1,2,3,4-tetrahydroquinolin-3-yl)-acetic acid (4.3) 
A mixture of 3-carboxymethyl-4-oxo-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl 
ester (4.34, 0.198 g, 0.648 mmol) and TFA (0.050 mL) in 10 mL CH2Cl2 was stirred at r.t..  Chapter 4 
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The reaction mixture was stirred over two days, and a total of 0.3 mL TFA was added in 
portions. The solvent was evaporated. The crude product was subjected directly to column 
chromatography (silica, CH2Cl2: MeOH 25:1). The pure product was obtained as a brightly 
yellow solid (75.4 mg, 57 %). 
1H NMR (200 MHz, CD3OD)   2.22-2.34 (dd, 1H, CH2COOH), 2.66-2.77 (dd, J=5.29, 16.75 
Hz, 1H, CH2COOH), 2.83-2.99 (m, 1H, COCH), 3.15-3.27 (m + solvent residual peak of 
CD3OD,  1H,  NHCH2),  3.43-3.52  (dd,  J=5.59,  11.75  Hz,  1H,  NHCH2),  6.49-6.59  (ddd, 
J=0.88, 7.93 Hz, 1H, ArH), 6.62-6.66 (d, J=8.52 Hz, 1H, ArH), 7.13-7.21, (ddd, J=1.47, 
7.05 Hz, 1H, ArH), 7.56-7.61 (dd, J=1.47, 7.94 Hz, 1H, ArH) ppm; 
13C NMR (50 MHz, 
CDCl3)   195.6, 174.5, 153.3, 135.2, 127.1, 117.7, 116.8, 115.9, 45.9, 43.0, 31.5 ppm; 
IR (KBr) 3367, 2920, 1689, 1654, 1616, 1517, 1240, 747 cm
-1; HRMS (M+H)
+ m/z obs. 
206.08124 calc 21.08117 (C11H12O3N1). 
 
Kynurenine aminotransferase activity in rat brain homogenate 
KAT  inhibitory  activity  was  determined  in  rat  brain  tissue  homogenate  as  described 
previously,  with  modifications.
33,  34  Rat  brain  (male  Wistar  rats,  whole  brain)  was 
homogenized  in  a  5  mM  Tris-acetate  buffer  at  pH  8.0,  containing  50  µM  pyridoxal  5’- 
phosphate  and  10  mM  2-mercaptoethanol  (10  %  w/v).  The  homogenate  was  dialyzed 
against  this  buffer  for  24  hours  at  4 
oC  (12  mL  homogenate  /  2.5  L  buffer).  Enzyme 
activity was tested in an assay consisting of 200 µL of dialyzed tissue homogenate, 150 
mM Tris acetate buffer, pH 8.0, 70 µM pyridoxal 5’-phosphate, 1 mM pyruvate, 10 µM L-
kynurenine  and  the  inhibitor  in  a  final  volume  of  250  µL  (all  concentrations  final).  The 
mixture was incubated at 37 
oC for 2 h. The reaction was terminated by addition of 100 µL 
7%  perchloric  acid.  The  mixture  was  centrifuged  for  15  minutes  at  14000  rpm,  4 
oC. 
Kynurenic acid concentrations were determined in the supernatant by HPLC (Supelcosil
TM 
HPLC column, 15 cm x 3 mm, 3 µm). The mobile phase consisted of a buffer containing 15 
% methanol, 10 g/L Na2HPO4.2H2O, 150 mg/L EDTA and 0.17 % (v/v) THF, adjusted to pH 
5.27 with phosphoric acid. The product was detected fluorimetrically at an extinction of 
344 nm and emission of 398 nm. Each concentration of inhibitor was assayed in triplo. The 
KYNA concentration in each sample was determined in triplo. 
 
Kynureninase activity in liver tissue homogenate 
Kynureninase  activity  was  determined  in  rat  liver  tissue  homogenate  as  described 
previously, with modifications.
35,  36 Liver tissue was homogenated in a buffer (10% w/v) 
consisting of 20 mM Tris-acetate pH 8.0, 0.5 mM 2-mercaptoethanol, and 50 µM pyridoxal 
5’-phosphate. The homogenate was centrifuged at 14000 rpm for 30 minutes at 4 
oC. The 
supernatant was dialyzed against the buffer as described above (12 mL supernatant / 2.5 
L  buffer)  for  24  hours  at  4 
oC.  Enzyme  activity  was  determined  using  100  µL  of  the 
dialyzed tissue, 50 µL of a solution consisting of 400 mM Tris-HCl buffer pH 8.0, 200 µM 
pyridoxal 5’-phosphate and 40 µM L-kynurenine (final concentration 10 µM), and 50 µL 
inhibitor at varying concentrations. The mixture was incubated at 37 
oC for 30 minutes. 
The reaction was terminated by mixing with 100 µL 7% perchloric acid. The samples were 
centrifuged at 14000 rpm for 15 minutes at 4 
oC. Anthranilic acid concentrations in the 
supernatant were measured by HPLC.  
The supernatant was applied to a Supelcosil
TM HPLC column (15 cm, 4.6 or 3 mm ID, 3 µm 
particle size). The mobile phase consisted of a buffer containing 26% methanol, 10 g/L 
Na2HPO4.2H2O,  150  mg/L  EDTA  and  0.17  %  (v/v)  THF,  adjusted  to  pH  5.27  with 
phosphoric acid. The product was detected fluorimetrically at an extinction of 313 nm and 
emission of 420 nm. Each concentration of inhibitor was assayed in triplo. The anthranilic 
acid concentration in each sample was determined in triplo. 
 
Kynurenine 3-hydroxylase activity in liver tissue homogenate 
Kynurenine  3-hydroxylase  activity  was  determined  in  rat  liver  tissue  homogenate  as 
described previously, with modifications.
35 The tissue was homogenized in icecold 0.32 M 
sucrose  solution (1 g tissue / 8 mL sucrose solution). The homogenate was centrifuged at KAT inhibitors: Quinolinones 
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11000  rpm,  4 
oC,  30  min.  The  supternatant  was  taken  off,  and  the  residue  was 
resuspended in sucrose solution (1 mL 0.32 M sucrose / residue of 1 mL homogenate). The 
tissue was centrifuged (11000 rpm, 4 
oC, 30 min). This washing procedure was repeated 
twice. The resulting tissue was resuspended in 0.14 M KCl, 20 mM potassium phosphate 
buffer at ph 7.0.  
Enzyme activity was measured using 75 µL of the tissue homogenate, 100 µL of a 100 mM 
potassium phosphate buffer pH 7.5, containing 1 mM NADPH, 4 mM MgCl2, and 20 µM L-
kynurenine (final concentration 10 µM), and 25 µL of a solution of the inhibitor at varying 
concentrations.  The  mixture  was  incubated  at  37 
oC  for  30  minutes.  The  reaction  was 
terminated by the addition of 100 µL 7% perchloric acid. The samples were centrifuged 
(14000  rpm,  15  minutes,  4
oC).  The  concentrations  of  3-hydroxykynurenine  in  the 
supernatant  were  determined  by  HPLC.  The  supernatant  was  applied  to  a  Supelcosil
TM 
HPLC column (15 cm, 4.6 or 3 mm ID, 3 µm particle size). The mobile phase consisted of a 
solution of 100 mg EDTA, 150 mg heptane sulphonic acid, 5.9 mL phosphoric acid, 9.0 mL 
triethylamine and 20 mL acetonitrile in 950 mL H2O.
37 Each concentration of inhibitor was 
assayed in triplo. The 3-hydroxykynurenine concentration in each sample was determined 
in triplo. 
 
Molecular Modeling 
Hardware  and  software  specifications  All  computations  were  preformed  on  an  Intel
® 
Pentium
® 4.0 3.0GHz computer with 2 Gb memory, running Ubuntu 8.10 (Intrepid Ibex) 
as  the  operating  system.  For  preparation  of  the  macromolecule,  ligands,  structure 
minimizations  and  analysis  of  ligand-protein  interactions  Sybyl  8.1  was  used.
38  For 
docking, structures were processed in AutoDockTools (ADT) version 1.5.4.
39 For docking, 
AutoDock  Vina
40  version  1.0.2  was  used  and  results  were  analyzed  in  PyMOL  version 
1.1beta3 (www.pymol.org) as distributed for Ubuntu. 
Conformational  Search  Ligands  were  built  in  Sybyl.  Conformational  searches  were 
preformed  for  L-KYN,  4.2  and  4.3  using  the  Random  search  function  in  Sybyl.  For 
minimization, the Powell method was used with a maximum of 1000 iterations, no Simplex 
iterations  were  done.  The  search  was  terminated  at  a  gradient  of  0.05.  Energies  were 
calculated using the Tripos Force Field and Gasteiger-Hückel charges. The Random search 
was  terminated  at  a  maximum  of  1000  cycles  or  a  maximum  of  50  hits  per  accepted 
conformation. The energy cutoff was set at 10 kcal/mol with an RMS threshold of 0.2 Å. All 
other parameters were kept at the default values. The bicyclic quinolinone core was built 
as a planar structure to unbias the search. All except the aromatic bonds were activated 
for the search.  
From each search, the conformation with the lowest energy was regarded as the global 
minimum. These conformations were inspected on the orientation of the aliphatic branch 
of  the  molecule.  The  global  minima  with  the  branch  in  an  equatorial  orientation  were 
selected  for  docking.  If  the  branch  was  oriented  axially,  the  conformation  with  an 
equatorial orientation at the lowest possible energy was selected for docking.   
All molecules selected for docking were aligned by the Database align function in Sybyl, 
using the aromatic ring and the carboxylic acid functions as template groups.  
Docking  For  docking,  the  crystal  structure  of  human  KYNase  in  complex  with  3-
hydroxyhippuric acid (PDB ID 3E9K
28, www.rcsb.org) was used as the enzyme structure. 
From this structure, the ligand was extracted. The biological dimeric unit was created in 
PyMOL. The dimeric enzyme structure without the ligand was loaded into AutoDockTools 
and prepared as the macromolecule. Only polar hydrogen atoms were taken into account. 
The small molecule structures were loaded into AutoDockTools and prepared as the ligand 
structure.  The  Grid  box  dimensions  were  determined  from  the  co-crystallized  ligand  3-
hydroxyhippuric acid according to the method as used for AutoDock Vina evaluation.
40 In 
summary, the smallest possible box was created around the co-crystallized ligand. Along 
each axis, this box was extended by 10 Å. For each axis, the box was extended by another 
5 Å in one of the two directions, (semi)-randomly chosen. If the resulting size of the box in 
either direction was less than 22.5 Å, the size was adjusted to this minimum value. This Chapter 4 
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resulted in a box with center coordinates (x,y,z)=(1.959, 2.830, 13.629) and dimensions 
in  Å  of  (x,y,z)  =  (23,  22.5,  23).  This  box  was  used  for  all  docking  experiments.  The 
exhaustiveness parameter was set to a value of 15. All other parameters were kept at 
their default values. The results were analyzed in PyMOL. Conformations were compared to 
the conformation of 3-hydroxyhippuric acid. In addition, conformations of  4.2, 4.3 and 
4.36 were compared to the conformation of docked L-KYN. Unless stated otherwise, the 
conformation with the lowest possible energy was regarded as the best docked hit. 
Analysis of interactions The best docked conformations for each ligand were merged into 
the macromolecule structure in Sybyl. Static hydrogen bonds were added, using standard 
settings of Sybyl. 
Figures Figures 1-7 were generated in PyMOL (www.pymol.org). 
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5.1  Introduction 
Kynurenic acid (KYNA) is one of the major products of the kynurenine pathway, 
the  major  route  of  tryptophan  metabolism.  The  compound  is  an  endogenous 
antagonist at the strychnine insensitive glycine coagonist site of NMDA receptors 
and  a  non-competitive  antagonist  at   7*  nicotinic  acetylcholine  receptors.  At 
higher  concentrations,  KYNA  is  an  antagonist  at  all  ionotropic  glutamate 
receptors.  In  general,  KYNA  is  neuroprotective  by  reducing  excitotoxicity. 
However, elevated levels of KYNA have been found in patients suffering from 
schizophrenia and can cause cognitive impairment.
1-5 
KYNA  is  synthesized  by  kynurenine  aminotransferase  (KAT)  from  kynurenine 
(KYN,  5.1,  Scheme  1).  At  least  four  different  isoforms  of  KAT,  KAT  I-IV,  are 
known. KAT II is the isoform that is responsible for most of the KYNA production 
in the human brain.
6-8 
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Key  intermediate  KYN  is  metabolized  by  two  other  enzymes,  kynureninase 
(KYNase)  and  kynurenine  3-hydroxylase  (kynurenine  mono-oxygenase,  KMO), 
resulting  in  production  of  anthranilic  acid  (AA)  and  neurotoxic  3-
hydroxykynurenine  (3-OH-KYN)  and  quinolinic  acid  (QUIN).  QUIN  is  an 
endogenous NMDA receptor agonist and direct precursor of NAD. A delicate, site 
specific,  balance  exists  between  the  routes  of  kynurenine  metabolism  in  the 
human and rodent brain. 
 
To  study  effects  of  elevated  or  decreased  KYNA  levels,  the  ability  of 
pharmacological  interference  in  the  KYN  metabolism  is  useful.  The  most 
straightforward  way  of  influencing  the  balance  between  KYNA  and  QUIN 
production is inhibition of the metabolic enzymes KAT, KYNase and KMO. Several 
close KYN analogs have been published that are able to inhibit one or more of 
these enzymes, eg. ref
9-16. It has been proven that inhibition of either KYNase or 
KMO causes elevated KYN levels and enhanced KYNA production.
10, 12 Recently, KAT inhibitors: Flexible analogs 
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the first compound was published that is able to decrease KYNA levels.
16 This 
compound,  S-4-(ethylsulfonyl)-benzoylalanine  (S-ESBA,  5.2,  Scheme  1)  is  an 
inhibitor that is selective for KAT over KYNase and KMO. This study aims for the 
further  elucidation  of  structural  requirements  of  selective  KAT  inhibitors. 
Compounds  5.3  –  5.6  (Scheme  2)  were  synthesized  and  tested  for  KAT 
inhibition and selectivity towards KAT over KYNase and KMO inhibition. 
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5.2  Chemistry 
Compound  5.3  was  synthesized  as  published  previously,  with  minor 
modifications (Scheme 3).
17 
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Reagents  and  conditions:  a.  glyoxylic  acid,  110 
oC;  b.  1.  H2,  Pd/C,  EtOH/EtOAc,  2. 
MeOH, H2SO4, reflux; c. 4N NaOH, MeOH. 
 
Briefly, 2’-nitroacetophenone was reacted with neat glyoxylic acid to obtain the 
unsaturated  acid  5.8.  This  compound  was  reduced  with  H2  and  esterified  to 
obtain  the  methyl  ester  5.9.  In  literature
17,  the  final  product  was  directly 
isolated  after  reduction  of  the  double  bond  by  purification  on  HPLC.  By 
introduction of the esterification step, purification can occur by simple acid/base Chapter 5 
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extraction  and  silica  column  chromatography.  Finally,  hydrolysis  yielded  pure 
5.3 after quick purification on column. 
 
Synthesis  of  tetrazole  derivative  5.4  proved  to  be  more  challenging.  The 
commonly used method for the synthesis of tetrazoles is from nitrile functions 
by reaction with sodium azide. A nitrile function spaced two carbon atoms from a 
carbonyl  function  can  be  obtained  from  Mannich  bases.  The  corresponding 
retrosynthetic approach for the synthesis of 5.4 is shown in Scheme 4. 
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Although published previously
18, 19, in our hands, the Mannich reaction resulted 
in  unidentified  side-products  only.  Neither  the  Mannich  base  5.13  nor  the 
alkylated  derivative  5.12  could  be  isolated.  Although  after  alkylation  of  the 
crude Mannich base with iodomethane a principal product could be isolated, NMR 
and  MS  analysis  could  not  confirm  that  this  product  was  the  desired  5.12. 
Therefore, alternative ways to synthesize nitrile 5.11 were investigated.  
 
The  first  alternative  approach  was  formation  of  5.11  via  1-(2-nitrophenyl)-
propenone 5.14, synthesized in a Stille type coupling (Scheme 5). KAT inhibitors: Flexible analogs 
  143 
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Two  methods  were  tested.  In  method  A,  the  aromatic  core  was  used  as  the 
organotin-containing compound. Coupling
20-22 with either acryloylchloride or 3-
bromopropionylchloride was not successful. In method B, tributylvinyltin
23 was 
used as the organotin moiety, and 2-nitrobenzoylchloride as the halide.
24 Using 
this  method
25,  intermediate  5.14  could  be  isolated.  As  the  major  by-product, 
decarboxylated 5.19 (Scheme 6) was isolated in equal quantities.  
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Reagents and conditions: a. PhCH2Pd(PPh3)2Cl, HMPA; b. HBr/AcOH, THF. 
 
Although in minor amounts, similar elimination of the carbonyl function has been 
found  in  literature  for  the  reaction  of  benzoyl  chloride  with  tetramethyltin, 
yielding  acetophenone  and  toluene.  The  proposed  mechanism  is  shown  in Chapter 5 
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Scheme 6 (box).
24 During the reductive elimination step, the coupled product 
5.14  is  formed  after  elimination  of  one  ligand  moiety  L.  Alternatively,  aryl 
migration can occur, resulting in formation of complex III. From this complex, 
decarbonylated  product  5.19  is  formed.  Interestingly,  undesired  1-nitro-2-
vinylbenzene was the major product of the Stille coupling when chloroform was 
used  as  solvent  and  PhCH2Pd(PPh3)2Cl  as  the  catalyst.
25  In  a  more  classical 
approach, HMPA was used as the solvent. Using the latter solvent, at a small (1 
g of 5.17) scale, product 5.14 and decarbonylated 5.19 were obtained in a 2:1 
ratio. At a slightly larger scale, the ratio was decreased to 1:1, but product was 
obtained in sufficiently high quantity for further experiments. Apparently, ratios 
of  carbonylated/decarbonylated  products  can  be  influenced  by  the  choice  of 
solvent. 
From the crude reaction mixture, tin residues could be removed efficiently by 
column  chromatography,  using  a  mixture  of  KF  and  silica.
26  Unfortunately, 
attempted introduction of the nitrile function in compound 5.14, either directly 
or via brominated 5.20, was unsuccessful.  
 
Therefore,  in  the  third  attempt,  LHMDS  promoted  enolization  of  2’-
nitroacetophenone  and  subsequent  coupling  with  bromoacetonitrile  was 
applied.
27 In earlier studies, similar methods were applied using tetralone-based 
structures (see Chapters 2 and 4). Using this method, compound 5.11 could be 
synthesized in one step (Scheme 7). 
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Reagents and conditions: a. 1. LHMDS, THF, -80 
oC 2. BrCH2CN, -80 
oC; b. AlCl3, NaN3, 
THF; c. H2, Pd/C, MeOH.   
 KAT inhibitors: Flexible analogs 
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A commonly known method for the formation of tetrazoles from nitriles is the 
reaction with sodium azide and ammonium chloride in DMF. This method was 
unsuccessful  for  reaction  of  5.11.  Only  minor  amounts  of  product  5.10  were 
obtained. In an alternative method, reaction with aluminum chloride and sodium 
azide in THF over 3 days
28 gave the nitrated tetrazole 5.10. Reduction of the 
nitro  group  by  mild  hydrogenation  at  atmospheric  pressure  yielded  desired 
compound 5.4. 
 
The  third  compound  in  this  series,  5.5,  was  synthesized  by  straightforward 
methods as shown in Scheme 8. 
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Reagents and conditions: a. 1. Na2SO3, NaHCO3, H2O, 2. EtBr, (n-Bu)4NBr; b. glyoxylic 
acid, AcOH, HCl; c. Zn, AcOH. 
 
In the first step, coupling of ethylbromide to sulfonyl chloride 5.21 yielded the 
ethylsulfonyl-substituted acetophenone 5.22.
29 The carboxylic acid function was 
introduced  in  a  condensation  reaction  with  glyoxylic  acid.
30  Zn-promoted 
reduction of the double bond yielded final product 5.5. 
 
The  first  strategy  for  the  synthesis  of   -methylkynurenine  5.6  employed 
alkylation  of  ethyl  nitropropionate  with  brominated  2’-nitroacetophenone  5.24 
and subsequent reduction and hydrolysis. Since this coupling reaction proved to 
be challenging, synthetic methods were tested on alkylation of less costly ethyl 
nitroacetate to obtain 5.25 (Scheme 9). Chapter 5 
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Reagents and conditions: a. Br2, CH3Cl. 
 
The alkylation reaction in this strategy employs base-catalyzed deprotonation of 
ethyl nitroacetate or ethyl nitropropionate. Although similar reactions are known 
from  literature,  coupling  attempts  with  either  ethyl  nitroacetate  or  ethyl 
nitropropionate  using  NaH
31-33,  t-butylammoniumbromide
34, K 2CO3  (ref
35)  or 
sodium methoxide
33, 36 as the base were unsuccessful. If any, the only products 
that could be isolated were compounds 5.27 and 5.28 as shown in Scheme 10 
(experimental data not shown). 
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Therefore,  an  alternative  precursor  of  the  amino  acid  moiety  was  chosen.  A 
conventionally  applied  protection  method  for  amino  acid  moieties  is  the 
oxazolidinone group. For the synthesis of KYN and KYN analogs, methods using 
oxazolidinone-containing  substructures  can  be  found  in  literature.
16,  37,  38  In 
these  procedures,  oxazolidinones  are  readily  obtained  from  aspartate.  The 
protected aspartyl chloride derivatives are coupled in a Stille coupling reaction to 
an  aromatic  stannane  derivative.  The  use  of  oxazolidinone  and  related 
imidazolidinones for synthesis of amino acids was also discussed in Chapter 3.  KAT inhibitors: Flexible analogs 
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For the synthesis of 5.6 however, no  , -disubstituted amino acid was available. 
Therefore,  the  oxazolidinone  derivative  of  alanine  was  chosen  as  the  starting 
point.  Formation  of  the  Schiff  base  with  benzaldehyde  and  subsequent 
cyclization with benzoylchloride yielded key intermediate 5.29.
39, 40 As shown in 
Scheme 11, after enolization with LHMDS, this compound could successfully be 
coupled to 2-bromo-1-(2-nitrophenyl)-ethanone (5.24).
41, 42 
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Reagents and conditions: a. Br2, CH3Cl; b. LHMDS, THF, -80 
oC; c. NaOH, H2O/MeOH, 
reflux; d. Fe, H2O, AcOH, 95 
oC; e. LiOH, H2O/EtOH. 
 
In the subsequent step, the oxazolidinone ring was opened in a reaction with 
NaOH in H2O and MeOH. Surprisingly, during this reaction, the methyl ester was 
formed  rather  than  the  free  acid.  This  was  published  before  to  occur  under 
either alkaline
41 or acidic
43 conditions. In our experience, careful inspection of 
the course of the reaction was crucial. Once the mixture became a clear solution, 
all starting material had been converted into the methylated product. Quenching 
at this point was necessary to prevent ester hydrolysis into the free acid, which 
obviously is less convenient to handle at purification.  
In the next deprotection step, the nitro group was reduced in a reaction with Fe 
in acetic acid.
15 During this reaction, concomitant hydrolysis of the methyl ester 
occurred. Finally, the benzamide was hydrolyzed with NaOH to obtain  -methyl-
kynurenine 5.6. Chapter 5 
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5.3  Enzyme inhibition 
Compounds  5.3-5.6  were  tested  for  their  ability  to  inhibit  KAT,  KYNase  and 
KMO. Rat brain homogenate was used as the enzyme source for the KAT assay. 
Liver  homogenates  were  used  to  assay  activities  of  KYNase  and  KMO.  As  a 
reference compound, racemic (S,R)-5.2 (ESBA) was tested. Data are shown in 
Table 1. 
 
Table 1 Enzyme inhibition 
Compound  % KAT activity 
(inhibitor 
concentration) 
% KYNase activity 
(inhibitor 
concentration) 
% KMO activity 
(inhibitor 
concentration) 
O
O
OH
NH2  
5.3 
70.3±1.7 (3 mM)  14.6±0.2 (1 mM)  24.7±0.1 (1 mM) 
O
NH2
N N
NH
N
 
5.4 
51.0±0.8 (3 mM)  32.9±0.5 (1 mM)  32.0± (1 mM) 
O
O
OH
S
O O  
5.5 
76.5±1.2 (3 mM)  95.0±1.2 (1 mM)  79.2±1.8 (1 mM) 
O
O
OH
NH2
NH2  
5.6 
77.5±2.1 (3 mM)  100.3±1.6 (1 mM)  94.0±1.1 (1 mM) 
O
O
OH
NH2
S
O O  
(S,R)-5.2 
57.7±1.9 (1 mM) 
44.7±1.6 (3 mM) 
94.2±3.3 (1 mM) 
74.5±2.8 (3 mM) 
87.6±2.5 (1 mM) 
85.6±1.3 (3 mM) 
5.4  Discussion 
This study aimed for pharmacological tools to selectively reduce KYNA levels in 
vivo.  For  this  purpose,  compounds  were  desired  that  inhibit  KYNA  producing 
enzyme KAT. Moreover, selectivity towards KAT inhibition over KYNase and KMO 
inhibition  is  necessary.  If  KYNase  and  KMO  are  inhibited,  this  leads  to  an 
increase  in  levels  of  key  intermediate  KYN.  Increased  availability  of  KYN  and KAT inhibitors: Flexible analogs 
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concomitant inhibition of KYNase and KMO leads to increased KYN turnover by 
KAT  into  KYNA.  Therefore,  if  KAT  inhibition  is  not  selective  over  KYNase  and 
KMO inhibition, the compounds are expected to increase, rather than decrease 
KYNA levels in vivo. 
 
As is common for many PLP dependent aminotransferases
44, the key interaction 
in binding of KYN to the active site of KAT is an interaction between a conserved 
arginine residue and the carboxylic acid moiety in the substrate. The aromatic 
moiety  interacts  in  a  relatively  hydrophobic  pocket,  which  is  more  closely 
defined in KAT I than in KAT II.
45, 46 In the catalytic cycle, the  -amino group is 
transaminated to obtain the  -keto acid. From this intermediate, KYNA is formed 
by spontaneous ring closure. The role of the  -amino group in substrate binding 
seems to be less critical. In the crystal structure of KAT II in complex with KYN, 
no  covalent  interaction  is  found  between  the  substrate  and  co-enzyme  PLP.
46 
This  suggests,  that  in  the  first  phase  of  interaction  between  enzyme  and 
substrate,  the  carboxylic  acid  moiety  rather  than  the   -amino  group  plays  a 
prominent role.  
In the work presented here, a set of close KYN analogs is studied. The structures 
vary in the substitution around the C  atom. The compounds were synthesized 
and tested for their KAT inhibitory activity and selectivity over KYNase and KMO. 
 
The  first  three  compounds  (5.3-5.5)  are  KYN  analogs  that  lack  the   -amino 
group. Compound 5.3 was synthesized to directly investigate the effect of the 
lack of this group. This compound had already been known from literature. It 
was  found  in  significant  quantities  in  normal  and  cataractous  lenses  and  is 
thought  to  be  formed  in  situ  by  spontaneous  deamination  of  KYN  and 
subsequent NAD(P)H-aided reduction. Compound 5.3 and its glutathione-adduct 
play a role in UV filtering in lenses. No published data could be found regarding 
the effects of this compound on kynurenine pathway enzymes.
17, 47  
The  second  compound,  5.4,  is  the  bioisosteric  equivalent  of  5.3.  In  this 
molecule,  the  tetrazole  ring  replaces  the  carboxylic  acid  function.  Bioisosteric 
replacement of carboxylic acid moieties by a tetrazole moiety is widely applied 
and  can  have  different  advantages.  Although  the  tetrazole  is  charged  at 
physiological  pH,  the  moiety  is  far  more  lipophilic  than  the  carboxylate 
counterpart. This might increase biological availability. In addition, the moiety 
can form 2 hydrogen bonds. This can be favorable for interaction in the active 
site. Furthermore, chemical and metabolic stability can be enhanced.
48  Chapter 5 
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As  the  third  analog  in  the  series  of   -amine  lacking  KYN  derivatives,  4-(4-
ethanesulfonylphenyl)-4-oxobutyric acid (5.5), the  -amine lacking analog of S-
ESBA (5.2), was synthesized. In preliminary docking studies with 5.2, hydrogen 
bond formation between the sulfonyl oxygen atom and a serine side chain was 
found  for  rat  KAT  II.  This  interaction  was  stated  to  optimize  the  interaction 
between  the  ligand  in  the  rat  KAT  II  binding  site.
49  Analogously  to  5.2,  the 
aromatic sulfonyl side chain in 5.5 should have a positive effect on selectivity if 
compared to 5.3.  
Inhibitory profile on KYN metabolizing enzymes was examined for compounds 
5.3-5.5  and  compared  to  racemic  ESBA  (Table  1).  If  compared  to  ESBA, 
compound  5.3  inhibits  KAT  less  potently.  In  contrast,  the  compound  shows 
pronounced  KYNase  and  KMO  inhibitory  activity.  Apparently,  the  des-amino 
analog of KYN fits very well into the binding site of KYNase and also has good 
affinity to the KMO binding site. If compared to compound 5.3, KAT inhibitory 
activity is improved by bioisosteric replacement of the carboxylic acid function 
by a tetrazole in compound 5.4. In fact, potency of 5.4 is comparable to the 
potency of ESBA. The reason for this could be indeed the double charge on the 
tetrazole  moiety  interacting  with  the  conserved  Arg  in  the  KAT  binding  site. 
KYNase and KMO inhibitory activity are less potent than for 5.3, but still rather 
pronounced. In ethylsulfonyl analog 5.5, some of the KAT inhibitory potency is 
lost compared to amino acid analog ESBA. As in ESBA and compared to 5.3 and 
5.4, inhibitory potency for rat liver KYNase and KMO is strongly reduced. This 
confirms that the ethylsulfonyl substituent on the aromatic ring is detrimental 
for KYNase and KMO inhibition.  
In summary, if compared to reference compound ESBA, the inhibitory profiles of 
compounds 5.3-5.5 are not optimal for decreasing KYNA levels in vivo. Due to 
the  KYNase  and  KMO  inhibitory  potency  of  5.3  and  5.4,  the  compounds  will 
increase  rather  than  decrease  KYNA  levels  in  vivo.  The  major  drawback  of 
compound 5.5 if compared to ESBA is, that it inhibits KAT less potently. What 
can  be  learned  from  this  set  of  compounds  is  that  omittance  of  the   -amino 
group  in  KYN  analogs  is  not  detrimental  for  binding  to  the  enzymes.  This  is 
important,  since  omittance  of  the   -amino  group  has  certain  advantages  for 
potential pharmaceutical candidates. In the first place, it results in simplification 
of the chemical structure of the compounds. Synthetic methods for carboxylic 
acid analogs are straightforward if compared to methods to synthesize the  -
amino acids. Whereas  -amino acids are chiral, the chiral center is lost in the 
desamino compounds. A second advantage is, that covalent interaction between 
the inhibitor and the enzymes is unlikely in the absence of the  -amino group. If KAT inhibitors: Flexible analogs 
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an amino acid analog is used to inhibit KAT, the possibility exists, that instead of 
the substrate, the inhibitor is transaminated. Apart from the fact that this results 
in  loss  of  the  compound,  transamination  of  the  inhibitor  might  result  in 
production of biologically active metabolites. No such metabolites can be formed 
by transamination from the desamino analogs.  
 
Once  the  substrate  is  bound  in  the  catalytic  site  of  KAT,  the  key  step  in  the 
catalytic  cycle  is  transfer  of  the   -amino  group  of  the  substrate  to  the  co-
enzyme. During this transfer, the  -keto acid of KYN is formed (Scheme 12).
50 
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In the transamination reaction, the presence of a proton in the  -position of KYN 
is  essential.  This  proton  is  extracted  from  the  complex  by  a  catalytic  base  in 
order  to  allow  migration  of  the  aldimine  double  bond  (Scheme  12).
51,  52  KYN 
analog 5.6 was designed as a potential inhibitor based on the essential role of 
the  -proton in the transamination reaction. In this structure, the  -proton was 
substituted by a methyl group. In the ideal situation, the methyl group should 
not interfere with binding of the compound to the enzyme. Once the compound 
is  bound  however,  the  base  cannot  extract  the  methyl  group  from  the   -
position. This should inhibit the transamination reaction and subsequent release 
of  product.  Concomitantly,  the  inhibitor  occupies  the  active  site  and  prevents 
KYN transamination into KYNA. Chapter 5 
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The  idea  of  methyl  substitution  in  the   -position  of  aminoacids  to  create 
pharmacologically  functional  derivatives  is  known  from  literature.  Extensive 
research has been done on the synthesis of such compounds. In many cases, 
oxazolidinone building blocks have been applied. For example,  -methyl-DOPA is 
a clinically used antihypertensive drug. The compound is in vivo converted to its 
active  metabolite   -methyl-noradrenaline  and  in  this  form  stimulates  the   2-
adrenoceptor.
53 Concomitantly,  -methyl-DOPA is an inhibitor of aromatic amino 
acid decarboxylase, which converts DOPA to dopamine.  -Methyl-DOPA can be 
synthesized  using  imidazolidinones.  Imidazolidinones  are  close  analogs  of 
oxazolidinones.
54 A second example of  -substituted amino acids is found in the 
group  of  metabotropic  glutamate  antagonists.
55  Examples  are  2-ethyl-2-
(carboxycyclopropyl)glycine (MCCG) and 2-amino-2-methyl-4-phosphonobutyric 
acid  (MAP4).  These  compounds  have  been  synthesized  by  alkylation  of 
oxazolidinones  of  alanine.
56   -Methyl-substituted  derivatives  of  naturally 
occurring  amino  acids  are  used  because  they  are  conformationally  more 
restricted than their unsubstituted counterparts. The  -methyl amino acids are 
useful in protein synthesis for their helix-inducing properties.
41  
Most interestingly, already in 1959, a study of  -methyl-aspartate in aspartate 
aminotransferase was published. Like KAT, aspartate aminotransferase is a PLP-
dependent enzyme and the transamination reaction is similar to that in KAT.  -
Methyl-aspartate was found to inhibit the enzyme.
57 The mechanism of catalysis 
was  studied  based  on  interactions  of  asparate,   -methyl-aspartate  and  2-
hydroxymethylaspartate.  The   -substituted  aspartate  derivatives  appeared  to 
undergo the initial Schiff base formation with coenzyme PLP, but could not be 
transaminated.
58, 59 This corresponds to the mechanism of inhibition as aimed for 
in compound 5.6. 
To our knowledge, only one  -methyl-substituted direct KYN analog has been 
published. In search of selective inhibitors of KMO, compound 5.33 (Scheme 13) 
was  synthesized.  KMO  inhibitory  potency  was  limited  for  the  compound.  KAT 
inhibitory activity was not tested.
60 
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After  synthesis  of  5.6,  the  compound  was  tested  for  KAT,  KYNase  and  KMO 
inhibitory  activity  (Table  1).  In  comparison  to  reference  compound  ESBA,  the 
potency of 5.6 for inhibition of rat brain KAT is less pronounced. Interestingly 
however,  the  compound  has  virtually  no  potency  for  inhibition  of  rat  liver 
KYNase or KMO at an inhibitor concentration of 1 mM. This is most surprising if 
results of inhibitory profile of compound 5.3 are taken into account. Whereas 
compound 5.3 primarily inhibits KYNase and KMO, analog 5.6 has lost all of its 
inhibitory potency for these enzymes.  
The limited KAT inhibitory activity can most probably be ascribed to the steric 
bulk  that  is  introduced  into  the  compound  by  the  methyl  group.  The 
corresponding proton in KYN is supposed to be beneath the plane of the external 
aldimine bond that is formed by the KYN  -amino group and the co-enzyme. In 
this position, the proton is in close vicinity to the catalytic base that extracts the 
proton  from  the  complex.  To  assure  exact  positioning  for  efficient  interaction 
with the base, the proton is most probably accommodated in a relatively tight 
pocket. Obviously, accommodation of the much larger methyl group in the same 
position would suffer from significant steric hindrance. Therefore, optimization of 
the structure should include  -substitution with a smaller group or atom. In our 
laboratory, attempts have been made to synthesize the  -fluor analog of 5.6. 
The  fluor  substituent  has  been  used  frequently  for  modifications  of  natural 
occurring compounds. As for 5.6, double bond migration should be prevented by 
substitution of the  -proton by a fluor atom. Since a fluor atom equals a proton 
in size, steric effects are of less influence on binding of the ligand if compared to 
the  -methyl analog. Unfortunately however, synthesis of the compound could 
not be achieved. Nevertheless, in view of the present results, this derivative is 
interesting for future studies.  
 
In  summary,  studies  on  the  optimal  substitution  pattern  at  the C    atom  for 
selective inhibition of KAT over KYNase and KMO resulted in 4 compounds. In 
three of the compounds, the amino acid in KYN was reduced to a carboxylic acid 
group or an equivalent of this group. This substitution was tested as modification 
of both KYN (compounds 5.3 and 5.4) and published selective KAT II inhibitor 
5.2 (compound 5.5). As could be concluded from in vitro results, compounds 
5.3  and  5.4  inhibit  KYNase  and  KMO  more  potently  than  KAT.  Interestingly, 
substitution of the carboxlate group in 5.3 by the tetrazole moiety improved KAT 
inhibition.  Compound  5.5  inhibited  KAT  less  effectively  than  its  counterpart 
ESBA. However, selectivity over KYNase and KMO inhibition was preserved.  Chapter 5 
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On the other hand, addition of a substituent at C  resulted in structure 5.6. The 
compound  weakly  inhibited  KAT,  but  showed  no  KYNase  and  KMO  inhibitory 
activity. The weak potency of KAT inhibition is most probably explained by the 
steric bulk of the methyl group.  
 
Although in this study only compounds of limited interest in terms of inhibitory 
potencies could be presented, suggestions can be made for further studies based 
on the present results.  
In the first place, the synthesis and pharmacological profile of the  -fluor analog 
of  compound  5.6  was  already  suggested  for  further  study  of  effects  of   -
substituted KYN analogs as selective KAT inhibitors. Furthermore, combination of 
the modifications in compounds 5.3-5.5 in a compound that lacks the  -amino 
group  but  contains  the  bioisosteric  tetrazole  moiety  and  the  ethylsulfonyl 
substituent  could  be  interesting.  In  such  a  compound,  the  tetrazole  moiety 
would  enhance  biological  availability  and  inhibition  of  KAT.  The  ethylsulfonyl 
substituent would assure selectivity over KYNase and KMO. 
Concerning enzyme activities, the compounds should be characterized using KAT 
enzymes  from  alternative  sources.  It  was  shown  for  S-ESBA,  that  inhibitory 
potency  varies  for  different  sources  of  the  enzyme.  KAT  II  in  rat  liver 
homogenate was inhibited with an IC50 of 71  M, and partially purified rat liver 
KAT  II  was  inhibited  with  an  IC50  of  6.1   M.
16  Potency  of  inhibition  for 
recombinant human KAT II was much less pronounced. At a concentration of 1 
mM, KAT II activity was reduced to 36% of its original activity.
49 In the assay 
performed in this study, both KAT I and KAT II isoforms were taken into account 
by adjustment of the pH to 8, which is in between pH optima for KAT I and KAT 
II.
6  Furthermore,  racemic  ESBA  was  tested.  Inhibition  under  these 
circumstances  is  less  effective,  with  58%  of  KAT  activity  remaining  at  an 
inhibitor concentration of 1 mM. This illustrates that species differences should 
be taken into account, and that indeed, compounds can show different potencies 
for different enzyme isoforms in different types of enzyme assays.   
5.5  Experimental section 
General NMR spectra were taken on a Varian spectrometer, at the frequency as stated in 
the  text.  Chemical  shifts  are  given  in  ppm.  The  splitting  patterns  are  designated  as 
follows: s = singlet, d = doublet, t = triplet, m = multiplet, bs = broad singlet. Coupling 
constants  are  given  in  hertz  (Hz).  IR  spectra  are  taken  on  an  ATI-Mattson 
spectrophotometer. GCMS analysis were performed on a Shimadzu GCMS-QP500 system 
equipped an AOC-20i auto injector and a CP-Sil 5 CB column (15m x 0.25mm; 0.10µm 
film thickness). Mass spectra (ESI) were taken on an API 3000 MS/MS system. Accurate 
mass  measurements  (HRMS)  were  performed  using  a  flow  injection  method  on  a  LTQ-KAT inhibitors: Flexible analogs 
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Orbitrap XL mass spectrometer (Thermo Electron, Bremen, Germany) with a resolution of 
60000 at m/z 400. All final compounds had at least 95% purity, as determined by HPLC. 
Solvents and reagents were obtained from general sources and used as such. THF was 
dried by distillation over Na. 
 
4-(2-Nitrophenyl)-4-oxo-but-2-enoic acid (5.8) 
Glyoxylic acid (11.15 g, 0.121 mol) was heated to 60 
oC. To the molten substance, 2’-
nitroacetophenone (5.7, 2.54 g, 2.00 mL, 15.4 mmol) was added. The mixture was set 
under vacuum and heated at 110 
oC overnight. The mixture was coated on silica directly, 
and  purified  by  column  chromatography  (silica,  CH2Cl2/MeOH).  1.26g  (37%)  of  an  off- 
white solid was yielded.  
1H  NMR  (200  MHz,  CD3OD)     6.28-6.36  (d,  J  =  16.16  Hz,  1H,  CH=CH),  7.16-7.24  (d, 
J=15.86Hz, 1H, CH=CH), 7.51-7.56 (dd, J = 1.76, 7.35 Hz, 1H, ArH), 7.69-7.87 (m, 2H, 
ArH), 8.15-8.19 (dd, J=1.18, 7.94Hz, 1H, ArH) ppm; 
13C NMR (50 MHz, CD3OD)   193.8, 
167.9, 140.4, 136.1, 135.7, 134.7, 132.8, 130.0, 125.7 ppm; IR (KBr) 1705, 1679, 1520, 
1341, 1295, 986, 739 cm
-1; MS m/z 220 (M-H)
-, 266 (M+HCOOH-H)
-, 441 (2M-H)
-, 662 
(3M-H)
-. 
 
4-(2-Aminophenyl)-4-oxobutyric acid methyl ester (5.9)  
A mixture of 4-(2-nitrophenyl)-4-oxo-but-2-enoic acid (5.8, 1.24 g, 5.61 mmol), and 10 
% Pd/C (0.201 g) in 12.5 mL EtOH and 50 mL EtOAc was stirred under an atmosphere of 
H2 overnight. The mixture was filtered over Celite
®, and the solvent was evaporated. The 
crude mixture was heated in 50 mL MeOH and 1 mL concentrated H2SO4 at reflux for 5 
hours. The mixture was left to cool to room temperature. Saturated NaHCO3 was added, 
and the MeOH was evaporated. The aqueous layer was extracted with EtOAc (5x). The 
combined organic layers were washed with brine, dried (MgSO4), filtered, and the solvent 
was evaporated. The product was isolated by column chromatography (silica, Hex/EtOAc) 
as a brown oil (0.351 g, 30%). 
1H  NMR  (200  MHz,  CDCl3)     2.68-2.74  (t,  J=6.76Hz,  2H,  CH2),  3.27-3.34  (d,  J=6.76, 
6.46Hz, 2H, CH2), 3.70 (s, 3H, CH3), 6.03 (bs, 2H, NH2), 6.61-6.69 (m, 2H, ArH), 7.21-
7.30 (t, 3H, ArH), 7.74-7.79 (d, J=8.23Hz, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   
200.2, 173.8, 150.3, 134.6, 131.1, 118.0, 117.7, 116.2, 52.0, 34.1, 28.5 ppm; IR (NaCl) 
3468, 3350, 1730, 1647, 1615, 1219, 1160, 752 cm
-1; GCMS m/z 207 (M). 
 
4-(2-Aminophenyl)-4-oxobutyric acid (5.3) 
4-(2-Aminophenyl)-4-oxobutyric acid methyl ester (5.9, 0.202 g, 0.974 mmol) was stirred 
in 5 mL MeOH and 0.5 mL 4 N NaOH at room temperature overnight. The solution was 
then neutralized with sat. NH4Cl, and the MeOH was evaporated. The product was isolated 
by  column  chromatography  (silica,  CH2Cl2/MeOH),  yielding  0.134  g  (71%)  of  a  yellow 
solid. 
1H NMR (200 MHz, CD3OD)   2.62-2.68 (t, J = 6.46 Hz, 2H, CH2), 3.22-3.29 (t, J = 6.46 
Hz), 2H, CH2), 6.55-6.63 (ddd, J = 1.18, [6.76, 7.05], 8.08 Hz, 1H, ArH, 6.69-6.74 (dd, J 
= 0.88, 8.52 Hz, 1H, ArH), 7.18-7.26 (ddd, J = 1.47, 7.06, 8.52 Hz, 1H, ArH), 7.77-7.82 
(dd, J = 1.47, 8.23 Hz, 1H, ArH) ppm; 
13C NMR (50 MHz, CD3OD)   201.7, 177.0, 135.3, 
132.0,  118.5,  118.3,  116.2,  34.8,  29.2  ppm;  MS  m/z  193  (M-H)
-,  385  (2M-H)
-;  HRMS 
(M+H)
+ m/z obs. 194.08110 calc. 194.08117 (C10H12O3N1). 
 
1-(2-Nitrophenyl)-propenone (5.14) 
2-Nitrobenzoylchloride (5.17, 3.89 g, 21.0 mmol) was dissolved in HMPA (7 mL, dried on 
4 Å molsieves) in a dry flask under N2, and PhCH2Pd(PPh3)2Cl was added. The mixture was 
placed in an ultrasone bath and degassed. Then, tributylvinyltin
24 (6.71 g, 21.2 mmol) in 3 
mL HMPA was added, and the mixture was degassed again. The flask was placed in an oil 
bath  preheated  to  65-70 
oC.  After  several  minutes,  evolution  of  gas  occurred  and  the 
catalyst precipitated as a black solid, marking the end of the reaction. The mixture was left 
to cool to r.t. and poured over 1 N HCl. The aqueous layer was extracted with EtOAc (3x). Chapter 5 
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The combined organic layers were washed with brine (1x) and subsequently treated with 5 
N KF aq.. The white precipitate was filtered off over Celite
®. The mixture was treated once 
more with 5 N KF solution and filtered. The layers were separated and the organic layer 
was  dried  (MgSO4),  filtered,  and  the  solvent  was  evaporated.  The  crude  mixture  was 
purified by column chromatography (silica + 10% KF w/w, Hex/EtOAc). Two products were 
obtained: the desired 5.18 (1.00 g, 27 %) , and decarbonylated 5.19 (0.97 g, 31 %). 
1H NMR (300 MHz, CDCl3)   5.81-5.87 (d, J = 17.94 Hz, 1H, CH=CH2), 6.02-6.06 (d, J = 
10.62 Hz, 1H, CH=CH2), 6.60-6.69 (q, J = 10.62, 17.57 Hz, 1H, COCH), 7.43-7.46 (d, J = 
7.32 Hz, 1H, ArH), 7.62-7.67 (t, J = 7.69 Hz, 1H, ArH), 7.73-7.75 (t, J = 7.32 Hz, 1H, 
ArH), 8.14-8.17 (d, J = 8.06 Hz, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   136.8, 135.6, 
131.6, 131.0, 129.1, 124.7 ppm; GCMS m/z 150 (M-CHCH2); IR (NaCl) 1670, 1528, 1347 
cm
-1. 
Spectral data of 5.19: 
1H NMR (300 MHz, CDCl3)   5.47-5.51 (d, J = 10.99 Hz, CH=CH2), 5.72-5.78 (d, J = 17.21 
Hz, 1H, CH=CH2), 7.13-7.17 (q, J = 10.98, 17.21 Hz, 1H,  CH=CH2), 7.39-7.41 (t, 1H, 
ArH), 7.56-7.64 (m, 2H, ArH), 7.92-7.95 (d, J = 8.05 Hz, 1H, ArH); 
13C NMR (50 MHz, 
CDCl3)   133.6, 133.4, 132.7, 128.7, 128.6, 124.7, 119.2 ppm; IR (NaCl) 1522, 1348 cm
-
1; GCMS m/z 149 (M). 
 
4-(2-Nitrophenyl)-4-oxo-butyronitrile (5.11) 
A solution of 2’-nitroacetophenone (5.7, 2.00 g, 12.1 mmol) in 50 mL dry THF was cooled 
to -80 
oC under N2. LHMDS (2.46 g, 14.7 mmol) in 24 mL THF was added dropwise. The 
mixture was left to warm up slowly to -25 
oC over 1.5 h. Then, the solution was cooled to -
80 
oC and bromoacetonitrile (1.0 mL, 14.4 mmol) was added at once. The reaction was left 
to warm up slowly. After 2 h (temperature -4 
oC), water and saturated NH4Cl were added 
to quench the reaction, and EtOAc. The layers were separated. The aqueous layer was 
extracted  with  EtOAc.  The  combined  organic  layers  were  washed  with  brine,  dried 
(MgSO4),  filtered  and  the  solvent  was  evaporated.  The  product  was  purified  by  column 
chromatography (silica, Hex/EtOAc). 0.528 g (21%) of the product was yielded as a brown 
solid.  
1H NMR (200 MHz, CDCl3)   2.81-2.885 (t, 2H, CH2), 3.12-3.19 (t, 2H, CH2), 7.39-7.44 
(dd, J = 1.47, 7.64 Hz, 1H, ArH), 7.62-7.82 (m, 2H, ArH), 8.16-8.21 (dd, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   176.45, 135.0, 131.4, 131.4, 127.4, 125.0, 118.8, 38.6, 12.3 
ppm; MS m/z 205 (M+1)
+, 222 (M+NH4)
+, 426 (M+Na)
+, 426 (2M+NH4)
+, 431 (2M+Na)
+; 
IR (NaCl) 2251, 1712, 1536, 1346 cm
-1. 
 
1-(2-Nitrophenyl)-3-2H-tetrazol-5-yl)-propan-1-one (5.10)  
AlCl3 (0.294 g, 2.20 mmol) was added to dry THF (10 mL), cooled on ice under N2. After 
30 minutes, the ice bath was removed. NaN3 (0.584 g, 8.96 mmol) was added. After 25 
minutes, a solution of 4-(2-nitrophenyl)-4-oxo-butyronitrile (5.11, 0.407 g, 1.99 mmol) in 
6 mL THF was added. The mixture was heated at reflux for 3 days. The mixture was left to 
cool to room temperature. 1 N HCl was added, followed by water and EtOAc. The layers 
were  separated.  The  aqueous  layer  was  extracted  with  EtOAc.  The  combined  organic 
layers were washed with brine, dried (MgSO4), filtered, and the solvent was evaporated. 
The  crude  mixture  was  purified  by  trituration  with  Et2O/CH2Cl2  and  column 
chromatography (silica, CH2Cl2/MeOH), yielding 0.363 g (74 %) of an off-white solid. 
1H NMR (300 MHz, CD3OD)   3.35-3.39 (m, 2H, CH2), 3.42-3.47 (m, 2H, CH2), 7.61-7.63 
(d, J = 7.69 Hz, 1H, ArH), 7.68-7.73 (t, 1H, ArH), 7.79-7.84 (t, 1H, ArH), 8.11-8.14 (d, J 
= 8.42 Hz, 1H, ArH) ppm; 
13C NMR (75 MHz, CD3OD)   200.7, 155.8, 136.8, 134.3, 131.2, 
127.6, 124.4, 80.5, 39.4, 17.6 ppm; IR (KBr) 3026-2620, 1711, 1523, 1349 cm
-1; MS m/z 
248 (M+H)
+, 265 (M+NH4)
+, 270 (M+Na)
+. 
 
1-(2-Aminopheynyl)-3-(2H-tetrazol-5-yl)-propan-1-one (5.4) 
A  mixture  of  1-(2-nitrophenyl)-3-2H-tetrazol-5-yl)-propan-1-one  (5.10,  0.307  g,  1.24 
mmol) 30 mL MeOH and 10% Pd/C (19 mg) was stirred under an atmosphere of H2 for 3h. KAT inhibitors: Flexible analogs 
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The  mixture  was  then  filtered  over  Celite
®  and  the  solvent  was  evaporated.  The  crude 
product  was  purified  by  column  chromatography  (silica,  CH2Cl2:  MeOH  1:1     MeOH), 
yielding  0.246  g  of  a  yellowsolid  (94%  purity).  The  product  was  recrystallized  from 
EtOAc/Hex, yielding 0.164 g (61%) of an off-white solid.  
1H NMR (200 MHz, CD3OD)   3.24–3.31 ((m, 2H), overlapped by solvent residual peak, 
CH2), 3.51-3.58 (t, J = 6.76 Hz, 2H, CH2), 6.55-6.62 (t, 1H, ArH), 6.70-6.74 (d, J = 8.22 
Hz, 1H, ArH), 7.19-7.26 (t, 1H, ArH), 7.76-7.80 (d, J = 8.23 Hz, 1H, ArH) ppm; 
13C NMR 
(50 MHz, CD3OD)   199.4, 156.6, 151.5, 134.4, 130.8, 117.1, 116.9, 115.0, 35.7, 17.8 
ppm; IR (KBr) 3445, 3339, 1648, 1613, 1548n 1197, 972, 751 cm
-1; HRMS (M+H)
+ obs. 
218.10381 calc. 218.10364 (C10H12O1N5). 
 
1-(4-Ethanesulfonyl-phenyl)-ethanone (5.22) 
A mixture of 4-acetylbenzenesulfonyl chloride (5.21, 2.51 g, 0.0115 mol), Na2SO3 (2.68 g, 
0.0213 mol) and NaHCO3 (1.76 g, 0.0210 mol) in 13 mL H2O was heated to 100 
oC. After 
1.75 h, the mixture was left to cool to 30 
oC. Then, ethyl bromide (15 mL, 21.8 g, 0.200 
mol) and tetra-N-butyl ammonium bromide (0.331 g, 1.03 mmol) were added, and the 
mixture was stirred at 50 
oC under reflux conditions for 22 h. Water was added, and the 
aqueous layer was extracted with EtOAc (4x). The combined organic layers were washed 
with brine, dried (MgSO4), filtered, and the solvent was evaporated. The crude product 
was purified by column chromatography (silica, Hex:EtOAc 1:1/1:2). A white solid (1.47 g, 
60 %) was yielded. 
1H NMR (200 MHz, CDCl3)   1.25-1.32 (t, J = 7.35 Hz, 3H, CH2CH3), 2.67 (s, 3H, COCH3), 
3.09-3.20 (q, J = 7.64, 7.35 Hz, 2H, CH2CH3), 7.98-8.03 (d, J = 8.52 Hz, 2H, ArH), 8.10-
8.15 (d, J = 8.52 Hz, 2H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   142.5, 141.1, 129.3, 
128.9, 50.7, 27.2, 7.6 ppm; IR (KBr) 3089, 2929, 1689, 1277, 1144, 793, 730, 616 cm
-1; 
GCMS m/z 212 (M). 
 
4-(Ethanesulfonylphenyl)-4-oxobut-2-enoic acid (5.23) 
A  mixture  of  1-(4-ethanesulfonyl-phenyl)-ethanone  (5.22,  1.10  g,  5.17  mmol)  and 
glyoxylic acid.H2O (0.568 g, 6.17 mmol) in acetic acid (20 mL) and 37% HCl (2 mL) was 
heated at reflux overnight. The mixture was left to cool to room temperature and water 
was added. The mixture was brought to pH 8 with NaHCO3 (s), and washed with EtOAc. 
The aqeous layer was the acidified with 25% HCl and extracted with EtOAc. The organic 
extract was washed with brine, dried (MgSO4), filtered, and the solvent was evaporated. 
The  crude  product  (0.863  g  of  a  yellow  solid)  was  sufficiently  pure  to  use  in  the  next 
reaction step. A sample was further purified for analysis. 
1H NMR (400 MHz, CD3OD)   1.22-1.25 (t, J = 7.33 Hz, 3H, CH3), 3.25-3.3 (q, 2H, CH2), 
6.81-6.85 (d, J = 15.4 Hz, CH=CH), 7.90-7.93 (d, J = 15.4 Hz, CH=CH), 8.08-8.10 (dd, J 
= 1.84, 6.60 Hz, 2H, ArH), 8.23-8.25 (dd, 2H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   
188.5, 169.7, 143.2, 140.5, 137.5, 133.1, 129.8, 129.2, 129.1, 50.8, 7.5 ppm; IR KBr 
3431, 2980, 1698, 1671, 1399, 1298, 1144, 742 ppm; MS m/z 267 (M-H)
-, 313 (M+formic 
acid)
-. 
 
4-(4-Ethanesulfonylphenyl)-4-oxobutyric acid (5.5) 
4-(Ethanesulfonylphenyl)-4-oxobut-2-enoic  acid  (5.23,  0.517  g,  1.929  mmol)  and  zinc 
dust (0.211 g, 3.23 mmol) in acetic acid (10 mL) were heated at 100 
oC for 1 h. The 
mixture  was  left  to  cool  to  room  temperature.  Water  and  EtOAc  were  added  and  the 
mixture  was  brought  to  pH  8  with  solid  NaHCO3.  The  layers  were  separated  and  the 
organic layer was extracted with saturated NaHCO3. The combined aqueous layers were 
acidified with 5 N HCl and extracted with EtOAc. The combined extracts were washed with 
brine, dried (MgSO4), filtered, and the solvent was evaporated. The product was purified 
by column chromatography (silica, CH2Cl2:MeOH 20:1). The product was obtained as an 
off-white solid (0.368 g, 70%). 
1H NMR (400 MHz, CD3OD)   1.20-1.24 (t, 3H, J = 7.33, 7.70 Hz, CH3), 2.72-2.75 (m, 2H, 
2H, CH2CH2), 3.23-3.29 (q, 2H, J = 7.33, 7.70 Hz, CH2CH3), 3.35-3.38 (m, 2H, CH2CH2), Chapter 5 
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8.03-8.06 (dt (2H, ArH), 8.21-8.24 (dt, 2H, ArH) ppm; 
13C NMR (50 MHz, CD3OD)   198.2, 
175.2, 142.5, 141.0, 128.8, 128.5, 49.9, 33.7, 27.6, 6.3 ppm; IR (KBr) 3389-2573, 1713, 
1699,  1392,  1233,  1147,  785,  733  ppm;  HRMS  m/z  (M+H)
+  obs.  271.06345  calc. 
271.06345 (C12H15O5S1). 
 
2-Bromo-1-(2-nitrophenyl)-ethanone (5.24) 
To a solution of 2’-nitroacetophenone (5.7, 50 g, 15.1 mmol) in 20 mL dry CH3Cl, Br2 
(2.42g, 15.1mmol) in 19 mL CH3Cl was added dropwise. The solution was stirred at r.t. 
overnight.  The  solvent  was  evaporated.  The  crude  product  was  purified  by  column 
chromatography (silica, Hex/EtOAc). The product was obtained as 2.63 g (71 %) of an off-
white solid. 
1H NMR (300 MHz, CDCl3)   4.30 (s, 2H, CH2), 7.49-7.52 (dd, J = 1.47, 7.33 Hz, 1H, ArH), 
7.45-7.70 (dt, 1H, ArH), 7.77-7.82 (dt, 1H, ArH), 8.21-8.24 (d, J = 8.06 Hz, 1H, ArH) 
ppm; 
13C NMR (50 MHz, CDCl3)   194.6, 135.2, 135.0, 131.5, 129.4, 124.7, 34.1 ppm; IR 
(KBr)  1721,  1530,  1345,  1190  cm
-1;  GCMS  m/z  150  (M-CH2Br);  MS  m/z  261/263 
(M+NH4)
+. 
 
3-Benzoyl-4-methyl-2-phenyl-oxazolidin-5-one (5.29)  
D,L-Alanine (1.00 g, 11.2 mmol) was added to a solution of 0.448 g (11.2 mmol) NaOH in 
1.5 mL water. Methanol (7.5mL) was added to dissolve the D,L-alanine. The mixture was 
concentrated  in  vacuo.  Benzaldehyde  (1.79  g,  16.9  mmol)  and  7.5  mL  ethanol  were 
added.  The  mixture  was  stirred  at  r.t.  for  3  h.  The  solvent  was  evaporated,  and  the 
residue  was  dried  by  azeotropic  distillation  with  ethanol  (3x).  An  off-white  solid  was 
obtained which was dried at high vacuum overnight. To this intermediate product, 15 mL 
dry CH2Cl2 was added. This suspension was cooled on ice. Benzoylchloride (1.30 mL, 11.2 
mmol) in 3 mL dry CH2Cl2 was added dropwise. The mixture was slowly left to warm up to 
r.t. and stirred at r.t. overnight. The solvent was evaporated. The residue was taken up 
into water and EtOAc. The layers were separated, and the aqueous layer was extracted 
with  EtOAc.  The  combined  organic  layers  were  washed  with  saturated  NaHCO3,  brine, 
saturated NH4Cl and brine, dried (MgSO4), filtered, and the solvent was evaporated. The 
residue was triturated with Et2O/CH2Cl2 to obtain a total of 1.46 g (46%) of the product as 
a  white  solid.  Column  chromatography  of  the  remaining  mother  liquor  afforded  an 
additional 0.48 g (15 %) of the product (total yield: 61%).  
1H NMR (200 MHz, CDCl3)   1.51 (bs, 3H, CH3), 4.78-4.88 (q, 1H, CHCH3), 6.78 (s, 1H, 
NCHO), 7.30-7.43 (m, 10H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   172.6, 136.6, 135.4, 
131.6, 130.2, 129.0. 127.2, 126.8, 90.6, 53.1, 18.0 ppm; IR (KBr) 1789, 1632, 1405, 
1243,  1021,  726,  698  cm
-1;  GCMS  m/z  176,  207,  281  (M);  MS  m/z  282  (M+1)
+,  299 
(M+NH4)
+, 304 (M+Na)
+, 580 (2M+NH4)
+. 
 
3-Benzoyl-4-methyl-4-[2-(2-nitrophenyl)-2-oxo-ethyl]-2-phenyl-oxazolidin-5-
one (5.30) 
A solution of 3-benzoyl-4-methyl-2-phenyl-oxazolidin-5-one (5.29, 0.875 g, 3.11 mmol) 
in 20 mL dry THF was cooled to -80 
oC under N2. LHMDS (0.717 g, 4.29 mmol) in 5 mL 
THF was added dropwise. After 30 minutes, 2-bromo-1-(2-nitrophenyl)-ethanone (5.24, 
0.802 g, 3.29 mmol) in 5 mL THF was added dropwise. The mixture was stirred at -80 
oC 
for  3 h. Then, the reaction was quenched by the addition of saturated NH4Cl solution. The 
mixture was left to warm up to room temperature. The layers were separated, and the 
aqueous layer was extracted with EtOAc. The combined organic layers were washed with 
brine,  dried  (MgSO4),  filtered,  and  the  solvent  was  evaporated.  The  crude  mixture  was 
treated  with  Et2O/CH2Cl,  obtaining  the  first  crop  of  product  as  an  off-white  precipitate 
(0.393  g,  28  %).  A  second  crop  was  isolated  from  the  remaining  mixture  by  column 
chromatography  (silica,  Hex/EtOAc),  yielding  0.304  g  (22  %)  of  product  as  a  red  solid 
(total yield 50 %). 0.431 g of a mixture of both starting materials was isolated (app. 50 % 
each by GC). KAT inhibitors: Flexible analogs 
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1H NMR (200 MHz, CDCl3)   2.13 (bs, 3H, CH3), 3.10 (bs, 1H, CH2), 3.85-3.87 (d, J = 
3.82Hz, 1H, CH2), 6.70 (s, 1H, NCHO), 6.91-6.95 (d, 2H, J = 7.05 Hz, 2H, ArH), 7.03-7.24 
(m, 8H, ArH), 7.46-7.54 (dt, J = 1.47 Hz, 1H, ArH), 7.58-7.66 (dt, J = 1.47 Hz, 1H, ArH), 
7.85-7.89 (dd, J = 1.47 Hz, 1H, ArH), 8.09 (bs, 1H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   
170.7,  137.0,  136.3,  136.0,  133.7,  132.2,  132.1,  130.5,  130.3,  130.0,  128.8,  128.4, 
127.3, 126.7, 125.0, 91.5, 67.0, 54.7, 22.6 ppm; IR (KBr) 1791, 1670, 1519, 1346, 1221, 
1181,  692  cm
-1;  GCMS  m/z  281  (M-[2’-NO2PhCOCH2]),  340  (M-PhCO);  MS  m/z  445 
(M+1)
+, 462 (M+NH4)
+, 467 (M+Na)
+. 
 
2-Benzoylamino-2-methyl-(2-nitrophenyl)-4-oxo-butyric acid methyl ester (5.31) 
A mixture of 3-benzoyl-4-methyl-4-[2-(2-nitrophenyl)-2-oxo-ethyl]-2-phenyl-oxazolidin-5-
one (5.30, 0.511 g, 1.15 mmol) and NaOH (0.0926 g, 2.32 mmol) in H2O (2 mL) and 
MeOH (15 mL) was heated at reflux. After 45 minutes, the mixture was cooled on ice and 
acidified  with  1  N  HCl.  The  MeOH  was  evaporated,  and  the  residue  was  taken  up  into 
H2O/EtOAc. The layers were separated and the aqueous layer was extracted with EtOAc. 
The  combined  organic  layers  were  washed  with  brine,  dried  (MgSO4),  filtered,  and  the 
solvent  was  evaporated.  The  product  was  purified  by  column  chromatography  (silica, 
Hex:EtOAc 1:1), yielding 0.250 g (59 %) of a colorless oil. 
1H NMR (200 MHz, CDCl3)   1.59 (bs, 3H, CH3), 3.14 (bs, 1H, CH2), 3.77 (s, 4H, CH2 and 
OCH3), 7.17 (bs, 1H, ArH), 7.39-7.58 (m, 4H, ArH), 7.64-7.663 (bd, 2H, ArH), 7.74-7378 
(dd, 2H, ArH), 8.00 (bs, 1H, NH) ppm; 
13C NMR (50 MHz, CDCl3)   166.7, 134.1, 133.2, 
132.1,  130.1,  128.9,  127.3,  125.1,  61.3,  60.9,  53.3,  52.8,  20.7  ppm;  IR  (KBr)  3409, 
1737,  1666,  1536,  1479,  1351,  1294,  1259,  1130,  1033,  954,  713  cm
-1;  MS  m/z  371 
(M+1)
+, 388 (M+NH4)
+, 393 (M+Na)
+, 409 (M+K)
+. 
 
4-(2-Aminophenyl)-2-benzoylamino-2-methyl-4-oxo-butyric acid (5.32) 
To a mixture of 2-benzoylamino-2-methyl-(2-nitrophenyl)-4-oxo-butyric acid methyl ester 
(5.31, 0.446 g, 1.20 mmol) in acetic acid, heated at 95 
oC, H2O was added at time points 
0, 20, 40, and 60 minutes (4 x 1.25 mL). At the same time points, a portion of Fe powder 
(total 0.335 g, 6.00 mmol) was added. After addition, the mixture was stirred at 95 
oC for 
another 30 minutes. The mixture was then left to cool to room temperature. Water was 
added,  and  the  aqueous  layer  was  washed  with  EtOAc.  The  aqueous  layer  was  then 
brought to pH 8-9 by addition of solid NaHCO3, and extracted with EtOAc. The combined 
organic  extracts  were  washed  with  brine,  dried  (MgSO4),  filtered  and  the  solvent  was 
evaporated, yielding 0.218 g (56 %) of the pure product as a white solid.  
1H NMR (400 MHz, CD3OD)   1.36 (s, 3H, CH3), 4.57-4.66 (q, 2H, CH2), 6.88-6.90 (d, J = 
8.07 Hz, 1H, ArH), 7.04-7.08 (t, J = 7.33, 7.10 Hz, 1H, ArH), 7.24-7.27 (t, J = 7.70 Hz, 
1H, ArH), 7.42-7.45 (t, J = 6.97, 7.33 Hz, 2H, ArH), 7.56-7.59 (d, J = 7.70 Hz, and t, 2H, 
ArH), 7.90-7.92 (d, J = 7.69 Hz, 2H, ArH) ppm; 
13C NMR (50 MHz, CDCl3)   174.0, 166.4, 
135.1, 133.5, 129.9, 129.8, 129.6, 128.7, 128.0, 125.6, 124.0, 115.6, 74.2, 67.0, 58.5, 
18.9 ppm; IR (KBr) 3276, 2920, 1721, 1685, 1596, 1488, 1375, 1269, 1114, 711 cm
-1; 
MS m/z 327 (M+1)
+. 
 
2-Amino-4-(2-aminophenyl)-2-methyl-4-oxobutyric acid (5.6) 
A  mixture  of  4-(2-aminophenyl)-2-benzoylamino-2-methyl-4-oxo-butyric  acid  (5.32, 
0.339 g, 1.04 mmol) and LiOH (0.0505 g, 2.11 mmol) in H2O (5 mL) and EtOH (5 mL) was 
placed in an oil bath preheated to 95 
oC.  The mixture was stirred at that temperature 
under  reflux  conditions  for  1  h.  The  EtOH  was  evaporated  and  water  was  added.  The 
aqueous  layer  was  washed  with  CH2Cl2,  acidified  with  1  N  HCl  and  again  washed  with 
CH2Cl2.  The  combined  organic  layers  were  back-extracted  with  H2O.  The  combined 
aqueous layers were concentrated in vacuo. The residue was taken up into methanol and 
coated on silica. The product was purified by column chromatography (silica, CH2Cl2:MeOH 
1:1) and was obtained in quantitative yields. 
1H NMR (200 MHz, CD3OD)   1.45 (s, 3H, CH3), 4.22-4.28 (d, J = 11.75 Hz, 1H, CH2), 
4.40-4.56 (d, J = 11.75 Hz, 1H, CH2), 6.96-7.00 (d, J = 7.93 Hz, 1H, ArH), 7.07-7.15 (t, J Chapter 5 
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= 7.64 Hz, 1H, ArH), 7.30-7.43 (d (J = 7.93 Hz) + t (J = 8.52 Hz), 2H, ArH) ppm; IR 
(KBr) 3650-2850, 1696, 1614, 1594, 1464, 1372, 1106, 768 cm
-1; HRMS m/z (M+H)
+ obs. 
223.10791 calc. 223.10772 (C11H15O3N2). 
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6.1  Introduction 
The  kynurenine  pathway  is  the  major  metabolic  pathway  of  tryptophan.  The 
metabolic  key  intermediate  is  kynurenine  (KYN).  From  KYN,  the  pathway 
descends into two different branches. One branch has 3-hydroxykynurenine (3-
OH-KYN)  and  quinolinic  acid  (QUIN)  as  the  main  products.  In  general,  these 
products  are  considered  neurotoxic.  3-OH-KYN  generates  reactive  oxygen 
species. QUIN is an agonist at NMDA receptors and can cause excitotoxicity. The 
second  branch  has  kynurenic  acid  (KYNA)  as  the  main  product.  KYNA  is  an 
antagonist at the strychnine insensitive glycine coagonist site of NMDA receptors 
and  a  non-competitive  antagonist  at   7*  nicotinic  acetylcholine  receptors.  At 
higher concentrations, KYNA antagonizes all ionotropic glutamate receptors. In 
general,  KYNA  is  considered  neuroprotective.  However,  excessive  biosynthesis 
and release of KYNA can result symptoms of CNS disorders. Elevated levels have 
been associated with schizophrenia
1-3 and cognitive disfunction
4. 
 
In the mammalian brain, KYNA is synthesized directly from KYN by kynurenine 
aminotransferases (KAT). Only two compounds are known that selectively inhibit 
the  enzyme,  named  S-ESBA
5  and  BF  122
6.  For  the  rational  design  of 
pharmacologically  active  and  selective  compounds  that  either  increase  or 
decrease KAT activity, knowledge of the structural properties of the enzyme is of 
crucial  importance.  Nowadays,  sophisticated  computational  and  experimental 
tools are available to gain knowledge of enzymatic structures. For KAT isoforms, 
several  crystal  structures  have  been  published.  Moreover,  evolutionary 
relationships  in  the  large  group  of  PLP  dependent  enzymes  are  being  studied 
extensively. Many common features can be found within the superfamily of PLP 
dependent enzymes and similarities are even more apparent within the group of 
aminotransferases.  Therefore,  predictions  of  enzymatic  properties  of  rather 
unknown structures belonging to these groups based on structural data of family 
and  subfamily  members  is  a  straightforward  way  of  proceeding  towards 
characterization of the unknown members. 
 
This chapter focuses on the current knowledge of KATs, KAT II in particular. KAT 
is a member of the group of pyridoxal 5'-phosphate (PLP) dependent enzymes. 
Since PLP is an active form of vitamin B6, these enzymes are also referred to as 
B6-dependent enzymes. An overview will be given of the position of KAT within 
the  superfamilies  of  PLP  dependent  enzymes  and  in  the  families  of 
aminotransferases.  The  focus  will  then  be  on  the  similarity  of  these  enzymes Molecular modeling: Kynurenine aminotransferase II 
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between  different  isoforms,  species  and  to  other  close  members  of  the 
aminotransferase  groups.  Homology  models  were  constructed  for  KAT  II, 
representing four different states of the enzymatic cycle. The homology models 
are compared to crystal structures that have become available since the start of 
this  study.  Docking  studies  were  performed  and  conformations  of  docked 
structures will be compared to the conformations of co-crystallized ligands from 
crystal structures.  
6.2  PLP dependent enzymes: Position of kynurenine aminotransferase 
6.2.1  The subdivision of PLP dependent enzymes 
PLP dependent enzymes are abundant in all organisms and form a group that is 
particularly suitable for examination of evolutionary relationships. PLP dependent 
enzyme activities constitute 4% of all known enzymatic activities.
7 
 
As  evolutionary  relationships  point  out,  PLP  dependent  enzymes  most  likely 
originate  from  a  common  progenitor  protein  that  was  already  present  in  the 
universal  ancestor  cell.  Upon  evolution  into  three  biological  kingdoms  of 
eubacteria, archebacteria and eukariotes, specification and specialization of the 
protein led to the wide range of functionalities that are found in this group of 
enzymes.  It  is  assumed  that  in  the  common  progenitor  protein,  reaction 
specificity  evolved  first,  followed  by  substrate  specificity.  Reaction  specificity 
mainly refers to binding of the PLP co-enzyme to the protein, probably facilitated 
by the formation of the internal aldimine linkage between PLP and an active site 
lysine residue. At this stage of evolution, a rudimentary binding site for incoming 
substrates must have been formed in the close proximity to PLP. In the second 
stage of evolution, the substrate binding site has evolved, and is still evolving 
into  many  substrate  specific  binding  sites.  In  terms  of  the  development  of 
specificity,  accelerated  speed  of  catalytic  activity,  and  prevention  of  catalytic 
side reactions and compartmentalization within cells and organisms have most 
likely been of major importance.
8, 9  
 
In the course of evolutionary and structural analysis of PLP dependent enzymes, 
the still growing group of known enzymes was divided into families, based on 
different  criteria.  The  first  division  was  based  on  catalytic  functionality. 
Accordingly, enzymes were divided into  ,   and   divisions. Enzymes in the   
division comprised the enzymes that catalyze a reaction at the C  atoms of the Chapter 6 
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substrate. Enzymes in the   and   divisions catalyze reactions at the C  and C  
positions of the substrate, respectively.
10, 11 
The majority of PLP dependent enzymes consists of functional homodimers or 
higher oligomers. After structural analysis of the assemblies of monomers and 
structure within the monomers, a division in superfamilies based on the folds of 
the enzymes was proposed. For this purpose,   and   divisions were merged into 
the fold type I superfamily. Members of the fold type II superfamily represent 
the former   division. At least 3 additional fold-type superfamilies were defined, 
named after the respective prototypical enzymes: 
I.  Aspartate aminotransferase (AspAT) family; 
II.  Tryptophan synthase beta (TRP ) family; 
III. Ornithine decarboxylase (ODC) and alanine racemase (AR) family; 
IV.  D-amino acid aminotransferase (DAAT) family; 
V.  Glycogen phosphorylase family. 
Superfamilies VI-VII were suggested for PLP-dependent enzymes with unknown 
structure.  Superfamily  V  is  considered  just  distinctly  related  to  the  other 
superfamilies.  Members  of  this  superfamily  catalyze  reactions  in  which  the 
phosphate arm of PLP is involved rather than the imine linkage in a catalytic 
mechanism  that  is  unrelated  to  the  mechanisms  used  by  members  of  other 
superfamilies.
12, 13  
 
Aminotransferases form a distinctive group within the PLP dependent enzymes. 
They  catalyze  the  reversible  transfer  of  amino  groups  from  amino  acids  to 
oxoacids. Aminotransferases are found in fold type I and IV superfamilies of PLP 
dependent  enzymes.  Based  on  mutual  structural  relatedness,  the 
aminotransferases can be further divided into the following families, represented 
by prototypical enzymes: 
I.  Aspartate,  alanine,  tyrosine,  histidinol-phosphate  and  phenylalanine 
aminotransferases; 
II.  Acetylornithine,  ornithine,   -amino  acid,  4-aminobutyrate  and 
diaminopelargonate aminotransferases; 
III. D-Alanine and branched-chain L-amino acid aminotransferases; 
IV.  Serine and phophoserine aminotransferases. 
 
Family III of the aminotransferases corresponds to the fold-type IV superfamily 
of PLP dependent enzymes. It has been proven that members of family III are 
structurally unrelated to aminotransferase families I, II and IV. It is thought that Molecular modeling: Kynurenine aminotransferase II 
  169 
in  terms  of  functionality,  this  family  has  evolutionary  converged  towards  the 
other aminotransferase families.
8, 14, 15 
 
The  largest  and  most  extensively  studied  aminotransferase  family  is  family  I. 
Hypothetically, for this group of aminotransferases, a common broad-specificity 
aminotransferase enzyme existed at a certain point in evolution. This common 
protein functionally diverged into different subfamilies. The largest subfamily is 
subfamily  I .  Two  smaller  subfamilies  were  found,  named  subfamilies  I   and 
I .
10 Later on, subfamilies I , I , I  and I  were defined.
9 
KAT  is  a  member  of  subfamily  I .  Subfamily  I   has  members  with  relatively 
broad substrate specificity, and is considered to be most related to the common 
ancestor aminotransferase enzyme. The subfamily contains four different types 
of enzymes
9: 
1.  Kidney  cysteine  conjugate   -lyase,  glutamine  transaminase  K  and 
kynurenine aminotransferase, which are synonymous to KAT I; 
2.  A group of enzymes that are highly specific aspartate aminotransferases, 
catalyzing the interconversion of aspartate to oxaloacetate; 
3.  A  group  of  aspartate  aminotransferases  that  also  catalyze  the 
interconversion of alanine and pyruvate; 
4.  A  group  represented  by  rat  tyrosine  aminotransferase,  specialized  in 
tyrosine catabolism. 
Alternatively,  family  I  aminotransferases  and  in  particular  aspartate 
aminotransferases (AspAT) from family I, were divided into subfamilies Ia and 
Ib.
16  The  division  is  based  on  amino  acid  sequences.  Although  homology 
between the groups is low (<15-16% identity
16, 17), amino acids are conserved 
around  the  binding  sites.  Subfamily  Ia  is  defined  by  sequences  from  E.  coli, 
yeast, chicken and pig AspATs. Subfamily Ib is defined by AspAT sequences from 
Bacillus sp. YM-2 and Sulfolobus solfataricus.
16 
6.2.2  Aminotransferases: Common enzyme properties 
Within  the  group  of  aminotransferases  (AT),  several  common  features  are 
defined.  Most  aminotransferases  belong  to  the  fold  type  I  superfamily  of  PLP 
dependent  enzymes.  The  major  exceptions  are  the  members  of 
aminotransferase  family  III,  which  belong  to  fold  type  IV  PLP  dependent 
enzymes. The structure of fold type I aminotransferases is well defined. Each 
monomer folds into three subunits: a large domain, a small domain and an N-
terminal arm.  Chapter 6 
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In  terms  of  primary  structures,  a  group  of  4  amino  acid  residues  is  invariant 
within  the  entire  group  of  aminotransferases.  An  additional  group  of  7  amino 
acids is invariant in family I aminotransferases. Most of the invariant residues 
are functional at or near the PLP and substrate binding site. In Table 1, invariant 
amino acids are listed, together with their function and level of invariance. For 
numbering,  the  commonly  used  numbering  scheme  of  pig  cytosolic  aspartate 
aminotransferase  (PcAspAT)
18  is  applied.  Corresponding  amino  acids  in  the 
sequence  of  human  KAT  II  (AADAT_HUMAN
19,  as  obtained  from  sequence 
alignment (Experimental section)) are listed. 
 
Table 1 Conserved amino acid residues
9, 10, 14 
Amino acid in 
PcAspAT 
Amino acid in 
KAT II 
Function  Level of invariance 
K258  K263  Internal aldimine  AT 
D/E222  D230  Salt bridge with PLP-pyridine  AT 
G197  G205  Participates in turn at domain 
interface 
AT 
R386  R399  Salt bridge with anionic moiety in 
substrate 
AT 
Y70, R266  Y74, R270   H-bonding with PLP-phosphate  AT family I, exception: 
R266 in family I  
N194, Y225  N202, Y233  H-bonding with hydroxyl-O in PLP  AT family I 
G110  G116  Unknown  AT family I 
P195  P203  Cis-conformation  AT family I 
G268  G272  Unknown  AT family I 
 
For  catalytic  activity,  the  aminotransferases  depend  on  the  co-enzyme  PLP. 
Therefore, within a catalytic site, two binding sites can be distinguished. These 
are the PLP binding site and the substrate binding site. The PLP binding site is 
situated at the bottom of the substrate binding site and is highly defined. In the 
‘resting  state’  of  the  enzyme,  the  co-enzyme  PLP  is  covalently  linked  to  the 
protein through the side chain of a conserved lysine residue, Lys258 in PcAspAT. 
The covalent linkage of the co-enzyme and the Lys residue is commonly referred 
to as an internal aldimine linkage.  
The  pyridine  moiety  is  held  in  place  by  a  salt  bridge  with  an  aspartate  or 
glutamate residue (Asp/Glu222 in PcAspAT). A conserved pattern of interactions 
of the enzyme with the PLP phosphate group is seen throughout PLP dependent 
enzymes.  As  shown  by  Denesyuk  et  al.
20,  21,  the  interactions  of  residues 
surrounding the phosphate moiety can be defined in two nearly parallel planes, 
together  called  the  phosphate  binding  cup.  In  family  I  aminotransferase 
enzymes studied, the first layer of the binding cup is formed by 5-7 atoms and 
lies closest to the PLP-pyridine ring. The second layer contains 3-7 atoms. In 
most  of  the  family  I  aminotransferases,  the  relative  orientation  of  interacting Molecular modeling: Kynurenine aminotransferase II 
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atoms within the layers is conserved. Atoms of the first layer are arranged in a 
plane with corner points a-g, each representing an interacting atom from the 
enzyme.  The  second  layer  accommodates  a  more  variable  set  of  atoms,  with 
designated positions h-j. Each position refers to an atom or a group of atoms 
interacting  with  one  of  the  non-ester  phosphate  O-atoms.  An  example  of  the 
designations  of  positions  is  shown  in  Figure  1  for  PcAspAT  (crystal  structure 
1ajs
22, www.rcsb.org). 
 
Figure 1 
   
Phosphate binding cup with atom positions for PcAspAT. Left panel: layer 1 positions a-g, 
top view; right panel: layer 2 positions h-j, side view. 
 
The substrate binding site is situated on top of the co-enzyme binding site. The 
main  function  of  the  substrate  binding  site  is  the  proper  orientation  of  the 
substrate  relative  to  the  co-enzyme,  in  order  to  facilitate  rapid  catalysis.  The 
common  point  of  linkage  for  the  incoming  substrate  is  a  highly  conserved 
arginine residue (Arg386 in PcAspAT). The side chain of this residue is involved 
in salt bridge interactions with the carboxylate moiety of the substrate. This is 
thought  to  be  the  first  anchoring  point,  assuring  proper  orientation  for 
interaction  with  the  co-enzyme  and  catalysis.  The  internal  aldimine  linkage 
between the lysine side chain and PLP is broken and an external aldimine linkage 
is formed between the substrate and the co-enzyme. The stereochemistry of the 
enzymatic reaction is detemined by the relative orientation of the lysine residue, 
the substrate and the co-enzyme.
8,  23 The remainder of the substrate binding 
site  defines  substrate  specificity  and  is  more  variable  between  different 
members of the aminotransferase family. 
e 
f 
g 
h 
i 
j 
j 
d 
c 
b  a Chapter 6 
  172 
6.2.3  Aminotransferases: Common interactions between substrate and 
enzyme 
The interactions between substrate and co-enzyme, which initiate the enzymatic 
reaction, are conserved throughout aminotransferase families I, II and IV. The 
common  reaction  mechanism  for  the  transformation  of  the  substrate  into  the 
enzymatic product, as adapted from references
8, 23, is outlined in Scheme 1. 
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In the first step the aldimine linkage between the co-enzyme and the active site 
Lys  is  broken  and  an  external  aldimine  linkage  is  established  between  the 
incoming substrate and the co-enzyme. This occurs by transaldimination via a 
tetrahedral  intermediate  of  the  co-enzyme,  the  lysine  side  chain  and  the 
substrate.
24  It  is  assumed  that  proper  orientation  of  the  C -H  bond  of  the 
substrate is crucial for optimal catalytic activity. The plane that is formed by this 
bond  and  the  C -N  bond  between  substrate  and  co-enzyme  should  be 
orthogonal to the plane of the co-enzyme. This allows a maximum overlap of the 
 -system of the C4’=N bond of the co-enzyme and the  -system of the C -H 
bond of the substrate. A base that approaches from the si-face of the co-enzyme 
then extracts the proton from the C  atom of the substrate. In general, the side 
chain  amino  group  of  the  lysine  residue  that  is  also  involved  in  the  internal 
aldimine linkage is the catalytic base. The co-enzyme functions as an electron Molecular modeling: Kynurenine aminotransferase II 
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sink.  After  extraction  of  the  proton,  the  electrons  can  delocalize  over  the 
conjugated  substrate  -  co-enzyme  system.  In  the  following  phase,  the  base 
returns the proton to the C4’ atom of the co-enzyme. Then the bond between 
the  substrate  and  the  co-enzyme  is  hydrolyzed  and  the  enzymatic  product,  a 
keto-acid, is released. This leaves the co-enzyme in the pyridoxamine phosphate 
(PMP)  form.  Subsequently,  the  reverse  reaction  takes  place  with  an  incoming 
keto-acid (co-substrate), restoring the PLP state of the co-enzyme. The exact 
nature  of  the  keto-acid  varies  for  different  enzymes.  In  general,  small  keto-
acids,  like  pyruvate  or   -ketoglutarate  are  preferred  co-substrates.  From  the 
reaction between the keto-acid and the co-enzyme in the PMP form, the amino 
acid form of the keto-acid is released. After the reaction, the co-enzyme is back 
in the resting PLP state.
8, 23 
Interestingly,  in  family  III  aminotransferases,  stereochemistry  is  reversed  by 
approach of the base from the re-face of the co-enzyme.
8 
6.2.4  Kynurenine aminotransferases 
KAT  shares  common  structural  and  catalytic  properties  with  other 
aminotransferases.  
The  enzyme  is  a  functional  homodimer.  This  is  shown  for  KAT  II  (crystal 
structure 2vgz, www.rcsb.org) in Figure 2 (left panel). 
 
Figure 2 
   
KAT II homodimer (left panel, monomer 1 in red, monomer 2 in green) and structure of 
a monomer (right panel). For the pictures, crystal structure 2vgz was used.  
 
The monomers are clustered in an S-shaped structure with a 2-fold axis. Each 
monomer  consists  of  a  small  domain,  a  large  domain  and  an  N-terminal  arm 
(Figure  2,  right  panel).  The  small  domain  is  defined  by  a   -sheet,  which  is 
Small domain 
Large domain 
N-terminal arm 
BS1 
BS2 
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encapsuled  by  helices  at  the  surface  side  of  the  enzyme.  The  large  domain 
consists of a 7-stranded  -sheet that is sandwiched between two layers of  -
helices. In each homodimer two identical binding sites can be found. The binding 
sites  are  at  the  dimer-  and  domain  interface.  Amino  acid  residues  originating 
from the small and large domains of one monomer form the majority of binding 
site 1 (BS1, Figure 2). A smaller portion is of the binding site formed by amino 
acid side chains originating from the second monomer. The largest portion of the 
second binding site (BS2, Figure 2) is formed by the second monomer and a 
smaller portion originates from the first monomer.
25, 26  
KAT converts KYN into KYNA. Catalytic transfer of the  -amino group results in 
formation  of  the   -keto  acid  of  KYN.  KYNA  is  formed  by  spontaneous  ring 
closure. During the catalytic cycle, the enzyme adopts different conformations 
and the co-enzyme and substrate are associated in different covalent and non-
covalent  interactions.  Based  on  the  mechanism  as  shown  in  Scheme  1,  in 
Scheme 2, the catalytic cycle for KAT is outlined.  
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In the scheme, states I, II and III are defined, representing key intermediate 
states of the co-enzyme. Transitions from one state to the next are defined by 
phases. Molecular modeling: Kynurenine aminotransferase II 
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Each phase represents a distinct step in the catalytic reactions. Accordingly, the 
‘resting’ state of the enzyme is state I. In this state, the co-enzyme forms an 
internal aldimine link with the side chain amino group of a conserved lysine side 
chain,  Lys263  in  KAT  II.  The  co-enzyme  covalently  bound  to  the  lysine  side 
chain is designated LLP (2-lysine-(3-hydroxy-2-methyl-5-phosphonooxymethyl-
pyridin-4-yl methane). In phase I, KYN approaches the co-enzyme and two key 
interactions  take  place  within  the  phase,  named  Phase  Ia  and  Phase  Ib  in 
Scheme  2.  Phase  Ia  represents  the  interaction  between  the  KYN  carboxylate 
group and the side chain of an Arg residue in the binding site, Arg399 in KAT II. 
This interaction is highly conserved and important for proper positioning of the 
substrate in the binding site. Phase Ib defines the transaldimination. The internal 
aldimine link is exchanged for an external aldimine link with KYN. The Lys263 
side chain is released upon formation of the external aldimine. In state II, the 
co-enzyme is covalently bound to KYN by the external aldimine linkage. In phase 
II, the PLP-KYN linkage is hydrolyzed. The keto-acid of KYN is released as the 
enzymatic  product.  From  the  keto-acid,  the  final  product  KYNA  is  formed  by 
spontaneous  ring  closure.  The  co-enzyme  is  released  in  the  pyridoxamine 
phosphate (PMP) form. This form is represented by state III. In phase III, the 
resting  state  I  is  regenerated  by  the  reaction  with  an  incoming  keto-acid  co-
substrate and formation of the internal imine linkage with the lysine residue side 
chain. 
 
Four isoforms of human, rat and mouse KAT have been identified, named KAT I-
IV. KAT I and II were the first isoforms that were discovered. KAT I is identical 
to glutamine transaminase K (EC 2.6.1.64). KAT II is identical to  -aminoadipate 
aminotransferase (EC 2.6.1.7).
27 From studies in KAT II knock out (kat2
-/-) mice, 
KAT III was identified.
28 Finally, KAT IV was identified and found to be identical 
to mitochondrial aspartate aminotransferase (EC 2.6.1.1).
29 
Relative abundances, based on activity for KAT I, II and IV have been compared 
for mouse, rat and human brain. In human and rat brain, KAT II is the most 
abundant (54% and 59%, respectively) isoform. In mouse brain, KAT IV is most 
abundant  (63%).
29  Data  on  relative  contribution  of  KAT  III  have  not  been 
published. 
6.3  Structural examination of kynurenine aminotransferases 
In  studies  focusing  on  the  pharmacological  functions  of  kynurenine  pathway 
metabolites  and  on  compounds  that  influence  KAT  and  other  kynurenine 
pathway enzymes, mice and rats are the most frequently used animal species. Chapter 6 
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Ultimately, in most cases, research is focused on pharmacological function and 
manipulation of the human kynurenine pathway. Therefore, the emphasis in this 
chapter is on KATs from these species. 
In this study, available information on KATs, KAT II in particular, is summarized 
and compared. For this purpose, crystal structures of KATs from human, mouse 
and rat isoforms were retrieved. In addition, published crystal structures of KATs 
from other species and crystal structures of closely related enzymes were taken 
into account. Primary sequences were compared for evaluation of evolutionary 
relationships  and  examination  of  structural  relationships.  Crystal  structures  of 
KATs have only become available in recent years. Before the release of these 
structures,  for  the  study  on  structural  requirements  of  selective  KAT  II 
inhibitors, homology models of the human isoform were used in our laboratory.
30 
Binding of KYN in KAT II was studied in these models based on docking of the 
structure into the models. The KAT II homology models and KYN docking results 
are evaluated against the now available crystal structures and conclusions will 
be drawn on the reliability and predictive value of homology modeling.  
6.3.1  Results 
6.3.1.1  Sequences and crystal structures of kynurenine aminotransferases 
This work focuses on a number of KATs and closely related enzymes. The main 
criterium  for  inclusion  of  enzymes  in  this  work  is  the  availability  of  crystal 
structures. Therefore, these structures are described first.  
Published crystal structures of human and mouse KAT I-III enzymes as available 
at  the  time  of  conductance  of  the  study  are  shown  in  Table  2.  No  crystal 
structures have been found for KATs originating from rat. Molecular modeling: Kynurenine aminotransferase II 
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Table 2 Crystal structures of mouse and human KATs  
KAT 
isoform 
Source  PDB ID  Resolution 
(Å) 
Co-factor 
form 
Ligand  Ref 
1w7l  2.00  LLP   
1w7m  2.70  LLP  L-Phe 
human 
1w7n  2.90  PMP   
31 
3fvs  1.50  LLP   
32 
3fvu  1.55  LLP  Indole -3-acetic acid   
KAT I 
human 
3fvx  1.50  LLP     
human  2vgz  2.30  LLP   
25 
2qlr  2.30  LLP    human 
2r2n  1.95  PMP  KYN 
26 
KAT II 
human  3dc1  2.48  LLP   -keto-glutarate 
33 
mouse  2zjg  3.00  LLP    rcsb.org 
3e2f  2.59  LLP   
3e2y  2.26  PMP  Gln 
KAT III 
mouse 
3e2z  2.81  PMP  KYN 
34 
 
For  KAT  I,  crystal  structures  from  two  different  studies  were  published.  The 
structures 1w7l, 1w7m and 1w7n were the first KAT structures published from 
mammalian  species.
31  Recently,  the  enzyme  was  further  characterized  using 
indole-based inhibitors.
32 For KAT II, crystal structures are available for the LLP 
bound  state  and  the  kynurenine  and  PMP  bound  state.
25,  26  Furthermore,  a 
structure is available of KAT II in complex with co-substrate  -keto-glutarate.
33 
For KAT III, crystal structures are available for the mouse homolog. These are of 
particular  interest  in  view  of  the  relatively  high  abundance  of  this  isoform  in 
mouse brain.
34 
KAT IV is identical to mitochondrial aspartate aminotransferase. Several crystal 
structures  of  mitochondrial  aspartate  aminotransferase  are  available  from 
mammalian species. However, no crystal structures of enzymes from mouse, rat 
or human are available.  
 
Genes and amino acid sequences corresponding to KATs have been published for 
many  organisms.  Identified  enzymes  with  published  crystal  structures  are  of 
particular interest. The first crystal structure of an aminotransferase that was an 
equivalent  to  human  KAT  I  was  from  glutamine:phenylpyruvate 
aminotransferase from Thermus thermophilus (TtGlnAT).
35 Another mammalian 
KAT  I  homolog  was  isolated  and  crystallized  from  Aedes  aegyti  (AeKAT).
36 
Ligand  bound  structures  of  this  homolog  were  crystallized  later.
37  The  first 
crystal  structure  of  a  human  KAT  II  homolog  was  from  Pyrococcus  horikoshii 
(PhKAT).
38 In Saccharomyces cerevisiae, genes were identified that accounted 
for proteins involved in NAD
+ synthesis. Open reading frame BNA3 was ascribed Chapter 6 
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to a protein (Bna3p) with formamidase functionality. However, upon biochemical 
characterization  and  crystallization  of  the  protein,  it  was  concluded  that  the 
protein was a KAT rather than a formylkynurenine formamidase.
39 Recently, the 
crystal  structure  of  a  protein  from  Methanococcus  jannaschii,  named  MJ0684, 
was  published.  Although  the  function  of  the  protein  was  not  established 
biochemically,  based  on  the  crystal  structure  and  sequence  homology,  the 
protein  was  claimed  to  be  an  archaeal  homolog  of  KAT.
40  From  Anopheles 
gambiae,  the  vector  of  malaria  parasite  Plasmodium  falciparum,  3-
hydroxykynurenine aminotransferase (Ag3HKT) has been studied. The enzyme 
transaminates  both  3-OH-KYN  and  KYN  into  xanthurenic  acid  and  KYNA, 
respectively  and  is  distinctly  related  to  mammalian  KATs.
41  Finally,  a  crystal 
structure with PDB ID 1vp4 has been deposited (www.rcsb.org). The putative 
aminotransferase  (TmPAT)  originates  from  Themotoga  maritima  and  is 
structurally similar to KATs. No data were published of the catalytic function and 
biochemical characterization of this protein. Details of the crystal structures are 
summarized in Table 3. 
 
Table 3 Crystal structures of kynurenine aminotransferases (other species) 
Enzyme 
name  
Source  PDB ID  Resolution 
(Å) 
Associated 
mammalian 
KAT 
Ref 
1v2d  1.90 
1v2f  2.35 
TtGlnAT  Thermus thermophilus 
1v2e  2.60 
KAT I 
35 
1yiz  1.55  AeKAT  Aedes aegypti 
1yiy  1.90 
KAT I 
36 
2r5c  1.96  AeKAT  Aedes aegypti 
2r5e  1.84 
KAT I 
37 
PhKAT II  Pyrococcus horikoshii  1x0m  2.20  KAT II 
38 
Bna3p  Saccharomyces cerevisiae  3b46  2.00  KAT I 
39 
MJ0684  Methanococcus jannaschii  2z61  2.20  archaeal 
40 
2ch1  2.40    Ag3HKT  Anopheles gambiae 
2ch2  2.70   
41 
TmPAT  Thermotoga maritima  1vp4*  1.32    n.a. 
*Function of enzyme needs to be established. 
 
Table  4  summarizes  details  for  5  enzymes  that  are  more  distinctly  related  to 
KATs.  These  structures  were  found  during  template  identification  for  KAT  II 
homology models (see Experimental section). 
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Table 4 Crystal structures of related aminotransferases 
Enzyme 
name  
Source  PDB ID  Resolution 
(Å) 
AT 
subfamily 
Ref 
1bjw  1.80  TtAspAT  Thermus thermophilus 
1bkg  2.60 
Ib 
17 
TmAspAT  Thermotoga maritima  1o4s  1.90  Ib 
42 
TcTAT  Trypanosoma cruzi  1bw0  2.50  I  
43 
1gd9  1.80 
1gde  1.80 
44  PhAAT  Pyrococcus horikoshii 
1dju  2.10 
I  
 
45 
 
Thermus  thermophilus  AspAT  (TtAspAT)  is  a  prototypical  enzyme  from 
aminotransferase subfamily Ib.
16 It has been used as a template structure in the 
solvation of the crystal structure of KAT I.
31 Another enzyme of subfamily Ib is 
aspartate aminotransferase from Thermotoga maritima (TmAspAT).
42 The crystal 
structure of Trypanosoma cruzi tyrosine aminotransferase (TcTAT) was the first 
published crystal structure of an aminotransferase belonging to subfamily I .
43 
Another  well-studied  member  of  subfamily  I   aminotransferases  is  aromatic 
aminotransferase from Pyrococcus horikoshii (PhAAT).
45 
6.3.1.2  Sequence comparison and evaluation of evolutionary relationships 
The  homology  of  primary  amino  acid  sequences  of  KAT  I-IV  originating  from 
human, mice and rats was analyzed by pairwise comparison. Results are shown 
in  Table  5.  In  summary,  KAT  I  isoforms  from  human,  mouse  and  rat  share 
>80% identity and around 90% similarity. Human, mouse and rat KAT II share 
>70% identity and >85% similarity. Identities and similarities between human, 
mouse and rat KAT III are >80% and >90%, respectively. For KAT IV, identities 
between human, mouse and rat isoforms are 94% or higher. The proteins share 
98-99% similarity.  
Homology between isoforms is variable. KAT I and KAT II share 21-24% identity 
and  42-45%  similarity.  KAT  I  and  KAT  III  are  50-54%  identical  and  67-72% 
similar. Similarities and identities between KAT II and KAT III are 22-26% and 
41-45%, respectively. Interestingly, no clear similarity or identity was found for 
KAT  IV  towards  any  of  the  other  isoforms.  There  was  a  hint  of  homology 
between KAT III and KAT IV. Identities for human KAT III compared to human, 
mouse and rat KAT IV were 21-22% and similarities were 41-42%, but ranged 
over a limited part of the amino acid sequence only (approximately 200 aligned 
pairs). 
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Results for pairwise comparison of human KAT I-IV with KATs from lower species 
and  related  enzymes  are  shown  in  Table  6.  Pig  cytosolic  aspartate 
aminotransferase  (PcAspAT)  was  the  first  aminotransferase  with  a  fully 
elucidated amino acid sequence. The enzyme frequently functions as reference 
enzyme and is included here for reference purposes.  
 
Table 6 Human KATs compared to other enzymes* 
  KAT1_human  KAT2_human  KAT3_human  KAT4_human 
35  26  31  25 
49  43  50  41 
TtGlnAT 
396  361  401  235 
48  21  45  LS 
65  40  68   
AeKAT 
413  382  429   
21  30  24  LS 
40  52  43   
PhKATII 
422  426  450   
34  25  33  23 
53  45  54  35 
Bna3p 
403  225  390  206 
28  23  31  LS 
50  41  51   
MJ0684 
330  339  314   
LS  LS  LS  LS 
       
Ag3HKT 
       
21  27  23  LS 
42  47  41   
TmPAT 
335  395  351   
31  26  31  21 
49  45  54  35 
TtAspAT 
392  370  322  212 
29  24  29  24 
48  43  48  41 
PhAAT 
397  415  401  209 
25  22  25  20 
45  39  44  44 
TcTAT 
263  327  309  183 
30  22  29  LS 
50  42  48   
TmAspAT 
358  349  368   
LS  26  LS  49 
  43    67 
PcAspAT 
  218    407 
*For the legend, see Table 5; LS: low score Chapter 6 
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Sequences from KAT enzymes from lower species share moderate identity (21-
35%)  and  similarity  with  human  KATs.  One  exception  is  Aedes  aegyptii  KAT, 
which  shares  relatively  high  identity  (45/48%)  and  similarity  (65/68%)  with 
human KAT I and KAT III, respectively. Lowest homology is found for human 
KAT IV. Compared to most of the sequences, no or limited homology was found. 
An  interesting  exception  is  PcAspAT.  KAT  IV  and  PcAspAT  share  much  higher 
identity and similarity (49% and 67%, respectively). 
No  homology  was  found  for  Anopheles  gambiae 3 -hydroxykynurenine 
aminotransferase towards any of the human KAT isoforms. 
 
The  evolutionary  relationships  between  isoforms  and  species  can  be  derived 
from  alignments  of  primary  structures  and  subsequent  construction  of  a 
phylogenetic tree. The phylogenetic tree for the structures considered in Tables 
3-6 is shown in Figure 3. 
 
Figure 3 
 
Phylogram of kynurenine aminotransferases and related structures 
 
The tree shows distinct clusters for the KAT isoforms. KAT II isoforms cluster 
with  PhKATII  and  TmPAT.  KAT  I  and  KAT  III  are  evolutionarily  related  and 
cluster with several other KATs and related structures. KAT IV is more distinctly 
related  to  KAT  II  and  KAT  I/III,  and  clusters  with  PcAspAT.  Ag3HKT  is 
categorized as a distinct ancestor of the other KATs. Molecular modeling: Kynurenine aminotransferase II 
  183 
6.3.1.3  Human KAT II homology modeling 
Homology models of human KAT II were constructed before the release of any 
mammalian KAT II crystal structure. In this work, amino acid numbering will be 
used of the human KAT II sequence (AADAT_HUMAN), unless stated otherwise.  
 
Sequence alignment  
Sequences considered for alignment are from human, mouse and rat KAT I and 
KAT  II,  and  sequences  from  TtAspAT,  TmAspAT,  PhAAT,  TmPAT  and  TcTAT. 
These sequences were summarized and discussed in section 6.3.1.1 (Tables 2, 3 
and 4). The sequences originate from enzymes that are members of subfamily 
I  or Ib of aminotransferases.  
For  sequence  alignment,  alignments  from  two  different  alignment  algorithms 
were combined and manually adjusted. The resulting alignment was inspected 
on proper positioning of the conserved anchor residues (Table 1). Around these 
anchor  residues  a  conserved  pattern  was  reported  for  family  I .
9  Both  the 
strictly conserved anchor residues and the conserved pattern were found to be 
aligned  successfully.  An  exception  is  Arg270  (compares  to  R266  in  PcAspAT), 
which is not fully conserved in the present alignment. This is in agreement with 
the literature.
9   
Next to the primary structure, the secondary structure was taken into account 
for alignment. The secondary structure was predicted for KAT II in Jpred
46. The 
results  were  compared  to  secondary  structure  elements  of  crystal  structures. 
Predicted  secondary  structure  elements  corresponded  well  with  the  secondary 
structure elements of the crystal structures.  
 
KAT II homology models 
From the aligned sequences, available crystal structures were selected for model 
building. Four KAT II models were built, representing different states or phases 
in the KAT catalytic cycle (Scheme 2). The homology models are summarized in 
Table 7.  
 
Table 7 Crystal structures from related aminotransferases 
Model  Template  Resolution (Å)  Enzyme 
State I  1bjw  1.80  TtAspAT 
Phase Ia  1w7m  2.70  human KAT I 
Phase Ib  1gde  1.80  PhAAT 
Phase III  1bkg  2.60  TtAspAT 
 Chapter 6 
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For the model in the unliganded PLP bound form (state I), a crystal structure of 
TtAspAT  with  PDB  ID  1bjw  was  used  as  the  template  structure.
17  A  phase  Ia 
model was built from the liganded PLP bound crystal structure of human KAT I, 
with  PDB  ID  1w7m.
31  Structure  1w7m  contains  co-crystallized  phenylalanine. 
This  ligand  molecule  was  preserved  during  model  building.  The  model  is 
designated a phase Ia model, because no interaction between the ligand and the 
co-enzyme takes place. The primary interaction is between the ligand and the 
Arg  side  chain.  A  phase  Ib  model  was  built  from  the  crystal  structure  of 
hyperthermophilic PhAAT with glutamate as its substrate (PDB ID 1gde).
44 In the 
1gde  crystal  structure,  the  co-crystallized  Glu  is  covalently  bound  to  the  co-
enzyme  (state  II).  To  make  KYN  docking  studies  possible,  prior  to  model 
building,  the  Lys-PLP  imine  bond  was  reconstructed  and  the  glutamate-ligand 
molecule was kept in the structure as an unbound ligand. Although the ligand is 
not  covalently  bound,  the  resulting  model  represents  an  intermediate  state 
between the internal and external aldimine bound form (phase Ib). The TtAspAT 
crystal structure with PDB ID 1bkg was used to model the PMP-bound phase III 
model.
17 The structure contains co-crystallized maleate as a co-substrate, which 
was preserved during model building.  
The  quality  of  the  models  was  assessed  by  submission  of  each  model  to 
Procheck
47, 48. Based on Ramachandran plot statistics, the overall quality of the 
models is moderate. In all four models, about 70% of the residues were located 
in the core regions, and about 95% in the core and allowed regions.  
 
Binding site characteristics 
For further discussion of binding site characteristics, a numbering scheme will be 
used in which amino acid numbering of the first monomer starts at 1 and amino 
acid numbering of the second monomer starts at 500. Binding site 1 (BS1) is 
primarily lined by amino acids from the first monomer. Binding site 2 (BS2) is 
primarily lined by amino acids from the second monomer. Amino acids of binding 
site  1  that  are  designated  by  a  number  >500  originate  from  the  second 
monomer.  For  binding  site  2,  amino  acids  designated  by  a  number  <500 
originate from the first monomer. During the general discussion of binding site 
characteristics, amino acid numbering will be from BS1/BS2. For example, the 
lysine residue that forms the internal aldimine link with PLP is Lys263 in BS1 and 
Lys763 is BS2. In the general discussion, the residue is called Lys263/763. 
 
The KAT II binding site is divided into a co-enzyme binding site and a ligand 
binding site. The co-enzyme is attached to the enzyme by a covalent imine bond Molecular modeling: Kynurenine aminotransferase II 
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with Lys263/763 in the state I and the phase Ia and Ib models. In the phase III 
model, the co-enzyme is in its PMP form. PMP is not covalently linked to the 
enzyme. In this model, the two amino-groups point out of the ‘bottom’ into the 
ligand binding site. 
In  all  models,  the  PLP  phosphate  group  is  involved  in  a  tight  network  of 
hydrogen bonds and salt bridges. As described earlier (Section 6.2.2), for fold 
type  I  PLP  dependent  enzymes,  the  interactions  of  the  phosphate  arm  were 
defined in a phosphate binding cup.
20, 21 The first layer was defined by a layer of 
atoms in positions a-g, and the second layer by atoms in positions h, i and j 
(Figure 1). Analysis of the present models reveals that most of the interacting 
residues  can  be  assigned  to  a  defined  position.  This  is  exemplified  by  the 
interactions as found for the state I model, shown in Figure 4.  
 
Figure 4 
 
Interactions in the phosphate binding cup in the state I model, BS2.  
 
The positions a and b are defined by the side chain OH groups of Ser762 and 
Ser760, respectively. Main chain nitrogen atoms of Ser617 and Gln618 are in 
positions c and d. According to the definitions given in ref
20, the side chain of 
either  Ser617  or  Gln618    should  interact  with  the  phosphate  group  to  define 
position e. However, in all models, distances between these groups and any of 
the  phosphate  oxygen  atoms  were  too  large  to  allow  for  hydrogen  bond 
formation. A molecule of water is seen in a place that corresponds with position 
f. Finally, the side chain OH of Tyr74 is in position g. The core interaction in the 
second layer is between the phosphate group and the side chain of Arg770. In 
all models, the corresponding atoms were within a distance to form hydrogen 
bonded  salt  bridges  (positions  i  and  j).  In  analogy  to  interactions  in  PcAspAT 
(Figure 1), the C  atom of Gly616 defines position h. The interaction between a 
(a) Ser762 
(b) Ser760 
(c) Ser617 
(d) Gln618 
(f) H2O 
(g) Tyr74 
(i) 
(h)  
Gly616 
Arg770 
 (j)  Chapter 6 
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CH group that is positioned within a defined distance to one of the phosphate 
oxygen  atoms  was  defined  as  a  short  C-H
...O  contact,  which  is  similar  to  a 
hydrogen bonding interaction.
20 
 
The remainder of the co-enzyme is bound to the enzyme by an extensive set of 
hydrogen bonding interactions. Primarily, the negatively charged oxygen atom of 
the PLP aromatic ring interacts with residues Asn202/702 and Tyr233/733. The 
phenol  ring  of  Tyr142/642  is  oriented  parallel  to  the  pyridine  ring  of  the  co-
enzyme.  The  distance  between  the  planes  of  the  aromatic  moieties  ranges 
between 3.1 and 4.7Å.  
 
Ligand binding site characteristics are described from a view along the PLP-imine 
linkage towards the PLP-pyridine ring or into the corresponding direction in the 
PMP-bound  model.  The  substrate  binding  site  is  located  at  the  dimeric  and 
domain interface. The residues on the bottom, left, left front, bottom right and 
back sides are from the first monomer. The residues on the top right layer and 
right front side are from the second monomer. The top of the binding site is 
formed by the N-terminal arm. A schematic representation of the ligand binding 
site, as derived from the homology models, is given in Figure 5. 
 
Figure 5 
 
Schematic representation of the KAT II binding site as derived from homology models. 
Amino acid numbering refers to BS1. Molecular modeling: Kynurenine aminotransferase II 
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The bottom of the ligand binding site is formed by the co-enzyme. At the sides, 
the  residues  lining  the  binding  site  form  two  layers.  The  bottom  layer  is 
hydrophilic,  the  top  layer  is  more  hydrophobic.  In  general,  the  hydrophilic 
bottom layer is characterized by Arg399/899 and Asn202/702 on the left and 
Arg270/770 on the right side. In the top layer, Leu382/882 and Phe387/887 are 
located on the left, and Leu793/293 on the right. In the phase Ia model only, 
His794/294 points into the binding site in the right top layer. In the state I and 
phase III models, the His side chain is bent away from the binding site. In the 
front, a loop with Gly39/539 in the main position points into the binding site. On 
its right, the plane of the Tyr574/74 phenolic side chain faces the site. In the 
back, Tyr142/642 lies in parallel to the plane of the co-enzyme. The aromatic 
side chain interacts by  -stacking with the pyridine ring of the co-enzyme.  
In the state I model, the N-terminal arm is bent to the left upper side of the 
enzyme and does not reach the binding site. In the closed state models (phase I 
and III), residues of the N-terminal arm form a lid that closes the binding cup 
from the top side. In the phase Ia model, Arg20/520 points into the site. In the 
phase  Ib  and  the  phase  III  models,  Asn15/515  reaches  down  from  the  N-
terminal arm to close the site.  
For correct substrate binding, the distance between the lysine bound co-enzyme 
and Arg399/899 should be optimal. For the stage I and phase Ia binding sites, 
the distances seem proportional to accommodate the substrate. The distances 
are larger for the phase Ib model than for the other PLP-bound models.  
6.3.1.4  Docking of kynurenine 
The  enzyme’s  natural  substrate,  KYN,  was  docked  into  the  phase  Ia  and  Ib 
models. Each enzyme model accommodates two binding sites (BS, see Figure 
2). The ligand was docked in both binding sites (BS1 and BS2) of both models. 
The docking results revealed several main characteristics. The KYN carboxylate 
group  forms  a  hydrogen  bonding  salt  bridge  with  Arg399/899.  Asn202/702 
either  interacts  with  the  carboxylate  group  directly  or  via  Arg399/899.  The 
backbone  amide-N  of  Gly39/539  is  the  third  residue  interacting  with  the 
carboxylate  group.  In  the  docked  conformation,  KYN  forms  intramolecular 
hydrogen bonds between the aniline-NH2, carbonyl, and the  -amino group. The 
 -amino group points down towards the PLP-imine linkage.  
Docking of KYN into the binding sites of the phase Ia model was done in two 
runs per binding site. In the first run, a randomly oriented ligand was used with 
7.5M energy evaluations. In the second run, the best docked structure of the 
first hit was used to refine the position of the grid box. 10M energy evaluations Chapter 6 
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were  used.  The  best  hit  of  the  second  run  was  regarded  as  the  final  docked 
orientation. 
Docking of KYN into BS1 of the phase Ia model gave one main cluster of docked 
conformations. Docking in BS2 gave one cluster with similar orientation to the 
orientation found for BS1 and one additional cluster. In the orientation found for 
both  binding  sites,  the  amino  acid  part  of  the  structure  is  interacting  with 
Arg399/899, Asn202/702 and Gly39/539. The aromatic part leans towards the 
upper right corner of the binding site. Interactions are mainly hydrophobic. The 
aniline  moiety  interacts  with  His794/294  via  hydrogen  bonding.    The 
conformation of the ligand is highly stabilized by intramolecular hydrogen bonds. 
In Figure 6, the full set of interactions is shown for KYN docked into BS1 of the 
phase Ia model. 
 
In BS1, water molecules were taken into account during model building. In BS2, 
no water molecules were modeled. Consequently, the residue side chains in the 
upper right corner of BS2 lean into the binding site. Water molecules prevented 
these  side  chains  in  BS1  to  occupy  this  space.  This  difference  influences  the 
binding of the substrate. In BS1, the molecule leans towards the right upper side 
into  a  pocket  originally  conserved  by  the  water  molecules.  The  aromatic  ring 
shows  -stacking interactions with Tyr574. In BS2, this pocket is less spacious, 
and the ligand leans more to the left side of the binding site.  
 
In  the  phase  Ib  model,  two  docking  runs  were  performed  with  the  randomly 
oriented starting position of KYN for both binding sites. In the first run, 7.5M 
energy evaluations were used. In this run, three main clusters were found. The 
number of energy evaluations was increased to 10M in the second run. Again, 
three  main  clusters  of  docked  structures  were  found.  The  three  orientations 
found in the first run strongly resemble the orientations found in the second run. 
In  all  docked  orientations,  the  KYN  amino  acid  moieties  are  anchored  in  the 
Arg399/899 and Asn202/702 network with their carboxylate groups. The amines 
point  down  towards  PLP.  Asn15/515  adopts  a  very  central  position  in  both 
binding sites. Its end group points towards the  C  atom of KYN and forms a 
hydrogen bond with the KYN carboxylate group (BS1 only). The KYN aromatic 
moieties are oriented in 3 ways around the Asn15/515 residue side chain. This is 
shown in Figure 7. 
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Figure 6 
 
Schematic representation of KYN docked into BS1 of the phase Ia model 
 
 
Figure 7 
   
Three positions of KYN in BS1 (left panel) and BS2 (right panel) of the phase Ib model. 
 
One  out  of  the  three  orientations  in  each  binding  site  strongly  resembles  the 
ones  found  for  the  phase  Ia  models  (shown  in  yellow  in  Figure  7).  In  these 
orientations, the aromatic part of the ligand points to the right front side of the 
binding site. Hydrophobic interactions are seen with Leu793/293 and Tyr574/74. 
The  NH3  groups  are  hydrogen  bonded  to  Gly39/539  (not  shown  in  Figure  7). 
However, the distances between the KYN-NH3 group and the imine-nitrogen are 
rather high.  
Asn515 
Arg899 
Leu293 
LLP 
Arg399 
Asn15 
Leu793 
LLP 
Tyr574 Chapter 6 
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6.3.2  Discussion 
6.3.2.1  Sequence comparison and evolutionary relationships 
KATs  form  a  distinct  group  of  enzymes  within  the  large  group  of 
aminotransferases.  Much  work  has  been  published  in  recent  years  on 
characterization  of  isoforms  and  elucidation  of  structural  properties  of  the 
enzymes.  Large  amounts  of  data  are  available  that  can  give  insight  into  the 
structural relatedness of the enzymes. Information on evolutionary relatedness 
and divergence could form an interesting background for observed and predicted 
substrate and inhibitor specificity. 
Primary  structures  of  human,  mouse  and  rat  KATs  were  compared  with  each 
other and with similar enzymes. Pairwise analysis of sequence homology reveals 
that the isoforms of the enzymes are no close relatives. Considerable deviations 
exist even within the KAT isoforms between different species. This suggests, that 
basic functionality of the enzyme is not strictly related to the overall sequence, 
but rather to a conserved core part of the enzyme. An exception is KAT IV. For 
this  isoform,  high  homologies  were  found  between  different  species. 
Interestingly, based on homology, this KAT isoform is only distinctly related to 
KAT I, II and III.  
KAT I and KAT III share considerably more homology to each other than to KAT 
II.  Apparently,  KAT  I  and  KAT  III  are  closely  related  enzymes.  This  is  in 
accordance with similar observed enzyme properties, like the high pH optimum 
and preference for keto acid substrates.
34 
Homologies of human KAT to KATs from lower species and related enzymes are 
in the same ranges as homologies between KAT II and KAT I/III. For most KAT 
enzymes, a clearly higher homology is apparent towards either KAT I and III or 
KAT  II.  TtGlnAT,  AeKAT  and  Bna3p  were  published  human  KAT  I  homologs. 
Indeed,  homology  towards  KAT  I  and  also  towards  KAT  III  is  higher  than 
towards KAT II. In contrast, PhKATII, a published KAT II homolog, has clearly 
higher  homology  to  human  KAT  II  than  to  KAT  I  and  KAT  III.  MJ0684  was 
published  as  an  archaeal  analog  of  KAT.  Based  on  homology  patterns,  the 
enzyme is a KAT I/III homolog. In contrast, TmPAT shares higher homology with 
KAT II, and can be categorized in the group of KAT II homologs. For the KAT 
related enzymes, a similar division into KATI/III or KAT II groups can be made. 
Clearly,  TtAspAT,  PhAAT  and  TmAspAT  are  KAT  I/III  homologs.  TcTAT  shows 
lower homology to either group.  
 Molecular modeling: Kynurenine aminotransferase II 
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Therefore,  from  primary  sequence  comparisons,  kynurenine  aminotransferase 
can be divided into a KAT I/III and a KAT II group. This observation was further 
studied  by  construction  of  a  phylogenetic  tree  (Figure  3).  The  tree  confirms 
observations  from  pairwise  comparison.  KAT  I  and  KAT  III  are  very  closely 
related.  Moreover,  the  tree  confirms  that,  apart  from  the  published  KAT  I 
homologs,  archaeal  KAT  MJ0684  as  well  as  KAT  related  enzymes  PhAAT, 
TtAspAT and TmAspAT are members of the KAT I/III group. In the tree, TcTAT is 
distinctly  related  to  the  KAT  I/III  group.  As  expected,  PhKATII  and  TmPAT 
cluster with the KAT II group.  
From  pairwise  comparison  of  the  sequences  it  was  clear  that  KAT  IV  is  not 
closely related to KAT I, II and III. High homology with PcAspAT was found. In 
the phylogenetic tree, these enzymes cluster in a group that is distinctly related 
to the KAT II and KAT I/III groups. Probably, the position of this group within 
the tree reflects the degree of relatedness to other aminotransferases. 
 
An interesting exception from all studied structures here is Ag3HKT. The enzyme 
has  proven  aminotransferase  activity  with  KYN  and  3-OH-KYN  as  substrate, 
producing KYNA and xanthurenic acid, respectively. However, the enzyme seems 
to  be  not  directly  related  to  the  other  KATs.  Therefore,  either  very  early 
deviation  from  the  ancestral  enzyme  or  convergence  of  function  must  have 
occurred.  The  enzyme  originates  from  a  malaria  parasite.  The  relatively  low 
relatedness to mammalian KATs makes the enzyme an optional target for anti-
malarial medication. 
6.3.2.2  Homology models 
For evaluation of the KAT II homology models, the binding sites of the models 
are compared to the sites in crystal structures of KAT II. In the first instance, 
the resting state I model is compared to crystal structures of the resting state, 
with  PDB  ID  2vgz
25  and  2qlr
26.  In  general,  amino  acid  positions  and  spatial 
arrangements  correspond  very  well  between  the  model  and  the  crystal 
structures.  PLP  is  bound  to  Lys263.  The  negatively  charged  oxygen  atom 
interacts with Tyr233 and Asn202. The atom positions a-j of the PLP binding cup 
as defined from the models (Figure 4) is confirmed by the crystal structures. 
Interaction of Tyr574/74 in position f or g is confirmed by the crystal structures. 
Position  e  was  not  clearly  defined  by  the  models,  but  the  side  chain  of 
Ser117/617  was  the  supposed  functional  group  to  take  the  corresponding 
position. In the crystal structures, the side chain of Ser117 is in a position that 
corresponds to the position in the models. In the crystal structures however, the Chapter 6 
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exact  position  is  within  hydrogen  bonding  distance  to  the  phosphate  group. 
Therefore indeed, this residue occupies position e. 
The ligand binding site characteristics found for the homology models (Figure 5) 
are in accordance with the characteristics found in the crystal structures. At the 
left side of the binding site, Arg399/899 and Asn202/702 define the carboxylate 
anchoring point of the substrate. From crystal structures of KAT I and from the 
docking studies performed, it appeared that the front right corner of the binding 
site was most important for binding the aromatic moiety of the ligand. This part 
is defined by Tyr574/74 from the front, and His794/294 and Leu793/293 from 
the  right  side.  In  all  models,  Tyr574/74  and  Leu793/293  were  found  at  the 
correct  position.  The  position  of  the  side  chain  of  His794/294  varies  slightly 
between  the  models.  Closer  inspection  of  the  crystal  structures  and  models 
reveal, that Leu293 and His294 are positioned in a loop attached to an  -helix. 
The loop lines the right part of the ligand binding site at the position of Leu293. 
The position of His294 can be seen as a corner point in the loop, bending away 
from the binding site towards the helix. The next residue is Pro295, which is 
almost completely conserved in the alignment. Gln300 is situated in the helix, 
approximately one turn away from His294 and is also well conserved. The Gln 
side chain points out of the helical turn, towards the corner point of the loop. In 
Figure  8  (left  panel),  this  is  shown  for  KAT  II  in  crystal  structure  2qlr.  For 
comparison,  the  corresponding  loop  in  KAT  I  from  crystal  structure  1w7l  is 
shown (right panel). 
 
Figure 8 
   
Upper right corner loop of the binding site in KAT II (model 2qlr, left) and in KAT I 
(model 1w7l, right). 
 
In the sequence alignment for the KAT II models, the region between Leu293 
and Gln300 could not be aligned reliably based on primary sequence. However, 
LLP 
Leu293 
His294 
Pro295 
Gln300 
His279 
Phe278 
Cys280 
Pro281 
Gln285 
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upon closer inspection of the crystal structures, the alignment could be adjusted, 
as shown in Figure 9. 
 
Figure 9 
 
 
KAT1_Human  278  F  H  C  -  P  -  T  Q  S  Q  285 
KAT1_Rat  312  F  H  C  -  P  -  T  Q  A  Q  319 
KAT1_Mouse  278  F  H  C  -  P  -  T  Q  A  Q  285 
KAT2_Human  293  L  H  -  -  P  S  T  F  N  Q  300 
KAT2_Rat  293  L  H  -  -  P  C  T  L  S  Q  300 
KAT2_Mouse  293  V  H  -  -  A  C  T  L  S  Q  300 
TtAspAT  265  T  -  S  -  P  D  T  I  A  Q  272 
TmAspAT  265  S  -  C  -  I  N  T  V  A  Q  272 
PhAAT  264  T  -  C  -  P  V  T  F  I  Q  272 
TmPAT  278  L  -  C  S  P  -  A  I  T  H  285 
TcTAT  289  C  -  G  -  P  C  T  V  V  Q  296 
Fragment of sequence alignment. 
 
The first residue in the alignment in Figure 9 represents the residue that points 
out of the loop into the binding site. For KAT II, this is Leu293. The residues that 
are located in the corner position in the loop are bold in the alignment in Figure 
9. For all but KAT enzymes, a relatively small residue, mostly Cys, occupies this 
position.  The  nature  of  the  residue  does  not  directly  influence  binding  site 
characteristics in the models. In KAT II sequences, a histidine is located at the 
corner point. Due to its larger size, this residue has a more defining function for 
the  binding  site  characteristics.  Interestingly,  in  KAT  I,  both  His  and  Cys 
residues are present. The extra Cys residue directs the His side chain towards 
the  front,  right  into  the  binding  site.  In  KAT  II,  because  only  one  residue  is 
present in the corner position, the orientation of the residue side chain is more 
flexible  at  that  position.  This  might  be  an  important  observation  in  terms  of 
ligand design. Due to the more spacious nature of the binding site at the loop 
corner, probably larger ligands can be accommodated. In fact, this could be the 
cause of the KAT II selectivity of inhibitor S-ESBA. The molecule is a kynurenine 
analog with an ethylsulfonyl substitution in the aromatic ring. Whereas in KAT I, 
the extended His-Cys combination occupies the corner space of the binding site, 
in KAT II, the ethyl sulfonyl side chain can be accommodated next to the His 
residue side chain.  
In  the  homology  models,  His794/294  is  present  in  the  state  I,  phase  Ia  and 
phase III models. The state I and phase III models were constructed from cystal 
structures  originating  from  TtAspAT.  For  the  models,  the  Ser  residue  was 
substituted for His. For the phase Ib model, a structure from PhAAT was used. 
Due  to  the  apparent  conservation  of  Cys  in  the  sequences,  Cys  was  not 
substituted for His during model building. In the state I and the phase III model, Chapter 6 
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His  points  away  from  the  binding  site,  towards  the   -helix.  In  the  phase  Ia 
model,  His  points  directly  into  the  binding  site.  The  position  is  more  directly 
influencing  the  binding  site  characteristics.  From  the  crystal  structures,  it 
appears  that  in  KAT  II,  the  His  side  chain  holds  an  intermediate  position 
compared to the position in the models. Probably, in reality, the position of the 
side chain is rather flexible, depending on the size of the incoming ligand. 
 
In the homology models, a  -stacking interaction was found between the PLP 
pyridine ring and Tyr142/642. In the unliganded crystal structures, the distance 
between the Tyr142 side chain and the PLP pyridine ring is significantly larger 
and suboptimal for  -stacking. In these structures, the ring is situated in close 
vicinity to Pro232, which interacts from the bottom with the pyridine ring. In the 
models, the pyridine ring is lifted up. Whereas this causes an optimal position for 
interaction  with  Tyr142/642,  interaction  with  Pro232/732  and  salt  bridge 
formation with Asp230/730 is prevented. Apparently, the gain in stability due to 
hydrophobic interactions during model energy minimization overruled the gain 
by  dipole  interactions  with  Asp230/730  and  stacking  with  Pro232/732. 
Interestingly, from the KYN bound crystal structure it was concluded that there 
is a shift of Tyr142 towards the substrate and that the co-enzymatic pyridine 
ring is tilted.
26 Indeed, in the KYN bound crystal structure, the ring of Tyr142 is 
oriented parallel to the PMP pyridine ring. Therefore, in the models, the relative 
orientation  of  the  pyridine  ring  and  Tyr142/642  is  the  orientation  adopted  at 
ligand binding, rather than the orientation in the resting state. 
 
From the crystal structures of KAT II enzymes it appeared that the position of 
the N-terminal arm is different in these enzymes from the conformations of the 
arms in other related structures. The N-terminal arm is important in holding the 
two monomers together. In addition, the arm forms a lid on top of the ligand 
binding  site  (see  Figure  5).  Usually,  the  arm  that  closes  the  binding  site 
originates from the same monomer as the major part of the residues lining the 
binding  site.  For  KAT  II  only,  it  was  found  that  the  N-terminal  arm  of  one 
monomer reaches over to the other monomer, and forms a lid of the binding site 
of the opposite monomer.
25 Upon binding of a ligand, a conformational change of 
the  N-terminal  arm  occurs.  The  change  is  less  pronounced  in  subgroup  I  
aminotransferases  than  in  other  aminotransferases.  In  the  KAT  II  crystal 
structures, a corresponding movement of the N-terminal arm is observed.  
Obviously, the position of the N-terminal arm being located on the binding site 
of the opposite monomer could not be predicted from the homology models. In Molecular modeling: Kynurenine aminotransferase II 
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the  phase  Ia,  Ib  and  III  models,  the  N-terminal  arm  originates  from  the 
monomer that also forms the major part of the binding site. In all three models 
an amino acid side chain from the arm was found to point into the binding site. 
For  the  phase  Ia  model,  this  was  Arg20/520.  In  both  the  phase  Ib  and  III, 
Asn15/515 pointed into the binding site. Remarkably, in the crystal structure of 
kynurenine bound KAT II, Arg20 was found to interact with the ligand. Although 
the Arg20 residues are from opposite monomers in the phase Ia and the KYN 
bound crystal structure, the corresponding function was found for the residue in 
the model. In both cases, the residue is located in a helix that is directed from 
the back to the front of the binding site. This is shown in Figure 10. 
 
Figure 10 
   
Position of the N-terminal arm helix and Arg20 in the phase Ia model (BS1, left) and in 
the  KYN  bound  crystal  structure  (PDB  ID  2r2n,  right).  Monomer  1  is  colored  green, 
monomer 2 is colored cyan. 
 
The phase Ia model was built from a template structure originating from KAT I. 
In KAT I, Trp18 is in the position of Arg20 in KAT II. As in KAT II, Trp18 in KAT I 
interacts with the bound ligand. Therefore, although the helices originate from 
opposite monomers, they seem to adopt a functionally conserved position. It is 
tempting to speculate about swapping of the substructure during evolution from 
one monomer to the other.  
6.3.2.3  Docking studies 
Figure 11 shows KYN docked in the phase Ia model (left panel, compared to KYN 
as bound in the KAT II crystal structure (PDB ID 2r2n, right panel). 
 
 
N-terminal helix  N-terminal helix 
Arg20  Arg20 Chapter 6 
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Figure 11 
   
KYN (cyan) bound in the phase Ia model (BS1, left panel) and in crystal structure 2r2n 
(right panel).  
 
In both instances, the KYN carboxylate forms salt bridges with Arg399/899. The 
aromatic moiety interacts in the hydrophobic upper right corner of the binding 
site. In the phase Ia model, the amino acid moiety KYN is positioned closer to 
the PLP imine bond than in the crystal structure. In the crystal structure, the 
amino acid moiety is pointing upwards. Whereas in the model the amino group is 
oriented in parallel to the plane of the co-enzyme, the crystal structure shows a 
more perpendicular orientation of this group towards the bottom of the binding 
site. This difference could be related to different states of the co-enzyme. In the 
crystal  structure,  the  co-enzyme  is  in  the  PMP  bound  form.  In  between  the 
amino group of PMP and the amino group of lysine, there is space available for 
easy  accommodation  of  the  KYN  amino  group.  In  contrast,  in  the  phase  Ia 
model, the internal aldimine bond occupies the space that is taken by the KYN 
amino group in the PMP bound structure. The KYN amino group is located higher 
in the binding site, but in an orientation to replace the lysine side chain. It can 
be envisioned from these results that in reality, binding of the carboxylate group 
to  Arg399  ‘pushes’  the  amino  group  towards  the  internal  aldimine  linkage  to 
initiate transaldimination. This is a dynamic process and cannot be shown in a 
static model or crystal structure. 
 
For the phase Ib model (see Figure 7), three orientations of the aromatic moiety 
were  found  for  each  of  the  binding  sites.  The  orientations  were  highly 
determined  by  Asn15/515,  pointing  into  the  binding  site  from  the  N-terminal 
arm. Although in the crystal structures, Arg20 points into the binding site (see 
Figure 10, right panel), the function of Asn15/515 in the phase Ib model seems 
to be similar. In both cases, the residue side chain directs the orientation of the 
Arg399 
KYN 
PLP 
Tyr574 
KYN 
PMP 
Arg399 
Lys263 
Tyr574 Molecular modeling: Kynurenine aminotransferase II 
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KYN  aromatic  ring.  One  of  the  orientations,  shown  in  yellow  in  Figure  7, 
corresponds to the orientation of KYN in the crystal structure.  
6.3.2.4  General discussion and conclusion 
In summary, comparison of sequences and evolutionary analysis revealed, that 
the  KAT  isoforms  can  be  divided  into  a  KAT  I/III  group  and  a  KAT  II  group. 
Although the homologies between the groups are limited, characteristics of the 
ligand and co-enzyme binding sites are highly conserved. KAT IV is structurally 
unrelated to the KAT I/III or KAT II groups. High homology of the enzyme to 
PcAspAT was found. 
The  homology  models  of  KAT  II,  constructed  from  other  subfamily I   
aminotransferases could reliably predict the co-enzyme and ligand binding site 
properties of KAT II. Comparison of the right hand side loop lining the ligand 
binding site revealed, that an extra residue at the corner position of the loop 
causes a more limited binding space in KAT I if compared to KAT II. Although 
KAT  II  displays  a  formerly  unknown  orientation  of  the  N-terminal  arm,  the 
function  of  the  helix  covering  the  binding  site  is  conserved.  Therefore,  the 
residue pointing into the binding site could be predicted from the KAT I model. 
The binding orientation of the ligand could be predicted by docking studies. The 
conserved  point  of  ligand-enzyme  interaction  is  a  salt  bridge  between  the 
positively charged guanidine group of Arg399/899 and the negatively charged 
carboxylate group of KYN. The aromatic part of KYN interacts at the top right 
corner, close to Tyr574/74, His794/294 and Leu793/293. Based on differences 
between  the  homology  models  and  the  KYN  bound  crystal  structure,  it  was 
proposed that interaction of the KYN carboxylate group with Arg399 causes the 
KYN  -amino group to be directed towards the internal aldimine bond to initiate 
transaldimination. 
 
Taken  together,  the  work  on  homology  models  of  KAT  II  in  comparison  with 
available crystal structures shows that the majority of information important for 
binding  site  characterization  and  ligand  design  could  be  predicted  from  the 
models. In view of rapidly growing computational power and availability of more 
reliable algorithms for prediction of structures, the use of homology modeling 
should  not  be  underestimated.  Although  crystallization  studies  are  considered 
most  accurate  and  reliable  for  structure  prediction,  disadvantages  like 
environmental  burden  of  chemicals  used  and  time-consuming  method 
development should ultimately lead to the preference of computational methods 
over  experimental  methods.  In  particular,  in  the  case  of  large  groups  of Chapter 6 
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structurally  related  enzymes  or  substructures,  computational  methods  can  be 
considered  as  a  more  efficient  substitution  of  or  at  least  useful  addition  to 
experimental work.  
Crystal  structures  represent  static  situations  of  the  enzyme.  Computational 
resources  allow  for  simulation  of  more  dynamic  systems  to  add  value  to  the 
static  information  as  gained  from  the  crystal  structures.  This  is  of  particular 
interest  in  the  field  of  enzymatic  systems,  since  these  proteins  are  very 
dynamic. To achieve reliable prediction of dynamic processes, reliable structures 
representing  natural  states  of  enzymes  are  needed  as  a  starting  point. 
Generation  of  stable  crystals  requires  precisely  controlled  conditions  of  the 
crystallization  medium.  As  exemplified  by  the  KYN  bound  crystal  structure  of 
KAT  II  (PDB  ID  2r2n),  this  can  lead  to  states  of  the  enzyme  that  are  not 
expected in nature. According to the catalytic cycle as shown in Scheme 2, the 
simultaneous  presence  of  KYN  and  the  PMP  form  of  the  co-enzyme  is  not 
expected,  since  it  is  not  favorable  for  catalysis.  Therefore,  efforts  should  be 
made to generate structures that form a natural starting point for the simulation 
of the dynamic process of binding and interaction of KYN in the binding site.  
Overall,  combination  of  experimental  and  computational  methods  can  lead  to 
valuable information for understanding biological systems and to form a basis for 
structure based drug design. 
6.4  Experimental section 
Sequence and structure comparison 
Retrieval  of  primary  sequences  and  crystal  structures  Primary  amino  acid  sequences  of 
KAT  were  retrieved  from  the  Swiss  Prot/TrEMBL  database.
19  Published  KAT  crystal 
structures were found in literature and in the Protein Data Bank (www.rcsb.org). For the 
retrieval of template structures for homology models and further related structures, the 
primary amino acid sequence of human KAT II (entry AADTA_HUMA, accession number 
Q8N5Z0) was used as input in SAS
49 and Consensus
50. For the hits obtained, the amino 
acid  sequences  of  structure  that  represented  naturally  occurring  proteins  (mutants 
excluded) were selected.  
Sequence  pairwise  comparison  Pairwise  comparison  was  performed  using  NCBI  BlastP: 
Bl2Seq.
51 Standard settings of alignment parameters were used. Results were expressed 
as percentage identity and similarity, indicating the chain length over which the alignment 
was performed in number of aligned amino acids. 
Construction of phylogram tree The phylogram tree was constructed from primary amino 
acids  sequence  as  found  in  Swiss  Prot/TrEMBL.
19  The  structures  were  aligned  in 
ClustalW2.
52,  53 Default settings were used. The aligned sequences were used directly for 
input in ClustalW2 for phylogenetic tree construction. For the tree construction, distance 
correction was applied and the UPGMA clustering method was used.
53, 54 
 
KAT II homology modeling  
Hardware and software specifications All computations were done on an Intel Pentium 4.0, 
3.0GHz computer, with 1280MB memory, running Debian GNU/Linux OS. Sybyl
55 version 
7.0  was  used  for  model  building.  Docking  calculations  were  done  in  AutoDock  4
56. Molecular modeling: Kynurenine aminotransferase II 
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AutoDockTools (ADT)
57 versions 1.4.4 and 1.4.5 were used for analysis and preparation of 
ligand/receptor  and  parameter  files,  respectively.  Ligplot
58  version  4.5.3  was  used  for 
analysis of ligand-enzyme interactions and generation of Figure 6. 
Sequence alignment For sequence alignment, sequences from 11 different enzymes were 
used.  KAT  I  and  KAT  II  sequences  were  used  from  human,  rat  and  mouse 
(AADAT_HUMAN, AADTA_RAT and AADAT_MOUSE for KAT II; KAT1_HUMAN, KAT1_RAT, 
KAT1_MOUSE  for  KAT  I).  At  the  time  of  model  building,  KAT  III  and  KAT  IV  were  not 
known. Furthermore, sequences were taken into account from TtAsAT, TmAspAT, PhAAT, 
Tm_PAT  and  TcTAT.  From  these  seqences,  crystal  structures  were  available  and  were 
found as hits from SAS
49 or Consensus
50, indicating structural relatedness to human KAT 
II.  Multiple alignments of the selected structures were obtained from ClustalW (version 
1.8)
52  and  Dialign
59.  ClustalW  results  were  taken  as  the  primary  alignment  and  results 
were adjusted manually based on Dialign results. Then, in the second round of alignment, 
secondary structure elements of known crystal structures were taken into account. For this 
purpose, the secondary structure elements were predicted for human KAT II in Jpred
46. 
The  predicted  secondary  structure  elements  were  matched  with  secondary  structure 
elements  of  known  crystal  structures.  Finally,  the  results  were  checked  on  the  proper 
alignment of known conserved amino acids.
9, 43, 45 
Model  building  Four  published  crystal  structures  were  chosen  from  the  set  of  aligned 
structures as templates for model building. The template structures were downloaded from 
the  protein  databank  (PDB,  www.rcsb.org)  into  Sybyl
55  as  the  functional  dimers.  The 
template  structures  were  mutated  into  the  target  structures  gradually.  Co-crystallized 
water and ligand molecules were preserved during model building, unless stated otherwise 
in the text. The structures were energy minimized, using the Powell method without initial 
optimization.  The  minimization  was  terminated  at  a  gradient  of  0.1  kcal/(mol*Å).  The 
Tripos force field was applied with Gasteiger-Hückel charges and a dielectric constant of 
0.5. Other parameters were kept at their default values. End groups were capped with FOR 
or AMD. The final model was minimized to a gradient of 0.05. The amino acid residues 
were  renumbered  according  to  the  numbering  of  human  KAT  II  (AADAT_HUMAN).  To 
distinguish between the two monomers, the numbering scheme of the second monomer 
was started at 500. The structures were submitted to Procheck
47, 48 analysis for structure 
validation.  
Docking The structure of L-KYN was built in Sybyl, and energy minimized. The structure 
was loaded into ADT and processed as ligand following standard procedures for automated 
docking in AutoDock 4.  
The  KAT  II  models  were  read  into  ADT  1.4.4.  Lone  pairs  and  polar  hydrogens  were 
merged. Water molecules and any ligands were deleted. AutoDock AD4 atom types were 
assigned. Gasteiger-Hückel charges as used for model building were preserved. Grid and 
docking parameter files were prepared in ADT 1.4.5. The grid box was positioned around 
the ligand binding site. The grid box had dimensions of 40 grid points in each direction, 
with a spacing of 0.375Å, resulting in a total of 64000 grid points per map. The ligand was 
docked  into  both  binding  sites  of  the  model.  In  all  cases,  the  maximum  number  of  6 
flexible torsions was used. Docking was performed with the Lamarckian Genetic Algorithm 
in 100 runs and 7.5 or 10 million energy evaluations, until convergence was reached. For 
the local search, the pseudo-Solis & Wets local optimizer object was set. Other parameters 
were kept at their default values. For flexible docking, standard procedures were followed. 
Evaluation/analysis of homology models and docking results KAT II models were analyzed 
in Sybyl. Docking results were analyzed in ADT. Ligand-protein interactions were analyzed 
in  Sybyl  and  with  Ligplot.  Salt  bridge  formation  was  determined  using  the  criteria 
published by Kumar and Nussinov
60. In short, these criteria are: 
-  Salt bridges are established between oppositely charged functional groups. 
-  The maximum distance between the centroids of the functional groups is 4.0Å. 
-  The maximum distance between the heavy atoms being directly involved in the salt 
bridge is 4.0Å. Chapter 6 
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-  Salt  bridges  are  hydrogen  bonded  salt  bridges  if  the  distance  between  the  salt-
bridging heavy atoms is 3.5Å or less.  
Figures Figures 2, 4, 7, 8, 10 and 11 were generated in PyMOL (www.pymol.org). 
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7.1  Summary, general discussion and conclusion 
Research  in  the  field  of  kynurenine  metabolism  as  a  pharmaceutical  target  is 
relatively new. Although the pathway had been known already in the mid-20
th 
century, the major effort to elucidate its pharmacological relevance only started 
in the 1980s. For a long time, only a few academic research groups believed in 
the pathway as a relevant target. In recent years, a vastly expanding group of 
industrial laboratories have started working on the pathway. This delay is not 
surprising, taking into account the complexity of the pathway that is in many 
ways  not  only  contradictory,  but  also  physiologically  ‘different’  from  what  is 
commonly believed about ‘how things work’.  
Much  of  the  complexity  of  the  pathway  arises  from  the  fact  that  the  two 
branches of the pathway result in metabolites with opposite functions. Whereas 
KYNA antagonizes the glutamatergic system, QUIN is a glutamatergic agonist. A 
detailed regulation of the branches by differentiated enzyme distribution at the 
cellular and subcellular level results in a balance that is at some points hard to 
capture,  let  alone  predictable.  For  the  glutamatergic  system,  a  level  of 
complexity is added by the different functions (brake vs. accelerator) in which 
the system is involved. Added to that are affinities of the kynurenine metabolites 
for  their  biological  targets.  The  commonly  expected  affinities  for  endogenous 
compounds  at  receptor  activation  sites  are  in  the  low  nanomolar  range.  For 
enzyme and non-agonist sites, the expected affinities are slightly higher, up to 
the higher nanomolar ranges. However, affinities of - for example - KYNA for its 
targets  are  in  the  micromolar  range.  This  seems  to  be  non-physiological  and 
usually would be the first reason to declare the pathway of no relevance. On the 
other  hand,  an  increasing  body  of  evidence  suggests,  that  the  kynurenine 
pathway  is  a  major  exception  to  this  rule.  Disturbances  of  the  balance  of 
kynurenine  pathway  metabolite  levels  are  associated  with  many  known  CNS 
disorders.  Moreover,  evidence  exists,  that  at  the  very  local  level,  micromolar 
metabolite concentrations can easily be reached. Taken together, currently, it is 
understood  that  this  pathway,  although  seemingly  different  from  other 
regulatory  mechanisms,  might  be  a  key  player  in  many  physiological  and 
pathological  mechanisms.  Therefore,  efforts  should  be  made  and  resources 
combined to get the ‘big picture’ of physiological relevance of the pathway in 
order to finally utilize this knowledge for the design of pharmaceutically valuable 
compounds.   
 Summary, general discussion and conclusion 
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This  thesis  focuses  on  the  KYNA  branch  of  the  pathway.  KYNA  has 
neuroprotective  properties  by  counteracting  excitatory  pathways.  Therefore, 
usually, a shift of the pathway towards this metabolite is desired. Elevated levels 
of the metabolite have been found in patients suffering from schizophrenia. In 
addition,  in  recent  years,  cognitive  disorders  were  associated  with  elevated 
levels of KYNA. For this reason, tools to decrease KYNA levels are desired. The 
most straightforward method to achieve a decrease in KYNA levels is inhibition 
of the biosynthetic enzyme KAT. As should be clear from the literature and from 
the  work  of  this  thesis,  the  major  challenge  is  to  find  compounds  that  do  so 
without  inhibiting  KYNase  and  KMO.  To  add  a  level  of  complexity  to  the 
challenge,  the  inhibitors  should  also  easily  cross  the  blood-brain  barrier. 
Although this issue was not discussed within the scope of the thesis, this is a 
point  of  major  importance.  In  the  ideal  case,  the  compound  should  be 
bioavailable by oral administration. If the compound is not able to quickly cross 
the blood brain barrier, its effects will be limited to peripheral effects. In that 
case, even if KAT is the only one of the three KYN metabolizing enzymes that is 
inhibited, a peripheral rise in KYN and migration of this key intermediate into the 
brain will ultimately lead to enhanced KYN turnover into KYNA in the brain. On 
the  other  hand,  if  the  inhibitor  is  readily  available  in  the  brain,  local  KYNA 
production from the physiological KYN pool and the KYN overflow caused by KAT 
inhibition in the periphery will be prevented, resulting in the desired decrease of 
local KYNA levels in the brain. 
 
Chapters 2-4 describe the synthesis and pharmacological evaluation in vitro of 
conformationally  restricted  compounds.  The  compounds  have  a  bicyclic  core 
structure  that  is  derived  from   -tetralone.  The  synthesis  of  the  amino  acid 
derivatives  proved  to  be  challenging.  Many  commonly  used  methods  were 
explored, but none of the strategies proved to be successful for the synthesis of 
the  desired  compounds.  Surprisingly,  the  method  using  the  SmI2-catalyzed 
coupling  reaction  was  successful  and  applicable  to  even  the  most  challenging 
quinolinone derivative of this series. A drawback of the method is, that it is not 
suitable for enantioselective synthesis of the amino acid derivatives. In the first 
instance, it seemed that this problem could partly be solved by separation of 
diastereomers  during  purification  by  column  chromatography.  However,  the 
acidity  of  the  proton  at  the   -position  of  bicyclic  ring  structure  caused 
racemization in later steps of the synthesis. This was observed for all structures.  
The difficulties experienced in synthesis of the compounds led to the decision to 
screen the compounds as racemic mixtures for their in vitro activities. The same Chapter 7 
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strategy was applied for the bicyclic carboxylic acid derivatives in chapters 2 and 
4  and  for  the  monocyclic  KYN  derivatives  of  chapter  5,  wherever  applicable. 
Drawback  of  this  approach  is,  that  activity  could  be  largely  underestimated. 
However, this decision allowed for synthesis of a wider range of compounds. A 
next  step  in  such  a  project  would  certainly  have  been  the  development  of 
approaches  that  allow  for  enantioselective  synthesis  of  the  most  promising 
compounds and design of compounds that are less complex in terms of chirality. 
Final compounds presented in the thesis are depicted in Scheme 1.  
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Looking at results of activity screening of the compounds, it must be concluded 
that none of the compounds presented in this thesis is optimal to achieve the 
desired KYNA decrease in vivo.  Summary, general discussion and conclusion 
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The bicyclic carboxylate derivatives 2.3 – 2.8 in Chapter 2 are more potent in 
inhibition  of  KYNase  and  KMO  than  in  inhibition  of  KAT.  The  most  interesting 
observation  is  the  exception  on  this  observation,  as  seen  for  ethylsulfonyl 
substituted compound 2.7. This compound seemed to activate KYNase in vitro. 
The  possibility  to  activate  this  enzyme  sheds  a  new  light  on  the  research  on 
compounds that lower KYNA levels. In theory, activators of KYNase, KMO or both 
should be able to reduce availability of KYN for KAT. This could be an alternative 
way to reduce turnover by KAT into KYNA to achieve the decrease in levels of 
this metabolite. 
After  successful  efforts  to  synthesize  the  bicyclic  amino  acids  3.4a  -  3.4c 
described in Chapter 3, these compounds appeared not to have extraordinary 
potency in inhibition of KAT. Again, compounds were not selective for KAT over 
KYNase  and  KMO.  In  Chapter  4,  the  quinolinone  analogs  4.2  and  4.3  of  the 
series  of  bicyclic  compounds  are  presented.  An  interesting  difference  was 
observed in KYNase inhibitory potency between the carboxylic acid analog and 
the  amino  acid  analog.  Whereas  the  amino  acid  analog  showed  virtually  no 
KYNase inhibition, the carboxylate analog inhibited the enzyme potently at the 
same bath concentration. This prompted us to study the characteristics of the 
KYNase binding site. From docking studies it appeared, that the additional bulk 
present in the amino acid analog prevented simultaneous proper orientation of 
both the aromatic moiety and the carboxylate moiety in 4.2. In contrast, the 
smaller  carboxylate  side  chain  in  4.3  allowed  for  optimal  interaction  of  both 
these anchor points with the enzyme, explaining the good inhibitory potency of 
the compound for this enzyme.  
Compounds 5.3 – 5.6 described in Chapter 5 are close KYN analogs that are not 
conformationally restricted. Within these compounds, the substitution pattern at 
the C  atom of KYN is varied. In three compounds, the  -amino group is omitted 
from  the  structure.  In  the  fourth  compound,  the  proton  in  this  position  is 
substituted by a methyl group. The most interesting finding of this chapter is, 
that  the  C   methyl  substituted  compound  has  no  KYNase  and  KMO  inhibitory 
activity. KAT activity was limited, but present. It would be most interesting to 
explore the properties of a compound that has a fluor atom in the corresponding 
position. In theory, such a compound would fit better into the KAT binding site. 
However, effects on KYNase and KMO inhibitory potency are hard to predict. 
In Chapter 6, structural properties of KAT, especially KAT II are explored. The 
evolutionary  background  of  KATs  as  member  of  the  large  group  of 
aminotransferases is most fascinating. For drug design, the recent publication of 
crystal structures of the enzymes is of major importance. During the course of Chapter 7 
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this  project,  the  crystal  structures  were  not  yet  available.  To  learn  about  the 
properties of the enzyme, homology models were built, based on close family 
members  of  the  enzyme.  From  comparison  of  the  models  with  the  published 
crystal structures it could be concluded, that the reliability of the models was 
sufficient to explore the properties of the enzyme. In view of these conclusions 
and  the  availability  of  an  increasing  number  of  crystal  structures,  it  was 
discussed that in early phases of drug design, molecular modeling should be a 
principal tool. 
 
For  future  work,  in  terms  of  direct  continuation  of  the  compound  series 
presented here, combinations of structural variations should be considered. In 
Chapter 2 and in Chapter 5, compounds were presented that contain a tetrazole 
bioisosteric replacement of the carboxylate group (compounds 2.8 and 5.4). In 
both cases, this improved KAT inhibition and selectivity profiles if compared to 
the carboxylate equivalents. Furthermore, the ethylsulfonyl group as found for 
S-ESBA  is  a  useful  tool  for  introduction  of  selectivity.  Exploration  of  the 
possibility to vary the nature of the substituent in that position might lead to 
alternative options. However, what seems to be most urgent in the compound 
design  is  more  variation  in  structures.  In  Chapter  1,  an  overview  is  given  of 
compounds known from literature that were tested for KAT, KYNase and KMO 
inhibtion. Especially in the field of KAT inhibitors, most structures are close KYN 
analogs. Also in this thesis, structures are based on the structure of KYN. Using 
the  crystallographic  data  of  human  KATs,  virtual  screening  of  fragment  and 
larger  compound  libraries  can  lead  to  structurally  more  diverse  candidates. 
Cooperation  between  computational  and  synthetic  chemistry  groups  to  design 
these compounds and groups that can test the compounds in a diverse array of 
in vitro and in vivo models originating from different species would enable an 
accelerated and focused way to achieve the goals of designing pharmacologically 
interesting  compounds.  Once  these  compounds  are  available,  functional 
importance  of  the  kynurenine  pathway  and  associated  pathophysiological 
relevance can be explored further. 
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List of abbreviations 
 
3-HAO  3-hydroxyanthranilic acid oxygenase 
3-OH-AA  3-hydroxyanthranilic acid 
3-OH-KYN  3-hydroxykynurenine 
4C3HPG  4-carboxy-3-hydroxyphenylglycine 
5-Cl-KYN  5-chlorokynurenine 
5-HT  5-hydroxytryptamine, serotonin 
7-Cl-KYNA  7-chlorokynurenic acid 
AA  anthranilic acid 
ACh  acetylcholine 
ACN  acetonitrile 
AcOH  Acetic acid 
AD  Alzheimer's disease 
AFMID  arylformamidase, kynurenine formamidase 
AIDS  acquired immunodeficiency syndrome 
AMPA  alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
BOC  tert-butyl carbonate protecting group or di-tert-butyl-
dicarbonate reagent 
CAN  ceric ammonium nitrate 
cDNA  complement DNA 
CNS  Central nervous system 
COX  cyclo-oxygenase 
CSF  cerebrospinal fluid 
DA  dopamine 
DIBAL-H  Di-isobutylaluminium hydride 
DMAP  dimethylaminopyridine 
DMF  dimethylformamide 
EC50  effective concentration (50% effect) 
ECF  extracellular fluid 
ESI  electrospray ionization 
EtOAc  ethyl acetate 
FAD  flavin adenine dinucleotide 
FMO  flavin monooxygenase 
GABA   -aminobutyric acid 
GC  gas chromatography 
GCMS  gas chromatography – mass spectrometry 
HD  Huntington's disease List of abbreviations 
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Hex  hexane 
HIV  Human immunodeficiency virus 
HPLC  high performance liquid chromatography 
HRMS  high resolution mass spectrometry 
IC50  Inhibitory concentration (50%) 
IDO  Indole-2,3-dioxygenase 
IFN  interferon 
iGluRs  ionotropic glutamate receptors 
IL  interleukine 
IPA  indolepyruvic acid 
IR  infrared (spectroscopy) 
KAT  kynurenine aminotransferase 
KMO  kynurenine mono-oxygenase, kynurenine-3-hydroxylase 
KP  kynurenine pathway 
KYN  kynurenine 
KYNA  kynurenic acid 
KYNase  kynureninase 
L-AP4  L-(+)-2-amino-4-phosphonobutyric acid 
L-DOPA  L-3,4-dihydroxy-L-phenylalanine 
LHMDS  Lithium hexamethyl disilazine/lithium bis(trimethylsilyl) amide 
L-SOP  L-serine-O-phosphate 
mGluRs  metabotropic glutamate receptors 
MIF  migration inhibitory factor 
MLA  methyllycaconitine 
mNBA  m-nitrobenzoylalanine 
MS  mass spectrometry 
MPP+  1-methyl-4-phenylpyridinium 
MPTP  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
nAChRs  nicotinic acetylcholine receptors 
NAD  nicotinamide adenine dinucleotide 
NADPH  nicotinamide adenine dinucleotide phosphate 
NE  norepinephrine 
NMDA  N-methyl-D-aspartate 
NMR  nuclear magnetic resonance 
NO  nitric oxide 
NOS  nitric oxide synthetase 
NR  NMDA receptor subunit Appendix 
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NSAIDs  nonsteroidal anti-inflammatory drugs 
oMBA  o-methoxybenzoylalanine 
PCP  phencyclidine 
PD  Parkinson's disease 
PFC  prefrontal cortex 
PLP  pyridoxal 5'-phosphate 
PMP  pyridoxamine phosphate 
PPA  polyphosphoric acid 
p-TosCl  p-toluenesulfonyl chloride / tosyl chloride 
QRPT  quinolinic acid phosphoribosyl transferase 
QUIN  quinolinic acid 
ROS  reactive oxygen species 
r.t.  room temperature 
SAM  S-adenosylmethionine 
S-ESBA  S-4-(ethylsulfonyl)-benzoylalanine 
SIN-1  3-morpholinosydnonimine 
SN  substantia nigra 
SNAP  S-nitroso-N-acetylpenicillamine 
TDO  tryptophan-2,3-dioxygenase 
TFA  trifluoroacetic acid 
TGF  transforming (tumor) growth factor 
THF  tetrahydrofurane 
TLC  thin layer chromatography 
TMSCl  trimethylsilyl chloride 
TNF  tumor necrosis factor 
trans-PDC  trans-pyrrolidine-2,4-dicarboxylate 
VTA  ventral tegmental area 
XA  xanthurenic acid 
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Samenvatting 
 
Dit  proefschrift  beschrijft  farmacochemisch  onderzoek  naar  remmers  van 
kynurenine aminotransferase (KAT), een enzym van de ‘kynurenine pathway’. 
In hoofdstuk 1 wordt een inleiding gegeven in de kynurenine pathway. Deze 
pathway  zorgt  voor  catabolisme  van  het  grootste  gedeelte  van  het  in  het 
organisme aanwezige tryptofaan. De belangrijkste intermediair in deze route is 
kynurenine  (KYN).  KYN  kan  worden  omgezet  door  KAT  in  kynureninezuur 
(kynurenic  acid,  KYNA).  KYNA  remt  excitatoire  effecten,  voornamelijk  door 
antagonisme van NMDA receptoren en  7* nicotinerge acetylcholine receptoren. 
Een  alternatieve  route  voert  langs  3-hydroxykynurenine  (3-OH-KYN), 
anthranilzuur  (anthranilic  acid,  AA)  en  3-hydroxyanthranilzuur  (3-
hydroxyanthranilic acid, 3-OH-AA) naar het tweede hoofdproduct, quinolinezuur 
(QUIN). QUIN  is  een  NMDA  receptor  agonist  en  heeft  daardoor  een excitatoir 
effect.  
Van KAT, het biosynthetisch enzym van KYNA, zijn vier isovormen bekend. Voor 
productie van KYNA in het menselijk lichaam is KAT II de belangrijkste isovorm. 
KAT  II  produceert  circa  75%  van  het  KYNA  in  het  centraal  zenuwstelsel.  De 
productie  van  KYNA  is  afhankelijk  van  verschillende  factoren,  zoals  transport-
mechanismen,  energetische  status  van  de  cel,  ionenconcentraties, 
beschikbaarheid  van  het  substraat,  co-substraat  en  co-enzym  en  eventueel 
aanwezige remmers. Verder wordt de productie van KYNA beïnvloed door enkele 
neurotransmitters. Op zijn beurt oefent KYNA direct en indirect invloed uit op 
verschillende neurotransmittersystemen. Het meest onderzochte systeem in dit 
opzicht is het dopaminerge systeem. 
De kynurenine pathway is een uitgebalanceerd systeem. Verdeling van enzymen 
over verschillende hersendelen, celtypes en subcellulaire systemen zorgt ervoor, 
dat  specifieke  regulatie  mogelijk  is.  De  twee  takken  van  de  pathway, 
uitmondend  in  respectievelijk  KYNA  en  QUIN,  zijn  in  dynamisch  evenwicht. 
Verstoring  van  dit  evenwicht  kan  leiden  tot  ernstige  pathofysiologische 
aandoeningen.  Voorbeelden  hiervan  zijn  aandoeningen  die  een  relatie  hebben 
tot  het  immuunsysteem  (AIDS,  ziekte  van  Lyme,  malaria),  de  ziekte  van 
Huntington,  de  ziekte  van  Alzheimer,  de  ziekte  van  Parkinson  en  epilepsie. 
Tenslotte zijn verhoogde concentraties KYNA gevonden bij patiënten die lijden 
aan schizofrenie. Een directe manier om de KYNA-concentratie te verlagen is het 
remmen van het biosynthetisch enzym KAT. KAT-remmers zouden een nieuwe 
strategie  kunnen  bieden  voor  het  behandelen  van  de  symptomen  van 
schizofrenie  en  daarmee  gepaard  gaande  cognitieve  stoornissen.  Echter  zijn Appendix 
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KAT-remmers  slechts  in  zeer  beperkte  mate  beschikbaar.  Het  doel  van  dit 
onderzoek richt zich daarom op het synthetiseren van nieuwe KAT-remmers en 
het bestuderen van KAT II om inzicht te verkrijgen in de werking van dit enzym. 
Hoofdstuk  2  beschrijft  de  synthese  en  in  vitro  evaluatie  van  6  bicyclische  
carbonzuur-analoga  van  KYN.  In  de  structuren  is  een  alifatisch  ringsysteem 
geïntroduceerd  om  de  conformaties  een  meer  rigide  karakter  te  geven.  De 
activiteit  van  de  carbonzuur-analoga  als  KAT-remmers  was  beperkt.  De 
moleculen  bleken  niet  selectief  ten  opzichte  van  kynurenine  3-hydroxylase  en 
kynureninase. Kynurenine 3-hydroxylase is betrokken bij omzetting van KYN in 
3-OH-KYN,  kynureninase  is  verantwoordelijk  voor  synthese  van  AA  uit  KYN. 
Remming  van  deze  enzymen  is  ongewenst,  aangezien  dit  de  beschikbare 
hoeveelheid  KYN  verhoogt.  Verhoogde  concentraties  van  KYN  leiden  tot  een 
verhoogde  aanmaak  van  KYNA  door  KAT.  Wel  konden  interessante 
verschuivingen  in  de  mate  van  remming  van  de  drie  enzymen  worden 
waargenomen door variatie in de bicyclische structuur enerzijds en bioïsostere 
vervanging of substitutie anderzijds. De meest interessante stof uit deze serie is 
ethylsulfonyl-analoog 2.7. Deze stof heeft een ethylsulfonyl-substituent op de 6-
positie  in  de  aromatische  ring,  analoog  aan  de  selectieve  KAT  II-remmer  S-
ESBA.  2.7  remde  KAT,  had  geen  uitgesproken  effect  op  kynurenine  3-
hydroxylase,  maar  leek  de  activiteit  van  kynureninase  te  verhogen.  Enzym-
inducerende  stoffen  vormen  een  interessante  groep  binnen  farmacologisch 
onderzoek. Hoewel het mechanisme van activatie van 2.7 niet bekend is, zou 
deze verbinding een aanknopingspunt kunnen vormen voor een nieuwe klasse 
van modulatoren van de kynurenine pathway. 
In hoofdstuk 3 worden de tetralon-, chromanon- en thiochromanon-aminozuur-
analoga  van  de  in  hoofdstuk  2  gepresenteerde  bicyclische  KYN-analoga 
beschreven.  Voor  de  synthese  van  deze  stoffen  werd  de  bicyclische  kern 
gekoppeld aan een aldimine-structuur door middel van een SmI2-gekatalyseerde 
koppelingsreactie.  Na  de  koppelingsreactie  werd  de  p-methoxybenzeen-groep 
oxidatief  verwijderd  en  vervangen  door  een  acetyl-groep.  Hydrolyse  van  de 
beschermende groepen leverde het aminozuur als eindproduct op. De bicyclische 
aminozuren bleken slechts zwakke remmers van KAT te zijn en waren potenter 
in het remmen van kynurenine 3-hydroxylase en kynureninase.  
Hoofdstuk  4  beschrijft  de  quinolinon-analoga  van  de  bicyclische  moleculen 
gepresenteerd in hoofdstuk 2 en 3. Door de chemisch bijzondere eigenschappen 
van de quinolinon-structuur vormden deze analoga een aparte groep binnen de 
serie  van  bicyclische  KYN-analoga.  De  aminozuur-analoog  4.2  kon 
gesynthetiseerd  worden  met  behulp  van  de  SmI2-gekatalyseerde  koppelings-Samenvatting 
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reactie  beschreven  in  hoofdstuk  3.  Zowel  voor  vervanging  van  de  p-
methoxybenzeen-groep  als  voor  bescherming  van  de  aminogroep  in  de 
heterocyclische ring werden BOC-groepen toegepast. De bicyclische carbonzuur-
analoog  4.3  kon  volgens  methodes  als  beschreven  in  hoofdstuk  1  worden 
gesynthetiseerd. Zoals verwacht op basis van de structuren uit hoofstuk 2 en 3, 
hadden ook de quinolinonen geen exceptioneel hoge potentie in het remmen van 
KAT. Echter werd een groot verschil in kynureninase-remming door deze twee 
stoffen waargenomen. Bij een badconcentratie van 1 mM van de remmer werd 
de kynureninase-activeit vrijwel niet geremd door aminozuur-analoog 4.2. Het 
enzym  werd  bij  deze  concentratie  vrijwel  volledig  geremd  door  carbonzuur-
analoog 4.3. Om dit verschil in activiteit te kunnen verklaren werd de interactie 
van  elk  van  de  stoffen  met  kynureninase  bestudeerd.  Hieruit  bleek  dat 
carbonzuur  4.3  op  een  energetisch  gunstige  manier  kan  binden  aan 
kynureninase, waarbij een hoge mate van flexibiliteit gewaarborgd is. Aminozuur 
4.2 daarentegen bindt weliswaar, echter is de ruimte voor het molecuul door de 
extra  aminogroep  beperkt,  wat  zich  uit  in  minder  flexibiliteit  bij  binding.  Het 
entropieverlies bij binding is daardoor beduidend groter voor 4.2 dan voor 4.3. 
Het relatief kleine entropieverlies van 4.3 tijdens binding met kynureninase zou 
de  verhoogde  potentie  van  kynureninase-remming  door  dit  molecuul  ten 
opzichte van 4.2 kunnen verklaren.  
In hoofstuk 5 worden vier flexibele KYN-analoga beschreven. Deze analoga zijn 
verwant aan de rigide structuren gepresenteerd in hoofdstukken 2-4. De eerste 
drie structuren zijn KYN-analoga waarbij de  -aminogroep ontbreekt. Structuur 
5.3  is  de  directe  des-amino-KYN-analoog.  In  structuur  5.4  is  bovendien  de 
carbonzuurgroep vervangen door een tetrazool. Structuur 5.5 is de des-amino-
analoog van S-ESBA. Structuur 5.3 was reeds bekend uit de literatuur en komt 
voor in de lens van het oog. Uit de hier gepresenteerde studie bleek, dat de stof 
voornamelijk de activiteit van kynurenine 3-hydroxylase en kynureninase remt. 
De tetrazool-analoog 5.4 had een verbeterde KAT-remming, maar ook deze stof 
bleek kynurenine 3-hydroxylase en kynureninase te remmen. De ethylsulfonyl-
analoog  5.5  daarentegen  remde  kynurenine  3-hydroxylase  en  kynureninase, 
maar ook KAT slechts in beperkte mate. 
De vierde flexibele analoog gepresenteerd in hoofstuk 5 is  –methyl-KYN (5.6). 
In  de  transamineringsreactie  van  KAT  speelt  het   -proton  van  KYN  een 
essentiële rol. In theorie zou door introductie van een substituent op deze plaats 
de transaminering voorkomen kunnen worden. Een stof die enerzijds wel met 
hoge affiniteit aan KAT kan binden, maar anderzijds niet kan deelnemen in de 
transamineringsreactie, zou een goede potentiële KAT-remmer kunnen zijn. In Appendix 
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de  enzymassay  werd  geen  remming  van  kynurenine  3-hydroxylase  en 
kynureninase in aanwezigheid van  -methyl-analoog 5.6 waargenomen. Echter 
werd  ook  KAT  in  slechts  beperkte  mate  geremd.  Een  mogelijke  verklaring 
hiervoor  is  de  relatief  sterke  mate  van  sterische  hindering  door  de   -methyl-
groep  bij  binding  aan  het  enzym.  Vervanging  van  deze  groep  door  een 
fluoratoom zou de sterische hindering kunnen beperken.  
Hoofdstuk 6 beschrijft de karakterisering van KAT, met name KAT II. In het 
eerste  deel  van  dit  hoofdstuk  wordt  de  positie  van  KAT  binnen  vitamine  B6-
afhankelijke  enzymen  en  binnen  de  groep  van  aminotransferases  beschreven. 
Op  basis  van  primaire,  secundaire  en  tertiaire  structuur  zijn  aanverwante 
enzymen  geïdentificeerd.  Zowel  uit  vergelijkingen  van  primaire  structuren  als 
door het analyseren van evolutionaire relaties bleek, dat de KAT I- en KAT III- 
isovormen nauw verwant zijn en onderdeel uitmaken van een grotere groep van 
verwante  enzymen.  De  KAT  II-isovorm  is  gerelateerd  aan  KAT  I  en  KAT  III, 
maar vormt een aparte aftakking in de evolutionaire ontwikkeling. KAT IV staat 
in structureel opzicht betrekkelijk los van de andere isovormen van KAT. 
De functionele vorm van KAT II is een dimeer. Per dimeer zijn twee substraat-
bindingsplaatsen te onderscheiden. Bindingsplaats 1 is voornamelijk gelegen in 
monomeer 1 van het enzym. Bindingsplaats 2 ligt voornamelijk in monomeer 2. 
De  bindingsplaatsen  zijn  identiek.  Voor  het  bestuderen  van  de  eigenschappen 
van  de  bindingsplaats  van  KAT  II  zijn  vier  homologiemodellen  van  dit  enzym 
geconstrueerd.  Deze  zijn  vergeleken  met  recentelijk  gepubliceerde  KAT  II-
kristalstructuren. De bodem van de bindingsplaats wordt gevormd door het co-
enzym PLP. De interacties van de fosfaatarm van het co-enzym met het enzym 
kwamen overeen met de in de literatuur beschreven ‘phosphate binding cup’. De 
zijkanten  van  de  bindingsplaats  bestaan  uit  een  onderste,  voornamelijk 
hydrofiele  laag  en  een  meer  hydrofobe  bovenlaag.  Dockingstudies  met  KYN 
wezen  uit  dat  voor  binding  van  het  stubstraat  zoutbrugvorming  tussen  de 
carboxylaatgroep  van  het  substraat  en  Arg399  van  groot  belang  is.  De 
aromatische  kern  van  KYN  had  interactie  in  een  hydrofoob  gebied  aan  de 
rechterzijde  van  de  bindingsplaats.  In  dit  gebied  werden  verschillen  in 
aminozuuroriëntaties  geïdentificeerd  tussen  KAT  I  en  KAT  II.  Deze  verschillen 
zouden de gevonden selectiviteit van referentieremmer S-ESBA voor KAT II ten 
opzichte van KAT I kunnen verklaren.  
De  bindingsplaats  wordt  aan  de  bovenkant  afgedekt  door  de  zogenaamde  ‘N-
terminal arm’. In aan KAT II verwante structuren, bijvoorbeeld in isovorm KAT I, 
is de N-terminal arm die een bindingsplaats in een monomeer afdekt afkomstig 
van hetzelfde monomeer. Uit gepubliceerde kristalstructuren van KAT II bleek, Samenvatting 
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dat  de  N-terminal  arm  in  dit  geval  van  de  tegenovergestelde  monomeer 
afkomstig  is.  Dit  kon  niet  voorspeld  worden  uit  de  homologiemodellen. 
Interessant is echter de observatie, dat ongeacht de herkomst van de arm, de 
functie gelijk is. Hierin spelen aminozuren Asn20 in KAT II en Trp18 in KAT I een 
belangrijke en vergelijkbare rol.  
Uit  de  resultaten  beschreven  in  hoofdstuk  6  kon  geconcludeerd  worden  dat 
constructie van modellen op basis van homologie een betrouwbare techniek is 
voor het bestuderen van enzymeigenschappen. 
Tenslotte  geeft  hoofdstuk  7  een  samenvatting,  discussie  en  conclusie  over 
resultaten van dit onderzoek. Hoewel binnen de hier gepresenteerde structuren 
het  optimale  profiel  van  een  selectieve  KAT-remmer  niet  is  gevonden,  zijn 
belangrijke aanknopingspunten geleverd voor verder onderzoek. Het gebruik van 
molecular  modeling  en  in  het  bijzonder  ‘virtual  screening’-methodes  zou  de 
efficiëntie van dit proces kunnen maximaliseren.  
 Appendix 
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